publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
propensityscor
match
analysi
compar
clinic
benefit
antimicrobi
deescal
nonswitch
adult
communityonset
monomicrobi
escherichia
coli
klebsiella
speci
proteu
mirabili
bacteremia
background
hospit
nation
antimicrobi
prescrib
survey
audit
platform
enabl
facil
determin
appropri
antimicrobi
prescrib
australian
hospit
particip
survey
collect
prescrib
data
sinc
method
data
facil
survey
submit
januari
decemb
analys
assess
appropri
assess
guid
top
antimicrobi
inappropri
prescrib
determin
total
antimicrobi
percentag
prescrib
top
indic
highest
rate
inappropri
prespr
determin
result
antimicrobi
prescript
analys
top
inappropri
prescrib
antimicrobi
ceftriaxon
prescript
amoxycillinclavulan
acid
next
inappropri
prescript
follow
piperacillintazobactam
prescript
antimicrobi
highest
percentag
inappropri
prescrib
cefaclor
kenacomb
gramicidinneomycinnystatin
dapson
although
small
number
antimicrobi
prescrib
respect
indic
antimicrobi
inappropri
prescrib
ceftriaxon
commun
acquir
pneumonia
infect
exacerb
chronic
obstruct
pulmonari
diseas
urinari
tract
infect
amoxycillinclavulan
acid
commun
acquir
pneumonia
infect
exacerb
chronic
obstruct
pulmonari
diseas
urinari
tract
infect
piperacillintazobactam
commun
acquir
pneumonia
hospit
acquir
pneumonia
cellul
erysipela
conclus
antimicrobi
high
number
percentag
inappropri
prescrib
ceftriaxon
amoxicillinclavulan
acid
cefalexin
azithromycin
inappropri
prescrib
respiratori
tract
infect
evid
obviou
target
target
qualiti
improv
activ
patient
critic
ill
econom
resist
impact
deescal
strategi
bloodstream
infect
rare
report
method
patient
communityonset
monomicrobi
escherichia
coli
klebsiella
speci
proteu
mirabili
ekp
bacteremia
empir
treat
broadspectrum
betalactam
includ
cephalosporin
gc
carbapenem
analyz
categor
accord
antimicrobi
spectrum
definit
therapi
deescal
group
agent
empir
antibiot
noswitch
group
broaderspectrum
antibiot
escal
group
clinic
inform
retrospect
collect
chart
record
propens
score
calcul
independ
predictor
mortal
patient
deescal
group
match
basi
noswitch
group
closest
individu
propens
score
result
elig
adult
categor
deescal
patient
noswitch
escal
group
gener
deescal
therapi
femal
less
critic
ill
less
fatal
comorbid
higher
surviv
rate
two
group
appropri
propensityscor
match
deescal
noswitch
group
critic
ill
onset
pitt
bacteremia
score
vs
p
day
vs
p
fatal
comorbid
vs
p
also
time
defervesc
vs
day
p
hospit
stay
vs
day
p
vs
p
crude
mortal
rate
similar
howev
lower
antibiot
cost
mean
vs
us
p
less
complic
bloodstream
infect
due
resist
pathogen
vs
p
observ
deescal
group
conclus
adult
communityonset
ekp
bacteremia
empir
treat
appropri
broadspectrum
betalactam
deescal
narrowspectrum
cephalosporin
safe
costeffect
establish
auxiliari
mechan
intim
remind
improv
ration
antibiot
util
huiyun
liang
iigl
chen
hungjen
tang
background
surgeri
time
lose
howev
effect
manag
use
prophylact
antibiot
challeng
remind
mechan
like
ad
window
user
want
see
content
want
close
multiori
check
affect
conduct
surgeri
establish
auxiliari
mechan
intim
remind
human
manag
educ
use
correct
concept
antibiot
also
improv
ration
antibiot
util
method
first
time
immedi
start
procedur
includ
antibiot
prophylaxi
within
hour
prior
incis
ask
reason
follow
use
antibiot
halflif
surgeri
time
calcul
use
music
remind
team
add
antibiot
oper
amount
blood
loss
ml
also
way
remind
team
assess
prepar
add
antibiot
result
antibiot
prophylaxi
within
hour
prior
incis
arriv
proport
antibiot
ad
drug
surgeri
see
effect
manag
signific
conclus
right
time
use
appropri
antibiot
prevent
occurr
surgic
site
infect
use
intim
remind
achiev
goal
improv
patient
safeti
continu
implement
contact
precaut
environment
clean
mrsa
huiyun
liang
iigl
chen
hungjen
tang
background
increas
drug
resist
one
import
issu
global
concern
effect
way
stop
transmiss
drugresist
strain
must
antibiot
stewardship
isol
protect
measur
strain
mrsa
first
found
evid
concert
effort
includ
surveil
cultur
contact
precaut
isol
hospit
reduc
mrsa
implement
isol
measur
need
spend
manpow
cost
accord
tni
system
taiwan
nosocomi
infect
surveil
system
statist
report
mrsa
detect
implement
contact
hospit
isol
great
burden
polici
formul
implement
need
mani
consider
method
hospit
mrsa
patient
standard
protect
begin
first
detect
patient
implement
contact
isol
cohort
patient
discharg
final
disinfect
first
isol
mrsa
patient
must
immedi
check
use
antibiot
relat
medic
behavior
unit
isol
mrsa
hand
hygien
audit
environ
clean
disinfect
joint
inspect
patient
discharg
weekli
fix
view
new
case
detect
distribut
trend
result
number
new
case
isol
mrsa
reduc
usag
densiti
antibiot
per
beddayoccup
declin
penicillin
declin
conclus
continu
monitor
trend
drug
resist
distribut
time
prudent
use
antibiot
use
antibiot
stewardship
import
thing
implement
contact
isol
hand
hygien
medic
environ
clean
disinfect
infect
control
measur
reduc
transmiss
drugresist
bacteria
pharmaci
effici
censor
inappropri
antibiot
prescript
pharmacist
infect
specialist
commun
teach
hospit
meeishou
kuo
hueim
pan
pharmaci
st
joseph
hospit
home
medicin
st
joseph
hostip
purpos
overus
antibiot
induc
increas
number
antibiot
resist
bacteria
side
effect
evid
suggest
proper
use
antibiot
help
control
qualiti
effici
build
censor
mechan
pharmacist
infect
specialist
increas
clinic
take
care
qualiti
method
data
retrospect
collect
item
control
antibiot
censor
meet
commun
hospit
januari
decemb
pharmacist
analysi
appropri
antibiot
prescript
within
hour
infect
specialist
censor
indic
clinic
use
conclus
total
analysi
result
inappropri
antibiot
prescript
pharmacist
case
rank
case
first
item
wrong
adjust
renal
function
case
suitabl
dose
case
incompat
cultur
result
case
mistak
frequenc
case
rel
laboratori
data
case
improp
indic
case
ignor
drug
alleg
histori
case
prolong
use
durat
case
side
effect
case
total
analysi
result
inappropri
antibiot
prescript
infect
specialist
case
first
item
wrong
adjust
renal
function
case
incompat
cultur
result
chang
narrow
spectrum
antibiot
case
improp
case
use
kind
case
ignor
bodi
weight
case
prolongus
durat
case
compar
result
inappropri
antibiot
prescript
pharmacist
infect
specialist
opinion
mani
way
total
result
result
rank
result
inappropri
antibiot
prescript
pharmacist
infect
specialist
first
item
wrong
adjust
renal
function
although
doctor
adjust
antibiot
dose
dose
calcul
formular
procedur
censor
meet
follow
within
hour
prescript
help
doctor
use
sensibl
proper
antibiot
improv
commun
pharmacist
doctor
hand
hoist
safeti
use
antibiot
patient
preval
fluoroquinolon
resist
rectal
flora
patient
undergo
transrect
ultrasound
guid
prostat
needl
biopsi
prospect
multicent
studi
myung
soo
kim
eu
chang
hwang
ho
song
yu
seung
ii
jung
dong
hoon
lim
jin
jo
hyun
sop
choe
seungju
lee
sung
woon
park
depart
urolog
chonnam
nation
univers
medic
school
gwangju
korea
chosun
univers
school
medicin
gwangju
korea
cathol
univers
korea
st
vincent
hospit
suwon
korea
kwangju
christian
hospit
gwangju
korea
background
estim
preval
fluoroquinolon
resist
rectal
flora
patient
undergo
repeat
transrect
ultrasound
guid
prostat
needl
biopsi
identifi
high
risk
group
method
januari
march
rectal
swab
men
institut
undergo
transrect
ultrasound
guid
prostat
needl
biopsi
obtain
result
total
patient
cultur
posit
fluoroquinolon
resist
bacteria
overal
rate
incid
fluoroquinolon
resist
extendedspectrum
betalactamas
product
respect
common
fqr
bacteria
e
coli
total
fqr
bacteria
total
rectal
flora
univari
multivari
analysi
clinic
paramet
affect
fqr
show
factor
associ
fq
resist
rectal
flora
clinic
paramet
associ
infecti
complic
prostat
biopsi
oper
histori
within
month
rr
ci
p
conclus
preval
fqr
rectal
flora
rectum
transrect
prostat
biopsi
common
fqr
bacteria
e
coli
howev
antibiot
resist
rectal
flora
predict
clinic
factor
risk
base
approach
recommend
consid
target
antibiot
prophylaxi
extend
antibiot
prophylaxi
relationship
antibiot
consumpt
antibiot
resist
pseudomona
aeruginosa
weilung
tsai
mengchiao
lin
chunhsiang
yu
chunm
lee
depart
pharmaci
st
joseph
hospit
depart
intern
medicin
st
joseph
hospit
background
antimicrobi
resist
global
concern
preval
antibiot
resist
speci
increas
time
make
us
spend
money
time
medic
resourc
fight
diversifi
use
antimicrobi
agent
seem
effect
reduc
growth
antimicrobi
resist
method
use
retrospect
studi
evalu
correl
antipseudomon
antibiot
comsumpt
antimicrobi
resist
pseudomona
aeruginosa
pearson
correl
coeffici
data
collect
region
hospit
middl
taiwan
antibiot
use
express
ddd
defin
daili
dose
per
patientsday
develop
atcddd
result
studi
consumpt
ceftazidim
ciprofloxacin
levofloxacin
increas
significantli
consumpt
gentamicin
amikacin
decreas
signific
chang
consumpt
imipenemcilastatin
cefepim
piperacillintazobactam
suscept
rate
pseudomona
aeruginosa
ciprofloxacin
levofloxacin
imipenemcilastatin
decreas
other
remain
stabl
correl
antibiot
suscept
modestli
neg
correl
ciprofloxacin
r
p
piperacillintazobactam
r
p
other
although
show
neg
correl
pvalu
statist
signific
conclus
studi
show
modestli
correl
antipseudomon
antimicrobi
usag
pseudomona
aeruginosa
resist
conclud
divers
antibiot
use
delay
antimicrobi
resist
develop
rais
consumpt
suscept
pseudomona
aeruginosa
agent
go
therefor
keep
antimicrobi
stewardship
diversifi
use
antibiot
good
infect
control
import
strategi
overcom
problem
antibiot
resist
analysi
c
difficil
associ
diarrhea
antibiot
use
huiyun
liang
iigl
chen
hungjen
tang
background
patient
expect
antibiot
treatment
upper
respiratori
tract
infect
urti
observ
increas
antibiot
prescrib
primari
care
clinic
phenomenon
less
well
understood
timestrap
emerg
depart
sought
assess
nonclin
factor
associ
antibiot
prescrib
adult
acutecar
hospit
emerg
depart
ed
singapor
method
conduct
crosssect
studi
consecut
patient
present
uncompl
urti
ed
may
feb
intervieweradminist
questionnair
institut
medic
record
particip
access
inform
antibiot
prescript
multivari
logist
regress
model
construct
assess
independ
nonclin
factor
associ
antibiot
prescrib
result
particip
mean
age
sd
year
tend
male
almost
half
receiv
diplomaand
universitylevel
educ
major
preexist
medic
condit
antibiot
prescrib
onethird
particip
amoxycillinclavulan
commonli
prescrib
antibiot
although
particip
report
expect
receiv
antibiot
ed
visit
ill
inform
physician
expect
expect
receiv
antibiot
like
nt
prescrib
antibiot
p
among
expect
antibiot
differ
antibiot
prescrib
pattern
inform
physician
expect
versu
p
adjust
age
preexist
comorbid
present
complaint
fever
expect
antibiot
aor
ci
p
higher
educ
level
aor
ci
p
marginallysignificantli
associ
antibiot
prescrib
major
particip
satisfi
consult
ed
differ
satisfact
level
receiv
versu
receiv
antibiot
p
conclus
patient
higher
educ
level
expect
antibiot
regardless
whether
explicitli
inform
physician
associ
increas
antibiot
prescrib
studi
warrant
better
understand
influenc
nonclin
factor
antibiot
prescrib
decis
make
investig
relationship
mdr
multidrug
resist
pathogen
isol
defin
daili
dose
ddd
antibiot
prescript
one
teach
hospit
midtaiwan
chunghsin
liao
frank
san
fan
changhua
hospit
ministri
health
welfar
background
chunghua
hospit
avail
hospit
midtaiwan
contain
abil
medic
surgic
intens
long
term
care
facil
mdr
pathogen
progress
becom
major
threat
immunocompromis
nonimmunocompromis
patient
want
investig
relationship
mdr
pathogen
antibiot
use
hospit
method
way
tami
system
retrospect
collect
ddd
inject
form
antibiot
main
class
import
bacteri
includ
mdr
companion
quarter
clinic
divis
antibiot
use
regulatori
nonregulatori
antibiot
stratifi
record
import
bacteri
includ
e
coli
k
pneumonia
p
aeruginosa
baumannii
aureu
enterococci
mdr
companion
cre
crpa
crab
mrsa
vre
collect
analyz
way
tstudent
test
ddd
antibiot
proport
mdr
pathogen
compar
differ
cultur
mdr
pathogen
also
compar
main
class
antibiot
result
hivaid
infect
deadli
diseas
haart
well
adher
case
manag
good
qualiti
life
mtr
multipl
tablet
regimen
gradual
repac
str
studi
outcom
adher
immunolog
recoveri
viral
suppres
report
bacteremia
antimicrobi
resist
prescript
pattern
pediatr
patient
prospect
observ
studi
teach
hospit
southern
taiwan
baixiu
jian
wenliang
lin
wenchuan
lin
chinglan
cheng
background
antimicrobi
resist
taiwan
studi
adult
children
studi
aim
estim
pediatr
antimicrobi
resist
bloodstream
infect
rate
pathogen
describ
antimicrobi
prescrib
pattern
monthli
point
preval
survey
pp
method
conduct
prospect
observ
studi
blood
cultur
report
studi
pathogen
pediatr
patient
tertiari
teach
hospit
august
april
monthli
pp
day
randomli
chosen
month
pediatr
patient
ongo
antimicrobi
survey
day
receiv
antibiot
surgeri
previou
day
includ
result
bacteremia
isol
patient
enrol
resist
least
antibiot
frequent
organ
salmonella
speci
n
yeild
children
age
month
e
coli
n
frequent
resist
organ
suscept
ampicillinsulbactam
cefazolin
respect
pp
conduct
icu
gener
pediatr
ward
elig
persontim
prescrib
antimicrobi
antimicrobi
prescrib
fig
therapi
prophylaxi
presrib
prophylaxi
sulfonamidestrimethoprim
combin
penicillin
prescrib
therapeut
indic
common
indic
therapeut
antimicrobi
lrti
background
hospit
tangerang
district
indonesia
antimicrobi
restrict
antimicrobi
program
arcp
implement
sinc
rate
bacteria
drugresist
antimicrobi
suscept
extrem
crucial
enhanc
program
therefor
studi
share
inform
susceptibilti
eleven
broadspectrum
antibiot
includ
carbapenem
fourth
gener
cephalosporin
glycylcyclin
glycopeptid
oxazolidinon
method
limit
broadspectrum
antibiot
therapi
appli
inpati
outpati
order
supervis
control
prescrib
system
request
integr
enclos
inform
clinic
relev
reason
futhermor
rational
antibiot
util
shown
comprehens
form
provid
data
extract
juli
decemb
data
base
retrospect
result
total
case
infect
multidrug
resist
gram
negatif
bacteria
common
pathogen
acinetobact
baumanii
klebsiella
pneumonia
pseudomona
aeruginosa
stenotrophomona
maltophilia
increas
suscept
trend
gram
neg
bacteria
gnb
notic
almost
group
broadspectrum
antibiot
drug
suscept
juli
decemb
cefepim
cefpirom
carbapenem
tigecyclin
piperacillintazobactam
cefoperazonesulbactam
amikacin
side
susceptibilti
level
linezolid
vancomycin
gram
positif
bacteria
staphylococci
streptococci
remain
conclus
result
present
tendenc
toward
improv
suscept
level
broadspectrum
antibiot
although
number
mdrgnb
still
quit
high
outcom
pharmacist
intervent
antibiot
use
yungm
huang
yishan
chen
tsaiyen
liu
depart
pharmaci
hualien
tzu
chi
hospit
buddhist
tzu
chi
medic
foundat
hualien
taiwan
roc
background
launch
new
antibiot
becom
rare
recent
year
impact
therapeut
option
treat
infect
caus
multidrugor
extens
drugresist
bacteria
respons
challeng
optim
use
antibiot
control
resist
rate
need
confront
method
pharmacist
particip
committe
antibiot
infecti
diseas
control
implement
mean
direct
intervent
educ
routin
evalu
improv
util
antibiot
inform
technolog
set
screen
secondlin
antibiot
prescript
also
provid
realtim
recommend
poor
renal
function
patient
dose
adjust
consumpt
antibiot
count
defin
daili
dose
ddd
resist
rate
report
evalu
everi
month
everi
half
year
background
prevent
increas
antibiot
resist
among
microb
antibiot
stewardship
program
asp
perform
outpati
clinic
opd
ward
surgic
prophylaxi
emerg
depart
ed
includ
howev
empir
antibiot
often
prescrib
patient
ed
stay
previou
public
address
initi
prescript
appli
ed
often
continu
ward
result
compar
differ
initi
antibiot
regimen
ed
ward
evalu
whether
empir
antibiot
continu
ward
method
conduct
retrospect
review
medic
record
within
march
may
record
belong
patient
age
less
patient
admit
without
antibiot
part
treatment
exclud
initi
antibiot
prescrib
ed
grade
medic
staff
prescrib
antibiot
ward
initi
antibiot
use
ward
record
made
judgement
consist
deescal
escal
antibiot
comparison
initi
antibiot
ed
ward
ibm
spss
version
use
statist
softwar
result
studi
period
medic
record
includ
review
medic
staff
prescrib
initi
antibiot
ward
consist
postgrad
year
one
resid
first
fifth
year
nurs
specialist
np
made
prescript
guidanc
visit
staff
proport
respect
among
antibiot
prescrib
ward
proport
consist
escal
deescal
comparison
ed
respect
consider
grade
staff
ward
appli
antibiot
ed
np
antibiot
order
significantli
high
coher
rate
ed
p
comparison
np
conclus
antibiot
prescrib
ed
medic
continu
ward
around
junior
doctor
result
implant
asp
ed
import
evalu
broadspectrum
antibiot
prescript
tunisian
infecti
diseas
depart
adnen
toumi
ikbel
kooli
abir
aouam
hajer
ben
brahim
chawki
loussaief
moham
chakroun
depart
infecti
diseas
ur
monastir
univers
hospit
tunisia
background
emerg
bacteri
resist
public
health
problem
lead
broadspectrum
antibiot
prescript
consequ
particular
attent
must
paid
broadspectrum
antibiot
prescript
order
preserv
effect
hospit
recommend
exist
broadspectrum
antibiot
use
aim
studi
describ
modal
broad
spectrum
antibiot
prescript
infecti
diseas
depart
confront
guidelin
method
carri
profession
practic
evalu
assess
broadspectrum
antibiot
prescript
made
infecti
diseas
depart
fattouma
bourguiba
teach
hospit
monastir
tunisia
januari
decemb
evalu
broadspectrum
antibiot
imipenem
ertapenem
fluoroquinolon
aminoglycosid
tigecyclin
colimycin
evalu
done
two
infecti
diseas
specialist
base
nation
intern
guidelin
result
nineti
eight
prescript
includ
patient
mean
age
year
year
sex
ratio
broadspectrum
antibiot
mostli
use
skin
infect
case
urinari
tract
infect
case
commun
acquir
infect
case
nosocomi
infect
case
antibiot
combin
use
case
broadspectrum
antibiot
first
line
prescrib
prescript
document
case
extendedspectrum
betalactamas
produc
escherichia
coli
isol
case
fluoroquinolon
use
case
imipenem
case
aminoglycosid
case
colimycin
case
tigecyclin
case
ertapenem
case
broadspectrum
antibiot
usag
judg
adequ
case
otherwis
antibiot
durat
adequ
case
posolog
case
use
antibiot
combin
case
twentysix
case
initi
prescript
seem
adapt
identifi
bacteria
conclus
depart
global
evalu
show
third
prescript
inadequ
moreov
broadspectrum
antibiot
prescrib
communityacquir
infect
case
order
improv
qualiti
broadspectrum
prescript
standard
protocol
must
implement
supervis
antibiot
stewardship
team
studi
evalu
stabil
daptomycin
serum
variou
temperatur
method
daptomycin
serum
sampl
prepar
store
longterm
refriger
freezer
well
assum
bodi
temperatur
stabil
daptomycin
variou
condit
evalu
repeatedli
measur
concentr
result
although
decreas
daptomycin
concentr
serum
sampl
store
freezer
less
day
month
concentr
sampl
store
refriger
decreas
period
furthermor
daptomycin
concentr
serum
sampl
store
close
bodi
temperatur
decreas
h
figur
rate
daptomycin
elimin
serum
sampl
increas
rise
temperatur
especi
condit
assum
live
bodi
result
present
studi
demonstr
measur
serum
concentr
daptomycin
need
perform
rapidli
sampl
collect
patient
store
freezer
analysi
close
bodi
temperatur
daptomycin
unstabl
stabil
affect
variat
temperatur
daptomycin
elimin
live
bodi
pharmacokinet
may
affect
instabl
serum
hsinwen
ko
weijen
chen
shuwen
lin
depart
pharmaci
nation
taiwan
univers
hospit
graduat
institut
clinic
pharmaci
nation
taiwan
univers
background
therapeut
rang
pharmacokinet
pk
properti
vancomycin
address
mani
research
ensur
optim
antibacteri
efficaci
avoid
potenti
toxic
variou
dose
method
develop
nonobes
patient
howev
avail
inform
scant
come
obes
patient
studi
aim
analyz
data
medic
center
order
improv
current
dose
method
obes
patient
method
hospit
vancomycin
dose
calcul
base
bauer
method
built
assist
pharmacist
dose
vancomycin
essenti
inform
includ
patient
profil
predict
pk
paramet
measur
concentr
document
fix
format
retrospect
collect
record
jan
may
definit
obes
bodi
mass
index
adult
year
old
least
measur
steadi
state
trough
level
includ
treatment
period
patient
acut
kidney
injuri
serum
creatinin
mgdl
dialysi
concomit
use
mannitol
miss
data
exclud
measur
perform
dose
calcul
obes
patient
percentag
patient
whose
predict
ctrough
within
mgl
measur
ctrough
calcul
result
overal
obes
patient
includ
sixtytwo
percent
obes
patient
whose
trough
concentr
fell
rang
mgl
initi
dose
mean
dose
per
kg
achiev
level
significantli
lower
obes
patient
mgkg
mgkg
compar
differ
predict
measur
concentr
obes
patient
predict
concentr
within
mgl
measur
concentr
predict
concentr
within
mgl
measur
concentr
conclus
lower
dose
per
kg
need
achiev
therapeut
rang
obes
patient
may
impli
pk
chang
vancomycin
clearanc
nt
correl
linearli
total
bodi
weight
therefor
empir
give
guidelin
recommend
initi
dose
mgkgday
lower
daili
dose
per
kg
might
consid
obes
patient
perform
calcul
obes
patient
well
compar
nonobes
patient
epiderm
lesion
due
toxidermia
case
drug
imput
establish
pharmacovigil
investig
allopurinol
n
salazopirin
n
carbamazepin
n
ceftazidim
n
ampicillin
n
meglumin
antimoni
n
cefotaxim
n
lamotrigin
n
discontinu
incrimin
drug
indic
case
good
progress
without
prescript
corticosteroid
therapi
conclus
studi
show
drug
reaction
eosinophilia
system
symptom
dress
syndrom
sever
rare
diseas
clinic
seem
autoimmunelik
reaction
corticotherapi
systemat
use
earli
diagnosi
allow
adequ
care
favor
outcom
effect
antimicrobi
antifung
human
drugmetabol
cytochrom
toshiro
niwa
school
pharmaci
shujitsu
univers
background
cytochrom
cyp
superfamili
enzym
catalyz
oxid
wide
varieti
endogen
exogen
chemic
although
subfamili
share
amino
acid
sequenc
ident
rather
distinct
substrat
specif
piperacillin
penicillinbas
antibiot
partial
metabol
predomin
form
express
human
liver
intestin
wherea
express
polymorph
azol
antifung
inhibit
cyp
includ
macrolidebas
antibiot
exhibit
mechanismbas
inhibit
howev
report
describ
effect
antimicrobi
antifung
human
drugmetabol
cyp
activ
method
express
recombin
escherichia
coli
bactosom
obtain
cypex
ltd
aminopyrin
ndemethyl
tolbutamid
hydroxyl
dopamin
format
ptyramin
testosteron
activ
determin
report
previous
result
inhibit
amoxicillin
ampicillin
piperacillin
mm
concentr
observ
howev
amoxicillin
piperacillin
inhibit
aminopyrin
ndemethyl
inhibitori
concentr
ic
mm
respect
predict
free
fraction
maximum
inflow
concentr
inhibitor
liver
calcul
report
pharmacokinet
paramet
much
lower
concentr
investig
studi
estim
ic
valu
although
fluconazol
itraconazol
voriconazol
concentr
neither
inhibit
stimul
aminopyrin
ndemethyl
activ
ketoconazol
miconazol
noncompetit
inhibit
aminopyrin
ndemethyl
inhibitori
constant
valu
respect
erythromycin
inhibit
testosteron
preincubationtimedepend
littl
influenc
metabol
activ
conclus
interact
three
penicillinbas
antibiot
drug
metabol
cyp
investig
would
clinic
signific
ketoconazol
miconazol
might
inhibit
addit
cyp
clinic
resist
gram
posit
pathogen
pneumonia
staphylococcu
aureu
enterococcu
use
assess
vitro
resist
develop
nemonoxacin
comparison
ciprofloxacin
levofloxacin
moxifloxacin
method
four
strain
bacteri
speci
includ
pneumonia
one
penicillin
resist
pneumonia
staphylococcu
aureu
one
methicillin
resist
aureu
enterococcu
faecium
one
vancomycin
resist
enterococcu
faecium
enterococcu
faecali
one
ampicillin
resist
enterococcu
faecali
isol
test
patient
specimen
clinic
isol
confirm
wildtyp
gyra
gyrb
parc
pare
invitro
test
stepwis
resist
select
conduct
mic
dna
sequenc
qrdr
gyras
topoisomeras
gene
perform
result
induc
vitro
antimicrobi
suscept
test
ciprofloxacin
levofloxacin
moxifloxacin
nemonoxacin
three
differ
strain
staphylococcua
auru
enterococcu
faecium
enterococcu
faecali
streptococcu
pneumonia
nemonoxacin
shown
lowest
mic
among
quinolon
exampl
mic
three
aureu
strain
ml
nemonoxacin
compar
moxifloxacin
levofloxacin
ciprofloxacin
respect
mic
induc
test
nemonoxacin
shown
low
resist
potenti
quinolon
exposur
mic
nemonoxacin
increas
aureu
e
faecium
e
feacali
increas
pneumonia
three
cycl
select
conclus
vitro
induc
antimicrobi
suscept
test
reveal
nemonoxacin
low
propens
select
resist
gram
posit
pathogen
compar
fluoroquinolon
chuchung
lin
hungchuan
chen
chiahui
wang
chiayn
chiang
taigen
biotechonolgi
co
ltd
taipei
taiwan
background
increas
multidrug
resist
seriou
gramneg
bacteri
pathogen
post
emerg
threat
public
health
novel
target
mechan
action
multidrug
resist
need
avoid
preexist
antibiot
resist
mechan
lipopolysaccharid
lp
major
compon
outer
membran
gramneg
bacteria
gnb
serv
permeabl
barrier
protect
bacterium
mani
antibiot
gnb
pseudomona
aeruginosa
member
enterobacteriacea
inabl
synthes
lp
bactericid
effect
thu
interfer
lp
assembl
small
molecul
inhibitor
would
result
antibacteri
activ
nacetylglucosamin
deacetylas
lpxc
encod
lpxc
essenti
enzym
control
first
commit
step
lp
biosynthesi
gramneg
bacteria
moreov
counterpart
enzym
human
method
computeraid
drug
design
ration
drug
design
taigen
discov
proprietari
seri
select
potent
lpxc
inhibitor
result
report
demonstr
novel
class
lpxc
inhibitor
show
good
equal
potenc
p
aeruginosa
k
pneumonia
e
coli
bacteri
growth
inhibit
assay
mic
ugml
reduc
lp
biosynthesi
lpxc
enzym
assay
ic
nm
significantli
conclus
novel
chemic
class
lpxc
inhibitor
provid
potenti
new
antibacteri
agent
treatment
gramneg
infect
vitro
kill
curv
tedizolid
linezolid
clinic
strain
isol
patient
china
wang
yun
li
yuan
lyu
feng
xue
jian
liu
wei
yang
jia
zhang
institut
clinic
pharmacolog
peke
univers
first
hospit
beij
china
background
tedizolid
novel
antibacteri
oxazolidinon
deriv
approv
oral
intraven
formul
treatment
acut
bacteri
skin
skin
structur
infect
gramposit
pathogen
includ
methicillinresist
staphylococcu
aureu
mrsa
certain
countri
studi
determin
vitro
kill
activ
tedizolid
linezolid
recent
clinic
strain
isol
patient
china
method
timekil
curv
gener
recent
clinic
isol
mrsa
penicillinresist
streptococcu
pneumonia
prsp
linezolidresist
enterococcu
faecali
lref
use
also
atcc
control
strain
bacteri
cultur
inocul
approxim
cfuml
grown
appropri
liquid
medium
hour
tedizolid
linezolid
ad
cultur
baselin
clinic
relev
concentr
base
upon
standard
dosag
human
mg
oncedaili
mg
twicedaili
respect
also
base
upon
recent
minimum
inhibitori
concentr
mic
data
sampl
remov
fix
time
point
plate
onto
standard
cultur
medium
incub
hour
curv
plot
use
coloni
count
method
base
clsi
guidelin
result
key
data
display
tabl
control
clinic
strain
suscept
drug
except
linezolidresist
e
faecali
clinic
strain
mic
tedizolid
linezolid
display
notabl
bactericid
effect
prsp
bacteriostat
inhibitori
effect
mrsa
clinic
relev
concentr
lref
drug
exert
inhibitori
effect
independ
concentr
conclus
tedizolid
exert
greater
bactericid
effect
linezolid
streptococc
speci
vitro
exert
bacteriostat
mrsa
lref
background
last
decad
colistin
polymyxin
e
use
last
line
defens
infect
caus
multidrug
resist
pathogen
unfortun
reus
drug
obvious
follow
emerg
colistin
resist
mediat
chromosom
gene
mutat
pmra
pmrb
phopphoq
ccraccrb
lpxa
lpxc
lpxd
mgrb
mutat
induc
complex
gene
regul
cascad
lead
synthesi
addit
lipid
membran
induc
therefor
colistin
resist
howev
describ
first
time
plasmidmedi
colistin
resist
gene
nowaday
worldwid
dissemin
report
use
phylogeni
approach
investig
gene
origin
method
describ
plasmid
collect
ncbi
databas
plasmid
type
perform
plasmidfind
databas
size
gc
content
estim
use
infoseq
homolog
sequenc
collect
blastp
analysi
phylogenet
analysi
perform
use
maft
fasttre
rhizom
analysi
perform
segment
latter
fragment
amino
acid
phylogenet
analysi
fragment
conduct
result
compar
genom
plasmid
reveal
wide
divers
latter
compos
differ
incompat
plasmid
group
plasmid
distinguish
three
group
accord
size
rang
gc
content
rang
identifi
sever
enterobacteriacea
gramneg
bacteria
gene
share
plasmid
locat
transposon
gc
compos
insert
sequenc
sulfatas
encod
gene
blastp
analysi
reveal
total
homolog
sequenc
phylogenet
analysi
sequenc
reveal
huge
number
phosphoethanolamin
transferas
within
campylobact
genu
moreov
analysi
reveal
close
relat
homolog
sequenc
identifi
moraxella
speci
high
similar
find
confirm
rhizom
analysi
clearli
show
latter
chimer
sequenc
moraxella
catarrhali
moraxella
pluranimalium
psychrobact
urativoran
part
gene
pluranimalium
conclus
gene
dissemin
transmit
transposon
campylobact
could
potenti
sourc
new
phosphoethanolamin
transferas
gene
origin
gene
moraxella
genu
especi
pluranimalium
identif
molecular
support
intrins
resist
colistin
proteu
vulgari
genom
compar
approach
vitro
test
sophi
baron
jean
marc
rolain
background
sever
year
face
colistin
use
last
line
antimicrobi
drug
treatment
multidrug
resist
gram
neg
bacteria
infect
unfortun
renew
interest
antimicrobi
peptid
led
emerg
acquir
resist
especi
enterobacteriacea
also
increas
infect
due
intrins
colistinresist
bacteria
mechan
resist
colistin
complex
misunderstood
particularli
bacteria
proteu
bacteria
natur
resist
colistin
surpris
recent
isol
p
vulgari
clinic
strain
suscept
colistin
propos
work
understand
molecular
support
colistin
resist
speci
compar
genom
phenotyp
approach
method
genom
p
vulgari
suscept
strain
csur
resist
one
csur
sequenc
compar
select
group
interest
gene
absent
truncat
mutat
suscept
strain
among
group
mutat
gene
select
alreadi
known
put
involv
antimicrobi
peptid
resist
realiz
sift
score
predict
probabl
mutat
could
alter
protein
function
use
electron
microscopi
lipid
analysi
mass
spectrometri
lipid
extract
help
us
understand
pathway
involv
colistin
susceptibilityresist
result
genom
csur
mb
length
gc
content
wherea
csur
genom
mb
contain
numer
resist
gene
particularli
aminosid
fluoroquinolon
cotrimoxazol
carri
variou
plasmid
found
signific
differ
outer
membran
glycosid
structur
suscept
resist
strain
corrobor
malditof
analysi
show
absenc
outer
membran
lipid
moieti
suscept
strain
compar
genom
analysi
other
resist
strain
proteu
vulgari
avail
local
databas
found
mutat
arnbcadtef
operon
studi
suscept
strain
transcriptom
analysi
gene
belong
arnbcadtef
operon
show
signific
decreas
mrna
express
level
test
gene
suscept
strain
support
addit
outer
membran
lipid
moieti
explain
increas
colistin
suscept
final
insert
arnd
gene
suscept
strain
led
fold
increas
colistin
mic
show
role
gene
proteu
vulgari
colistin
resist
conclus
show
arnd
gene
arn
operon
mutat
suscept
p
vulgari
known
sugar
fixat
lipid
key
pathway
polymyxin
resist
howev
certainli
one
lot
enigma
colistin
resist
remain
gene
absent
suscept
strain
could
link
colistin
resist
includ
whole
operon
involv
sialic
acid
metabol
current
develop
knockout
techniqu
studi
differ
hypothet
target
discov
new
pathway
involv
colistin
resist
bacteri
defens
system
antimicrobi
peptid
coexist
long
time
mechan
resist
colistin
complex
impli
lot
gene
first
report
describ
genom
differ
particular
suscept
strain
typic
p
vulgari
open
new
research
pathway
understand
colistin
resist
bunkyo
gakuin
univers
graduat
school
bunkyo
gakuin
univers
background
pseudomona
aeruginosa
p
aeruginosa
common
caus
chronic
airway
infect
patient
pulmonari
disord
diffus
panbronchiol
dpb
cystic
fibrosi
cf
dpb
cf
poor
prognosi
longterm
lowdos
macrolid
treatment
markedli
increas
surviv
rate
patient
dpb
consequ
research
interest
use
macrolid
erythromycin
clarithromycin
includ
antipseudomon
therapeut
weapon
absenc
bactericid
bacteriostat
activ
previou
studi
demonstr
macrolid
influenc
p
aeruginosa
virul
howev
studi
evalu
regulatori
effect
macrolid
p
aeruginosa
virul
factor
treatment
short
period
hour
studi
subcultur
p
aeruginosa
two
year
presenc
lowdos
macrolid
evalu
virul
factor
total
proteas
elastas
pyocyanin
addit
effect
macrolid
exposur
strain
cell
investig
method
p
aeruginosa
repeatedli
subcultur
time
two
year
muellerhinton
agar
contain
erythromycin
clarithromycin
macrolid
concentr
determin
referenc
maximum
drug
concentr
cmax
time
oral
administr
strain
subcultur
presenc
lowdos
macrolid
frozen
month
interv
macrolid
exposur
strain
use
examin
timedepend
chang
total
proteas
elastas
pyocyanin
cell
surviv
rate
result
product
virul
factor
gradual
decreas
macrolid
exposur
elasetas
pyocyanin
maxim
affect
month
also
period
macrolid
exposur
p
aeruginosa
increas
death
cell
bacteri
supernat
ad
decreas
surviv
rate
increas
conclus
show
three
virul
factor
gradual
inhibit
macrolid
cytotox
declin
macrolid
exposur
period
bacteria
becom
longer
find
exhibit
longterm
lowdos
macrolid
exposur
may
gradual
reduc
pathogen
p
aeruginosa
via
timedepend
inhibit
virul
factor
suggest
longterm
lowdos
macrolid
treatment
chronic
airway
infect
administ
least
month
achiev
optim
effect
p
aeruginosa
isol
associ
carbapenem
treatment
esblandor
ampcproduc
bacteri
infect
one
mechan
insert
outer
membran
protein
gene
variou
insert
sequenc
investig
effect
differ
carbapenem
develop
carbapenem
resist
associ
mutat
carbapenemsucept
esbl
nonesbl
produc
k
pneumonia
method
carbapenemsusceptible
isol
includ
esblproduc
isol
nonesblproduc
isol
incub
ertapenem
etp
imipenem
imp
meropenem
mem
induividu
concentr
h
isol
inhibit
zone
etp
ipm
mem
collect
analysi
insert
sequenc
type
an
carbapenem
resist
result
higher
carbapenem
concentr
x
stimul
resist
isol
esbl
nonesbl
produc
isol
high
concentr
mem
etp
treatment
induc
resist
carbapenem
esbl
produc
isol
etp
treatment
develop
resist
etp
nonesbl
produc
isol
among
select
esbl
isol
induc
carbapenem
insert
sequenc
found
mostli
isol
normal
pcr
size
gene
demonstr
carbapenem
resist
suggest
involv
mehcan
carbapenem
resist
conclus
esbl
nonesbl
produc
isol
could
develop
carbapenem
resist
associ
carbapenem
type
mutat
novel
aminoglycosid
evad
bacteri
resist
mechan
dev
p
arya
clemson
univers
background
aminoglycosid
inhibit
bacteri
growth
bind
asit
decod
region
bacteri
ribosom
rna
rrna
within
ribosom
subunit
previou
work
shown
approxim
fivefold
differ
affin
neomycin
human
asit
model
e
coli
model
methodolog
synthes
screen
ribosom
bindingselect
bacteri
growth
inhibit
rapid
analysi
data
provid
systemat
method
identif
bacteri
ribosom
specif
antibacteri
evad
bacteri
resist
pathway
method
develop
rapid
synthet
screen
method
rapidli
identifi
compound
discrimin
two
model
rrna
structur
result
novel
potent
aminoglycosid
show
high
select
bacteri
ribosom
mammalian
ribosom
identifi
conclus
approach
coupl
rapid
solid
phase
synthesi
peptid
aminosugar
identifi
activ
aminoglycosid
show
larg
differ
bind
affin
e
coli
asit
vs
human
asit
activ
efflux
pump
account
lowlevel
moxifloxacin
resist
mycobacterium
tuberculosi
isol
caus
urinari
tract
infect
xiangjun
chen
jungyien
chien
chongjen
yu
poren
hsueh
depart
laboratori
medicin
nation
taiwan
univers
hospit
nation
taiwan
univers
colleg
medicin
taipei
taiwan
depart
intern
medicin
nation
taiwan
univers
hospit
nation
taiwan
univers
colleg
medicin
taipei
taiwan
background
evalu
preval
mycobacterium
tuberculosi
isol
caus
urinari
tract
tuberculosi
utb
rate
resist
moxifloxacin
taiwan
method
patient
cultureconfirm
tb
nation
taiwan
univers
hospit
taiwan
period
patient
utb
includ
studi
isol
assess
mutat
gyra
gyrb
gene
minimum
inhibitori
concentr
mic
moxifloxacin
determin
presenc
absenc
efflux
pump
inhibitor
epi
includ
verapamil
reserpin
carbonyl
cyanid
respond
epi
defin
isol
show
least
reduct
mic
presenc
epi
result
studi
period
increas
trend
preval
utb
p
among
isol
resist
rifampicin
resist
isoniazid
resist
ofloxacin
resist
moxifloxacin
resist
streptomycin
among
isol
moxifloxacin
resist
lowlevel
resist
mic
mgl
patient
prior
exposur
fluoroquinolon
fq
like
nonexpos
patient
moxifloxacinresist
isol
vs
background
klebsiella
pneumonia
kp
member
famili
enterobacteriacea
pathogen
gramneg
bacterium
commonli
found
respiratori
intestin
tract
human
recent
year
multidrugresist
k
pneumonia
mdrkp
rapidli
increas
antibiot
overus
implic
varieti
nosocomi
infect
mdrkp
caus
problem
clinic
treatment
patient
refer
demonstr
antibodyimmun
respons
essenti
host
defens
bacteri
pathogen
studi
develop
monoclon
antibodi
treatment
mdrkp
dcb
human
singl
b
cell
antibodi
discoveri
platform
allow
screen
singl
cell
rapidli
isol
sequenc
fifti
antibodi
known
bind
specif
function
properti
method
fulli
human
monoclon
antibodi
singl
peripher
blood
b
cell
use
k
pneumonia
kp
sort
model
establish
platform
technolog
obtain
human
mab
kp
directli
singl
human
plasma
memori
b
cell
clone
vh
vl
variabl
region
peripher
blood
mononuclear
cell
isol
human
whole
blood
kpspecif
singl
memori
b
cell
sort
pcr
plate
fluorescenceactiv
cell
sorter
antibodi
gene
singl
cell
amplifi
rtpcr
express
freestyl
express
system
opsonophagocyt
kill
assay
opk
assay
target
k
pneumonia
grown
tsb
cell
differenti
dmf
n
ndimethylformamid
opk
assay
contain
cfu
bacteria
antibodi
differenti
cell
complement
reaction
plate
tsa
plate
incub
overnight
count
coloni
analyz
data
conclus
demonstr
establish
platform
gener
panel
human
monoclon
antibodi
human
pbmc
twentyf
antibodi
clone
select
high
affin
k
pneumonia
singl
b
cell
technolog
averag
kd
valu
vitro
opsonophagocyt
assay
demonstr
twenti
antikp
antibodi
increas
antibodymedi
phagocytosi
k
pneumonia
result
suggest
select
antibodi
potenti
lead
drug
test
k
pneumonia
infect
anim
model
recombin
ab
might
play
crucial
role
treatment
mdrkp
infect
background
rapid
emerg
multidrug
resist
mdr
bacteri
strain
global
public
health
challeng
acceler
overus
misus
antibiot
urgent
demand
antimicrobi
agent
effect
super
bug
natur
chemoprevent
compound
isothiocyan
itc
wide
found
crucifer
veget
shown
possess
cancer
chemoprevent
efficaci
antioxid
properti
immunomodulatori
activ
itc
allyl
isothiocyan
benzyl
isothiocyan
reveal
bactericid
unidentifi
mechan
previou
studi
indic
sulforaphan
isothiocyan
significantli
reduc
growth
staphylococcu
aureu
escherichia
coli
vibrio
vulnificu
though
itc
effect
bacteria
kill
applic
itc
mdr
bacteria
still
unknown
aim
evalu
applic
itc
mdr
e
coli
method
antibacteri
activ
itc
mdr
e
coli
assess
minim
inhibitori
concentr
mic
assay
growth
inhibit
assay
bacteria
surviv
rate
evalu
plate
count
calcul
percentag
control
group
experi
done
triplic
result
present
mean
analyz
student
ttest
result
mic
benzyl
isothiocyan
sulforaphan
mdr
e
coli
mm
respect
mdr
e
coli
effect
kill
bitc
within
bitc
treatment
also
inhibit
mdr
e
coli
growth
inhibit
could
revers
ad
thiol
reduc
agent
includ
nacetyl
cystein
nac
lglutathion
gsh
dithiothreitol
dtt
cultur
medium
background
econom
pressur
legal
constraint
increasingli
forc
hospit
pharmaci
purchas
gener
drug
rather
origin
brand
product
yet
differ
key
properti
note
supplier
antibiot
denomin
inn
even
approv
local
health
author
rais
concern
among
clinician
drug
qualiti
deal
patient
critic
condit
intens
care
unit
eas
prepar
efficaci
stabil
prescrib
antibiot
paramount
import
method
compar
rate
dissolut
experienc
nurs
ii
color
spectrophotometri
degrad
lcmsm
ward
storag
origin
meropenem
meronem
astrazeneca
vs
gener
meropenem
author
belgium
franc
andor
spain
sandoz
hospira
freseniuskabi
aurovit
sampl
prepar
follow
manufactur
recommend
expos
fix
temperatur
h
result
summari
key
result
present
tabl
product
mimick
administr
motoractiv
pump
extend
continu
administr
intens
care
unit
severelyil
patient
drug
dissolv
nacl
background
suggest
suscept
result
cephalosporin
report
accord
minimum
inhibitori
concentr
mic
regardless
whether
isol
produc
extendedspectrum
esbl
revis
breakpoint
mic
defin
suscept
cefotaxim
mgl
might
surrog
esbl
detect
cefotaximeresist
enterobacteriacea
challeng
organ
littl
treatment
option
carbapenem
imipenem
ertapenem
meropenem
frequent
use
emerg
carbapenem
resist
enterobacteriacea
concern
issu
may
hinder
use
carbapenem
although
cephamycin
flomoxef
effect
cefotaximeresist
enterobacteriacea
vitro
clinic
data
demonstr
effect
bloodstream
infect
bsi
caus
organ
method
perform
retrospect
observ
studi
adult
bsi
caus
flomoxefsuscept
cefotaximeresist
enterobacteriacea
investig
efficaci
flomoxef
compar
ertapenem
outcom
assess
evalu
propens
scorebas
match
logist
regress
analysi
result
demograph
clinic
characterist
adult
bsi
caus
flomoxefsuscept
cefotaximeresist
enterobacteriacea
treat
flomoxef
n
ertapenem
n
compar
crude
mortal
day
found
patient
adjust
multivari
model
patient
sever
sepsi
adjust
ci
p
high
bsi
mortal
score
adjust
ci
p
ultim
rapid
fatal
comorbid
adjust
ci
p
pneumonia
adjust
ci
p
independ
associ
mortal
propens
score
patient
flomoxef
therapi
match
treat
ertapenem
therapi
ratio
signific
differ
term
bsi
sever
comorbid
bsi
sourc
group
moreov
crude
mortal
rate
day
vs
p
differ
significantli
howev
length
hospit
stay
shorter
ertapenem
group
vs
day
p
conclus
ertapenem
therapi
associ
shorter
time
hospit
flomoxef
therapi
follow
flomoxefsusceptibil
cefotaximeresist
enterobacteriacea
bsi
adult
patient
guard
prognosi
p
lower
mortal
p
compar
initi
daptomycin
group
propens
score
age
pittsburgh
bacteremia
score
patient
initi
high
mainten
teicoplanin
dosag
group
match
initi
daptomycin
group
ratio
differ
signific
overal
mortal
rate
two
group
p
howev
kaplanmei
curv
mortal
revel
patient
initi
high
mainten
teicoplanin
dosag
group
better
surviv
initi
daptomycin
group
p
conclus
propens
score
match
age
patient
sever
clincal
outcom
initi
high
mainten
teicoplanin
dosag
group
inferior
initi
daptomycin
treatment
group
year
old
antibiot
initi
baselin
serum
creatinin
scr
measur
within
hour
antibiot
initi
receiv
minimum
one
dose
pt
v
within
hour
either
pt
v
initi
concurr
one
agent
initi
first
follow
addit
anoth
exclus
criteria
patient
exclud
medic
record
incomplet
receiv
dialysi
histori
chronic
kidney
diseas
ckd
stage
iv
higher
recent
histori
acut
kidney
injuri
defin
increas
scr
mgdl
greater
increas
scr
dl
greater
ckd
data
collect
medic
record
review
collect
demograph
data
antibiot
use
scr
concentr
comorbid
condit
concomit
nephrotox
agent
event
nephrotox
manag
outcom
record
primari
secondari
endpoint
primari
endpoint
incid
nephrotox
defin
increas
baselin
scr
concentr
increas
baselin
scr
mgdl
nephrotox
base
rifl
classif
focus
chang
scr
secondari
endpoint
associ
nephrotox
potenti
confound
factor
may
increas
risk
nephrotox
statist
analysi
baselin
demograph
clinic
characterist
present
mean
standard
deviat
sd
median
interquartil
rang
iqr
continu
variabl
frequenc
proport
categor
variabl
secondari
endpoint
assess
univari
analysi
chisquarefish
exact
simpl
logist
regress
attempt
result
patient
screen
elig
patient
exclud
studi
final
studi
sampl
includ
patient
patient
visit
record
incid
rate
nephrotox
nephrotox
group
margin
signific
lower
baselin
scr
pt
v
initi
mean
vs
p
nephrotox
group
higher
mortal
nonnephrotox
group
death
rate
vs
p
conclus
nephrotox
incid
rate
figur
abstract
ps
abstract
icc
intern
journal
antimicrobi
agent
background
tissu
stroma
known
import
regul
hpmediat
inflamm
molecular
basi
interact
hp
potenti
crosstalk
dendrit
cell
dc
remain
determin
end
potenti
crosstalk
h
pylori
hp
infect
gastric
stromal
cell
hpgsc
dc
investig
method
express
indic
activ
dc
cell
respect
evalu
primari
experiment
readout
primari
gsc
cancer
adjac
normal
tissu
gener
gastric
cancer
patient
monocytederiv
dc
obtain
healthi
individu
level
cytokin
prostaglandin
e
pge
measur
elisa
ctype
lectin
express
gsc
assess
flow
cytometri
immunohistochemistri
result
transwel
cocultur
system
significantli
upregul
dcderiv
express
found
dc
cocultur
hpinfect
gsc
hpgsc
pge
hpgsc
discov
possess
prime
effect
could
inhibit
collectin
subfamili
member
block
ab
knockdown
futb
strain
hp
use
also
express
coloc
stromal
cell
cancer
tissu
furthermor
hpgscscondit
dc
abl
induc
express
cell
could
inhibit
ab
conclus
result
suggest
import
receptor
involv
hpstromal
cell
interact
subsequ
condit
effect
dc
cellulos
releas
cellobios
either
nonreduc
reduc
end
hydrolyz
cellobios
glucos
method
glucanas
gene
cbh
thermophil
bacterium
thermotoga
maritima
atcc
dna
place
control
promotor
plasmid
bp
integr
genom
escherichia
coli
transform
high
enzymat
activ
strain
select
design
e
coli
cultiv
shake
flask
iptg
induct
differ
concentr
time
sdspolyacrylamid
gel
electrophoresi
assay
cell
bound
supernat
reveal
singl
band
kda
moreov
recombin
e
coli
manifest
possess
abil
carboxymethyl
cellulos
util
carbon
sourc
result
cbh
improv
catalyt
kinet
characterist
matter
utmost
import
withstand
current
robust
industri
environ
recombin
cellobiohydrolas
produc
e
coli
exhibit
maximum
activ
ph
temperatur
indic
thermophil
acid
glucanas
worthi
denim
biofinishingwash
research
carri
appropri
medium
batch
ferment
conclus
iptg
induct
magnifi
glucanas
activ
iuml
glucanas
secret
recombin
e
coli
repres
appeal
potenti
research
textil
industri
applic
effect
post
translat
phosphoryl
halophil
methanoarcha
molecular
chaperon
dnak
atpas
substrat
protein
refold
activ
weil
chen
shihshan
chen
shihwen
fang
meichin
lai
depart
life
scienc
nation
chung
hsing
univers
taichung
taiwan
roc
background
molecular
chaperon
play
import
role
assist
fold
assembl
nascent
polypeptid
prevent
protein
misfold
aggreg
damag
temperatur
ph
osmot
stress
dnak
belong
heat
shock
protein
molecular
chaperon
cooper
cochaperon
dnaj
nucleotid
exchang
factor
grpe
atp
requir
dnak
activ
remodel
substrat
client
protein
although
gener
recogn
molecular
chaperon
dnak
system
highli
conserv
within
three
domain
life
investig
molecular
chaperon
system
archaea
limit
gene
relat
molecular
chaperon
halophil
methanogen
methanohalophilu
portucalensi
analyz
dnak
dnaj
grpe
gene
induc
heat
salt
stress
moreov
phosphoproteom
analysi
strain
indic
four
phosphoryl
site
dnak
wu
et
al
method
phosphoryl
site
mpdnak
mutat
alanin
dephosphomim
state
also
aspart
acid
phosphomim
state
sitedirect
mutagenesi
method
pcr
overexpress
wild
type
mutant
mpdnak
induc
iptg
e
coli
ril
purifi
nickel
affin
chromatographi
atpas
activ
mpdnak
measur
colorimetr
assay
inorgan
phosphat
structur
model
mpdnak
construct
easi
model
highest
ident
speci
templat
result
atpas
kinet
assay
reveal
substrat
atp
hydrolyt
veloc
phosphomim
type
mpdnak
similar
wildtyp
suggest
phosphoryl
affect
atp
hydrolyt
activ
structur
model
analysi
reveal
phosphoryl
locat
lid
domain
mpdnak
relat
openclos
substrat
bind
pocket
initiatetermin
disaggreg
process
distanc
measur
within
wild
type
dephosphomim
phosphomim
substrat
bind
pocket
residu
show
phosphoryl
distanc
shortest
shorter
distanc
may
contribut
stabl
conform
lid
close
promot
effici
disaggreg
process
analyt
result
suggest
posttransl
phosphoryl
may
involv
regul
substrat
bind
disaggreg
conclus
phosphoryl
affect
atp
hydrolyt
activ
mpdnak
wherea
ptmphosphoryl
lid
promot
lidsubstr
bind
pocket
interact
may
enhanc
refold
activ
xuehua
ling
shangkwei
wang
changyih
duh
depart
marin
biotechnolog
resourc
nation
sun
yatsen
univers
kaohsiung
taiwan
depart
microbiolog
immunolog
kaohsiung
medic
univers
taiwan
background
therapeut
drug
bortezomib
carfilzomib
ixazomib
target
ubiquitinproteasom
system
up
licens
treat
multipl
myeloma
moreov
up
inhibitor
demonstr
attenu
progress
neural
degen
diseas
up
versatil
complex
compos
multipl
subunit
proteolyt
function
up
involvo
divers
import
biochem
pathway
cell
therapeut
prospect
up
inhibitor
promis
valuabl
aim
establish
highcont
imagebas
drug
screen
assay
direct
up
natur
compound
purif
formosan
soft
coral
distinct
structur
elucid
method
human
cytomegaloviru
interact
proteasom
regulatori
subunit
proteasom
cell
transientexpress
fusion
protein
exhibit
distinct
nuclear
aggresom
fluoresc
intens
phenotyp
behavior
use
marker
proteasom
inhbit
imag
acquisit
accomplish
use
imagexpress
micro
widefield
highcont
screen
system
molecular
devic
imagng
data
analyz
metaxpress
softwar
packag
proteasom
inhibitor
bortezomib
clastolactacystin
use
paradigm
control
valid
screen
efficaci
result
phenotyp
behavior
intens
profil
respons
treatment
three
known
proteasom
inhibitor
dosedepend
manner
cellbas
highcont
screen
system
establish
employ
search
proteasom
inhibitor
marin
natur
product
one
hundr
forti
structur
elucid
natur
product
assess
among
three
group
structur
disctinct
group
purifi
formosan
soft
coral
shown
inhibitori
activ
proteasom
conclus
establish
effici
highcont
system
screen
up
inhibitor
wast
water
taiwan
area
small
littl
arabl
land
use
land
subject
heavi
metal
pollut
water
irrig
accumul
soil
residu
heavi
metal
soil
result
reduc
area
cultiv
land
main
assess
p
chrysosporium
treat
heavi
metal
abil
experi
use
sdb
basic
medium
carbon
sourc
respect
sawdust
starch
ad
calcium
sulfat
g
calcium
carbon
g
medium
best
toler
test
white
rot
fungi
also
studi
influenc
remov
heavi
metal
differ
ph
cultur
period
calcium
ion
anion
common
metal
experi
ad
calcium
test
calcium
ion
liquid
cultur
promot
degrad
white
rot
fungu
heavi
metal
especi
copper
ion
lead
ion
copper
ion
degrad
concentr
ppm
ppm
lead
ion
degrad
concentr
ppm
ppm
explor
degrad
abil
zinc
copper
mercuri
lead
good
result
zinc
ion
zinc
copper
except
ion
mix
solut
zinc
ion
degrad
strain
experi
starch
medium
sawdust
medium
provid
nutrient
prompt
white
rot
fungi
produc
catalas
may
advers
strain
secret
peroxid
dismutas
help
resist
advers
sawdust
medium
although
activ
sod
sawdust
medium
low
degrad
rate
better
could
buffer
ph
valu
polar
acid
stabl
sustain
suppli
nutrient
bacteri
genotoxin
enhanc
radiosensit
cancer
stem
cell
regul
autophagi
yuan
chen
yu
chen
chihho
lai
background
cytoleth
distend
toxin
cdt
produc
campylobact
jejuni
genotoxin
induc
cell
cycl
arrest
apoptosi
mammalian
cell
recent
report
cdt
overcom
radioresist
prostat
cancer
pca
cell
interven
repair
radiationinduc
doublestrand
break
dsb
howev
detail
mechan
underli
effect
cdt
radioresist
pca
cell
requir
investig
method
recombin
c
jejuni
cdt
subunit
clone
purifi
subject
function
analysi
cdt
impair
radiationinduc
autophagi
flux
investig
use
immunofluoresc
microscopi
molecular
mechan
underli
cdt
regul
autophagi
enhanc
radiosensit
pca
cell
explor
result
result
demonstr
c
jejuni
cdt
suppress
irinduc
autophagi
pathway
pca
cell
attenu
cmyc
express
therefor
sensit
pca
cell
radiat
show
cdt
prevent
format
autophagosom
via
decreas
highmobl
group
box
express
inhibit
acid
vesicular
organel
avo
format
associ
enhanc
radiosensit
pca
cell
conclus
find
reveal
c
jejuni
cdt
inhibit
cmyc
reduc
result
prolong
irinduc
dsb
impair
autophagi
thu
convert
radioresist
radiosensit
pca
cell
shihwen
cheng
yutz
horng
pochi
soo
depart
laboratori
medicin
biotechnolog
tzuchi
univers
hualien
taiwan
background
klebsiella
pneumonia
import
opportunist
pathogen
nosocomi
infect
usual
caus
urinari
tract
infect
pneumonia
pyogen
liver
abscess
pla
human
k
pneumonia
produc
mani
virul
factor
contribut
pathogen
human
bacteri
biofilm
repres
key
virul
determin
promot
bacteri
persist
resist
antibiot
abil
bacteri
adher
biotic
abiot
substrat
essenti
step
biofilm
format
adher
mediat
bacteri
fimbria
also
import
virul
factor
mani
bacteria
enterobacteria
cyclic
amp
camp
receptor
protein
crp
play
vital
role
global
regul
crp
protein
regul
sever
essenti
bacteri
virul
gene
express
includ
fimbria
biofilm
format
respons
intracellular
concentr
camp
report
crpcamp
complex
regul
type
fimbriat
escherichia
coli
method
use
system
perform
target
gene
knockout
transgen
intergr
homolog
recombin
hr
use
suitabl
donor
sequenc
result
conclus
preliminari
data
indic
gene
encod
eiia
homolog
upregul
biofilm
format
thu
purpos
clarifi
crpcamp
complex
mediat
biofilm
format
lossoffunct
mutagenesi
import
tool
character
gene
function
crispr
cluster
regularli
interspac
short
palindrom
repeat
crisprassoci
protein
system
emerg
effici
precis
gene
edit
tool
target
mutagenesi
microorgan
recent
year
present
studi
show
design
crp
mutant
klebsiella
pneumonia
use
system
follow
evalu
efficaci
crispr
system
k
pneumonia
genom
edit
examin
import
crp
k
pneumonia
ps
type
vi
secret
system
proteu
mirabili
yihwa
chou
zhongt
chiu
yilin
tsai
shwujen
liaw
depart
graduat
institut
clinic
laboratori
scienc
medic
biotechnolog
colleg
medicin
nation
taiwan
univers
taipei
taiwan
background
proteu
mirabili
common
human
pathogen
caus
urinari
tract
infect
uti
especi
patient
indwel
urinari
cathet
mani
regulatori
mechan
evolv
bacteria
adapt
chang
divers
environ
type
vi
secret
system
known
contribut
bacteri
pathogen
exert
toxic
effect
host
cell
compet
bacteri
speci
involv
broad
varieti
function
biofilm
format
stress
sens
larg
array
function
reflect
divers
regulatori
mechan
regul
p
mirabili
remain
unclear
recent
transcriptom
analysi
reveal
p
mirabili
regul
global
regul
crp
method
first
confirm
regul
crp
use
realtim
rtpcr
promot
report
assay
identifi
one
main
structur
operon
four
hcpvgrg
effector
operon
use
sequenc
specif
rt
pcr
investig
whether
crp
bind
directli
promot
region
use
dnasei
footprint
assi
overexpress
effector
toxin
perform
disclos
function
growth
predomin
test
kill
assay
use
observ
competit
wild
type
crp
mutant
contruct
vipab
encod
sheath
mutant
confirm
crpregul
kill
also
purifi
possibl
toxin
assess
function
kill
e
coli
result
crp
posit
regul
bind
directli
promot
region
also
posit
regul
express
effector
toxin
overexpress
effector
toxin
wildtyp
p
mirabili
result
kill
crp
mutant
e
coli
accordingli
growth
predomin
test
kill
assay
demonstr
p
mirabili
confer
growth
predomin
wildtyp
crp
mutant
e
coli
conclus
crp
posit
regul
express
p
mirabili
affect
kill
function
contribut
growth
predomin
crp
mutant
e
coli
suggest
p
mirabili
antibacteri
weapon
protect
mice
lpsinduc
endotoxemia
cecal
ligat
punctureinduc
polymicrobi
sepsi
borchyuan
su
han
huang
taiwen
lin
chwandeng
hsiao
jyhyih
chen
background
antimicrobi
peptid
epi
identifi
epinephelu
coioid
may
clinic
applic
treat
sepsi
epi
shown
amelior
antibioticresist
bacteriainduc
sepsi
mice
evalu
mixedflora
model
descript
protect
mechan
essenti
establish
peptid
potenti
therapeut
method
therefor
first
test
protect
effect
epi
polymicrobi
sepsisinduc
bactericid
infect
inflamm
lung
injuri
result
cecal
ligat
punctur
mice
furthermor
sinc
lipopolysaccharid
lp
key
induc
inflamm
bacteri
infect
sepsi
also
test
lpsantagon
activ
relat
mechan
epimedi
protect
mice
lpsinduc
endotoxemia
lpstreat
mous
macrophag
cell
result
epi
rescu
mice
polymicrobi
sepsi
endotoxemia
delay
administr
suppress
lung
system
inflammatori
respons
attenu
lung
injuri
diminish
bacteri
load
vitro
studi
reveal
epi
suppress
lpsinduc
inflammatori
cytokin
product
mechanist
epi
disrupt
interact
lp
lp
bind
protein
compet
lp
bind
cell
surfac
inhibit
tolllik
receptor
endocytosi
result
inhibit
lpsinduc
reactiv
oxygen
signal
subsequ
cytokin
product
conclus
overal
result
demonstr
epi
promis
therapeut
agent
endotoxemia
polymicrobi
sepsi
openlabel
random
compar
studi
evalu
efficaci
safeti
cefoperazonesulbactam
comparison
cefepim
treatment
hospit
acquir
pneumonia
healthcareassoci
pneumonia
fuder
wang
jienwei
liu
yenhsu
chen
wensen
lee
jungchung
lin
chingtai
huang
hsihsun
lin
yungch
liu
hungjen
tang
yaoshen
chen
wenchien
ko
minchi
lu
taipei
veteran
gener
hospit
kaohsiung
chang
gung
memori
hospit
kaohsiung
medic
univers
hospit
wan
fang
hospit
triservic
gener
hospit
chang
gung
memori
hospitallink
eda
hospit
shuang
ho
hospit
chi
mei
medic
center
kaohsiung
veteran
gener
hospit
nation
cheng
kung
univers
hospit
chung
hospit
background
compar
efficaci
safeti
cefoperazon
sulbactam
cefepim
treatment
hospit
acquir
pneumonia
hap
healthcareassoci
pneumonia
hcap
openlabel
random
phase
trial
randomli
assign
patient
age
year
older
hap
hcap
receiv
cefoperazonesulbactam
cefepim
primari
endpoint
compar
clinic
respons
cefoperazonesulbactam
cefepim
test
cure
toc
visit
evalu
within
day
last
dose
secondari
endpoint
overal
surviv
object
respons
patient
assess
intentiontotreat
itt
studi
period
subject
receiv
least
one
dose
studi
drug
includ
safeti
popul
monitor
safeti
issu
result
sep
aug
total
subject
hospit
screen
total
subject
includ
evalu
popul
clinic
respons
rate
toc
visit
cefoperazonesulbactam
group
cefepim
group
itt
popul
clinic
respons
rate
cefoperazonesulbactam
group
cefepim
group
noninferior
cefoperazonesulbactam
cefepim
demonstr
popul
noninferior
margin
pvalu
thirtyf
advers
event
judg
relat
studi
medic
statist
signific
differ
regard
advers
event
observ
two
group
conclus
studi
indic
combin
cefoperazonesulbactam
inferior
cefepim
use
treat
patient
haphcap
report
seriou
advers
event
relat
studi
drug
incid
advers
drug
reaction
low
therefor
cefoperazonesulbactam
everi
hour
toler
effect
treat
patient
haphcap
studi
risk
prognost
factor
invas
streptococcu
pneumonia
infect
hiroki
kurata
naoki
iwanaga
yosuk
nagayoshi
shinnosuk
takemoto
tadayoshi
oono
keiko
hisatomi
seiji
nagashima
depart
infecti
diseas
nation
hospit
organ
nagasaki
medic
center
depart
respiratori
medicin
nation
hospit
organ
nagasaki
medic
center
background
streptococcu
pneumonia
pneumococcu
frequent
isol
caus
pathogen
communityacquir
pneumonia
approxim
consid
invas
pneumococc
diseas
ipd
howev
report
influenc
risk
prognosi
factor
ipd
method
case
pneumococc
isol
two
set
blood
cultur
nagasaki
medic
center
april
march
design
ipd
compar
ipd
case
case
pneumococc
pneumonia
without
isol
blood
cultur
risk
prognost
factor
defin
pneumococc
pneumonia
pneumococci
isol
sputum
cultur
urin
antigen
test
posit
addit
respiratori
symptom
fever
cough
sputum
dyspnea
elev
inflammatori
respons
chest
abnorm
shadow
compar
studi
done
backwardli
underli
diseas
blood
test
quick
sequenti
organ
failur
assess
qsofa
score
antibiot
regimen
prognosi
result
pneumonia
rate
adult
ipd
mortal
rate
case
ipd
group
tendenc
select
broadspectrum
antimicrobi
initi
treatment
pneumococc
pneumonia
multivari
analysi
sever
independ
risk
factor
ipd
includ
malign
tumor
odd
ratio
confid
interv
ci
p
initi
qsofa
ci
p
associ
ipd
initi
qsofa
ci
p
also
elucid
prognost
factor
multivari
analysi
conclus
high
initi
qsofa
could
risk
prognost
factor
ipd
might
suspect
ipd
earlier
use
qsofa
lead
improv
prognosi
qsofa
extrem
easi
score
bedsid
background
anaerob
rare
caus
spinal
infect
constitut
less
case
method
report
present
case
parvimona
micra
gramposit
anaerob
coccu
spinal
infect
also
search
pubm
databas
use
term
spondylodisc
disciti
spondyl
osteomyel
spinal
vertebr
peptostreptococcu
micromona
parvimona
find
similar
case
english
literatur
clinic
inform
case
includ
extract
analyz
use
spss
softwar
result
total
addit
case
p
micra
spinal
infect
found
english
literatur
tabl
show
demograph
data
comorbid
outcom
patient
p
micra
spinal
infect
median
age
patient
year
half
patient
male
nearli
half
case
dental
problem
prior
histori
dental
work
back
pain
fever
common
symptom
median
durat
symptom
week
thorac
lumbar
vetebra
commli
involv
site
increas
valu
inflamm
marker
record
case
five
case
receiv
surgic
intervent
median
durat
antimicrobi
treatment
week
one
case
cure
without
clinic
relaps
abbrevi
iqrinterquartil
rang
includ
malais
anorexia
fever
headach
conclus
summari
p
micra
spinal
infect
consid
patient
medic
histori
dental
problem
work
acccompani
insidi
onset
backneck
pain
elev
inflamm
marker
acut
respiratori
distress
syndrom
associ
invas
pulmonari
aspergillosi
caus
influenza
viru
case
report
meiyu
su
wenliang
yu
chekim
tan
depart
intens
care
medicin
chimei
medic
center
tainan
citi
taiwan
background
invas
pulmonari
aspergillosi
ipa
sever
complic
influenza
report
taiwan
report
refractori
acut
respiratori
distress
syndrom
ard
due
aspergillu
pneumonia
patient
influenza
infect
method
man
type
diabet
mellitu
hypertens
old
cerebrovascular
accid
suffer
dyspnea
day
brought
emerg
depart
februari
laboratori
data
reveal
wbc
platelet
count
procalcitonin
ngml
lactat
mmolel
creatinin
mgdl
arteri
blood
ga
show
ph
pco
mmhg
po
mmhg
hco
mmoll
base
excess
mmoll
fio
pf
ratio
mmhg
real
time
pcr
flua
show
posit
antimicrobi
therapi
includ
oseltamivir
tamiflu
levofloxacin
piperacillintazobactam
cxr
show
diffus
mix
interstiti
alveolar
infiltr
bilater
lung
suspici
pneumonia
intub
admit
intens
care
unit
initi
hemodynam
support
fluid
resuscit
infus
vasopressor
administ
ard
occur
persist
hypoxemia
inhal
nitric
oxid
therapi
februari
aspergillu
antigen
index
high
intraven
voriconazol
use
februari
howev
spike
fever
note
sputum
cultur
yield
acinetobact
baumannii
eenterobact
aerogen
adjust
antibiot
therapi
imipenemcilastatin
teicoplanin
result
aggress
treatment
poor
prognosi
inform
famili
limit
medic
treatment
patient
critic
discharg
march
conclus
ipa
may
complic
influenza
pneumonia
previous
healthi
adult
earli
diagnosi
treatment
aspergillu
infect
complic
influenza
mandatori
high
mortal
given
rapid
symptomonset
deterior
clinician
must
vigil
promptli
diagnos
treat
influenzalik
ill
antibiot
bacteri
coinfect
antifung
therapi
consid
final
corticosteroid
patient
influenza
may
pose
risk
invas
fungal
infect
concurr
cytomegaloviru
coliti
aspergillu
pneumonia
patient
plasmacytoma
meiyu
su
wenliang
yu
chekim
tan
depart
intens
care
medicin
chimei
medic
center
tainan
citi
taiwan
background
cytomegaloviru
cmv
infect
gastrointestin
tract
commonli
affect
colon
follow
small
bowel
esophagu
clinic
present
larg
depend
digest
site
infect
hematemesi
occur
cmv
esophag
gastriti
duoden
report
lower
gastrointestin
bleed
caus
cmv
infect
patient
method
woman
histori
type
diabet
mellitu
right
femor
neck
plasmacytoma
patholog
fractur
post
bipolar
endoprothesi
septemb
suffer
dyspnea
two
day
brought
emerg
depart
march
laboratori
data
reveal
wbc
bandemia
platelet
count
creactiv
protein
mgl
procalcitonin
ngml
lactat
creatinin
mgdl
k
mmoll
cxr
show
consolid
bilater
lung
intub
done
desatur
transfer
intens
care
unit
piperacillintazobactam
levofloxacin
use
levoph
fluid
resuscit
given
initi
treatment
show
improv
bloodi
stool
note
colonoscopi
reveal
ulcer
ileocec
valv
proxim
colon
march
howev
bloodi
stool
persist
repeat
colonoscopi
show
lesion
dilut
bosmin
inject
hemoclip
colon
biopsi
show
ulcer
ileocec
valv
blood
cmvpcr
show
posit
cmv
viral
load
show
iuml
march
ganciclovir
given
bloodli
stool
improv
fever
hypotens
occur
cxr
showd
increas
infiltr
lung
right
side
shift
antibiot
piperacillin
tigecyclin
sputum
cultur
yield
proteu
mirabili
klebsiella
pneumonia
carbapenemresist
acinetobact
baumannii
result
unstabl
blood
pressur
abdomen
guard
note
left
decubitu
show
moder
free
air
liver
surfac
hollow
organ
perfor
periton
impress
profound
shock
requr
high
dose
vasopressor
discuss
surgeon
famili
inform
poor
prognosi
high
mortal
rate
famili
member
declin
surgeri
request
dnr
expir
march
later
blood
aspergillu
antigen
index
normal
conclus
cmv
diseas
major
caus
morbid
mortal
immunocompromis
patient
cmv
coliti
patient
plasmacytoma
quit
rare
challeng
broader
use
sensit
cmv
detect
method
certainli
bring
chanc
earli
diagnosi
infect
although
ganciclovir
result
symtomat
improv
blood
stool
hallow
organ
perfor
develop
suggest
colon
ulcer
perfor
concurr
aspergillu
pneumonia
unexpect
higher
mortal
sever
influenza
patient
probabl
aspergillosi
without
coinfect
wenliang
yu
depart
intens
care
medicin
chi
mei
medic
center
tainan
taiwan
depart
medicin
taipei
medic
univers
taipei
taiwan
background
aspergillusassoci
infect
might
compris
sever
influenza
patient
commun
throughout
stay
intens
care
unit
icu
taiwan
case
sever
influenza
aspergillosi
increasingli
report
therefor
describ
rel
risk
mortal
among
sever
influenza
patient
aspergillosi
coinfect
compar
sever
influenza
patient
without
aspergillu
coinfect
background
respiratori
infect
commonli
seen
clinic
herebi
report
young
male
diagnos
lemierr
syndrom
initi
present
sore
throat
dyspnea
method
previous
healthi
soldier
visit
emerg
room
er
sore
throat
dyspnea
fever
five
day
present
er
physic
examin
reveal
bilater
enlarg
tonsil
without
exud
right
lower
lung
crackl
rest
physic
find
otherwis
unremark
lab
show
neutropenia
metabol
acidosi
acut
kidney
injuri
chest
comput
tomographi
ct
without
contrast
show
right
lower
lung
consolid
suggest
pneumonia
thu
treat
intraven
moxifloxacin
empir
upon
admiss
result
despit
promptli
start
antibiot
intermitt
fever
progress
dyspnea
persist
blood
cultur
grew
anaerob
preliminari
report
hospit
day
shift
antibiot
intraven
imipenem
howev
dyspnea
fever
resolv
switch
imipenem
followup
ct
scan
hospit
day
show
worsen
bilater
pneumonia
final
blood
cultur
report
yield
fusobacterium
nucleatum
ambulatori
ultrasonographi
examin
persist
pain
right
neck
reveal
intravascular
mass
right
intern
jugular
vein
suggest
thrombosi
diagnosi
lemierr
syndrom
made
intub
hospit
day
ad
ampicillinsulbactam
addit
imipenem
neck
ct
scan
hospit
day
figur
clearli
demonstr
right
intern
jugular
vein
thrombosi
along
surround
fat
tissu
strand
right
intern
jugular
vein
ligat
perform
hospit
day
success
extub
surgeri
fever
transfer
gener
ward
hospit
day
deescal
antibiot
ampicillinsulbactam
subsequ
clinic
cours
smooth
patient
discharg
hospit
day
conclus
leimerr
syndrom
decreas
incid
describ
forgotten
syndrom
antibiot
advanc
young
patient
acut
pharyng
accompani
sign
septic
embol
lemierr
syndrom
alway
consid
background
mycoplasma
homini
well
known
caus
neonat
infect
report
pathogen
urogenit
infect
adult
howev
central
nervou
system
cn
infect
rare
report
first
case
homini
mening
china
post
neurosurg
treatment
intracerebr
haemorrhag
male
case
present
describ
develop
homini
mening
neurosurg
treatment
success
treat
combin
azithromycin
minocyclin
therapi
two
week
durat
despit
delay
treatment
gram
stain
cerebrospin
fluid
csf
yield
visibl
organ
diagnosi
requir
rdna
sequenc
analysi
cultur
isol
csf
literatur
review
homini
cn
infect
yield
case
instanc
brain
abscess
mening
delay
diagnosi
initi
treatment
failur
evid
case
appropri
microbiolog
test
antibiot
therapi
rang
day
week
often
multipl
surgic
intervent
almost
patient
improv
immedi
conclus
patient
find
literatur
review
highlight
pathogen
potenti
homini
togeth
challeng
prompt
rare
infecti
diseas
particular
develop
countri
lab
limit
diagnost
resourc
pulmonari
mucormycosi
kidney
transplant
recipi
yuan
chen
chiahui
chou
maowang
ho
background
fungi
order
mucoral
ubiquit
natur
rare
caus
human
infect
howev
rise
amount
immunocompromis
patient
incid
invas
fungal
infect
also
increas
one
case
report
pleural
empyema
relat
mucormycosi
date
report
first
case
taiwan
review
literatur
previou
report
method
man
histori
end
stage
diabet
nephropathi
present
hospit
day
receiv
kidney
transplant
complain
progress
dyspnea
pleurit
right
chest
pain
day
initi
laboratori
data
show
leukocytosi
wbc
cellsmicro
liter
chest
plain
film
show
right
side
illdefin
opac
pleural
effus
broadspectrum
antibiot
initi
clinic
improv
limit
pleural
effus
gram
stain
analysi
yield
mold
rhizopu
speci
result
pigtail
insert
pleural
effus
drainag
start
liposom
amphotericin
b
mold
rhizopu
speci
fever
subsid
respiratori
condit
also
improv
pigtail
remov
day
later
drainag
amount
decreas
ml
liposom
amphotericin
b
discontinu
day
therapi
shift
oral
posaconazol
mainten
current
patient
well
receiv
regular
followup
outpati
clinic
advanc
solid
organ
hematolog
stem
cell
transplant
improv
surviv
patient
hematolog
malign
increas
number
hivinfect
patient
contribut
enlarg
number
immunocompromis
patient
number
previous
rare
opportunist
infect
rise
time
obtain
adequ
sampl
make
right
diagnosi
revers
potenti
lifethreaten
infect
patient
paramount
import
achiev
longterm
surviv
patient
retrospect
analysi
posaconazol
prevent
acut
myeloid
leukemia
patient
receiv
induct
chemotherapyinduc
invas
fungal
infect
chiahsuan
wu
huichen
su
depart
pharmaci
chimei
medic
center
tainan
taiwan
background
acut
myeloid
leukemia
aml
consist
group
hematopoiet
neoplasm
treatment
includ
induct
chemotherapi
consolid
chemotherapi
allogen
hematopoiet
cell
transplant
induct
chemotherapi
induc
sever
neutropenia
immunocompromis
patient
often
becom
septic
shock
infect
clinician
prescrib
posaconazol
prevent
invas
fungal
infect
induct
chemotherapi
want
analyz
posaconazol
prevent
acut
myeloid
leukemia
patient
receiv
induct
chemotherapyinduc
invas
fungal
infect
method
retrospect
studi
patient
diagnos
aml
receiv
induct
chemotherapi
medic
center
southern
taiwan
includ
compar
incid
invas
fungal
infect
period
neutropenia
surviv
rate
two
group
one
group
consist
patient
posaconazol
prevent
group
consist
patient
without
posaconazol
prevent
result
patient
includ
analysi
patient
receiv
posaconazol
prevent
patient
nt
incid
invas
fungal
infect
two
group
period
neutropenia
prevent
group
day
day
group
without
prevent
surviv
rate
prevent
group
group
without
prevent
conclus
retrospect
analysi
reveal
incid
invas
fungal
infect
surviv
rate
show
statist
signific
differ
two
group
one
month
cost
posaconazol
nt
dollar
suggest
clinician
evalu
necess
posaconazol
prevent
aml
patient
induct
chemotherapi
accord
diseas
sever
risk
rate
infect
limit
retrospect
analysi
includ
small
sampl
size
absenc
diseas
sever
therefor
need
case
evalu
longterm
efficaci
valganciclovir
treatment
cytomegaloviru
diseas
kidney
allograft
recipi
hsinlin
lin
yufeng
tian
linghsien
lee
lile
chu
huichen
su
depart
pharmaci
chimei
medic
center
tainan
taiwan
divis
transplant
surgeri
depart
surgeri
chimei
medic
center
tainan
taiwan
background
cytomegaloviru
cmv
infect
frequent
complic
transplant
associ
morbid
poor
transplant
outcom
repres
seriou
threat
transplant
recipi
valganciclovir
offlabel
use
cmv
infect
renal
transplant
retrospect
chart
review
patient
cmv
diseas
treat
valganciclovir
method
retrospect
analyz
data
diagnosi
treatment
cmv
infect
complic
patient
transplant
men
women
age
time
transplant
year
result
overal
cmv
infect
rate
cumul
incid
cmv
infect
month
transplant
respect
patient
surviv
rate
graft
surviv
durat
valganciclovir
patient
renal
function
affect
cmv
infect
p
combin
immunosuppress
tacrolimu
plu
sirolimu
prednisolon
conclus
cmv
infect
renal
transplant
recipi
due
high
mortal
rate
cmv
infect
directli
affect
graft
surviv
rate
immunocompromis
patient
due
patient
expir
cmv
infect
renal
transplant
recipi
close
monitor
activ
treatment
increas
risk
pneumocysti
pneumonia
among
newli
diagnos
hivinfect
patient
pneumocysti
colon
nanyao
lee
mingchi
li
polin
chen
chiawen
li
wenchien
ko
depart
medicin
colleg
medicin
nation
cheng
kung
univers
depart
intern
medicin
center
infect
control
nation
cheng
kung
univers
hospit
tainan
taiwan
background
pneumocysti
jirvecii
pneumonia
pjp
lifethreaten
opportunist
infect
develop
primarili
among
hivinfect
person
low
count
epidemiolog
pneumocysti
colon
among
patient
unknown
aim
studi
estim
incid
pneumocysti
colon
risk
factor
pneumocysti
pneumonia
among
newli
diagnos
hivinfect
patient
method
prospect
studi
conduct
medic
center
southern
taiwan
oneyear
followup
enrol
p
jirovecii
dna
detect
realtim
pcr
sequenc
oral
swash
sampl
clinic
data
collect
medic
chart
uniform
data
record
form
result
enrol
case
p
jirovecii
dna
detect
asymptomat
case
recogn
colon
signific
differ
term
age
sex
comorbid
risk
factor
hiv
infect
among
particip
without
colon
eight
case
develop
pjp
follow
up
fatal
case
pneumocysti
colon
associ
lower
count
median
iqr
cellsmm
vs
cellsmm
p
higher
hiv
plasma
viral
load
vs
hiv
rna
copiesml
p
receipt
steroid
treatment
p
incid
pneumocysti
pneumonia
particip
without
colon
case
per
personyear
respect
kaplanmei
analysi
case
pneumocysti
colon
associ
higher
risk
pjp
without
colon
logrank
test
p
conclus
pneumocysti
colon
uncommon
newli
diagnos
hivinfect
patient
associ
increas
risk
pjp
increas
urinari
tract
infect
among
chronic
kidney
diseas
patient
asymptomat
bacteriuria
nanyao
lee
anbang
wu
yutzu
chang
chinchung
tseng
wenchien
ko
background
chronic
kidney
diseas
ckd
common
preval
increas
world
asymptomat
bacteriuria
also
refer
bacteriuria
asymptomat
urinari
infect
common
find
among
ckd
patient
vari
preval
age
sex
sexual
activ
men
women
abnorm
genitourinari
tract
aim
present
studi
determin
preval
risk
factor
asymptomat
bacteriuria
among
ckd
patient
method
prospect
studi
conduct
center
tainan
taiwan
particip
age
year
chronic
renal
diseas
attend
outpati
clinic
enrol
prospect
observ
studi
initi
visit
subject
interview
standard
questionnair
submit
midstream
urin
specimen
evalu
bacteriuria
pyuria
subsequ
followup
one
year
care
particip
follow
treatment
guidelin
clinic
practic
ckd
accord
decis
attend
physician
clinic
data
obtain
standard
medic
chart
abstract
use
uniform
data
abstract
form
result
particip
enrol
asymptomat
bacteriuria
identifi
among
particip
incid
per
personyear
particip
diabet
risk
asymptomat
bacteriuria
p
case
develop
urinari
tract
infect
follow
period
fatal
case
particip
asymptomat
bacteriuria
p
diabet
p
particip
risk
develop
uti
escherichia
coli
follow
enterococcu
speci
klebsiella
pneumonia
common
identifi
bacteria
asymptomat
bacteriuria
conclus
diabet
risk
factor
associ
asymptomat
bacteriuria
develop
uti
among
particip
chronic
kidney
diseas
ps
cmv
coliti
coexist
falseposit
ameb
coliti
hiv
patient
wenchi
hsu
liang
yu
depart
nurs
chi
mei
medic
center
tainan
taiwan
depart
intens
care
medicin
chi
mei
medic
center
tainan
taiwan
background
ameba
cytomegaloviru
cmv
viru
common
pathogen
caus
gastroenter
human
immunodefici
viru
hiv
infect
patient
symptom
includ
abdomin
pain
wateri
diarrhea
bloodi
stool
report
hiv
patient
delay
diagnosi
cmv
coliti
initi
treat
ameb
coliti
relaps
rapid
diagnosi
appropri
treatment
therefor
particularli
import
context
method
case
studi
result
yearold
man
hiv
infect
water
diarrhea
week
fever
gener
skin
rash
note
day
visit
hospit
examin
temperatur
blood
pressur
mm
hg
puls
beat
per
minut
diphenhydramin
methylprednisolon
use
suspect
allergi
initi
laboratori
data
show
wbc
count
creatinin
mgdl
sgot
ul
sgpt
ul
total
bilirubin
mgdl
amoebiasi
antibodi
titer
use
indirect
hemagglutin
assay
iha
metronidazol
use
day
howev
acut
hepat
sgot
ul
sgpt
ul
elev
bilirubin
total
mgdl
direct
mgdl
sever
coagulopathi
prothrombin
time
second
occur
transfer
intens
care
unit
suspect
sepsi
acut
liver
failur
colonoscopi
show
mucos
hyperemia
edema
whole
colon
multipl
ulcer
transvers
colon
descend
colon
sigmoid
colon
rectum
favor
ameb
coliti
piperacillintazobactam
metronidazol
given
one
week
condit
improv
transfer
gener
ward
howev
worsen
water
diarrhea
relaps
episod
hypotens
occur
patholog
mucos
biopsi
reveal
cmv
coliti
meanwhil
blood
cmv
viral
load
iuml
cmv
antigenemia
cell
per
pmn
cmvpcr
result
posit
blood
stool
sampl
theraft
intraven
ganciclovir
achiev
rapid
improv
diarrhea
liver
function
discharg
week
hospit
stay
conclus
falseposit
ameb
iha
ever
report
case
highlight
import
histopatholog
diagnosi
wateri
diarrhea
hiv
patient
blood
stool
cmvpcr
might
help
presumpt
diagnosi
howev
possibl
cmv
coliti
alon
follow
coexist
ameb
coliti
difficult
discern
cmv
activ
might
enhanc
steroid
therapi
care
hiv
patient
even
without
low
count
mycobacterium
avium
complex
lung
infect
patient
autoantibodi
previou
mycobacterium
abscessu
neck
lymphaden
lihshinn
wang
chiach
jacki
wang
chenglung
ku
jenjyh
lee
chiajung
chiang
poren
hsueh
background
mycobacterium
abscessu
extrem
difficult
treat
consid
incur
pulmonari
diseas
caus
avium
complex
mac
usual
occur
patient
chronic
lung
diseas
hivaid
report
case
mac
lung
diseas
previou
histori
abscessu
lymphaden
femal
chef
method
patient
present
chronic
cough
dyspnea
april
sputum
neg
acidfast
bacilli
afb
neck
comput
tomographi
ct
reveal
multipl
cervic
lymphadenopathi
figur
chest
hrct
reveal
rul
alveolar
lesion
right
hilar
lymphadenopathi
multipl
fix
enlarg
cervic
ln
found
along
level
iiv
right
later
neck
desmoid
adhes
surround
soft
tissu
surgeri
patholog
reveal
granulomat
inflamm
afb
posit
antituberculosi
tb
treatment
initi
herz
isoniazid
ethambutol
rifampin
pyrazinamid
sputum
cultur
later
grew
nontubercul
mycobacterium
ntm
pyrazinamid
switch
azithromycin
june
free
ng
dl
tsh
uiuml
antitg
iuml
antitpo
iu
ml
fine
needl
aspir
dec
reveal
hashimoto
thyroid
complet
antitb
treatment
jan
pu
cultur
grew
abscessu
antimycobacteri
treatment
switch
clarithromycin
ciprofloxacin
nation
taiwan
univers
hospit
feb
patient
could
toler
ciprofloxacin
chang
levofloxacin
doxycyclin
patient
respond
new
antintm
therapi
admit
tzu
chi
hospit
april
result
chest
film
reveal
rll
infiltr
mycoplasma
igm
posit
antintm
treatment
switch
intraven
tigecyclin
levofloxacin
amikacin
addit
oral
clarithromycin
sulfamethoxazoletrimethoprim
treatment
antiinterferon
ifn
autoantibodi
posit
sputum
cultur
grew
ntm
identifi
mac
offici
tb
center
tainan
patient
respond
new
antintm
therapi
nt
chang
regimen
eventu
neck
lymphadenopathi
relaps
chang
oral
antintm
treatment
clarithromycin
levofloxacin
sulfamethoxazol
trimethoprim
unfortun
patient
succumb
infect
conclus
patient
abscessu
lung
diseas
could
coexist
previou
histori
mac
pulmonari
infect
autoantibodi
may
play
role
mycobacteri
infect
particularli
person
without
predispos
condit
patient
abscessu
pulmonari
diseas
treat
multidrug
antimycobacteri
therapi
base
suscept
test
result
whenev
avail
surgic
resect
may
offer
favor
respons
select
case
mycobacterium
mucogenicum
infect
present
gener
follicular
hyperplasia
prurigo
nodulari
immunocompet
patient
lihshinn
wang
tingshu
wu
chiach
jacki
wang
chenglung
ku
yunghsiang
hsu
pauyuan
chang
background
mycobacterium
mucogenicum
rapidli
grow
mycobacteria
rgm
frequent
isol
tap
water
respiratori
specimen
associ
wide
spectrum
clinic
manifest
immunocompet
immunocompromis
host
method
male
florist
medic
histori
bph
anemia
hypertens
start
take
health
drink
call
imumio
miracl
water
hydrogen
enrich
water
super
lutein
produc
natur
plu
compani
mid
aug
develop
nodular
skin
lesion
involv
bilater
upper
limb
week
thereaft
lost
kg
weight
intermitt
fever
sinc
sep
stop
take
health
drink
late
sep
whole
bodi
gallium
scan
reveal
bilater
hilar
lymphadenopathi
chest
comput
tomographi
ct
reveal
cervic
axillari
mediastin
lymphadenopathi
esr
mmhr
crp
mgdl
cold
agglutinin
cmv
igg
auml
refer
infecti
diseas
servic
impress
kikuchi
diseas
result
skin
lesion
consist
prurigo
nodulari
figur
sputum
cultur
grew
nontubercul
mycobacteria
ntm
start
azithromycin
rifabutin
ethambutol
possibl
mac
although
hiv
test
neg
mac
pcr
neg
autoantibodi
also
neg
axillari
biopsi
show
lymphoma
toxoplasmosi
addit
lymph
node
biopsi
mediastinoscopi
reveal
lymphoid
hyperplasia
remain
febril
antintm
treatment
switch
tigecyclin
meropenem
possibl
rgm
bone
marrow
biopsi
neg
lymphoma
clarithromycin
ad
patient
becam
afebril
isol
final
identifi
mucogenicum
suscept
test
show
suscept
clarithromycin
tigecyclin
imipenem
sulfamethoxazoletrimethoprim
linezolid
patient
oral
clarithromycin
sulfamethoxazoletrimethoprim
linezolid
opd
soon
discontinu
sulfamethoxazol
trimethoprim
due
allergi
skin
lesion
resolv
week
initi
combin
treatment
repeat
ga
scan
chest
ct
demonstr
resolut
lymphadenopathi
follow
esr
crp
level
still
high
antintm
treatment
total
month
patient
thrombocytopenia
linezolid
treatment
throughout
cours
test
health
drink
show
mucogenicum
conclus
mucogenicum
often
clinic
signific
caus
system
ill
even
immunocompet
host
basi
combin
antimicrobi
therapi
base
suscept
test
result
whenev
avail
optim
durat
therapi
unknown
fulmin
liver
failur
secondari
system
lupu
erythematosu
reactiv
chronic
hepat
b
huichun
chao
depart
intens
care
medicin
chimei
medic
center
background
frequenc
liver
dysfunct
abnorm
liver
enzym
valu
cours
system
lupu
erythematosu
sle
rang
patient
sle
chanc
develop
abnorm
liver
test
lifetim
mani
case
preval
concomit
hepatopathi
higher
associ
sle
alon
use
drug
patient
previou
hbv
infect
result
sever
liver
damag
viru
reactiv
case
report
man
busi
man
work
china
previous
hepat
b
sle
began
leg
edema
bowel
habit
chang
hyperbilirubinemia
found
gastroenterologist
suspect
acut
cholestat
hepat
chronic
hepat
b
reactiv
decompens
statu
baraclud
start
howev
bloodi
stool
passag
occur
colonscopi
repeat
show
larg
nearli
circumfrenti
rectal
ulcer
outpouch
sac
larg
blood
clot
bloodcov
mucosa
rectum
termin
ileum
much
blood
clot
termin
ileum
admit
icu
intermitt
bloodi
stool
first
day
dyspnea
aggrav
suspect
due
lung
edema
ro
pneumonia
cxr
receiv
endotrach
intub
mechan
ventil
failur
diuresisalbumin
high
flow
nasal
cannula
use
fever
present
admiss
recur
degre
piperacillin
tazobactam
moxifloxacin
given
sinc
admiss
preliv
transplant
comput
tomographi
scan
show
suspici
lower
rectal
perfor
sigmoid
loop
colostomi
perform
discuss
radiologist
sle
vascul
involv
sever
major
vessel
suspect
render
liver
transplant
feasibl
accord
radiologist
suggest
liver
function
also
continu
deterior
due
sever
coagulopathi
recurr
bleed
occur
ich
suspect
dilat
fix
pupil
found
brain
imag
could
perform
due
unstabl
oxygen
hemodynam
discuss
wife
request
comfort
care
final
pass
away
later
conculs
liver
dysfunct
presenc
sle
caus
mani
factor
time
sle
onset
either
sle
drug
caus
featur
liver
dysfunct
caus
need
elucid
consid
treat
sle
multipl
opportunist
infect
patient
eosinophil
granulomatosi
polyangi
pinchuan
lin
lishinn
wang
shihtzu
tsai
yaju
wu
chihbin
lin
tengyi
lin
divis
infecti
diseas
divis
rheumatolog
immunolog
divis
chest
medicin
depart
intern
medicin
depart
intens
care
medicin
depart
laboratori
medicin
buddhist
tzu
chi
gener
hospit
hualien
taiwan
background
eosinophil
granulomatosi
polyangi
egpa
also
known
churgstrauss
syndrom
usual
present
recurr
asthma
control
without
system
steroid
unfortun
increas
risk
opportunist
infect
method
report
male
electron
process
staff
present
emerg
depart
rapid
onset
fever
product
cough
hospit
mani
time
recent
year
due
recurr
asthma
requir
oral
prednisolon
pneumonia
includ
pneumocysti
jiroveci
pneumonia
year
ago
aspergillosi
pneumonia
month
ago
recov
month
voriconazol
treatment
stop
month
complet
blood
count
show
peripher
eosinophilia
attack
also
develop
palpit
neuropathi
sinc
month
ago
physic
examin
demonstr
fever
tachycardia
bpm
wheez
basal
crackl
breath
sound
elast
nontend
purplish
nodul
finger
palm
paresthesia
muscl
atrophi
predominantli
thigh
chest
xray
show
interstiti
infiltr
lab
test
demonstr
leukocytosi
eosinophilia
elev
procalcitonin
ngml
elev
crp
mgdl
result
patient
given
piperacillintazobactam
empir
treatment
develop
ventricular
fibril
hospit
day
intub
transfer
medic
icu
cpcr
chest
xray
show
consolid
air
bronchogram
lung
figur
cardiac
echo
demonstr
global
hypokinesia
egpa
diagnos
accord
acr
diagnost
criteria
treatment
high
dose
intraven
methylprednisolon
rituximab
start
eosinophilia
leukocytosi
pulmonari
infiltr
chest
xray
gradual
subsid
intermitt
fever
persist
though
blood
urin
stool
cultur
neg
common
pathogen
influenza
hsv
cmv
cryptococcu
p
jirovecii
hiv
neg
sputum
cultur
grew
candida
albican
aspergillu
dna
test
equivoc
blood
sputum
patient
becam
afebril
procalcitonin
crp
level
return
normal
limit
antibiot
shift
combin
meropenem
tigecyclin
caspofungin
sever
attempt
final
patient
confirm
cmv
replic
posit
cmv
discharg
complet
day
ganciclovir
treatment
conclus
opportunist
infect
consid
fever
abnorm
procalcitonin
crp
level
persist
despit
egpa
grossli
control
cardiac
involv
may
lead
lifethreaten
arrhythmia
egpa
background
cytomegaloviru
cmv
infect
increasingli
recogn
critic
ill
immunocompet
patient
previou
studi
demonstr
associ
cmv
diseas
increas
mortal
rate
prolong
intens
care
unit
hospit
length
stay
prolong
mechan
ventil
nosocomi
infect
molecular
assay
consid
gold
standard
assess
human
cmv
infect
diseas
risk
sever
associ
clinic
manifest
nucleic
acid
sequencebas
amplif
assay
cmv
late
gene
transcript
suggest
publish
report
reliabl
prognosi
method
perform
retrospect
review
medic
record
patient
medic
surgic
burn
intens
care
unit
icu
posit
neg
detect
human
compar
characterist
patient
posit
patient
neg
result
univari
analysi
patient
posit
cmv
associ
higher
proport
sepsi
p
longer
icu
length
stay
p
longer
hospit
day
p
howev
consid
variabl
multivari
analysi
statist
signific
among
variabl
cmv
statu
addit
also
found
cmv
statu
associ
mortal
rate
ci
die
associ
differ
antibiot
use
ci
higher
percentag
vasopressor
use
ci
higher
preval
end
stage
renal
diseas
ci
shorter
hospit
day
ci
conclus
conclus
cross
section
studi
within
critic
ill
patient
correl
posit
cmv
characterist
assum
therefor
could
nt
tell
paramet
higher
posit
cmv
rate
addit
posit
cmv
nt
relat
higher
mortal
rate
owe
controversi
result
compar
previou
studi
larger
sampl
size
studi
necessari
develop
accur
correl
result
background
establish
bacteri
speci
identif
gene
sequenc
trigger
increas
report
case
nontubercul
mycobacteri
infect
caus
new
bacteri
speci
prompt
urgent
need
establish
diagnosi
treatment
regimen
method
patient
man
age
upon
observ
minor
hemoptysi
decemb
patient
visit
hospit
granular
pattern
observ
dominantli
rightlung
along
bronchodil
partial
cavitari
lesion
led
suggest
diagnosi
pulmonari
mycobacteriosi
sputum
bronchoscopicallyextract
bronchoalveolar
lavag
fluid
examin
mycobacteria
specimen
identifi
mycobacteria
cultur
posit
tb
macpcr
found
neg
confirm
unidentifi
dnadna
hybrid
ddh
case
follow
pulmonari
nontubercul
mycobacteri
infect
observ
gradual
progress
lesion
led
two
cours
sputum
cultiv
identifi
mycobacteria
septemb
cultur
identifi
posit
tblamp
macpcr
return
neg
result
ddh
fail
identifi
order
identifi
causal
bacteria
rrna
gene
sequenc
conduct
result
rna
gene
sequenc
found
phasic
shinjukuens
clinic
bacteriolog
find
suffic
criteria
american
thorac
societyinfecti
diseas
societi
america
guidelin
patient
diagnos
pulmonari
nontubercul
mycobacteri
infect
trigger
said
bacteria
conclus
shinjukuens
initi
report
japan
new
type
nontubercul
mycobacteria
belong
bacteri
group
runyon
classif
tuberculosi
complex
rapid
diagnost
techniqu
like
mycobacterium
tuberculosi
direct
mtd
transcriptionrevers
transcript
concert
method
trc
occasion
return
falseposit
result
diagnosi
requir
extra
caution
report
chemotherapi
use
camrfpeb
inhrfpeb
suggest
treatment
effect
probabl
case
mycobacterium
gordona
infect
present
cervic
lymphadenopathi
fever
unknown
origin
syharn
lian
lihshinn
wang
jenjyh
lee
yinghuei
chen
hueijen
chao
chiajung
chiang
school
medicin
buddhist
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
divis
chest
medicin
depart
intern
medicin
depart
laboratori
medicin
buddhist
tzu
chi
gener
hospit
hualien
taiwan
ministri
health
welfar
chest
hospit
tainan
taiwan
background
mycobacterium
gordona
scotochromogen
nontubercul
mycobacteria
ntm
ubiquit
mani
isol
repres
colon
contamin
specimen
true
infect
method
woman
nurs
local
clinic
present
histori
fever
start
intermitt
fever
bloodting
sputum
sore
throat
vertigo
hear
loss
tinnitu
nausea
vomit
headach
also
note
mass
right
neck
centimet
size
addit
recurr
oral
ulcer
grandmoth
histori
tuberculosi
histori
exposur
dog
drug
toxin
travel
histori
identifi
result
complet
blood
count
differenti
count
platelet
count
blood
cultur
blood
chemistri
esr
crp
urinari
analysi
purifi
protein
deriv
skin
test
abdomin
sonographi
chest
radiograph
high
resolut
comput
tomographi
chest
reveal
unremark
find
acidfast
stain
sputum
show
equivoc
result
one
initi
three
specimen
one
three
sputum
cultur
grew
ntm
head
neck
ct
show
bilater
enlarg
neck
lymph
node
level
iiiii
especi
right
level
ii
survey
streptococcu
cryptococcu
pneumonia
syphili
hiv
cmv
hsv
reveal
unremark
result
infecti
sourc
identifi
despit
investig
dermatologist
gynecologist
otolaryngologist
dentist
leukocyt
scan
malign
found
examin
cea
colonoscopi
survey
autoimmun
diseas
includ
tsh
antitg
antitpo
ferritin
iga
igg
igm
rheumatoid
factor
antinuclear
antibodi
antissa
antissb
anticenpb
antism
antirnp
antindna
neg
autoantibodi
also
neg
ntm
idntifi
gordona
pcr
offici
mycobacterium
refer
laboratori
diagnosi
establish
one
equivoc
afb
stain
one
posit
cultur
result
fit
american
thorac
societi
diagnosi
criteria
pulmonari
ntm
infect
howev
patient
becam
afebril
rifampicin
ethambutol
isoniazid
treatment
cervic
lymphadenopathi
resolv
week
later
associ
symptom
gone
patient
cure
without
relaps
total
antintm
treatment
month
followup
conclus
effect
treatment
regimen
gordona
establish
howev
clinic
respons
specif
antimycobacteri
therapi
indic
possibl
diseas
presenc
recommend
durat
therapi
known
accuraci
genexpert
test
firstlin
mycobacterium
tuberculosi
identif
tool
region
hospit
south
taiwan
chihhsiung
kao
chiungyin
chuang
tzuwei
juan
depart
laboratori
medicin
st
martin
de
porr
hospit
taiwan
background
genexpert
test
new
autom
molecular
test
detect
dna
mycobacterium
tuberculosi
mtb
well
test
genet
mutat
associ
resist
drug
rifampicin
rif
organ
claim
genexpert
test
go
revolution
diagnosi
care
patient
mtb
provid
result
directli
sputum
specimen
less
hour
recommend
test
use
initi
diagnosi
test
individu
suspect
multidrug
resist
tuberculosi
mdr
tb
purpos
studi
assess
perform
detect
drug
resist
mtb
genexpert
test
compar
convent
cultur
method
implement
normal
clinic
workflow
region
hospit
south
taiwan
method
emphas
genexpert
mtbrif
test
elimin
need
convent
microscopi
cultur
drug
sensit
test
dst
detect
live
dead
bacteria
assess
perform
genexpert
test
april
april
new
directli
sputum
smear
acidfast
bacilli
afb
stain
posit
tuberculosi
suspect
new
afb
smearposit
patient
specimen
process
reflect
genexpert
test
sent
referr
laboratori
convent
mtb
cultur
dst
result
total
patient
suspect
pulmonari
mtb
smear
posit
afb
sputum
specimen
enrol
studi
among
patient
prior
histori
mtb
retreat
mtb
case
overal
sampl
cultur
posit
sampl
cultur
neg
genexpert
convent
dst
reveal
mtb
isol
rif
resist
agreement
genexpert
convent
dst
result
detect
rif
resist
mtb
conclus
studi
show
verifi
accuraci
genexpert
test
result
similar
earli
experiment
find
previou
report
main
advantag
genexpert
test
diagnosi
reliabl
compar
sputum
microscopi
speed
get
result
compar
cultur
diagnosi
mtb
although
sputum
microscopi
quick
cheap
often
unreli
although
cultur
give
definit
diagnosi
get
result
usual
take
week
rather
hour
genexpert
test
multipl
skin
nodul
postrenaltransplant
woman
jiayin
guo
maowang
ho
chiahui
chou
yuanti
lee
chiuch
huang
wenshin
hsih
depart
intern
medicin
china
medic
univers
hospit
taichung
taiwan
background
nontubercul
mycobacteria
ntm
ubiquit
soiil
water
mostli
ntm
caus
diseas
impair
host
defens
immunosupress
patient
mycobacterium
haemophilum
belong
group
ntm
frequent
found
environment
habitat
known
caus
cutan
subcutan
infect
mycobacterium
haemophilum
infect
hard
treat
standard
guidelin
avail
henc
share
patient
infect
cutan
mycobacterium
haemophilum
respond
well
treatment
method
femal
histori
type
dm
end
stage
renal
diseas
receiv
renal
transplant
year
ago
mycophenol
mofetil
prednisolon
immunosuppress
drug
year
got
left
wrist
contuss
injuri
receiv
trandit
chines
herbal
medicin
appli
wound
month
initi
wound
swell
erythemat
base
later
much
erythemat
papul
develop
along
forearm
finger
face
progress
tender
nodul
ruptur
odor
pu
poor
heal
ulcer
left
admit
impress
cellul
pu
cultur
yield
ntm
mycobacterium
haemophilum
molecular
test
receiv
antibiot
rifampin
moxifloxacin
clarithromycin
immunosuppress
adjust
low
dose
prednisolon
howev
due
persist
poor
heal
wound
antibiot
adjust
rifabutin
ciprofloxacin
clarithromycin
doxycyclin
clarithromycin
withdrawn
second
week
suspect
side
effect
vomit
tigecyclin
ad
secondari
wound
infect
addit
plastic
surgeon
suggest
wound
care
hypochlor
acid
microdacyn
perform
local
debrid
result
admiss
one
month
progress
epitheli
skin
defect
left
hand
new
nodul
found
integu
discharg
oral
rifabutin
ciprofloxacin
azithromycin
month
treatment
skin
lesion
total
recov
conclus
immunocompromis
host
ulcer
skin
lesion
haemophilum
infect
taken
consider
especi
afb
seen
direct
microscopi
routin
mycobacteri
cultur
remain
steril
case
recoveri
prolong
antimycobacteri
treatment
common
control
commun
outbreak
multidrugresist
tuberculosi
three
aborigin
villag
hualien
counti
eastern
taiwan
cheng
popin
lee
jenjyh
lin
chihbin
sun
hungchieh
wang
lih
shinn
spoligotyp
identifi
beij
strain
predomin
genotyp
n
follow
haarlem
n
n
six
isol
match
spoligotyp
data
base
determin
isol
determin
uniqu
pattern
cluster
pattern
strain
classifi
cluster
largest
cluster
e
cluster
belong
beij
genotyp
includ
case
live
commun
shilintownship
inhabit
close
relationship
rel
neighbor
friend
second
largest
cluster
f
cluster
belong
haarlem
genotyp
compris
patient
live
anoth
commun
hechung
township
inhabit
close
relationship
rel
neighbor
friend
mdrtb
patient
three
aborigin
villag
enrol
dotsplu
program
five
case
still
treatment
among
patient
final
outcom
treat
success
preval
mdrtb
patient
improv
dramat
last
ten
year
proport
mdrtb
patient
cluster
pattern
strain
three
aborigin
villag
hualien
counti
eastern
taiwan
high
control
commun
outbreak
mdrtb
success
last
year
see
figur
ps
tuberculosi
patient
activ
malign
transplant
recipi
louisa
j
sun
heather
l
isenman
catherin
wm
ong
divis
infecti
diseas
nation
univers
health
system
singapor
background
transplant
recipi
patient
malign
high
risk
develop
tuberculosi
tb
diagnosi
may
delay
group
patient
often
present
atyp
symptom
review
clnical
characterist
treatment
outcom
cancer
patient
transplant
recipi
develop
tb
center
moder
tb
burden
countri
method
patient
malign
transplant
recipi
identifi
databas
total
activ
tb
case
januari
decemb
medic
record
review
analys
clinic
characterist
includ
mortal
outcom
site
infect
chemotherapi
regim
durat
transplant
infect
tb
drug
regimen
use
treatment
complic
result
year
found
cancer
patient
transplant
recipi
diagnos
tb
lung
haematolog
cancer
account
total
number
tb
case
diagnos
cancer
patient
median
age
year
old
pulmonari
tb
common
site
tb
site
includ
lymph
node
gut
concern
larg
major
patient
pulmonari
tb
smear
neg
diagnosi
made
posit
genexpert
cultur
patient
receiv
chemotherapi
includ
steroid
patient
treat
standard
firstlin
tb
drug
except
haematolog
patient
receiv
rifampicinspar
regim
oncolog
patient
receiv
levofloxacin
instead
pyrazinamid
patient
develop
treatmentrel
complic
causemort
transplant
group
compris
renal
haematopoiet
stem
cell
transplant
hsct
liver
transplant
recipi
median
age
year
old
patient
pulmonari
tb
posit
sputum
smear
indic
high
infect
rate
four
renal
transplant
recipi
develop
tb
median
year
posttranspl
rang
year
hsct
patient
develop
tb
within
month
posttranspl
patient
still
immunosuppress
time
tb
diagnosi
patient
complet
treatment
rifampicinspar
regim
use
drugassoci
complic
occur
patient
median
treatment
durat
month
rang
month
allcaus
mortal
conclus
transplant
patient
patient
activ
malign
develop
tb
risk
complic
diseas
treatment
high
mortal
rate
effort
decreas
activ
tb
rate
group
immunocompromis
patient
reduc
patient
morbid
mortal
serum
ferritin
level
predict
diseas
sever
pediatr
dengu
infect
tzongshiann
ho
han
lee
ning
chung
fuchun
kuo
chingfen
shen
shihmin
wang
chingchuan
liu
background
one
preval
mosquitoborn
infecti
diseas
dengu
result
variou
clinic
outcom
rang
mild
fever
fatal
hemorrhag
shock
continu
unmet
clinic
need
biomark
dengu
sever
macrophag
activ
recent
observ
sever
dengu
patient
serum
ferritin
also
one
macrophag
activ
marker
vivo
studi
aim
clarifi
relationship
serum
ferritin
level
develop
sever
dengu
children
method
patient
younger
year
admit
tertiari
medic
center
southern
taiwan
laboratoryconfirm
dengu
infect
dengu
outbreak
includ
current
studi
epidemiolog
characterist
clinic
manifest
laboratori
data
patient
analyz
electron
chart
record
serum
ferritin
level
determin
patient
avail
specimen
commerci
enzymelink
immunosorb
assay
kit
result
total
seventytwo
pediatr
dengu
patient
male
group
updat
world
health
organ
classif
among
patient
warn
sign
classifi
sever
dengu
serum
ferritin
level
significantli
increas
patient
clinic
sever
dengu
ngml
compar
dengu
warn
sign
ngml
agematch
healthi
particip
serum
ferritin
level
higher
sever
case
day
dengu
infect
cutoff
valu
ngml
also
predict
sever
dengu
children
area
curv
receiv
oper
characterist
curv
analysi
result
patient
histopatholog
confirm
kfd
mean
age
patient
year
male
femal
ratio
lymph
node
involv
often
cervic
featur
unilater
predisposit
polyadenopathi
tender
fever
cough
rhinorrhea
tonsil
common
present
laboratori
find
includ
leukopenia
monocytosi
posit
result
ebvca
igg
ebvca
igm
ebea
igg
ebna
igg
univari
analysi
prolong
fever
lymphopenia
monocytosi
thrombocytopenia
necrot
type
histopatholog
disclos
statist
signific
p
glucocorticoid
hydroxychloroquin
administ
patient
respect
along
symptomat
treatment
rest
recurr
occur
patient
without
hydroxychloroquin
treatment
situ
hybrid
perform
use
intern
repeat
fragment
dna
ebvcod
small
rna
ebv
show
case
neg
ebv
genom
conclus
kfd
suspect
children
febril
cervic
lymphadenopathi
especi
concomit
leukopenia
monocytosi
past
epsteinbarr
viru
infect
lymphopenia
monocytosi
thrombocytopenia
necrot
type
histopatholog
reliabl
predictor
prolong
fever
result
suggest
ebv
may
caus
role
pathogenesi
kfd
epidemiolog
rsv
nonrsv
acut
bronchiol
effect
palivizumab
chiawan
tang
kaishen
hsieh
depart
pediatr
antai
medic
care
corpor
tiansheng
memori
hospit
changgung
memori
hospit
taiwan
background
respiratori
syncyti
viru
rsv
caus
acut
bronchiol
pneumonia
almost
infant
infect
first
year
infect
age
two
reinfect
common
even
within
one
respiratori
season
children
tend
increas
risk
wheez
episod
rsv
infect
aim
studi
studi
epidemiolog
rsv
nonrsv
acut
bronchiol
effect
palivizumab
monoclon
antibodi
produc
recombin
dna
technolog
method
retrospect
review
medic
record
children
year
age
acut
bronchiol
hospit
tertiari
medic
center
vghk
southern
taiwan
januari
decemb
patient
group
two
rsv
posit
rsv
neg
check
gender
age
distribut
two
group
addit
review
durat
hospit
well
result
patient
hospit
acut
bronchiol
rsv
infect
male
femal
distribut
vs
rsv
posit
group
rsv
neg
group
rsv
bronchiol
longer
hospit
stay
vs
day
p
patient
suffer
rsv
relat
bronchiol
younger
age
vs
year
p
conclus
rsv
relat
acut
bronchiol
differ
season
taiwan
diseas
caus
higher
morbid
younger
infant
prolong
length
hospit
stay
children
receiv
palivizumab
less
rsv
relat
bronchiol
fever
unknown
origin
first
manifest
malign
albanian
adult
migena
qato
najada
como
arjan
harxhi
pellumb
pipero
iri
koshovari
dhimit
kraja
infecti
diseas
servic
uhc
mother
theresa
tirana
albania
background
last
year
mani
research
variou
caus
fever
definit
pattern
diseas
chang
serolog
imag
tool
improv
estabilish
way
diagnos
sooner
tumor
patholog
often
present
prolong
febril
syndrom
fever
domin
clinic
pattern
everyday
practic
also
repres
consider
number
misdiagnos
mainli
infecti
nosolog
consid
tumor
fever
alreadi
solid
clinic
binomi
febril
profil
becom
attract
part
tumor
patholog
method
studi
includ
case
age
group
year
epidemiolog
studi
base
survey
accord
gender
age
group
resid
clinicaldiagnost
studi
base
detail
anamnesi
epidemiolog
survey
clinic
biolog
biochem
microbiolog
serolog
research
result
epidemiolog
male
case
femal
case
mean
age
year
old
resid
town
countrysid
clinic
topographytumor
head
neck
cerebr
tumor
thyroid
thorax
pulmonar
adenocarcinoma
breast
gastrointestin
tract
gastric
cancer
colon
pancrea
liver
billiari
tract
blood
leucosi
lymphoma
myeloma
hairi
cell
leukemia
urogenita
tract
renal
cancer
prostat
seminoma
b
type
fever
tumor
continu
cerebr
thyroid
pulmonar
colon
intestin
pancrea
acut
leucosi
billiari
tract
renal
breast
remmit
cerebr
colon
intestin
pancrea
liver
billiari
tract
acut
leucosi
hcl
seminoma
breast
intermmit
cerebr
pulmonar
liver
billiari
tract
pancrea
colon
renal
recurr
lymphoma
acut
leucosi
myeloma
ondul
lymfoma
acut
leucosi
myeloma
conclus
identifi
type
febril
tumor
fever
first
clinic
manifest
tumor
fever
debut
differ
type
continu
fever
domin
case
diagnost
orient
malign
follow
detail
anamnest
laboratori
imageri
screen
exclud
import
infecti
diseas
first
place
end
studi
convinc
febril
profil
also
import
diagnost
tool
rapid
diagnosi
malign
epidemiolog
clinic
laboratori
therapeut
survey
hcv
infect
hemodyalisi
patient
najada
como
migena
qato
esmeralda
meta
pellumb
pipero
arjan
harxhi
elda
zogu
dhimit
kraja
faculti
medicin
univers
hospit
center
mother
theresa
background
patient
hemodialysi
actual
repres
target
group
close
relat
infect
hepat
c
viru
effort
manag
group
patient
strongli
focus
clinic
profil
infect
patient
adecu
treatment
alway
aim
efficaci
maximum
safeti
patient
method
one
year
period
hemodialysi
patient
select
patient
result
antihcv
igm
posit
agegroup
year
old
differ
underli
chronic
diseas
patient
evidenc
creatin
clearanc
ml
min
detect
antihcv
antibodi
hcvrna
serum
elev
serum
alanin
aminotransferas
alt
patient
hiv
hepat
b
coinfect
patient
decompens
hepat
cirrhosi
exclud
studi
patient
underw
monotherapi
pegyl
interferon
alfa
per
week
week
result
epidemiolog
clinic
find
patient
mean
age
year
f
ratio
averag
time
hemodialysi
year
underli
diseas
chronic
renal
failur
case
acut
pielonephr
renal
polycystosi
congenit
renal
atrophi
transplant
arteri
spondiloarthrosi
case
laboratori
data
evidenc
elev
serum
level
alt
vari
bilirubin
levl
mgdl
laboratori
data
also
evidenc
anemia
case
leucopenia
case
thrombocytopenia
case
therapeut
peginterferon
alfa
monotherapi
result
sustain
virolog
respons
case
mean
hcvrna
baselin
end
week
result
undetect
conclus
hcv
infect
hemodyalisi
patient
remain
major
caus
chronic
liver
complic
patient
evidenc
mild
clinic
form
hepatitisprob
relat
immunocompromis
statu
hd
procedur
advers
effect
peginterferon
therapi
appear
minim
compar
efficaci
treatment
patient
nevertheless
end
hcv
infect
neg
impact
surviv
dialysi
monomicrobi
necrot
fasciiti
predict
factor
prospect
case
seri
studi
singl
center
tsungyu
huang
yaohung
tsai
huiju
chuang
weihsiu
hsu
divis
infecti
diseas
depart
ascertain
whether
clinic
present
outcom
patient
diseas
differ
infect
gramneg
compar
gramposit
pathogen
method
seventi
patient
monomicrobi
necrot
fasciiti
examin
prospect
april
may
patient
receiv
prompt
radic
debrid
adequ
broadspectrum
antibiot
therapi
aggress
resuscit
without
adjuv
hyperbar
oxygen
therapi
thirtynin
patient
infect
gramneg
pathogen
group
patient
gramposit
pathogen
group
result
group
character
higher
incid
marin
relat
event
hemorrhag
bulla
tachypnea
septic
shock
higher
sequenti
organ
failur
assess
sofa
score
higher
rate
bandemia
bacteremia
hypoalbumenia
lower
preval
laboratori
risk
indic
necrot
fasciiti
score
lrinec
score
higher
intern
normal
ratio
inr
lower
level
creactiv
protein
crp
fibrinogen
preval
group
shorter
time
diagnosi
fewer
delay
diagnosi
necrot
fasciiti
higher
rate
acut
respiratori
failur
higher
admiss
rate
intens
care
unit
icu
admiss
common
group
multivari
analysi
marin
relat
event
odd
ratio
background
varicella
zoster
viru
vzv
wide
known
pathogen
usual
caus
chickenpox
shingl
primari
infect
patient
reactiv
endogen
latent
viru
host
respect
howev
vzvcaus
pneumonia
quit
rare
compar
skin
lesion
method
male
without
chronic
ill
admit
skin
erupt
fever
degre
cough
littl
sputum
gener
malais
muscl
sore
laboratori
data
reveal
leukocytosi
monocyt
predomin
percentag
band
form
neutrophil
atyp
lymphocyt
elev
liver
enzym
two
time
higher
upper
limit
result
admiss
chest
xray
film
show
coars
lung
mark
bilater
lung
diffus
reticulonodular
densiti
develop
interstiti
pneumon
medic
dexamethason
mg
acyclovir
mg
day
skin
lesion
start
crust
pulmonari
symptom
improv
conclus
first
proven
case
vzv
pneumonia
year
although
pulmonari
involv
vzv
uncommon
kept
mind
order
prevent
patient
sever
vzv
pneumonia
caus
disast
often
requir
ventil
support
background
diclofenac
one
nonsteroid
antiinflammatori
drug
nsaid
report
associ
allevi
sever
clostridium
difficil
infect
cdi
due
inhibitori
effect
phospholipas
play
import
role
disrupt
epitheli
integr
gut
inflammatori
respons
induc
c
difficil
toxin
aim
studi
investig
impact
nsaid
exposur
cdi
method
publish
mous
model
cdi
induc
prior
exposur
antibiot
proton
pump
inhibitor
use
mice
fed
diclofenac
dose
phosphat
buffer
salin
control
oral
gavag
prior
cdi
sever
cdi
includ
bodi
weight
chang
stool
consist
cecum
colon
length
bacteri
burden
c
difficil
cecum
stool
evalu
mrna
protein
level
prostaglandin
determin
colon
tissu
result
highli
express
colon
tissu
cdi
level
decreas
treat
diclofenac
sever
coliti
induc
c
difficil
includ
bodi
weight
loss
cecum
weight
loss
cecum
length
shorten
decreas
diclofenactr
mice
compar
vehicletr
control
mice
besid
treatment
diclofenac
either
dose
decreas
bacteri
burden
c
difficil
cecum
stool
also
revers
ratio
firmicut
bacteroidet
microbiota
cecum
stool
conclus
treatment
diclofenac
attenu
sever
cdi
murin
model
use
suppositori
form
metronidazol
avoid
encephalopathi
sideeffect
huaien
lu
lihsin
tsao
yuarnjang
lee
shuchen
chien
backgroundcas
present
man
diagnos
rectal
cancer
recurr
perian
abscess
sinc
year
pu
cultur
yield
proteu
mirabili
escherichia
coli
finegoldia
magna
eggerthella
lenta
anaerococcu
prevotii
bacteroid
uniformi
follow
infecti
outpati
depart
taken
metronidazol
plu
ceftibuten
relaps
perian
abscess
recent
sinc
dec
howev
dizzi
ataxia
develop
one
month
later
metronidazoleinduc
encephalopathi
diagnos
clinic
symptom
imag
studi
revers
improv
symptom
metronidazol
cessat
untoler
sideeffect
uncontrol
infect
note
receiv
antibiot
anaerob
pathogen
cover
thu
tri
rechalleng
metronidazol
achiev
well
infect
control
avoid
associ
sideeffect
discuss
problem
avoid
metronidazol
relat
encephalopathi
rechalleng
metronidazol
hospit
differ
dosag
form
metronidazol
includ
entericco
tablet
inject
suppositori
gel
thought
suppositori
form
supp
good
choic
base
pharmacokinet
metronidazol
perian
infect
rectal
absorpt
metronidazol
onehalf
even
less
oral
administr
hepat
firstpass
elimin
metronidazol
may
partial
avoid
rectal
administr
therefor
use
metronidazol
mg
supp
everi
night
day
titrat
supp
everi
six
hour
discharg
got
better
metronidazol
relat
encephalopathi
symptom
observ
conclus
encephalopathi
report
patient
receiv
metronidazol
antibiot
differ
dosag
form
drug
anoth
choic
avoid
sideeffect
also
need
consid
site
infect
sever
infect
bioavail
drug
salmonella
osteomyel
singl
center
retrospect
case
seri
literatur
review
chinkang
wan
dawei
wang
chenghua
huang
wenchun
hsu
minghsueh
tsai
limin
chang
depart
intern
medicin
cathay
gener
hospit
taipei
clinic
patholog
cathay
gener
hospit
taipei
background
salmonella
caus
broad
spectrum
ill
includ
gastroenter
typhoid
fever
extraintestin
manifest
hematogen
metastas
salmonella
osteomyel
uncommon
extraintestin
manifest
especi
rare
patient
without
predispos
factor
sickl
cell
diseas
system
lupu
erythematosu
immunocompromis
previou
studi
report
salmonella
osteomyel
account
salmonella
infect
type
osteomyel
herein
present
immunocompet
case
salmonella
osteomyel
without
sickl
cell
diseas
method
patient
diagnos
salmonella
bacteremia
januari
april
cathay
gener
hospit
clinic
data
retrospect
analyz
result
patient
older
three
femal
show
age
predilect
three
patient
diagnos
vertebr
osteomyel
one
patient
diagnos
tibial
osteomyel
remain
one
patient
suspect
sacroili
patient
receiv
protract
antibiot
treatment
accord
suscept
two
patient
receiv
prolong
antibiot
administr
addon
probenecid
recurr
salmonella
osteomyel
patient
underw
surgic
intervent
patient
surviv
diseas
conclus
salmonella
osteomyel
rare
seen
immunocompet
adult
durat
antibiot
paramount
treat
patient
avoid
relaps
failur
addon
therapi
probenecid
relaps
salmonella
osteomyel
never
report
preced
studi
efficaci
encourag
studi
studi
need
investig
approach
patient
salmonella
osteomyel
distribut
extendedspectrum
ampc
carbapenemas
among
enterobacteriacea
isol
caus
intraabdomin
urinari
tract
infect
asiapacif
region
result
studi
monitor
antimicrobi
resist
trend
smart
shioshin
jean
poren
hsueh
background
investig
antimicrobi
resist
assess
molecular
characterist
esbl
ampc
carbapenemas
among
enterobacteriacea
isol
caus
intraabdomin
infect
iai
patient
hospit
asiapacif
region
method
multiplex
pcr
assay
appli
detect
specif
type
isol
ertapenem
mic
gl
inhospit
acquisit
time
isol
also
delin
result
among
isol
proven
product
rate
nonsuscept
imipenem
low
averag
among
iai
enterobacteriacea
isol
asiapacif
countri
except
vietnam
philippin
stepwis
signific
increas
annual
rate
carbapenemas
product
among
isol
note
domin
esbl
variant
iai
enterobacteriacea
speci
abund
ampc
variant
bla
among
isol
escherichia
coli
bla
among
isol
klebsiella
pneumonia
addit
iai
enterobacteriacea
isol
harbor
bla
bla
allel
associ
high
communityacquir
rate
respect
ampc
act
mir
variant
mostli
detect
iai
enterobact
speci
iai
bla
isol
e
coli
k
pneumonia
enterobact
cloaca
mostli
commonli
identifi
among
iai
isol
vietnam
philippin
also
note
bla
harbor
iai
enterobacteriacea
isol
detect
vietnam
conclus
high
resist
burden
vietnam
philippin
warrant
aggress
control
polici
combat
worsen
resist
trend
antimicrobi
resist
among
enterobacteriacea
isol
caus
iai
background
brugada
syndrom
wellknown
autosom
domin
genet
disord
sodium
channel
scn
gene
predomin
male
one
major
reason
sudden
cardiac
death
middl
age
adult
brugada
syndrom
wide
discuss
preval
well
studi
risk
factor
still
debat
found
case
influenza
infect
induc
brugada
syndrom
method
patient
previous
healthi
nonsmok
man
travel
taitung
four
day
prior
admiss
deni
contact
experi
suffer
dri
cough
rhinorrhea
myalgia
three
day
visit
fenglin
veteran
hospit
rapid
flu
test
posit
influenza
patient
receiv
relenza
treatment
two
day
admiss
new
onset
intermitt
retrostern
pain
aggrav
exert
reliev
rest
could
radiat
upper
back
last
minut
fever
nausea
vomit
chest
tight
attack
emerg
room
afebril
c
blood
pressur
mmhg
heart
rate
beat
per
minut
physic
examin
cold
sweat
regular
heart
beat
without
murmur
chest
xray
film
show
bilater
lower
lung
infiltr
serial
ecg
show
intermitt
av
dissoci
downslop
stelev
result
admiss
troponin
level
elev
obviou
chest
pain
cardiopulmonari
distress
repeat
throat
swab
influenza
pcr
test
confirm
influenza
infect
serial
ecg
show
brugada
pattern
cardiac
echo
reveal
mild
anterior
wall
hypokinesi
coronari
angiogram
reveal
nonsignific
stenosi
left
main
arteri
left
anterior
descend
arteri
aspirin
statin
administ
gener
condit
much
improv
treatment
chest
xray
show
decreas
bilater
infiltr
discharg
much
improv
six
day
admiss
follow
infecti
diseas
cardiolog
opd
later
gene
laboratori
nation
taiwan
univers
confirm
gene
mutat
conclus
brugada
electrocardiograph
chang
yet
associ
influenza
current
medicin
two
case
report
found
pubm
howev
time
genet
clinic
evid
show
infuenza
may
relat
induc
brugada
syndrom
give
inform
studi
group
brugada
syndrom
taiwan
herp
zoster
sacral
dysfunct
urinari
bladder
anorect
muscl
como
najada
meta
esmeralda
kraja
dhimit
pipero
pellumb
harxhi
arjan
infecti
diseas
departa
uhc
mother
theresa
tiran
introduct
affect
viscer
organ
herp
zoster
rare
phenomena
althought
import
occur
diagnost
therapeut
error
exacerb
progress
diseas
case
presant
year
old
men
hospit
clinic
herp
zoster
sacral
multidermatom
present
vesicular
erupt
sacral
region
includ
dermatom
associ
urinari
retens
combust
preced
pain
lower
limb
start
week
day
abdomin
pain
occour
pain
right
testicl
fever
hipersensit
palpacion
right
part
abdomen
urinari
cathet
settl
result
urinari
retens
lab
exam
result
high
level
leukocyt
pyuria
blood
cultur
steril
urinari
cultur
p
aeruginosa
abdomin
imag
ultrasound
ct
scan
identifi
fluid
dugla
hydrocel
right
epidedimi
result
orchioepididim
emg
normal
physiolog
paramet
case
treat
acyclovir
oral
local
antibiot
nsai
defec
settl
day
hospit
erupt
began
disappear
day
persist
urinari
retent
urinari
cathet
remov
week
conclus
case
consid
herp
zoster
sacral
complic
urinari
bladder
dysfunct
extend
urinari
retens
urosepsi
p
aeruginosa
anorect
dysfunct
constip
erectil
emphat
erysipelothrix
rhusiopathia
bacteremia
uncommon
zoonot
pathogen
chuchun
lin
lihshinn
wang
hueijen
chao
sishiuan
peng
tengyi
lin
school
medicin
buddhist
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
depart
intern
medicin
buddhist
hualien
tzuchi
hospit
taiwan
depart
laboratori
medicin
buddhist
hualien
tzuchi
hospit
taiwan
background
erysipelothrix
rhusiopathia
usual
infect
anim
human
patient
histori
wild
anim
contact
consid
infect
caus
uncommon
zoonot
pathogen
method
patient
man
hbv
infect
alcohol
liver
cirrhosi
gastric
esophag
varic
hypertens
admiss
cellul
blood
cultur
grew
streptococcu
equinu
alway
abund
fece
hors
uncommon
human
sent
yuli
tzu
chi
hospit
alter
conscious
bloodi
vomit
hour
er
mild
fever
blood
pressur
mmhg
pale
conjunctiva
icter
sclera
notic
transfer
hualien
tzu
chi
hospit
lab
data
show
normocyt
anemia
hemoglobin
gdl
thrombocytopenia
platelet
count
white
blood
cell
count
normal
rang
bandemia
elev
ast
tbi
dbi
pt
aptt
decreas
albumin
note
diagnos
upper
gastrointestin
gi
bleed
system
infect
unknown
sourc
given
prbc
platelet
transfus
pantoprazol
tranexam
acid
terlipressin
flomoxef
initi
empir
antibiot
treatment
result
panendoscopi
reveal
gastric
varic
small
eros
shallow
bleed
ulcer
antrum
bodi
histoacryl
inject
argon
plasma
coagul
previou
equinu
bacteremia
patient
might
uniqu
contact
histori
second
hospit
day
blood
cultur
grew
uncommon
gramposit
bacillu
borderlin
gramneg
stain
figur
clear
rodshap
bacteria
seen
blood
smear
figur
b
coloni
grew
select
blood
agar
plate
figur
c
h
precipit
seen
tripl
sugar
iron
media
figur
isol
identifi
erysipelothrix
rhusiopathia
patient
inde
recent
exposur
wild
boar
deer
formosa
muntjac
flomoxef
switch
ceftriaxon
treatment
echocardiographi
reveal
veget
whole
bodi
inflamm
scintigraphi
demonstr
sourc
inflamm
patient
afebril
admiss
laboratori
data
improv
hospit
stay
discharg
day
ceftriaxon
treatment
conclus
e
rhusiopathia
occur
commonli
occup
diseas
penicillin
cephalosporin
drug
choic
treatment
fatal
case
primari
sternal
osteomyel
present
anterior
wall
abscess
chen
peichen
wang
lishin
chang
paoyuan
school
medicin
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
depart
intern
medicin
depart
radiolog
buddhist
tzu
chi
gener
hospit
hualien
taiwan
background
primari
sternal
osteomyel
pso
rare
yet
potenti
carri
devast
outcom
gener
caus
staphylococcu
aureu
caus
epidermidi
gramneg
bacilli
mycobacterium
tuberculosi
clinician
need
consid
pso
patient
present
anterior
chest
pain
swell
bacteremia
report
case
year
old
femal
present
pso
without
previou
chest
surgeri
trauma
patient
woman
medic
histori
diabet
mellitu
liver
cirrhosi
child
c
present
pain
anterior
chest
wall
swell
one
month
patient
deni
cardiac
surgeri
trauma
acupunctur
histori
began
fever
progress
dyspnea
day
prior
patient
sent
emerg
room
anoth
hospit
debrid
chest
wall
abscess
admit
intens
care
unit
pu
blood
cultur
grew
klebsiella
pneumonia
cefoperazonesulbactam
administ
liver
abscess
consid
possibl
sourc
confirm
transfer
hospit
result
physic
examin
cm
long
cm
wide
cm
deep
open
clean
surgic
wound
cauter
granul
tissu
white
blood
count
wound
cultur
grew
oxacillinresist
aureu
orsa
sputum
cultur
grew
pseudomona
aeruginosa
cefoperazon
sulbactam
switch
pipercillintazobactam
tigecyclin
patient
second
debrid
hospit
day
whole
bodi
inflamm
scan
chest
comput
tomographi
figur
show
sternal
osteomyel
mediastin
pericard
tigecyclin
switch
daptomycin
coverag
orsa
sternectomi
day
wound
cultur
grew
k
pneumonia
pipercillintazobactam
switch
cefmetazol
howev
infect
nt
well
control
alter
conscious
die
hospit
day
conclus
due
rare
clinic
experi
standard
approach
pso
howev
present
pso
insidi
diagnosi
often
delay
pso
born
mind
patient
present
anterior
wall
abscess
streptococc
toxic
shock
syndrom
present
purpura
fulminan
yuhshyan
wu
lihshinn
wang
yaru
wu
sishiuan
peng
background
purpura
fulminan
rare
syndrom
intravascular
thrombosi
hemorrhag
infarct
accompani
vascular
collaps
dissemin
intravascular
coagul
dic
typic
associ
meningococc
infect
rapidli
progress
patient
case
streptococc
toxic
shock
syndrom
present
symmetr
peripher
gangren
necrosi
larg
area
skin
limb
method
patient
obes
woman
came
hospit
yellowish
product
cough
one
week
fever
day
septic
shock
develop
hospit
stay
transfer
intens
care
unit
resuscit
progress
swollen
face
eyelid
neck
head
neck
chest
abdomen
ct
disclos
extens
cellul
neck
result
laboratori
data
admiss
reveal
leukocytosi
left
shift
acut
kidney
injuri
lactat
acidosi
blood
cultur
show
group
betahemolyt
streptococcu
examin
pleural
fluid
disclos
gramposit
cocci
cultur
sputum
pleural
fluid
urin
show
neg
find
patient
treat
vancomycin
meropenem
clindamycin
day
admiss
fever
blood
cultur
grew
candida
albican
sputum
cultur
also
grew
candida
albican
candida
tropicali
cathet
urin
cultur
steril
antifung
agent
administ
gangren
bilater
upper
lower
limb
right
upper
chest
hospit
day
manifest
consist
purpura
fulminan
dic
treat
platelet
transfus
anticoagul
day
admiss
bilater
knee
amput
day
admiss
dic
develop
laboratori
data
reveal
prolong
aptt
sec
low
platelet
ul
elev
level
dimer
ngml
amput
hand
also
suggest
famili
refus
manag
patient
hospic
discharg
due
termin
condit
conclus
purpura
fulminan
rare
commonli
occur
babi
small
children
rare
adult
sever
sepsi
purpura
fulminan
typic
develop
distal
extrem
progress
proxim
affect
whole
bodi
surfac
adult
patient
sepsisassoci
purpura
fulminan
die
histoplasmosi
usual
selflimit
local
immunocompet
individu
dissemin
diseas
usual
occur
immunocompromis
patient
patient
chronic
ill
describ
taiwanes
human
immunodefici
viral
infect
histoplasmosi
method
man
deni
major
system
disord
foreign
countri
travel
admiss
present
emerg
room
fever
cough
abdomin
full
bodi
weight
loss
associ
thrombocytopenia
platelet
ul
caviti
left
upper
lung
zone
hepatosplenomegali
note
initi
admiss
acut
human
immunodefici
viral
infect
diagnos
laboratori
data
also
reveal
hypertriglyceridemia
high
ferritin
receiv
antiretrovir
therapi
immedi
due
suspect
virusassoci
hemophagocyt
syndrom
bone
marrow
studi
also
arrang
hypotens
metabol
acidosi
respiratori
failur
still
develop
fifth
day
hospit
result
bone
marrow
studi
reveal
abund
yeastlik
microorgan
histiocyt
hemophagocytosi
serum
galactomannan
test
posit
result
also
liposom
amphotericin
b
administ
invas
fungal
infect
three
week
later
blood
fungal
cultur
collect
admiss
bone
marrow
fungal
cultur
yield
histoplasma
spp
liposom
amphotericin
b
switch
voriconazol
oral
extub
success
discharg
day
hospit
conclus
histoplasmosi
rare
diseas
taiwan
microbiolog
document
case
previous
report
commonli
diagnos
area
endem
frequent
overlook
area
nonendem
due
low
index
suspicion
among
physician
hivinfect
patient
present
thrombocytopenia
hemophagocytot
syndrom
cavitari
pulmonari
lesion
differenti
diagnosi
histoplasmosi
kept
mind
imag
sepsisassoci
encephalopathi
masaki
fujioka
akihiro
shindo
kei
suzuki
mie
univers
hospit
emerg
critic
care
center
mie
univers
graduat
school
medicin
depart
neurolog
background
sepsisassoci
encephalopathi
sae
refer
acut
neurolog
dysfunct
aris
context
extracrani
sepsi
despit
use
varieti
diagnost
techniqu
howev
sae
remain
clinic
diagnosi
could
repres
varieti
pathophysiolog
process
relat
unrel
coexist
sepsi
herein
describ
impress
imag
patient
sae
method
experienc
man
prolong
fever
diarrhea
progress
coma
brought
hospit
laboratori
test
reveal
multipl
organ
failur
comput
tomographi
scan
show
sever
intestin
inflamm
initi
resuscit
initi
septic
shock
due
sever
enter
gener
condit
gradual
improv
without
conscious
restor
day
glasgow
coma
scale
gc
score
mri
continuousuli
perform
result
mri
show
enhanc
fluidattenu
invers
recoveri
flair
signal
white
matter
susceptibilityweight
imag
reveal
multipl
microble
find
indic
sae
associ
extracrani
sepsi
pathophysiolog
thought
involv
bloodbrainbarri
leakag
gc
score
improv
flair
signal
enhanc
white
matter
decreas
day
furthermor
mri
show
decreas
enhanc
day
without
improv
conscious
diffus
sever
white
matter
abnorm
like
observ
patient
rare
associ
poor
outcom
case
show
sever
encephalopathi
extens
white
matter
lesion
might
revers
condit
clinician
realiz
condit
give
cautiou
eye
first
sign
improv
clinic
condit
deem
necessari
followup
repeat
mri
studi
scheme
test
clostridium
difficil
rapid
improv
perform
detect
c
difficileassoci
diarrhea
cdad
jiannyuan
chen
ijen
wang
lingna
shih
jiinchyr
hsu
depart
laboratori
medicin
taipei
hospit
ministri
health
welfar
taiwan
background
clostridium
difficil
cd
common
caus
hospitalacquir
diarrhea
usual
associ
previou
antibiot
use
c
difficileassoci
diarrhea
cdad
strongli
associ
fluoroquinolon
cephalosporin
carbapenem
clindamycin
common
caus
pseudomembran
coliti
pmc
clostridium
difficil
consid
diarrhea
case
histori
antibiot
use
within
last
week
communityassoci
cdi
hospit
stay
least
day
regardless
durat
antibiot
use
hospitalacquir
cdi
method
stool
collect
suspect
cd
infect
case
year
age
admit
two
region
hospit
north
taiwan
sampl
period
novemb
may
effect
analysi
glutam
dehydrogenas
antigen
gdh
toxin
ab
combin
assay
brand
rida
quick
versu
twostep
algorithm
optim
detect
toxigen
cd
twostep
algorithm
stool
use
rida
quick
gdh
screen
posit
test
toxin
rida
quick
toxin
ab
test
toxin
toxin
b
singl
brand
b
mascia
brunelli
doubl
check
underw
anaerob
stool
cultur
cycloserin
cefoxitin
fructos
agar
ccfa
result
month
calcul
laboratori
expens
less
combin
assay
alon
brand
b
test
kit
provid
rapid
turnaround
time
anaerob
stool
cultur
hour
vs
hour
total
suspect
cdi
patient
gdh
posit
toxin
ab
posit
distribut
sex
age
cd
colon
gdh
male
femal
age
group
year
two
gdhposit
toxin
ab
posit
test
risk
toxigen
cd
gdh
toxin
ab
infect
male
femal
signific
vs
conclus
studi
suggest
one
twostep
algorithm
detect
cd
infect
reliabl
costeffect
timesav
strategi
preval
toxicgen
cd
infect
base
twostep
algorithm
similar
report
previou
literatur
taiwan
gdh
antigen
posit
match
compar
cultur
ccfa
agar
indentifi
clostridium
difficil
also
prove
c
difficil
strain
appear
produc
cell
wallassoci
enzym
glutam
dehydrogenas
antigen
gdh
clinic
characterist
bacteraemia
caus
burkholderia
cepacia
complex
speci
antimicrobi
suscept
isol
medic
centr
taiwan
yingchun
chien
chunhs
liao
wanghuei
sheng
jungyien
chien
yutsung
huang
chongjen
yu
poren
hsueh
background
data
bacteraemia
caus
burkholderia
cepacia
complex
bcc
among
patient
without
cystic
fibrosi
limit
studi
intend
investig
clinic
characterist
outcom
patient
bacteraemia
due
differ
speci
bcc
method
patient
bcc
bacteraemia
treat
medic
centr
januari
februari
evalu
bcc
isol
identifi
speci
level
bruker
biotyp
malditof
ms
sequenc
analysi
rrna
reca
gene
antimicrobi
suscept
isol
determin
agar
dilut
method
result
sequenc
reca
gene
blood
isol
reveal
isol
b
cenocepacia
b
cepacia
isol
b
multivoran
one
isol
b
arbori
b
pseudomultivoran
b
seminali
b
vietnamiensi
overal
perform
bruker
biotyp
malditof
ms
system
correctli
identifi
bcc
isol
speci
level
better
rna
sequenc
analysi
bacteraem
pneumonia
n
catheterrel
bacteraemia
n
common
type
infect
higher
rate
ceftazidim
meropenem
resist
found
b
cepacia
isol
respect
isol
b
cenocepacia
respect
speci
respect
overal
mortal
rate
bacteraemia
caus
bcc
speci
b
cenocepacia
b
cepacia
adjust
odd
ratio
aor
p
high
sofa
score
aor
p
predict
higher
mortal
conclus
correct
identif
bcc
complex
speci
level
import
differ
bcc
complex
speci
associ
differ
outcom
bacteraemia
exhibit
differ
suscept
pattern
evalu
tpla
initi
syphilisscreen
test
ryosei
murai
koji
yamada
nozomi
yanagihara
satoshi
takahashi
divis
laboratori
medicin
sapporo
medic
univers
hospit
depart
infect
control
laboratori
medicin
sapporo
medic
univers
school
medicin
background
syphili
serolog
test
divid
nontreponem
treponem
test
neither
suffici
alon
diagnosi
tradit
initi
syphili
screen
begin
nontreponem
test
tradit
algorithm
howev
recent
advanc
instrument
enabl
autom
object
approach
treponem
test
revers
algorithm
revers
algorithm
initi
syphili
screen
limit
enzym
immunoassay
eia
chemiluminesc
immunoassay
cia
recent
tpla
method
use
treponema
pallidum
compon
coat
latex
particl
use
chemic
wide
use
automat
analyz
develop
evalu
use
reagent
instead
eia
cia
initi
syphili
screen
revers
algorithm
method
total
store
sampl
react
mediac
tpla
sekisui
medic
co
tokyo
japan
mediac
rpr
sekisui
medic
co
tokyo
japan
test
evalu
four
differ
autom
syphili
serolog
test
includ
architect
syphili
tp
abbott
diagnost
tokyo
japan
lumipuls
presto
tp
fujirebio
inc
tokyo
japan
serodia
fujirebio
inc
tokyo
japan
esplain
tp
fujirebio
inc
tokyo
japan
sampl
store
thaw
immedi
prior
analysi
confirm
result
ftaab
tppa
result
analysi
sampl
test
posit
mediac
tpla
fals
posit
rate
howev
falseneg
rate
mediac
tpla
wherea
lumipuls
presto
tp
architect
syphili
tp
conclus
perform
mediac
tpla
nearli
equival
lumipuls
presto
architect
syphili
tp
cost
per
test
mediac
tpla
lower
test
mediac
tpla
variou
advantag
low
cost
high
igmdetect
power
easi
oper
recommend
initi
screen
test
use
new
method
cultur
c
difficil
environ
chihchen
lin
changpan
liu
fuchieh
chang
infect
control
center
mackay
memori
hospit
depart
infect
mackay
memori
hospit
background
c
difficil
gramposit
bacillu
belong
anaerob
bacteria
contain
spore
previou
studi
bacterium
surviv
hard
situat
month
longer
clinic
nt
disinfect
complet
provid
chanc
spread
effici
method
cultur
bacterium
environ
would
use
infect
control
method
studi
use
banana
broth
select
broth
collect
sampl
environ
cdi
patient
use
use
swab
normal
salin
touch
surfac
put
swab
broth
cultur
without
anaerob
incubact
hour
check
color
broth
c
difficil
growth
broth
color
becom
yellow
result
studi
collect
sampl
environ
broth
chang
yellow
pcr
check
bacterium
c
difficil
say
broth
select
broth
c
difficil
conclus
studi
found
banana
broth
great
select
broth
cultur
c
difficil
without
anaerob
incub
otherwis
chang
color
easi
staff
check
result
nt
need
cultur
use
ccfa
agar
burkholderia
pseudomallei
caus
urinari
tract
infect
fever
case
report
yintai
tsai
tzuy
lee
ruotzu
li
chuanru
wang
chiahsin
hsieh
juihua
hsu
mengt
hsieh
wenshyang
hsieh
hsaiowei
wang
yungch
liu
present
case
urinari
tract
infect
fever
caus
burkholderia
pseudomallei
admit
northern
regin
hospit
taiwan
case
present
highlight
identif
rare
pathogen
organ
laboratori
sampl
collect
start
treatment
earli
better
prognosi
sinc
mortal
high
without
treatment
method
male
present
emerg
depart
symptom
breath
heavili
hematuria
fever
examin
patient
suspect
urinari
tract
infect
sampl
urin
blood
pu
collect
use
steril
swab
discharg
cellul
sent
microbiolog
laboratori
cultur
antimicrobi
suscept
test
microbiolog
cultur
identif
reveal
etiolog
agent
burkholderia
pseudomallei
organ
suscept
ceftazidim
trimethoprimsulfamethoxazol
strain
resist
amikacillin
colistin
fast
blood
glucos
mgdl
result
patient
start
ciprofloxacin
ceftazidim
doripenemimipenemmeropenem
least
day
put
antidiabet
therapi
second
sampl
blood
collect
five
day
neg
cultur
conclus
urinari
tract
infect
common
diabet
diabet
patient
b
pseudomallei
rare
pathogen
caus
infect
organ
overlook
routin
cultur
contamin
especi
bacteri
growth
cultur
plate
polymicrobi
identif
requir
great
deal
clinic
suspicion
well
alert
part
laboratori
personnel
melioidosi
caus
consid
differenti
diagnosi
diabet
men
urinari
tract
infect
especi
come
area
melioidosi
preval
appropri
treatment
must
initi
prevent
complic
diagnost
accuraci
releas
assay
latent
tuberculosi
infect
children
age
year
fangch
liu
yuanhsin
chu
divis
infecti
diseas
jenai
hospit
depart
infect
control
jenai
hospit
background
taiwan
cdc
promot
tb
prevent
program
introduc
intern
recommend
new
ltbi
diagnost
test
igra
releas
assay
treatment
prescript
tb
contact
age
group
march
igra
wide
use
diagnosi
latent
activ
tuberculosi
adult
role
diagnos
ltbi
children
younger
year
remain
debat
perform
ebm
approach
evalu
diagnost
accuraci
ltbi
children
age
year
method
pico
formul
p
children
year
old
igra
interferongamma
diagnost
accuraci
ltbi
term
synonym
engag
boolean
charact
keyword
search
cochran
librari
pubm
databas
clinic
diagnost
question
accord
oxford
level
evid
systemat
review
sr
crosssect
studi
refer
standard
would
best
evid
pubm
relev
sr
retriev
search
result
critic
apprais
conclus
though
taiwan
cdc
still
use
tst
diagnost
tool
ltbi
children
younger
year
probabl
due
blood
draw
difficult
young
kid
consider
costeffect
howev
level
evid
show
diagnost
perform
igra
slightli
higher
tst
use
support
assay
detect
ltbi
children
age
year
ps
case
hematolog
malign
caus
gastrointestin
perfor
kazuhiko
natori
daisuk
nagas
akiko
shibuya
yurika
mitsui
yasunobu
kuraishi
haruka
fujino
divis
hematolog
oncolog
toho
univers
medic
center
oomori
hospit
background
common
malign
lymphoma
infiltr
digest
tract
may
also
caus
gastrointestin
perfor
start
chemotherapi
result
good
respons
therapi
occurr
gastrointestin
perfor
chemotherapi
often
lead
fatal
outcom
report
experi
patient
develop
gastrointestin
perfor
observ
malign
lymphoma
method
among
patient
histopatholog
diagnos
hematolog
malign
patient
gastrointestin
perfor
select
histopatholog
diagnosi
consist
classif
tumour
haematopoiet
lymphoid
tissu
fourth
edit
result
ratio
men
women
median
age
year
rang
year
histopatholog
type
nonhodgkin
lymphoma
patient
subtyp
tcell
leukemialymphoma
atll
patient
follicular
lymphoma
patient
diffus
larg
bcell
lymphoma
patient
diffus
larg
tcell
lymphoma
patient
multipl
myeoma
case
malign
lymphoma
accord
ann
arbor
stage
system
clinic
stage
ie
patient
patient
iv
patient
perfor
occur
prior
chemotherapi
patient
complet
first
cycl
chemotherapi
patient
cycl
patient
cycl
patient
advanc
stage
chemotherapyrefractori
lymphoma
patient
recurr
complet
respons
patient
conclus
accord
experi
suggest
cur
resect
mandatori
patient
undergo
surgeri
gastrointestin
perfor
import
start
chemotherapi
earli
postop
period
select
safer
surgic
procedur
limit
surgeri
flexibl
assess
necess
remov
lesion
background
serum
procalcitonin
pct
tout
diagnost
marker
predict
sever
bacteri
infect
day
studi
perform
evalu
use
pct
diagnosi
variou
type
bacteri
infect
children
compar
inflammatori
marker
method
retrospect
review
medic
record
patient
age
year
admit
chung
ang
univers
hospit
juli
june
pct
valu
obtain
patient
categor
bacteri
infect
group
nonbacteri
infect
group
furthermor
bacteri
infect
group
categor
invas
bacteri
infect
ibi
mucos
bacteri
infect
mbi
toxigen
bacteri
infect
tbi
mycoplasma
infect
mi
group
ibi
defin
infect
steril
bodi
site
bacteremia
mening
osteomyel
pyelonephr
staphylococc
scald
skin
syndrom
scarlet
fever
includ
tbi
mi
defin
posit
mycoplasma
igm
iuml
mycoplasma
pcr
result
patient
patient
diagnos
bacteri
infect
among
bacteri
infect
group
case
identifi
ibi
case
mbi
case
tbi
case
mi
group
valu
pct
vs
creactiv
protein
crp
vs
white
blood
cell
wbc
vs
count
higher
bacteri
infect
group
nonbacteri
infect
group
p
howev
valu
pct
higher
ibi
group
bacteri
group
vs
mbi
tbi
mi
p
receiv
oper
characterist
roc
analysi
area
curv
pct
crp
wbc
erythrocyt
sediment
rate
esr
specif
serum
pct
diagnos
invas
bacteri
infect
significantli
larger
inflammatori
marker
crp
wbc
esr
conclus
pct
highli
effect
diagnost
marker
ibi
effect
differenti
mbi
tbi
mi
nonbacteri
infect
also
pct
use
marker
predict
bacteri
infect
crp
wbc
esr
investig
incid
antimicrobi
suscept
test
elizabethkingia
meningoseptica
teach
hospit
yaoshen
tung
anchi
chen
shenmin
huang
yuiyein
yang
lihung
wu
show
chwan
memori
hospit
depart
medic
laboratori
background
increas
emerg
antibioticresist
nosocomi
infect
worldwid
concern
e
meningoseptica
infect
inhuman
present
mening
outbreak
prematur
newborn
infant
uniqu
antibiot
suscept
pattern
resist
mani
antibiot
commonli
use
treat
infect
caus
gramneg
bacteria
challeng
clinician
treat
patient
method
studi
e
meningoseptica
clinic
isol
collect
teach
hospit
phoenix
autom
microbiolog
system
becton
dickinson
gn
panel
use
identifi
bacteria
confirm
antimicrobi
suscept
antimicrobi
suscept
kind
antibiot
test
result
incid
e
meningoseptica
isol
increas
among
sputum
blood
sampl
isol
form
intens
care
unit
icu
vitro
antimicrobi
suscept
test
result
present
tabl
e
meningoseptica
often
suscept
trimethoprimsulfamethoxzol
fluoroquinolon
includ
levofloxacin
ciprofloxacin
howev
antibiot
target
gramneg
bacteria
effect
conclus
e
meningoseptica
high
resist
variou
antimicrobi
agent
pneumonia
common
infect
caus
e
meningoseptica
mortal
rate
quit
high
howev
despit
high
mortal
rate
rate
appropri
antibiot
use
notabl
low
clinician
pay
attent
diseas
progress
evalu
respons
current
antibiot
possibl
consid
use
effect
antibiot
base
cultur
report
coresist
antimicrobi
agent
extendedspectrum
produc
e
coli
region
teach
hospit
southern
taiwan
implic
clinic
treatment
yipe
chen
poliang
lu
chunchi
huang
jengyih
wu
chenmin
kuo
tungnan
liao
background
extendedspectrum
produc
e
coli
esbl
coli
import
nosocomi
pathogen
taiwan
report
esbl
coli
isol
resist
multipl
antimicrobi
agent
relat
data
less
known
region
hospit
taiwan
method
retrospect
analyz
antimicrobi
resist
profil
e
coli
collect
sep
aug
region
hospit
southern
taiwan
first
isol
recov
one
person
includ
analysi
esbl
phenotyp
drug
suscept
test
perform
vitek
compact
system
odd
ratio
estim
sa
jmp
softwar
version
result
among
e
coli
isol
isol
produc
esbl
suscept
rate
antimicrobi
agent
esbl
coli
ampicillin
amikacin
ceftazidim
cefazolin
cefepim
coresist
esbl
phenotyp
observ
ampicillin
ceftazidim
cefazolin
cefepim
gemtamicin
sulfamethoxazol
levofloxacin
ampicillinsulbactam
conclus
epidemiolog
data
region
hospit
taiwan
reveal
esbl
coli
suscept
amikacin
ertapenem
tigecyclin
colistin
piperacillintazobactam
besid
coresist
esbl
phenotyp
test
betalactam
coresist
also
observ
gemtamicin
sulfamethoxazol
ampicillinsulbactam
levofloxacin
extent
coresist
may
impact
choic
empir
antimicrobi
therapi
acinetobact
calcoaceticusa
baumannii
complex
taiwan
tsail
yang
lauderdal
huiy
wang
yihru
shiau
juifen
lai
iwen
huanag
tsar
hospit
nation
institut
infecti
diseas
vaccinolog
nation
health
research
institut
background
calcoaceticusa
baumannii
acb
complex
compris
four
genospeci
baumannii
calcoaceticu
nosocomiali
pittii
consider
differ
exist
epidemiolog
clinic
relev
routin
differenti
genospeci
commonli
done
present
studi
investig
distribut
antimicrobi
suscept
acb
complex
genospeci
taiwan
surveil
antimicrobi
resist
tsar
program
method
acinetobact
isol
collect
biennial
part
tsar
program
hospit
use
collect
protocol
suscept
differ
antimicrobi
agent
determin
broth
microdilut
everi
studi
year
colistin
test
acb
complex
isol
subject
gyrb
genospeci
type
differenti
speci
data
group
togeth
compar
combin
data
result
total
acb
complex
isol
identifi
includ
isol
isol
isol
isol
isol
respect
isol
isol
isol
proport
baumannii
decreas
nosocomiali
increas
p
pitti
remain
stabl
around
specimen
distribut
differ
among
baumannii
nosocomiali
pitti
isol
respect
respiratori
tract
respect
blood
carbapenem
nonsuscept
acb
complex
overal
p
ns
significantli
higher
baumannii
nosocomiali
pitti
colistin
resist
detect
detect
conclus
preval
carbapenem
resist
baumannii
remain
high
taiwan
chang
acb
complex
genospeci
distribut
recent
year
plu
differ
antimicrobi
suscept
specimen
distribut
indic
need
continu
surveil
import
group
pathogen
studi
integron
multidrugresist
escherichia
coli
isol
chaotsai
liao
yachi
shin
tienyu
yeh
depart
medic
laboratori
scienc
biotechnolog
central
taiwan
univers
scienc
technolog
background
integron
genet
element
capabl
integr
mobil
gene
cassett
encod
antibiot
resist
determin
escherichia
coli
often
resist
multipl
antimicrobi
agent
often
associ
product
extendedspectrum
esbl
frequent
describ
part
complex
integron
facilit
horizont
transfer
relat
unrel
microb
aim
studi
defin
current
preval
phenotyp
multidrugresist
mdr
e
coli
isol
clinic
specimen
central
taiwan
investig
associ
multidrug
resist
exist
integron
method
nondupl
mdr
e
coli
isol
januari
juli
use
studi
firstli
suscept
isol
antibiot
determin
vitek
system
extendedspectrum
product
detect
disk
diffus
confirmatori
test
preval
class
integron
detect
mdr
strain
polymeras
chain
reactionrestrict
fragment
length
polymorph
pcrrflp
final
gene
cassett
array
class
integron
identifi
pcr
dna
sequenc
restrict
enzym
digest
result
extendedspectrum
product
detect
e
coli
isol
disk
diffus
confirmatori
test
antibiot
resist
pattern
follow
ampicillin
ampicillinsulbactam
amikacin
ceftazidim
ciprofloxacin
ceftriaxon
cefazolin
imipenem
gentamicin
cefoxitin
sulfamethoxazol
trimethoprim
piperacillintazobactam
pcrrflp
result
show
preval
integron
confirm
mdr
isol
class
integron
detect
respect
mdr
strain
moreov
strain
found
contain
class
integron
integron
class
detect
isol
integron
isol
contain
constant
gene
cassett
array
confer
resist
trimethoprim
streptomycin
conclus
studi
mdr
e
coli
isol
resist
four
differ
antibiot
common
data
suggest
multipl
complex
mechan
involv
mobil
genet
element
class
class
integron
antibiot
resist
develop
evolut
e
coli
strain
taiwan
clinic
characterist
patient
bloodstream
infect
caus
enterobacteriacea
tertiari
hospit
japan
nobuaki
mori
yasuko
aoki
akiko
higuchi
shoko
hiros
shiko
seki
depart
gener
intern
medicin
nation
hospit
organ
tokyo
medic
center
departmet
clinic
laboratori
nation
hospit
organ
tokyo
medic
center
depart
pharmacolog
nation
hospit
organ
tokyo
medic
center
depart
surgeri
nation
hospit
organ
tokyo
medic
center
background
infect
caus
carbapenemaseproduc
enterobacteriacea
report
worldwid
becom
great
threat
public
health
howev
clinic
characterist
patient
bloodstream
infect
bsi
due
metallo
mbl
produc
enterobacteriacea
well
studi
therefor
investig
clinic
characterist
patient
infect
mblproduc
enterobacteriacea
method
retrospect
conduct
chart
review
patient
mblproduc
enterobacteriacea
isol
blood
sampl
tertiari
care
hospit
japan
april
march
mblproduc
enterobacteriacea
defin
isol
blood
cultur
show
decreas
suscept
meropenem
minimum
inhibitori
concentr
mgdl
posit
result
test
use
sma
eiken
eiken
chemic
co
japan
clinic
microbiolog
characterist
therapeut
outcom
patient
investig
result
studi
period
total
adult
patient
identifi
median
age
year
women
patient
sever
underli
diseas
time
admiss
cardiopulmonari
arrest
n
invas
pneumococc
infect
n
bleed
esophag
varic
n
periton
due
diverticul
perfor
n
patient
admit
intens
care
unit
sourc
mblproduc
enterobacteriacea
bsi
follow
catheterrel
bsi
n
pyelonephr
n
cholang
n
bacteri
periton
n
bacteri
transloc
n
isol
enterobact
cloaca
klebsiella
pneumonia
immunochromatographi
assay
show
isol
imptyp
isol
resist
levofloxacin
aminoglycosid
patient
previou
histori
antibiot
treatment
isol
isol
day
hospit
patient
treat
either
levofloxacin
levofloxacin
aminoglycosid
microbiolog
respons
rate
base
result
cultur
test
use
sampl
origin
infect
site
howev
allcaus
mortal
rate
conclus
studi
show
mblproduc
enterobacteriacea
bsi
fatal
although
rare
patient
sever
diseas
longterm
hospit
research
necessari
studi
appropri
treatment
option
mblproduc
bsi
includ
levofloxacin
treatment
base
antimicrobi
suscept
test
result
object
increas
methicillinresist
staphylococcu
aureu
mrsa
world
surgic
sit
infect
caus
mrsa
also
increas
health
care
worker
hcw
carri
mrsa
role
transmiss
mrsa
hospit
studi
investig
carriag
rate
aureu
mrsa
surgic
hcw
hospit
molecular
epidemiolog
analysi
aureu
strain
method
pharynx
swab
collect
hcw
work
surgic
ward
medic
ward
oper
room
marchapril
swab
cultur
mannitol
salt
agar
choos
suspicion
coloni
isol
identifi
aureu
base
morpholog
coagulas
test
vitek
test
antibiot
suscept
test
isol
perform
modifi
kirbi
bauer
disc
diffus
method
isol
recogn
mrsa
resist
oxacillin
isol
analyz
epidemiolog
related
pulsedfield
gel
electrophoresi
pfge
result
healthcar
worker
carri
aureu
carri
mrsa
mrsa
carriag
rate
highest
among
nurs
carriag
rate
among
doctor
howev
differ
signific
p
carriag
rate
surgic
ward
ward
b
ward
c
ward
oper
room
similarli
differ
depart
ward
signific
p
pfge
analysi
isol
group
five
similar
group
ae
largest
number
isol
belong
group
e
account
hand
two
mrsa
isol
surgic
ward
c
ident
term
pfge
denderogram
conclus
mean
carriag
rate
aureu
among
healthcar
worker
similar
countri
world
mrsa
carriag
rate
lower
develop
countri
carriag
rate
surgic
ward
significantli
differ
ward
surgic
sit
infect
caus
aureu
relat
differ
hcw
aureu
carriag
pfge
denderogram
gave
popular
gene
group
aureu
might
help
surgic
sit
infect
control
ribotyp
antimicrobi
suscept
among
clinic
toxigen
clostridium
difficil
isol
taiwan
yuanpin
hung
yuanti
lee
hungjen
tang
hsiaoju
lin
hsiuchuan
liu
jenchieh
lee
peijan
tsai
boyang
tsai
poren
hsueh
wenchien
ko
background
clostridium
difficil
hypervirul
strain
includ
report
taiwan
data
toxin
gene
ribotyp
distribut
toxigen
c
difficil
isol
taiwan
remain
limit
method
studi
conduct
januari
decemb
five
hospit
taiwan
stool
cultur
c
difficil
done
fecal
sampl
patient
diarrhea
multiplex
pcr
use
detect
tcda
tcdb
cdta
cdtb
tcdc
delet
antimicrobi
suscept
investig
toxigen
c
difficil
isol
ribotyp
rt
isol
tcdc
delet
tcdatcdb
determin
result
c
difficil
isol
collect
five
hospit
isol
toxigen
tcdatcdb
tcda
tcdb
toxigen
isol
isol
tcdc
delet
binari
toxin
ie
hypervirul
isol
famili
isol
includ
famili
includ
predomin
tcdatcdb
isol
isol
identifi
metronidazol
vancomycin
resist
though
rare
present
respect
toxigen
isol
note
isol
resist
metronidazol
vancomycin
irrespect
toxigen
nontoxigen
isol
mic
doxycyclin
higher
tigecyclin
suggest
potent
antibacteri
activ
tigecyclin
doxycyclin
conclus
hypervirul
isol
account
toxigen
isol
taiwan
domin
ribotyp
famili
metronidazol
vancomycin
remain
activ
vast
major
c
difficil
isol
methicillinresist
staphylococcu
aureu
mrsa
clone
prefer
nasal
extranas
site
acut
subacut
healthcar
set
angela
chow
jani
ong
jiawei
lim
aungaung
hein
grace
tin
vanessa
lim
depart
clinic
epidemiolog
tan
tock
seng
hospit
infect
control
unit
tan
tock
seng
hospit
background
methicillinresist
staphylococcu
aureu
mrsa
common
healthcareassoci
multidrugresist
organ
intermediatecar
itc
longterm
care
ltc
facil
observ
greater
divers
mrsa
clone
acutecar
hospit
ach
differenti
factor
associ
colon
differ
mrsa
clone
well
studi
sought
compar
contrast
factor
associ
colon
variou
mrsa
clone
among
patient
contemporan
hospit
across
acut
subacut
healthcar
set
method
two
consecut
year
junejuli
junejuli
screen
randomlyselect
inpati
hour
stay
ach
inpati
affili
itc
ltc
facil
singapor
separ
nasal
axillari
groin
swab
cultur
mrsa
isol
subject
wholegenom
sequenc
clinic
data
subsequ
obtain
medic
record
account
cluster
multivari
multinomi
regress
model
construct
assess
factor
associ
colon
major
mrsa
clone
use
sa
proc
glimmix
result
total
sampl
patient
screen
mrsa
mrsa
isol
sampl
sequenc
type
howev
groin
time
like
nare
colon
aor
conclus
colon
mrsa
clone
differ
nasal
extranas
site
acut
subacut
healthcar
set
regardless
healthcar
facil
contact
precaut
taken
recent
mrsacolonizersinfect
prevent
mrsa
transmiss
epidemiolog
methicillinresist
staphylococcu
aureu
mrsa
colon
differ
health
care
associ
worker
hsini
shih
hsiangchin
hsu
chiayu
chi
background
methicillinresist
staphylococcu
aureu
mrsa
main
caus
health
careassoci
diseas
burden
health
care
worker
hcw
identifi
sourc
mrsa
numer
outbreak
investig
epidemiolog
mrsa
nasal
colon
rang
hcw
studi
yet
outofhospit
health
care
provid
limit
data
studi
aim
character
risk
factor
molecular
epidemiolog
characterist
mrsa
colon
outofhospit
health
care
provid
hcw
teritari
hospit
method
prospect
studi
particip
includ
outofhospit
health
provid
emerg
medic
technician
paramed
nurs
work
long
term
care
facil
inhospit
health
care
provid
physician
nurs
swab
obtain
nare
process
use
standard
laboratori
techniqu
standard
microbiolog
method
use
identifi
methicillinsuscept
aureu
mrsa
molecular
epidemiolog
method
includ
pulsedfield
gel
electrophoresi
pcr
detect
pantonvalentin
leukocidin
sccmec
multilocu
sequenc
type
result
total
outofhospit
health
care
provid
inhospit
hcw
particip
combin
preval
rate
mrsa
major
mrsa
colon
femal
inhospit
nurs
five
outhospit
provid
mrsa
colon
nurs
ci
clinic
servic
year
year
ci
higher
risk
mrsa
colon
eight
differ
strain
mrsa
identifi
pulsedfield
gel
electrophoresi
major
mrsa
sccmec
iv
v
strain
three
carri
pantonvalentin
leukocidin
uniqu
st
type
hospit
nurs
ever
travel
europ
identifi
studi
conclus
find
suggest
substanti
colon
mrsa
among
inhospit
outhospit
health
care
provid
implement
infect
control
strategi
appli
high
prioriti
hcw
trend
carbapenemaseproduc
klebsiella
pneumonia
taiwan
shengkang
chiu
ling
mingchin
chan
changphon
fung
tsulan
wu
yinch
chuang
poliang
lu
janntay
wang
jungchung
lin
kuom
yeh
background
preval
rate
carbapenemaseproduc
klebsiella
pneumonia
cpkp
among
carbapenem
nonsuscept
k
pneumonia
cnskp
isol
taiwan
present
dissemin
trend
cpkp
januari
august
method
twentyon
hospit
taiwan
enrol
studi
k
pneumonia
isol
minimum
inhibitori
concentr
mic
mgl
imipenem
meropenem
collect
carbapenemas
gene
screen
antimicrobi
suscept
test
result
total
cnskp
isol
collect
screen
carbapenemas
gene
test
antimicrobi
suscept
among
cpkp
isol
three
class
carbapenemas
gene
identifi
class
background
lancefield
group
b
streptococci
gb
increas
caus
invas
diseas
among
nonpregn
adult
set
character
gb
isol
adult
portug
method
gb
isol
n
serotyp
assign
clonal
complex
cc
multilocu
sequenc
type
character
surfac
protein
pilu
island
pi
gene
profil
antimicrobi
suscept
test
done
disk
diffus
resist
genotyp
identifi
pcr
high
throughput
sequenc
repres
isol
perform
result
overal
serotyp
ia
frequent
found
popul
follow
serotyp
ib
v
iii
serotyp
ib
increas
significantli
throughout
studi
period
p
becom
frequent
serotyp
isol
belong
includ
isol
serotyp
ib
n
v
n
share
surfac
protein
gene
overal
erythromycin
clindamicin
resist
rate
respect
increas
throughout
p
macrolid
resist
associ
p
serotyp
ib
p
genom
analysi
reveal
lineag
probabl
result
acquisit
type
ib
capsular
operon
singl
larg
recombin
event
kb
repres
macrolid
resist
lineag
conclus
serotyp
genet
lineag
detect
first
time
expand
portug
last
six
year
domin
among
gb
popul
caus
invas
diseas
adult
high
percentag
multidrugresist
pathogen
among
longterm
care
facil
resid
hospit
due
urinari
tract
infect
southern
taiwan
chiam
chang
hsini
shih
chichang
huang
dengchi
yang
yuwei
chen
wenchien
ko
divis
geriatr
gerontolog
depart
intern
medicin
divis
infecti
diseas
depart
intern
medicin
depart
emerg
medicin
nation
cheng
kung
univers
hospit
colleg
medicin
nation
cheng
kung
univers
tainan
taiwan
background
fever
infect
major
caus
transfer
hospit
among
resid
longterm
care
facil
ltcf
rare
studi
infect
ltcf
pathogen
resid
hospit
studi
aim
investig
clinic
characterist
pathogen
antimicrobi
suscept
ltcf
resid
hospit
due
urinari
tract
infect
uti
method
februari
januari
patient
ltcf
sent
emerg
room
er
due
diagnosi
uti
enrol
medic
center
southern
taiwan
clinic
inform
includ
demograph
data
comorbid
condit
function
statu
catheter
statu
collect
urin
cultur
obtain
emerg
room
within
hour
admiss
cultur
gramneg
rod
urin
suscept
result
disc
diffus
method
also
obtain
result
total
patient
enrol
februari
januari
among
patient
male
mean
age
year
rang
year
total
depend
adl
bed
bound
patient
use
urinari
cathet
e
coli
isol
k
pneumonia
p
aeruginosa
common
pathogen
extendedspectrum
betalactamas
esbl
produc
account
e
coli
k
pneumonia
nonesbl
isol
also
show
lower
percentag
suscept
gener
cephalosporin
fluoroquinolon
sulfonamid
suscept
fosfomycin
carbapenem
multidrugresist
mdr
resist
class
account
nonesbl
e
coli
k
pneumonia
isol
respect
p
aeruginosa
also
show
high
percentag
resist
fluoroquinolon
lower
resist
ceftazidim
carbapenem
two
isol
acinetobact
baumannii
pandrugresist
pdr
baumannii
isol
fluoroquinolon
resist
resist
carbapenem
conclus
find
highlight
mdr
resist
commonli
use
oral
antimicrobi
agent
among
ltcf
resid
uti
especi
fluoroquinolon
cephalosporin
empir
antimicrobi
therapi
might
optim
patient
molecular
epidemiolog
antimicrobi
suscept
enterococcu
faecium
clinic
isol
japanes
hospit
asami
matsumoto
yuka
yamagishi
hiroyuki
suematsu
kentaro
oka
motomichi
takahashi
hiroshig
mikamo
background
enterococcu
spp
wellknown
indigen
bacteria
often
isol
human
andor
anim
specimen
gener
speci
nonpathogen
sometim
induc
infecti
diseas
especi
compromis
host
purpos
studi
assess
molecular
type
enterococcu
faecium
isol
singl
site
evalu
associ
andor
differenti
genotyp
infect
site
patient
group
antimicrobi
sensit
method
extract
dna
e
faecium
isol
aichi
medic
univers
hospit
asses
random
amplifi
polymorph
dna
rapd
pcr
method
analys
genotyp
antimicrobi
sensit
examin
raisu
autom
method
nissui
pharmaceut
co
ltd
tokyo
retrospect
analys
patient
background
andor
infect
site
medic
record
character
correl
genotyp
result
result
rapdpcr
show
clinic
isol
e
faecium
classifi
genotyp
type
type
type
type
type
type
result
classif
strain
isol
pu
urin
urinari
cathet
venou
blood
categor
type
strain
isol
choler
ascit
categor
type
type
choler
type
type
ascit
type
type
addit
result
comparison
genotyp
clinic
depart
strain
isol
shown
statist
signific
correl
moreov
result
antimicrobi
sensit
resist
ampicillin
levofloxacin
minomycin
respect
howev
isol
sensit
linezolid
vancomycin
teicoplanin
furthermor
strain
categor
type
resist
ampicillin
levofloxacin
conclus
result
clearli
suggest
correl
genotyp
infect
site
e
faecium
need
analysi
detail
virulenceantimicrobi
resist
gene
genotyp
epidemiolog
studi
salmonella
serogroup
novemb
decemb
region
teach
hospit
middl
taiwan
fangch
liu
chiensheng
cheng
pediatr
jenai
hospit
tali
background
frequenc
salmonella
caus
diarrhea
antibiot
resist
increas
year
attempt
determin
pattern
serogroup
antimicrobi
suscept
salmonella
infect
region
teach
hospit
period
novemb
decemb
method
children
salmonella
enterocol
retrospect
review
epidemiolog
age
sex
clinic
manifest
laboratori
result
record
novemb
decemb
isol
suscept
salmonella
carri
accordingli
standard
microbiolog
method
result
case
record
children
review
beteen
novemb
decemb
patient
whose
stool
underw
complet
test
salmonella
serogroup
majotiri
group
b
group
eight
stool
test
posit
salmonella
rotaviru
infect
overal
case
three
year
age
younger
year
age
fever
diarhea
vomit
bloodi
stool
common
symptom
salmobella
infect
abdomin
pain
p
associ
salmonella
serogroup
infect
resist
rate
ampicillin
trimethoprimsulfamethoxazol
ceftriaxon
cefixim
ciprofloxacin
respect
major
crp
elev
mgdl
mgdl
symptom
salmonella
infect
admiss
day
averag
hospit
date
salmonella
infect
day
conclus
salmonella
gastroenter
import
caus
pathogen
infant
children
studi
less
year
age
preval
salmonella
serogroup
b
decreas
serogroup
predomin
studi
patient
coinfect
rotaviru
salmonella
infect
salmonella
serogroup
isol
studi
highli
suscept
third
cephalosporin
resist
ampicillin
bactrin
rise
resist
antimicrobi
agent
inform
us
ration
antibiot
uag
import
infect
control
background
mani
current
avail
epidemiolog
strain
type
method
includ
antibiogram
pulsedfil
gel
electrophoresi
restrict
fragment
length
polymorph
multilocu
sequenc
type
mlst
among
mlst
wide
use
method
evalu
clonal
mlst
unambigu
procedur
character
isol
use
pairwis
sequenc
analysi
intern
fragment
seven
housekeep
howev
major
disadvantag
mlst
highcost
laborintens
design
microsoft
excelbas
macro
system
autom
analysi
dna
sequenc
seven
housekeep
gene
method
use
excelbas
macro
sequenc
data
call
spreadsheet
stringtyp
text
next
sequenc
revers
primer
replac
complementari
base
sequenc
forward
sequenc
complementari
basereplac
revers
sequenc
assembl
align
match
sequenc
final
assembl
sequenc
compar
prebuilt
databas
construct
onlin
mlst
databas
http
wwwmlstnetdatabas
determin
type
allel
case
nontyp
allel
manual
check
onlin
databas
evalu
accuraci
compar
result
program
result
premanu
determin
sequenc
type
result
chose
fastaformat
text
file
raw
data
call
spreadsheet
analysi
process
raw
data
call
fasta
file
specifi
folder
automat
load
take
run
time
howev
main
advantag
program
runningtim
whole
process
minut
per
strain
much
faster
manual
type
method
would
gener
take
sever
hour
compar
result
manual
type
concord
rate
nontyp
allel
program
reveal
new
allel
type
confirm
manual
conclus
mlst
good
method
epidemiolog
evalu
howev
laborintens
major
disadvantag
design
macrobas
autom
analysi
concord
rate
manual
type
excel
also
program
may
prevent
cleric
error
manual
type
excelbas
macro
use
anyon
construct
uncompl
code
might
use
larg
scale
epidemiolog
studi
accuraci
bleach
concentr
use
medic
center
taiwan
peichun
pan
yingchun
chen
huimei
huang
zhiyuan
shi
infect
control
center
taichung
veteran
gener
hospit
taichung
taiwan
nurs
depart
taichung
veteran
gener
hospit
taichung
taiwan
background
clean
disinfect
contamin
equip
environ
essenti
prevent
healthcareassoci
infect
common
chemic
use
clean
hospit
environ
bleach
sodium
hypochlorit
concentr
bleach
decay
chang
temperatur
light
result
bleach
suboptim
concentr
kill
microorgan
effect
howev
concentr
bleach
routin
check
daili
clean
practic
aim
studi
investig
concentr
variou
brand
bleach
use
hospit
ensur
optim
concentr
bleach
achiev
method
twelv
bleach
chemic
compani
purchas
februari
juli
bleach
dilut
tap
water
presum
concentr
ppm
accord
procedur
suggest
manufactur
dilut
concentr
determin
bleach
concentr
meter
concentr
bleach
vari
averag
dilut
concentr
ppm
concentr
bleach
could
decay
gradual
concern
suboptim
concentr
kill
pathogen
effect
qualiti
assur
manufactur
focu
aspect
first
provid
product
certif
meet
requir
specif
contract
second
assur
appropri
storag
transport
dispens
product
third
perform
product
monitor
system
hospit
care
inspect
qualiti
bleach
reliabl
use
could
hocl
high
level
disinfect
solut
environ
clean
wenjun
yeh
fuchieh
chang
yale
chen
changpan
liu
nanchang
chiu
hsin
chi
infect
control
center
mackay
memori
hospit
depart
infect
mackay
memori
hospit
background
hocl
unstabl
weak
acid
vitro
product
kill
pathogen
studi
want
investig
function
produc
clinic
know
kill
pathogen
surfac
could
cultur
pathogen
surfac
use
tradit
method
check
fuction
method
studi
choic
bed
cultur
termin
disinfect
collect
sampl
environ
use
hocl
high
level
disinfect
solut
clean
disinfect
still
collect
sampl
environ
cultur
incub
hour
check
result
result
result
show
cultur
posit
hocl
clean
disinfect
otherwis
cultur
posit
ratio
chlorin
solut
studi
result
show
differ
method
price
hocl
higher
chlorin
solut
conclus
studi
hocl
solut
function
good
enough
replac
chlorin
solut
even
though
experi
great
vitro
accord
studi
nt
suggest
hospit
use
hocl
solut
high
level
disinfect
solut
environ
clean
improv
food
safeti
tablewar
wash
hospit
taiwan
yuhong
tsai
linlin
pan
depart
laboratori
medicin
chang
gung
memori
hospit
chiayi
background
qualiti
meal
provid
hospit
essenti
patient
nosocomi
food
contamin
caus
variou
foodborn
ill
patient
healthcar
staff
ministri
health
welfar
mohw
abrog
amend
regul
tablewar
examin
whether
regul
enough
monitor
food
safeti
base
experi
nonconform
method
surveil
perform
base
standard
method
test
food
microorganismstest
coliform
bacteria
announc
mohw
taiwan
lauryl
tryptos
broth
lst
eosinmethylen
blue
emb
agar
use
measur
probabl
number
mpn
coliform
bacteria
escherichia
coli
tablewar
meal
result
spoil
meal
inform
ward
first
neg
result
report
mpn
escherichia
coli
tablewar
meal
howev
result
reveal
mpng
coliform
bacteria
meal
threshold
mpng
regul
sanit
standard
gener
food
approv
food
drug
administr
fda
taiwan
klebsiella
pneumonia
isol
contamin
simultan
tablewar
meal
identif
thu
infect
control
teamdriven
intervent
activ
immedi
correct
procedur
tablewar
wash
perform
subcontractor
implement
condit
dryheat
min
food
industri
disinfect
tablewar
surveil
continu
monitor
confirm
clean
reusabl
tablewar
conclus
summari
identifi
contamin
meal
result
inadequ
tablewar
wash
improv
abnorm
procedur
suggest
regul
pathogen
isol
reusabl
dispos
tablewar
consid
establish
hospit
improv
food
safeti
patient
healthcar
staff
investig
abnorm
result
dialysi
water
yale
chen
jihroung
lu
fuchieh
chang
changpan
liu
background
accord
guidelin
dialysi
water
exam
everi
month
refer
rang
lower
cfuml
data
cfuml
higher
cfuml
clinic
staff
engin
find
possibl
reason
caus
data
higher
cfuml
investig
report
situat
caus
data
higher
cfuml
two
month
find
possibl
origin
chang
result
show
use
case
present
chang
method
studi
drew
pictur
check
possibl
site
ro
system
otherwis
collect
dialysi
water
ro
system
use
tgea
agar
cultur
media
hour
incub
check
coloni
count
result
incub
found
ro
system
dialysi
water
qualifi
outlet
ro
system
dialysi
water
unqualifi
otherwis
found
unqualifi
water
cultur
posit
fungu
result
show
fungu
belong
candida
aspergillu
check
data
tri
find
possibl
sourc
conclus
final
found
posit
cultur
site
someth
insid
someth
nearbi
outlet
good
tooth
person
belong
suggest
clinic
staff
clean
space
empti
space
outlet
thank
support
nurs
cultur
posit
data
present
system
analysi
cultur
data
termin
disinfect
yale
chen
fenmei
chen
lichuan
kao
fuchieh
chang
changpan
liu
infect
control
center
mackay
memori
hospit
depart
nurs
mackay
memori
hospit
depart
infect
mackay
memori
hospit
background
know
termin
disinfect
import
prove
new
patient
avoid
bacteria
environ
clinic
suggest
use
dispos
wipe
clean
chlorin
solut
ppm
termin
disinfect
otherwis
taught
cleaner
way
clean
studi
want
check
environ
still
multidrug
resist
organ
clean
method
studi
chose
bed
site
contain
mdro
clean
use
chromogen
agar
cultur
media
hour
incub
check
bacteria
growth
final
antibiot
suscept
test
check
mdro
still
present
result
experi
found
bed
cultur
posit
mdro
bacteria
carbapenemresist
acinetobact
baumannii
carbapenemresist
enterobact
cloaca
cultur
posit
bed
medic
intens
care
unit
conclus
accord
studi
educ
staff
medic
intens
care
unit
besid
ask
cleaner
use
dispos
wipe
everi
time
check
concentr
chlorin
solut
clean
background
accord
chemotherapi
bleach
detect
bacteria
assess
sop
environ
clean
perform
bacteria
test
cultur
dish
need
left
hour
sent
laboratori
cultur
facilit
environment
clean
monitor
petri
dish
inspect
often
laboratori
work
time
evalu
postharvest
petri
dish
place
chemotherapi
room
next
morn
laboratori
cultur
origin
work
manual
implement
process
differ
trap
evalu
test
feasibl
inspect
next
day
method
time
implement
bacteria
test
divid
control
group
immedi
check
collet
time
piec
test
group
petri
dish
everi
day
check
time
piec
observ
result
train
control
group
test
octob
novemb
januari
februari
march
april
test
group
octob
novemb
januari
februari
march
april
respect
implement
train
result
chemotherapi
room
blood
agar
plate
bap
mm
hour
collect
complet
sent
laboratori
train
control
group
submit
six
time
piec
specimen
test
group
submit
six
time
piec
specimen
total
nintysix
sampl
coloni
grown
result
control
group
test
group
consist
figur
conclus
experiment
result
whether
postharvest
petri
dish
immedi
sent
bacteri
chamber
cultur
inspect
petri
dish
everi
day
long
chemic
deploy
room
environ
clean
thoroughli
coloni
cultur
dish
inspect
dispos
appropri
get
good
environ
deploy
chemotherapi
drug
protect
patient
medic
safeti
reduc
hai
implement
environ
clean
separ
manag
measur
use
differ
color
dispos
wipe
swee
siang
wong
chiu
chu
yang
yi
pei
hsieh
chen
ni
kuo
yi
ru
chen
li
ching
chen
ko
chung
tsui
cheng
hua
huang
background
environment
clean
fundament
principl
infect
control
healthcar
set
howev
compar
applic
method
contamin
assess
techniqu
unknown
consensu
exist
around
benchmark
cleanli
sought
determin
whether
implement
environ
clean
separ
manag
measur
medic
intens
care
unit
micu
could
reduc
densiti
healthcar
associ
infect
method
perform
prospect
cohort
intervent
studi
august
decemb
medic
intens
care
unit
tertiari
care
hospit
follow
one
month
preintervent
phase
implement
educ
train
clean
staff
relat
personnel
use
environ
clean
separ
manag
measur
use
differ
color
dispos
wipe
clean
high
tough
surfac
clean
staff
ask
use
red
wipe
clean
toilet
door
knob
isol
room
wast
room
yellow
wipe
clean
patient
bedsid
green
wipe
clean
nurs
station
meet
room
blue
wipe
clean
procedur
tabl
refriger
handl
water
dispens
button
clean
effect
micu
environ
measur
use
atp
bioluminesc
densiti
healthcar
associ
infect
micu
monitor
everi
month
result
atp
bioluminesc
valu
determin
pass
determin
fail
within
studi
period
valu
pass
increas
valu
fail
decreas
numer
differ
trend
pass
valu
increas
fail
valu
decreas
show
use
differ
color
dispos
wipe
correct
wipe
method
wipe
process
improv
environ
cleanli
densiti
healthcar
associ
infect
one
month
intervent
phase
one
month
intervent
phase
conclus
use
environ
clean
separ
manag
measur
effect
cleanli
micu
environ
howev
declin
densiti
healthcar
associ
infect
experi
share
improv
surgic
hand
scrub
water
qualiti
chih
hao
tseng
infect
control
offic
clinic
laboratori
depart
background
accord
new
hospit
accredit
surgeri
anesthesia
depart
regularli
implement
bacteriolog
examin
yet
relev
literatur
suggest
regular
inspect
inspect
implement
associ
epidemiolog
data
requir
confirm
outbreak
howev
consider
healthcar
qualiti
patient
safeti
infect
control
ic
team
routin
collect
cultur
surgic
hand
scrub
water
sampl
total
faucet
oper
room
ic
technician
everi
month
result
less
cfuml
sep
cultur
result
water
sampl
show
abnorm
increas
cfuml
method
ic
team
discuss
head
nurs
rule
anthrop
factor
consciou
ultraviolet
germicid
lamp
uvgl
factor
discuss
public
work
depart
decay
uvgl
recogn
primari
caus
decreas
germicid
efficaci
improv
measur
subsequ
develop
implement
describ
check
wipe
dust
surfac
uv
lamp
everi
week
avoid
penetr
reduct
might
affect
germicid
efficaci
execut
sanitari
staff
includ
practic
routin
clean
work
staff
alway
awar
statu
uvgl
uv
system
alarm
beep
immedi
report
leader
nurs
call
manufactur
renew
uvgl
filter
cartridg
everi
year
everi
six
month
respect
ensur
germicid
abil
result
measur
taken
carri
follow
next
month
water
qualiti
faucet
normal
cfuml
conclus
uv
germicid
lamp
wide
use
steril
gener
thought
uvgl
sustain
germicid
intens
lamp
full
dim
thu
decay
uvgl
tend
neglect
case
fact
germicid
abil
associ
irradi
intens
time
therefor
dust
greas
surfac
uv
lamp
may
reduc
penetr
germicid
efficaci
hope
experi
share
remind
ic
healthcar
worker
link
decay
uv
lamp
incomplet
steril
close
relat
patient
safeti
experi
amelior
abnorm
revers
osmosi
water
qualiti
hemodialysi
room
regin
teach
hospit
huiy
chuang
yeafang
wu
shujiuan
tsai
yalan
chen
meilan
shen
chorngjang
lay
chenchi
tsai
background
typhoon
juli
found
dialysi
machin
bacteri
count
revers
osmosi
ro
dialys
hemodialysi
room
method
survey
found
typhooninduc
turbid
tap
water
contribut
shorten
life
ro
membran
made
provis
problem
includ
chang
ro
membran
disinfect
pipelin
everi
week
sampl
ro
dialysi
disinfect
result
ro
dialysi
sampl
achiev
month
frequenc
pipelin
disinfect
prolong
everi
week
addit
ro
dialysi
sampl
must
perform
immedi
typhoon
result
three
month
procedur
dialysi
machin
ro
dialys
dialysi
machin
ro
dialys
conclus
typhoon
sampl
ro
dialys
bacteri
count
perform
immedi
water
qualiti
abnorm
necessari
chang
ro
membran
reinforc
disinfect
pipelin
guarante
good
qualiti
ro
dialys
effect
ultravioletc
disinfect
system
reduct
multidrugresist
pathogen
juihsuan
yang
unin
wu
hueimin
tai
wanghuei
sheng
depart
intern
medicin
nation
taiwan
univers
hospit
taipei
taiwan
center
infect
control
nation
taiwan
univers
hospit
taipei
taiwan
background
healthcareassoci
infect
caus
multidrugresist
mdr
pathogen
significantli
associ
increas
mortal
morbid
environment
clean
reduc
transmiss
pathogen
often
inadequ
adjunct
touch
method
warrant
enhanc
effect
disinfect
particularli
hospit
set
healthcareassoci
infect
major
concern
method
studi
conduct
nation
taiwan
univers
hospit
acut
care
medic
center
taipei
northern
taiwan
period
octob
march
examin
effect
mobil
automat
devic
hyper
light
disinfect
robot
model
hyper
light
util
ultravioletc
uvc
nm
kill
clinic
strain
mdrpseudomona
aeruginosa
mdracinetobact
baumannii
vancomycinresist
enterococcu
faecium
vre
atcc
strain
methicillinresist
staphylococcu
aureu
mrsa
mycobacterium
abscessu
aspergillu
fumigatu
experiment
set
devic
wheel
differ
strateg
posit
meter
agar
plate
devic
wheel
distanc
meter
set
agar
plate
number
coloni
respect
experi
repeat
minut
exposur
time
perform
devic
disinfect
three
hospit
room
previous
admit
patient
harbor
mrsa
vre
also
assess
result
vitro
log
reduct
veget
bacteria
coloni
observ
uvc
irradi
minut
distanc
meter
devic
except
vre
abscessu
distanc
meter
substanti
compar
reduct
coloni
observ
across
test
bacteria
regardless
exposur
time
kill
effect
less
pronounc
fumigatu
particularli
distanc
meter
unclean
hospit
room
signific
reduct
number
bacteria
coloni
sampl
differ
surfac
uvc
irradi
minut
hour
incub
cfu
vs
cfu
p
hour
incub
cfu
vs
cfu
p
conclus
hyper
light
devic
effect
kill
mdr
pathogen
could
consid
adjunct
method
disinfect
hospit
environ
urinari
tract
infect
associ
crosscontamin
ureteroscop
junghui
chen
meihua
lin
weirong
huang
yich
hsieh
chunyi
lee
mei
huang
background
ureteroscop
minim
invas
procedur
wide
use
examin
treatment
urinari
tract
condit
clean
disinfect
ureteroscop
use
steril
procedur
follow
standard
guidelin
prevent
iatrogen
infect
associ
crosscontamin
may
urolog
depart
hospit
found
patient
fever
urin
cultur
posit
day
ureteroscop
infect
control
group
investig
took
relev
measur
order
avoid
similar
situat
happen
method
urolog
depart
hospit
inform
patient
underw
ureteroscop
may
fever
urin
cultur
posit
day
return
home
infect
control
group
track
data
found
peopl
fever
urin
cultur
posit
among
patient
underw
ureteroscopi
sinc
may
use
ureteroscop
furthermor
urin
cultur
pseudomona
aeruginosa
crpa
preliminari
judg
cluster
event
investig
reveal
ureteroscop
clean
staff
nt
perform
accord
standard
procedur
infect
control
group
interven
immedi
implement
infect
control
measur
follow
modifi
disinfect
method
soak
ureteroscop
enzym
minut
clean
purchas
ureteroscop
brush
clean
lumen
use
brush
clean
ureteroscop
strengthen
examin
ureteroscop
clean
process
suspend
use
problem
ureteroscop
test
qualifi
result
intervent
case
infect
due
ureteroscop
day
june
case
infect
appear
problem
ureteroscop
reus
june
therefor
prompt
anoth
investig
indic
ureteroscop
suspect
damag
longer
use
patient
conclus
contamin
ureteroscop
could
lead
transmiss
infect
result
increas
healthcar
cost
even
lifethreaten
advers
event
compet
train
period
audit
biolog
test
mainten
ureteroscop
import
ensur
qualiti
ureteroscopi
safeti
patient
investig
suspect
outbreak
nontubercul
mycobacteria
infect
associ
bronchoscopi
chunm
lee
hsiutzu
chiang
fuchieh
chang
changpan
liu
background
genu
bacillu
especi
bacillu
cereu
pathogen
patient
immunocompromis
underli
condit
also
contamin
reus
hand
towel
bacillu
cereu
spore
sometim
caus
sever
sepsi
wound
infect
follow
surgeri
howev
treatment
towel
disinfect
wash
process
hardli
remov
contamin
japan
beauti
salon
also
use
steam
reus
towel
remov
cream
facial
treatment
heal
howev
report
bacteri
contamin
steam
towel
studi
investig
contamin
bacteria
reus
towel
steam
warmer
beauti
salon
japan
method
five
steam
towel
use
randomli
select
steam
towel
warmer
test
object
cut
piec
cm
towel
extract
bacteria
salin
examin
contamin
steam
warmer
sampl
collect
cotton
swab
salin
extract
spread
blood
agar
incub
overnight
bacteri
identif
done
sequenc
result
cultur
towel
show
bacillu
spp
contamin
towel
bacteri
number
towel
cfucm
bacteria
detect
steam
warmer
conclus
steam
towel
beauti
salon
heavili
contamin
bacillu
spp
accordingli
recommend
use
dispos
hand
towel
treatment
beauti
salon
impact
regular
urin
drainag
bag
outlet
disinfect
urin
cultur
yuyi
yang
meiyu
wu
chunhs
liao
infect
control
center
far
eastern
memori
hospit
background
taiwan
cdc
prevent
cathet
relat
urinari
tract
infect
bundl
care
program
board
ask
particip
hospit
disinfect
outlet
urinari
drainag
bag
open
recommend
base
limit
evid
order
understand
effect
perform
prospect
studi
analyz
urin
cultur
urinari
bag
withwithout
outlet
disinfect
method
due
signific
risk
differ
contamin
shortterm
longterm
urinari
cathet
separ
studi
group
shortterm
cathet
day
longterm
cathet
day
test
group
ask
nurs
famili
member
disinfect
outlet
alcohol
swab
everi
time
outlet
open
control
group
disinfect
perform
sampl
urin
cultur
urin
bag
swab
cultur
urin
bag
outlet
cotton
swab
insert
outlet
collect
urinari
cathet
remov
result
shortterm
cathet
posit
urin
cultur
rate
test
group
control
group
outlet
swab
posit
rate
longterm
cathet
posit
urin
cultur
rate
test
group
control
group
outlet
swab
posit
rate
control
test
group
common
isol
microorgan
ecoli
enterococcu
spp
conclus
disinfect
urinari
drainag
bag
outlet
alcohol
swab
open
found
use
small
group
patient
background
observ
feedback
core
strategi
hand
hygien
hh
improv
direct
overt
observ
current
common
method
monitor
hh
observ
bia
also
known
hawthorn
effect
one
major
disadvantag
method
although
magnitud
hawthorn
effect
describ
sever
studi
subgroup
analysi
hawthorn
effect
clear
yet
method
casecontrol
studi
conduct
tertiari
teach
hospit
period
hh
overt
observ
result
match
categori
depart
observ
time
locat
observ
covertli
ratio
match
pair
analyz
hawthorn
effect
differ
variabl
result
among
studi
period
total
hh
opportun
observ
overt
observ
covert
observ
match
pair
case
control
match
overal
hh
complianc
overt
covert
observ
respect
overal
hawthorn
effect
hawthorn
effect
nurs
almost
three
time
larg
physician
tend
obviou
outpati
clinic
intens
care
unit
analysi
reveal
hawthorn
effect
significantli
differ
categori
healthcar
worker
observ
locat
p
valu
differ
depart
observ
time
hh
indic
conclus
heterogen
hawthorn
effect
hand
hygien
may
influenc
interpret
overt
observ
result
suggest
covert
observ
perform
least
health
facil
hh
observ
routin
realiz
heterogen
hawthorn
effect
may
help
identifi
target
popul
lower
hh
complianc
project
improv
rate
correct
hand
hygien
among
healthcar
worker
intermedi
care
nurseri
chiay
wu
liang
ling
ling
shute
chang
shengfen
hung
shule
chen
mihua
lee
yung
kung
campu
chimei
medic
center
background
sinc
launch
save
live
clean
hand
campaign
promot
provis
use
alcohol
hand
sanit
patient
care
area
enhanc
access
hand
hygien
facil
develop
guidelin
includ
five
moment
hand
hygien
aim
minim
complex
process
time
spent
hand
hygien
ensur
maximum
protect
emb
hand
hygien
integr
practic
promot
hand
hygien
hospit
cdc
taiwan
ministri
health
welfar
establish
hand
hygien
model
center
implement
hand
hygien
accredit
program
effort
improv
hand
hygien
behavior
practic
among
healthcar
worker
method
qualiti
improv
project
conduct
fishbon
diagram
use
identifi
problem
main
problem
identifi
lack
awar
knowledg
regard
hand
hygien
time
boundari
patient
care
nonpati
care
area
welldefin
step
hand
hygien
perform
seven
major
issu
improv
educ
train
evalu
feedback
systemat
strategi
implement
inward
medic
dispens
procedur
chang
distinct
patient
care
nonpati
care
area
import
hand
hygien
promot
healthcar
worker
ward
divis
meet
standard
handwash
repeatedli
demonstr
hand
hygien
auditor
reinforc
hand
hygien
complianc
crossaudit
conduct
infect
control
link
nurseshand
hygien
repres
monthli
basi
assess
complianc
five
moment
hand
hygien
seven
step
hand
wash
intermedi
care
nurseri
provis
feedback
team
continu
improv
addit
increas
number
locat
hand
sanit
placement
mous
pad
replac
one
print
hand
wash
diagram
strengthen
memori
foster
retent
result
implement
project
rate
correct
hand
hygien
improv
eight
consecut
month
complianc
rate
rose
conclus
intervent
approach
use
project
success
improv
correct
hand
hygien
hand
hygien
complianc
rate
achiev
consecut
month
hope
model
extend
pediatr
unit
enhanc
qualiti
care
reduc
healthcar
resourc
consumpt
social
cost
ensur
safeti
patient
healthcar
worker
data
review
staff
hand
hygien
complianc
local
hospit
tsao
ya
ching
longtan
minsheng
hospit
background
sinc
past
decad
hand
hygien
infect
control
prevent
proof
research
one
effect
method
decreas
healthcar
associ
infect
transmiss
among
patient
care
therefor
attitud
healthcar
staff
hospit
worker
perform
essenti
role
purpos
survey
discov
relationship
hand
hygien
complianc
attitud
employe
local
hospit
staff
work
year
yearli
averag
rate
hand
hygien
complianc
decreas
method
studi
conduct
mean
questionnair
divid
three
section
within
question
first
section
dealt
person
background
hand
hygien
train
experi
second
part
questionnair
concern
hand
hygien
knowledg
attitud
third
section
relat
hand
hygien
behavior
questionnair
given
staff
two
differ
period
septemb
septemb
staff
hospit
submit
questionnair
two
period
hand
hygien
surveil
also
appli
survey
submiss
result
survey
collect
particip
explain
hand
hygien
train
questionnair
follow
moment
hand
hygien
show
significantli
higher
handwash
surveil
inde
staff
wash
hand
hand
hygien
moment
observ
second
section
questionnair
discov
staff
posit
attitud
toward
hand
hygien
infect
control
prevent
contrast
hand
hygien
complianc
staff
complet
hand
wash
process
provid
healthcar
moreov
interview
answer
wore
dual
glove
care
patient
interview
result
found
chang
glove
handwash
opportun
well
conclus
studi
investig
staff
knew
hand
hygien
one
effect
easi
method
infect
control
prevent
virtual
difficult
perform
even
wore
glove
replac
handwash
moment
howev
regularli
hand
hygien
train
handwash
audit
program
requir
investig
cluster
diarrhea
staff
huiju
hu
mengchuan
lu
hsiuwen
yu
infect
control
unit
cheng
ching
hospit
background
twenti
staff
attend
staff
trip
yilan
januari
symptom
vomit
diarrhea
found
continu
staff
cluster
diarrhea
assum
report
depart
health
taichung
citi
govern
investig
sampl
collect
implement
soon
also
educ
staff
keep
caution
avoid
spread
method
twenti
staff
attend
staff
trip
yilan
januari
lunch
second
day
seafood
restaur
gonglian
sashimi
serv
three
staff
suffer
vomit
diarrh
januari
report
trade
union
welfar
depart
health
taichuni
citi
govern
diarrhea
cluster
eleven
staff
suffer
gastrointestin
symptom
one
staff
even
result
hospit
januari
eleven
staff
receiv
examin
stool
bacteri
cultur
three
stool
sampl
sent
laboratori
center
diseas
control
implement
measur
follow
educ
staff
symptom
keep
aerosol
contact
isol
rest
home
staff
took
care
patient
wear
mask
keep
hand
hygien
environ
patient
work
enhanc
cleans
watch
possibl
symptom
infect
inform
infect
control
depart
result
three
stool
sampl
reveal
noroviru
infect
conclus
norovirusi
contagi
viru
live
stool
vomitu
long
time
viru
transmit
fecal
contamin
food
water
persontoperson
contact
via
aerosoli
zation
vomit
viru
subsequ
contamin
surfac
noroviru
rapidli
activ
either
suffici
heat
chlorinebas
disinfect
polyquaternari
amin
viru
less
suscept
alcohol
deterg
earli
implement
help
import
prevent
spread
hope
share
special
experi
prevent
possibl
cluster
save
resourc
cost
outcom
implement
infect
control
strategi
psychiatr
unit
chingfeng
huang
shiufeng
lu
depart
chang
gung
univers
scienc
technolog
chiayi
campu
kaohsiung
veteran
gener
hospit
chiayi
taiwan
depart
nurs
kaohsiung
veteran
gener
hospit
kaohsiung
taiwan
background
psychiatr
unit
usual
close
space
mani
interact
among
patient
famili
chanc
cross
cluster
infect
higher
infect
control
strategi
implement
prevent
cross
cluster
infect
among
patient
visitor
health
profession
method
infect
control
strategi
conduct
year
strategi
includ
four
aspect
patient
famili
poster
post
remind
individu
suffer
fever
cough
cold
wear
mask
educ
visit
knowledg
hand
hygien
mask
promot
patient
group
educ
session
monthli
famili
forum
everi
two
month
chest
xray
perform
inpati
health
profession
staff
take
threehour
lesson
strengthen
knowledg
regard
infect
control
report
system
unit
audit
staff
complianc
hand
wash
reinforc
practic
develop
good
habit
staff
check
bodi
temperatur
bt
staff
arrang
bt
staff
could
duti
fever
hour
unit
also
evalu
infect
sign
symptom
inpati
implement
intrus
cauter
valid
period
healthcar
product
examin
staff
take
least
onehour
lesson
needlestick
sharp
injuri
prevent
yearli
new
staff
complet
cours
three
month
one
regist
nurs
rn
assign
respons
infect
control
anoth
act
infect
control
consult
liaison
rn
respons
monitor
safeti
use
healthcar
product
report
suspect
case
equip
hand
sanit
provid
fix
place
gate
unit
equip
vend
machin
mask
diarrhea
vomit
import
strengthen
environ
clean
disinfect
suspect
case
suspect
patient
held
isol
room
order
decreas
contact
other
relat
librari
test
examin
follow
patient
visitor
complianc
hand
hygien
mask
report
cluster
infect
year
rate
complet
chest
xray
examin
rate
complianc
hand
hygien
correctli
among
staff
conclus
effect
decreas
prevent
cross
infect
promot
infect
control
strategi
patient
visitor
health
care
provid
enhanc
healthcar
qualiti
effect
environment
cleans
improv
infect
control
upper
respiratori
infect
psychiatr
center
yupe
liu
shiunyin
jeng
hueilan
lu
tsojen
wang
chungshin
liao
jianan
psychiatr
center
chang
hua
hospit
background
environment
cleans
key
point
prevent
medic
care
psychiatr
patient
gener
poor
person
hygien
habit
therefor
infecti
diseas
occur
indirect
easi
make
environ
contamin
bacteria
clean
staff
effect
clean
disinfect
environ
contact
patient
infecti
diseas
would
increas
medic
carerel
infect
order
put
end
breed
infecti
diseas
environment
cleans
improv
intervent
import
method
retrospect
monitor
data
found
averag
upper
respiratori
tract
infect
rate
psychiatr
center
investig
cleaner
cleanli
statu
acut
rehabilit
ward
result
show
cleaner
familiar
process
clean
bleach
concentr
correct
clean
equip
use
separ
environ
clean
intervent
provid
improv
content
includ
educ
train
video
strengthen
prioriti
clean
process
clean
area
contamin
area
correct
bleach
concentr
way
repli
effect
teach
accept
provis
unifi
clean
applianc
measur
cup
bucket
clearli
mark
clean
applianc
manag
plan
area
mop
red
tape
clearli
identifi
use
divis
cloth
wipe
conduct
intern
extern
audit
audit
ward
staff
infect
control
divis
understand
cleanli
implement
cleaner
environ
result
improv
environment
cleanli
incid
upper
respiratori
tract
infect
clean
staff
also
express
inservic
educ
unifi
clean
applianc
manag
clearli
implement
environment
clean
disinfect
oper
process
conclus
environment
improv
effect
reduc
upper
respiratori
infect
inservic
educ
includ
clean
staff
futur
develop
cleaner
environ
clean
oper
process
familiar
continu
audit
implement
situat
order
maintain
best
hospit
environ
clean
qualiti
pseudooutbreak
nontubercul
mycobacterium
infect
caus
bronchoscop
contamin
yichuan
chen
tingi
chung
chunsui
lin
maocheng
ge
tingshu
wu
infect
control
committe
background
growth
rate
nontubercul
mycobacterium
ntm
bronchial
wash
specimen
reach
casesmonth
infect
control
threshold
casesmonth
report
microbiolog
laboratori
chang
gung
memori
hospit
linkou
branch
march
five
case
chelona
complex
method
infect
control
committe
investig
outbreak
enhanc
handwash
bronchoscop
room
perform
cultur
individu
bronchoscop
surfac
filter
water
clean
chemic
tube
automat
wash
machin
result
growth
ntm
cultur
bronchoscop
investig
handwash
complianc
bronchoscop
staff
reach
specimen
n
filter
water
automat
wash
machin
tap
water
cultur
show
growth
ntm
howev
strain
differ
outbreak
chelona
complex
strain
resteril
tube
system
staff
reeduc
ntm
outbreak
follow
month
conclus
threshold
monitor
alert
microbiolog
laboratori
clinic
staff
import
measur
infect
control
hospit
vancomycinresist
enterococci
vre
case
studi
dispos
experi
intens
care
unit
region
hospit
chunfeng
chiu
minhan
hsieh
tunchieh
chen
background
region
hospit
southern
taiwan
vancomycinresist
entorococci
vre
isol
four
patient
intens
care
unit
icu
one
month
site
ver
isol
bloodstream
urin
pu
ascit
one
four
patient
healthcareassoci
bloodstream
infect
studi
intend
analysi
possibl
caus
vre
transmiss
prevent
outbreak
four
patient
risk
vre
infect
hand
hygien
medic
staff
mean
complianc
rate
previou
month
lower
stander
icu
audit
termin
clean
ward
patient
transfer
ward
therefor
cultur
result
multidrugresist
organ
mdro
obtain
patient
transfer
icu
ward
ca
nt
accomplish
termin
clean
accord
standard
mdroexpos
ward
method
first
patient
vre
isol
place
singl
ward
isol
select
clean
tool
exclus
ward
second
hand
hygien
medic
staff
regular
monitor
goal
accuraci
rate
complianc
rate
respect
third
take
prevent
segreg
measur
regular
check
fourth
termin
clean
ward
regularli
monitor
fifth
educ
appropri
antibiot
use
held
medic
staff
result
result
follow
six
month
measur
includ
follow
vre
isol
icu
mean
accuraci
rate
complianc
rate
hand
hygien
medic
staff
respect
mean
rate
monitor
termin
clean
conclus
increas
use
antibiot
vancomycinresist
enterococci
kept
increas
icu
taiwan
region
hospit
studi
four
isol
vre
differ
site
antibiogram
also
differ
mean
outbreak
like
investig
intervent
measur
found
reduct
healthcar
associ
infect
achiev
improv
hand
hygien
make
sure
environ
clean
outbreak
investig
influenza
pediatr
intens
care
unit
medic
center
southern
taiwan
shuch
hsu
iigl
chen
hungjen
tang
background
total
medic
staff
symptom
upper
respiratori
tract
infect
includ
nurs
physician
nurs
caregiv
diagnos
group
pandem
pediatr
intens
care
unit
medic
center
southern
taiwan
midmay
type
influenza
confirm
total
symptom
includ
fever
cough
sore
throat
symptom
involv
relev
infect
control
measur
make
influenza
group
sudden
effect
control
method
hospit
southern
taiwan
bed
medic
center
pediatr
intens
care
unit
total
medic
staff
receiv
unit
charg
notif
unit
recent
staff
fever
upper
respiratori
tract
symptom
rapid
diagnosi
influenza
type
investig
interv
order
avoid
expans
incid
infect
control
divis
visit
site
discuss
unit
supervisor
initi
judg
atyp
influenza
group
order
avoid
event
incid
conduct
describ
analyz
review
epidemiolog
chang
cours
treatment
control
measur
segreg
infect
influenza
vaccin
staff
activ
inform
health
bureau
result
intervent
investig
daili
monitor
epidem
return
health
bureau
comprehens
staff
health
monitor
log
implement
measur
includ
strengthen
environ
disinfect
unnecessari
time
fulli
wear
mask
strengthen
implement
hand
hygien
relev
intervent
measur
influenza
cluster
event
effect
control
conclus
medic
personnel
histori
exposur
influenza
respiratori
symptom
seek
medic
diagnosi
earli
treatment
personnel
implement
abnorm
bodi
temperatur
notif
order
provid
safe
medic
environ
infect
control
divis
monitor
temperatur
feedback
system
daili
activ
surveil
soon
possibl
find
ward
unit
influenza
abnorm
cluster
event
earli
control
epidem
efficaci
infect
control
cours
caregiv
hospit
southern
taiwan
hsiuo
kuo
huiwen
sung
tepei
tang
chelung
su
shufeng
chang
infect
control
committe
depart
nurs
depart
medicin
mingjong
hospit
pingtung
taiwan
background
studi
discuss
educ
train
promot
efficaci
caregiv
infect
control
recognit
method
thirteen
caregiv
southern
hospit
studi
use
infect
control
recognit
evalu
chart
tool
test
perform
two
week
educ
train
result
studi
averag
work
year
caregiv
nation
taiwanes
vietnames
felt
relat
knowledg
infect
control
inadequ
gener
recognit
infect
control
progress
reach
tabl
conclus
intervent
educ
train
could
promot
caregiv
infect
control
recognit
protect
safeti
patient
hospit
investig
regard
tuberculosi
cluster
happen
intens
care
unit
tertiari
hospit
eastern
taiwan
yuncheng
wang
xinyi
zheng
huili
jiang
lihshinn
wang
hsiutzi
chiang
soonhian
teh
reduc
high
rate
clabsi
action
plan
work
intens
train
session
nurs
staff
implement
clear
microclav
needl
free
connector
system
implement
custom
made
close
iv
system
less
risk
introduc
infect
system
whole
process
intens
support
infect
control
depart
multiprofession
vascular
access
team
result
action
result
dramat
decreas
clabsi
tunnel
cathet
day
end
port
cathet
day
end
conclus
intens
staff
train
introduct
new
iv
prepar
system
introduct
needl
free
system
result
dramat
fall
central
line
infect
pediatr
hematooncolog
ward
appli
systemori
event
analysi
model
safeti
center
cathet
care
system
lin
shihua
chuang
sheuwen
hsueh
kueihsia
chen
hanhs
taipei
hospit
ministri
health
welfar
taipei
medic
univers
background
institut
medicin
iom
propos
err
human
build
safer
health
system
construct
safe
sanit
system
becom
modern
medic
industri
object
pursu
central
line
cl
bundl
prevent
central
lineassoci
bloodstream
infect
clabsi
wide
promot
howev
studi
also
polici
cl
bundl
often
present
frequent
well
implement
nation
healthcar
safeti
network
nhsn
therefor
understand
center
cathet
care
system
depth
interact
cross
relationship
becom
import
issu
addit
recent
year
develop
resili
engin
bring
new
opportun
enhanc
patient
safeti
therefor
studi
appli
systemori
event
analysi
model
soea
resili
engin
safeti
center
cathet
care
system
method
use
soea
qualit
research
interview
intens
care
unit
region
hospit
result
studi
found
goal
central
cathet
care
system
save
patient
live
control
clabsi
systemwid
three
import
subsystem
work
system
function
achiev
system
goal
use
soea
found
kind
hazard
central
cathet
care
system
howev
sampl
total
case
exposur
hazard
among
januari
march
case
get
clabsi
view
situat
interview
doctor
nurs
found
system
hazer
caus
variou
state
differ
reaction
practic
maintain
system
implement
function
continu
work
may
reduc
risk
patient
injuri
hand
soea
clarifi
relationship
variou
element
central
cathet
care
system
combin
resili
engin
understand
healthcar
worker
respond
system
daili
hazard
anticip
unanticip
occurr
variou
adapt
adjust
central
cathet
combin
practic
rather
blindli
follow
maintain
patient
safeti
practic
conclus
appli
soea
addit
abil
structur
system
complet
present
includ
relev
system
orderli
purpos
provid
system
improv
import
inform
soea
analysi
resili
system
allow
healthcar
worker
understand
occurr
learn
control
method
reaction
full
cognit
system
structur
order
achiev
goal
build
safer
health
system
staff
cognit
attitud
behavior
central
venou
cathet
bundl
care
program
medic
intens
care
unit
medic
center
southern
taiwan
wanch
wu
polin
chen
wenchien
ko
naiy
ko
background
promot
qualiti
care
central
venou
cathet
cvc
reduc
incid
catheterrel
bloodstream
infect
cvc
bundl
intervenion
program
implement
electron
health
manag
system
order
understand
staff
cognit
attitud
behavior
cvc
bundl
care
program
investig
questionnair
underw
juli
method
staff
member
includ
docto
nurs
medic
intens
care
unit
icu
invit
annyom
fill
questionnair
cvc
bundl
cultur
awar
itm
incldu
studi
questionnair
base
taiwan
cdc
guidelin
cvc
bundl
care
address
critic
procedur
cvc
placement
care
studi
ethic
approv
institut
review
borad
nation
cheng
kung
univers
hospit
irb
result
total
member
nurs
doctor
medic
icu
particip
studi
averag
year
servic
nurs
year
studi
subject
admit
catheterrel
bloodstream
infect
zerotoler
agre
doctor
evalu
necess
cathet
patient
everi
day
major
particip
agre
cvc
must
remov
within
h
insert
emerg
situat
addit
signific
proport
ever
propos
remov
cvc
cathet
insert
situat
major
contribut
factor
catheterrel
bloodstream
infect
recogn
colleagu
includ
critic
patient
need
multipl
venou
line
treatment
n
overt
bleed
process
cvc
placement
prolong
procedur
time
n
incomplet
disinfect
cvc
conector
n
patient
multipl
chronic
diseas
n
howev
respond
conisd
bund
care
would
increas
work
load
studi
subject
admit
bundl
program
would
fail
praction
take
serious
conclus
respond
recogn
cvc
bundl
care
program
would
reduc
risk
catheterrel
bloodstream
infect
howev
practition
worri
heavi
workload
would
obstacl
practic
bundl
care
investig
outbreak
caus
elizabethkingia
meningoseptica
respiratori
care
center
taiwan
guanjhou
chen
ning
ting
ichen
hung
janntay
wang
wanghuei
sheng
yeechun
chen
shanchwen
chang
background
elizabethkingia
meningoseptica
ubiquit
pathogen
could
found
clinic
environ
equip
surfac
e
meningoseptica
natur
characterist
resist
variou
antimicrobi
agent
carbapenem
increas
frequenc
human
infect
especi
healthcar
associ
infect
report
recent
decad
howev
effort
infect
control
outbreak
caus
e
meningoseptica
remain
less
report
method
respiratori
care
center
rcc
nation
taiwan
univers
hospit
unit
provid
care
ventilatordepend
patient
octob
novemb
patient
develop
bacteremia
due
e
meningoseptica
stay
rcc
significantli
higher
compar
background
incid
three
isol
ident
antimicrobi
suscept
pattern
environment
investig
infect
control
measur
outbreak
strict
hand
hygien
contact
isol
environment
clean
conduct
molecular
type
use
pulsedfield
gel
electrophoresi
pfge
use
investig
related
isol
isol
similar
consid
cluster
result
investig
outbreak
eight
clinic
isol
cultur
six
patient
includ
isol
blood
two
isol
sputum
two
addit
isol
cultur
hospit
environ
pfge
isol
reveal
three
differ
cluster
includ
three
three
two
isol
cluster
blood
isol
one
patient
ident
one
isol
medic
environ
cluster
figur
linkag
environment
isol
two
cluster
indic
possibl
cross
transmiss
healthcar
personnel
cluster
figur
use
strict
cohort
nurs
hand
hygien
environment
clean
outbreak
control
conclus
report
investig
e
meningoseptica
outbreak
rcc
medic
center
taiwan
result
demonstr
potenti
transmiss
e
meningoseptica
via
medic
environ
persontoperson
contact
vigor
infect
control
measur
appli
prevent
spread
e
meningoseptica
hospit
implement
care
bundl
reduc
ventilatorassoci
pneumonia
yuhsia
hen
yingchun
chen
huimei
huang
zhiyuan
shi
depart
infect
control
nurs
taichung
veteran
gener
hospit
taichung
taiwan
background
accord
previou
studi
hospit
patient
healthcareassoci
infect
nineti
percent
healthcareassoci
pneumonia
intens
care
unit
ventilatorassoci
pneumonia
compar
pneumonia
ventilatorassoci
risk
use
ventil
get
six
twenti
time
higher
patient
use
ventil
ventilatorassoci
pneumonia
estim
increas
day
length
hospit
stay
us
cost
taiwan
prevent
ventilatorassoci
pneumonia
improv
qualiti
medic
care
launch
campaign
promot
care
bundl
ventilatorassoci
pneumonia
method
implement
mani
strategi
promot
care
bundl
ventilatorassoci
pneumonia
june
decemb
daili
checklist
develop
five
element
includ
elev
head
bed
least
degre
daili
sedat
vacat
daili
assess
readi
extub
mouth
care
chlorhexidin
empti
water
tube
ventil
furthermor
educ
healthcar
worker
monitor
complianc
care
bundl
result
compar
data
introduc
care
bundl
ventilatorassoci
pneumonia
infect
rate
ventilatorassoci
pneumonia
reduc
per
ventil
day
util
rate
ventil
decreas
per
resid
day
complianc
rate
care
bundl
increas
decreas
ventilatorassoci
pneumonia
year
save
medic
cost
us
year
conclus
mani
benefit
adopt
care
bundl
includ
improv
qualiti
medic
care
hospit
avoid
suffer
infect
patient
reduc
medic
cost
social
insur
outbreak
surgic
site
infect
relat
mastectomi
without
reconstruct
medic
center
juchun
lo
yingi
chang
yahui
huang
janntay
wang
wanghuei
sheng
center
infect
control
nation
taiwan
univers
hospit
taipei
taiwan
depart
intern
medicin
nation
taiwan
univers
hospit
taipei
taiwan
background
nation
healthcar
safeti
network
classifi
breast
oper
clean
procedur
expect
cumul
incid
surgic
site
infect
ssi
ssi
increas
hospit
day
mortal
medic
cost
workload
staff
prevent
healthcareassoci
infect
alway
import
topic
medic
institut
incid
mastectomyrel
ssi
increas
nov
medic
center
outbreak
investig
relev
intervent
conduct
method
recent
four
year
incid
mastectomyrel
ssi
medic
center
rang
activ
surveil
infect
control
nurs
found
ssi
incid
increas
sinc
aug
sep
nov
even
went
higher
dec
jan
outbreak
therefor
suspect
order
realiz
caus
unusu
increas
ssi
outbreak
investig
conduct
analyz
probabl
factor
includ
staff
daili
work
environ
equip
clean
oper
procedur
postoper
wound
care
process
result
found
concentr
antimicrobi
deterg
enough
prophylact
antibiot
use
properli
surgic
hand
prepar
use
alcoholbas
handrub
adequ
wound
coverag
redrap
also
proper
alcoholbas
hand
hygien
equip
insuffici
treatment
room
standard
procedur
tissu
expand
inject
discuss
oper
team
establish
new
standard
procedur
tissu
expand
inject
improv
hand
hygien
asept
techniqu
ssi
incid
data
thereaft
also
feedback
oper
intervent
incid
mastectomyrel
ssi
decreas
sinc
april
conclus
time
implement
outbreak
investig
effect
intervent
stop
outbreak
ssi
ps
year
experi
implement
vap
bundl
medic
intens
care
unit
region
hospit
reduc
ventilatorassoci
pneumonia
incid
chint
lu
huichen
kuan
chiachun
chi
liangwen
ding
readinesstowean
assess
daili
check
endotrach
cuff
pressur
daili
diari
sedat
vacat
hand
hygien
oral
care
everi
hour
headofb
elev
degre
suction
oropharynx
endotrach
tube
correct
data
includ
complianc
rate
vap
bundl
icu
stay
day
rate
ventil
usag
case
number
vap
case
vap
rate
analysi
effect
vap
bundl
divid
period
preintervent
period
intervent
period
result
complianc
rate
vap
bundl
preintervent
period
increas
implement
first
year
ventil
usag
rate
decreas
implant
vap
bundl
icu
stay
day
decreas
day
patient
preintervent
period
confirm
period
vap
case
decreas
annual
averag
case
vap
bundl
implement
averag
case
year
vap
bundl
implement
decreas
implement
vap
bundl
three
year
got
total
reduct
case
vap
record
month
period
zero
vap
case
march
octob
confirm
period
month
form
januari
januari
mainten
period
achiev
conclus
experi
shown
implement
vap
bundl
effect
reduc
ventilatorassoci
pneumonia
occur
upgrad
bundl
care
reduc
catheterassoci
urinari
tract
infect
rate
pai
mei
chao
mei
fang
liang
yu
chen
yang
pao
tsuan
kao
director
nurs
depart
infect
control
center
background
accord
literatur
review
urinari
tract
infect
uti
common
infect
site
mani
hospit
uti
exist
health
care
associ
infect
hai
also
one
common
site
urinari
cathet
util
inpati
everi
one
day
use
urinari
cathet
increas
uti
rate
medic
ward
intens
care
unit
overal
urinari
cathet
util
rate
result
uti
rate
rang
order
implement
complet
effect
strategi
reduc
uti
rate
particip
invas
health
care
procedur
program
previou
strategi
prevent
uti
adequ
expect
reduc
uti
rate
implement
current
uti
bundl
care
method
sinc
februari
start
implement
strategi
follow
educ
health
care
provid
select
special
personnel
arrang
small
unit
train
basic
new
knowledg
urinari
cathet
applic
select
health
care
personnel
train
applic
urinari
catheter
skill
cathet
care
train
cours
share
skill
member
order
promot
facil
procedur
method
use
appropri
dispos
urinari
cathet
packag
facilit
health
care
provid
appli
shorten
durat
catheter
also
reduc
contamin
rate
util
chlorhexidin
disinfect
preconnect
urinari
cathet
urin
collect
bag
use
seal
valv
design
urin
collect
bag
urin
specimen
necessari
obtain
avoid
damag
close
circuit
wipe
cathet
open
alcohol
base
paper
collect
urin
warn
hand
hygien
contact
urinari
cathet
urin
bag
use
small
card
attach
urin
bag
warn
cathet
care
use
pictur
languag
chines
english
vietnam
easili
recogn
main
care
giver
cathet
placement
checklist
daili
care
checklist
monitor
effect
implement
result
follow
februari
june
medic
ward
icu
util
urinari
cathet
rate
cathet
relat
uti
rate
although
util
rate
differ
previou
rate
uti
incid
reduc
significantli
implement
current
uti
bundl
care
health
care
provid
strictli
follow
strategi
aspect
incid
uti
reduc
significantli
time
nurs
depart
adjust
standard
urinari
cathet
placement
procedur
urinari
cathet
care
manual
conclus
uti
bundl
care
strategi
reusabl
urinari
cathet
packag
replac
dispos
urinari
cathet
packag
support
hospit
author
health
care
provid
strengthen
implement
aspect
uti
bundl
care
keep
awar
cathet
care
knowledg
keep
proper
disinfect
urinari
catheter
assess
daili
catheter
requir
avoid
unnecessari
urinari
catheter
therefor
cathet
relat
uti
rate
reduc
significantli
survey
effect
implement
vap
ventilatorassoci
pneumonia
bundl
icu
region
hospit
taiwan
cathet
util
ratio
microbiolog
characterist
also
analyz
result
incid
rate
clabsi
crbsi
decreas
significantli
baselin
intervent
period
per
clday
per
clday
respect
p
yearli
incid
rate
decreas
incid
rate
ratio
irr
confid
interv
ci
clabsi
irr
ci
crbsi
sinc
initi
intervent
incid
rate
quarter
also
show
trend
decreas
clabsi
crbsi
figur
cathet
util
ratio
decreas
p
microbiolog
analysi
show
among
clabsi
isol
proport
coagulaseneg
staphylococci
significantli
decreas
intervent
period
conclus
implement
multimod
intervent
focus
cl
bundl
improv
effect
reduc
incid
rate
clabsi
crbsi
taiwan
adult
icu
effect
insert
mainten
bundl
prevent
centrallineassoci
bloodstream
infect
critic
ill
patient
experi
challeng
medic
intens
care
unit
yawen
chang
miaofang
tai
background
determin
effect
care
bundl
novel
line
mainten
procedur
reduc
rate
central
lineassoci
bloodstream
infect
clabsi
intens
care
unit
icu
aim
quantifi
effect
centrallin
bundl
insert
mainten
prevent
infect
method
prospect
intervent
qualiti
improv
project
aim
decreas
clabsi
one
adult
intens
care
unit
intervent
studi
conduct
period
month
plandostudyact
cycl
checklist
insert
standard
realtim
ultrasoundguid
cannul
intern
jugular
vein
adopt
implement
central
line
insert
bundl
clinic
practic
complianc
health
care
staff
central
venou
cathet
bundl
element
also
measur
implement
clabsi
prevent
bundl
includ
implement
centrallin
insert
mainten
bundl
proper
hand
hygien
person
protect
equip
maxim
barrier
precaut
iodin
alcohol
skin
prepar
line
insert
daili
discuss
cathet
necess
meticul
site
tube
care
rate
cvc
relat
infect
intervent
period
octob
april
compar
averag
month
prior
implement
result
rate
clabsi
decreas
per
cathet
day
p
length
icu
stay
cathet
durat
associ
higher
risk
infect
associ
devic
p
annul
intern
jugular
vein
achiev
patient
use
ultrasound
averag
access
time
skin
vein
significantli
reduc
ultrasound
group
patient
p
staff
adher
bundl
conclus
improv
reliabl
central
line
insert
bundl
reduc
infect
key
step
process
set
clear
aim
ensur
staff
understand
chang
process
measur
result
fundament
success
qualiti
improv
process
use
atp
bioluminesc
techniqu
reduc
surgic
site
infect
orthopaed
surgeriesth
clinic
experi
region
hospit
liangyi
wu
yuehi
hsieh
wenchuan
lin
yafang
wang
hsiaoyun
wen
yanghwei
tsuang
yongch
lau
infect
control
offic
depart
orthoped
oper
room
background
annual
rate
surgic
site
infect
associ
orthoped
oper
hospit
increas
compar
accord
investig
analysi
found
part
surgic
instrument
use
implant
prosthesi
implant
provid
orthoped
implant
supplier
also
charg
clean
steril
surgic
instrument
oper
intens
test
pass
rate
adenosin
triphosph
atp
bioluminesc
assay
test
instrument
orthoped
implant
supplier
method
follow
method
use
improv
infect
rate
develop
protocol
use
manag
rental
equip
oper
room
standard
protocol
process
surgic
instrument
clean
steril
develop
process
protocol
surgic
instrument
includ
item
decontamin
soak
clean
inspect
packag
steril
conduct
educ
train
program
personnel
respons
equip
clean
steril
use
atp
surfac
test
ng
luminomet
test
tool
randomli
test
oper
equip
clean
pass
valu
pass
rate
calcul
number
qualifi
item
divid
total
number
test
item
make
sure
extent
cleanli
reach
goal
effect
steril
result
pass
rate
atp
random
test
increas
continu
increas
infect
rate
ssi
decreas
kept
improv
conclus
studi
use
atp
bioluminesc
assay
object
rapid
tool
determin
environment
cleanli
effect
demonstr
decreas
rate
surgic
site
infect
caus
surgic
instrument
therefor
includ
protocol
standard
oper
procedur
creat
health
environ
implement
bundl
care
prevent
catheterassoci
urinari
tract
infect
medic
center
hsinhsin
chang
janntay
wang
yeechun
chen
wanghuei
sheng
center
infect
control
nation
taiwan
univers
hospit
taipei
taiwan
depart
intern
medicin
nation
taiwan
univers
hospit
background
accord
taiwan
nosocomi
infect
surveil
system
tni
common
hai
catheterassoci
urinari
tract
infect
cauti
cauti
result
signific
morbid
mortal
medic
cost
prompt
us
investig
impact
infect
control
measur
cauti
bundl
care
bundl
care
proven
effect
reduc
cauti
mani
literatur
wellstructur
infect
control
program
imper
order
prevent
cauti
method
prospect
surveil
perform
patient
admit
nation
taiwan
univers
hospit
ntuh
patient
develop
healthcareassoci
uninari
tract
infect
hauti
includ
cauti
stay
ntuh
enrol
analysi
cauti
bundl
care
implement
entir
hospit
particular
focu
icu
sinc
bundl
care
emphas
element
clean
practic
clean
product
clean
equip
clean
environ
comprehens
educ
program
includ
optim
catheter
process
demonstr
teach
video
learn
purpos
clinic
audit
object
structur
clinic
examin
osc
nurs
intern
competit
test
oper
practic
knowledg
skill
also
conduct
time
computerbas
infect
surveil
system
checklist
also
develop
monitor
adher
cauti
bundl
care
outcom
analyz
wilcoxonmannwhitney
test
p
valu
less
consid
statist
significantli
result
studi
period
patientday
total
episod
hauti
entir
hospit
identifi
cauti
account
hauti
among
episod
cauti
assess
patientday
catheterday
adult
icu
compar
incid
densiti
cauti
adult
icu
patient
implement
bundl
intervent
cauti
incid
densiti
remark
decreas
per
patientday
p
foley
util
seen
significantli
decreas
catheterday
catheterday
p
monthli
precauti
postcauti
bundl
care
conclus
cauti
incid
densiti
decreas
respons
implement
effect
bundl
care
intervent
multidisciplinari
teamwork
educ
comprehens
checklist
time
time
audit
feedback
improv
healthcar
worker
complianc
key
success
efficaci
daili
bath
chlorhexidin
reduc
healthcareassoci
bloodstream
infect
hematolog
patient
kueilian
tien
janntay
wang
wanghuei
sheng
chitai
fang
center
infect
control
nation
taiwan
univers
hospit
depart
medicin
nation
taiwan
univers
hospit
institut
epidemiolog
prevent
medicin
colleg
public
health
nation
taiwan
univers
background
hematolog
patient
undergo
immunocompromis
cytotox
chemotherapi
risk
healthcareassoci
infect
remain
unclear
whether
daili
bath
chlorhexidin
reduc
risk
aim
studi
compar
incid
healthcareassoci
bloodstream
infect
habsi
patient
use
chg
daili
bath
use
gener
antibacteri
cleanser
daili
bath
method
singlearm
prospect
intervent
studi
patient
admit
two
hematolog
unit
period
decemb
june
studi
popul
recruit
patient
receiv
chg
daili
bath
intervent
group
refus
particip
provid
gener
antibacteri
cleanser
daili
bath
control
group
incid
rate
skin
florarel
bloodstream
infect
skinbsi
central
venou
cathet
cvc
associ
bloodstream
infect
clabsicvc
habsi
intervent
group
compar
control
group
result
total
patient
enrol
intervent
group
patient
serv
control
group
compar
control
group
incid
rate
first
skinbsi
reduc
vs
per
patientday
p
incid
rate
first
clabsicvc
reduc
vs
per
patientday
p
incid
rate
first
habsi
reduc
vs
per
patientday
p
intervent
group
adjust
effect
confound
variabl
logist
regress
chg
daili
bath
reduc
risk
first
skinbsi
adjust
p
risk
first
clabsicvc
adjust
p
risk
first
habsi
adjust
p
contrast
risk
gutorigin
bacteremia
escherichia
coli
klebsiella
pneumoniaerel
bloodstream
infect
chang
adjust
p
conclus
daili
bath
chg
effect
reduc
skin
florarel
bloodstream
infect
cathetherrel
bacteremia
recommend
routin
adopt
simpl
lowcost
intervent
reduc
bsi
among
patient
hematolog
malign
investig
orthoped
arthroscop
surgeri
staphylococcu
aureu
infect
outbreak
li
chen
chen
tuzz
guang
young
wan
chen
lin
hui
chien
hung
hsiu
yu
peng
yuh
chyun
chiang
depart
infect
control
depart
laboratori
medicin
depart
nurs
administr
offic
background
octob
three
patient
underw
arthroscop
surgeri
staphylococcu
aureu
surgic
site
infect
hospit
use
fisher
exact
test
found
signific
p
infect
control
team
immedi
respond
investig
environment
survey
relev
infect
control
measur
also
initi
method
hospit
orthoped
depart
total
patient
underw
arthroscop
surgeri
octob
infect
control
nurs
review
daili
bacteriolog
report
medic
record
routin
survey
doctor
nurs
total
seven
nasal
swab
hand
specimen
hand
scrub
identifi
sourc
pathogen
includ
carrier
colon
pathogen
specimen
compar
rapd
random
amplifi
polymorph
dna
reconstruct
ribonucl
acid
distinguish
whether
strain
ident
result
found
infect
patient
receiv
surgeri
octob
caus
pathogen
aureu
thirti
nine
environment
specimen
neg
aureu
three
seven
staff
found
aureu
nasal
caviti
two
circul
nurs
show
posit
identif
aureu
scrub
hand
conduct
rapd
analysi
type
pathogen
found
patient
pathogen
pathogen
circul
nurs
ident
outbreak
surgic
site
infect
confirm
conclus
investig
found
circul
nurs
requir
wear
glove
furthermor
confirm
aureu
move
nurs
hand
surgic
site
ineffect
clean
process
nurs
sever
eczemat
skin
lesion
hand
group
meet
discuss
revis
process
circul
nurs
includ
hand
hygien
person
protect
equip
novemb
may
aureu
surgic
site
infect
well
explain
effort
outbreak
effect
success
effect
bundl
care
intervent
catheterassoci
urinari
tract
infect
rate
medic
intens
care
unit
mengyi
liu
chieni
su
yihsuan
chen
regist
nurs
depart
nurs
taipei
tzu
chi
hospit
buddhist
tzu
chi
medic
foundat
new
taipei
citi
taiwan
background
catheterassoci
urinari
tract
infect
cauti
common
health
careassoci
infect
hai
medic
intens
care
unit
micu
account
hai
cauti
prolong
hospit
stay
exacerb
mortal
rate
accord
nosocomi
infect
record
provid
infect
control
center
taipei
tzu
chi
hospit
infect
densiti
cauti
micu
elev
medic
cost
increas
therefor
collabor
practic
team
assembl
infect
control
center
center
qualiti
manag
promot
bundl
care
intervent
method
collabor
team
survey
bundl
care
intervent
brainstorm
causeandeffect
analysi
review
literatur
team
investig
current
state
indwel
cathet
implement
three
aspect
care
knowledg
placement
care
checklist
differ
understand
bundl
care
process
survey
medic
team
complet
rate
accur
cathet
care
calcul
nurs
team
score
daili
evalu
instrument
cathet
placement
care
investig
final
team
invit
extern
infect
control
expert
micu
intervent
measur
bundl
care
implement
standard
placement
daili
care
profession
train
session
instruct
film
placement
daili
care
patient
digit
platform
daili
care
evalu
team
expect
measur
would
allevi
cauti
rate
result
research
team
enhanc
health
care
profession
knowledg
bundl
care
intervent
cauti
revis
standard
oper
procedur
indwel
cathet
placement
care
lectur
instruct
selflearn
via
instruct
film
furthermor
studi
ensur
accur
implement
object
structur
clinic
examin
osc
group
discuss
subsequ
audit
cauti
infect
rate
decreas
indic
effect
intervent
osc
result
demonstr
educ
train
nurs
nurs
postgradu
nurs
year
train
program
npgi
program
clinic
nurs
teacher
higher
level
knowledg
bundl
care
intervent
cauti
clinic
nurs
npgi
nurs
receiv
year
dedic
train
wherea
clinic
nurs
teacher
must
receiv
relev
train
continu
mentor
npgi
nurs
therefor
clinic
nurs
regularli
receiv
latest
inform
enhanc
expertis
improv
health
care
qualiti
lung
cancer
postsurg
pleural
effus
caus
aspergillu
infect
case
report
ching
ting
chimei
medic
center
intens
care
unit
background
lung
infect
sever
consequ
chemotherapyinduc
immun
defect
aetiolog
caus
infect
includ
bacteria
virus
fungi
infect
caus
bacteria
virus
increasingli
identifi
diagnosi
difficult
frequent
timeconsum
immunosuppress
condit
diabet
mellitu
malnutrit
alcohol
connect
tissu
diseas
prolong
corticosteroid
therapi
also
situat
increas
risk
case
report
femal
patient
past
histori
right
side
low
lung
bronchioalveolar
carcinoma
post
oper
hepat
b
relat
liver
cirrhosi
hepatocellular
carcinoma
tachybradi
syndrom
post
perman
pacemak
chronic
kidney
diseas
discharg
due
adenocarcinoma
right
upper
lobe
post
ct
guid
biopsi
hospit
chest
ct
reveal
right
lung
mass
size
cm
chest
ctguid
biopsi
perform
patholog
show
adenocarcinoma
right
upper
lobe
time
admit
surgic
treatment
arrang
videoassist
thorac
surgeri
oper
post
oper
transfer
intens
treatment
icu
empir
antibiot
treatment
piperacillin
sodium
infect
control
success
ventil
wean
extub
howev
sudden
onset
pea
apnea
cyanosi
occur
emerg
intub
resuscit
provid
suspect
pulmonari
embol
survey
may
chest
ct
arrang
impress
discuss
chest
ct
report
famili
suggest
insert
pig
tail
agre
chest
ct
guid
pigtail
drainag
perform
right
pleural
effus
aspergillu
speci
add
voriconazol
mg
therapi
right
pleural
effus
aerob
cultur
growth
voriconazol
treatment
cours
howev
unstabl
hemodynam
done
renal
liver
function
failur
condit
poor
respons
discharg
discuss
definit
diagnosi
made
histolog
demonstr
tissu
invas
fungu
growth
aspergillu
speci
cultur
therapi
voriconazol
itraconazol
emerg
firstlin
treatment
safer
amphotericin
b
longterm
prognosi
patient
cnpa
well
document
ideal
treatment
durat
yet
defin
depend
extens
diseas
patient
respons
treatment
base
diseas
patient
immunolog
condit
case
lifelong
therapi
may
requir
enhanc
qualiti
bundl
care
patient
ventil
associ
pneumonia
crossdisciplinari
teamwork
wanl
hsu
nihuang
lin
yihsuan
chen
depart
nurs
taipei
tzu
chi
hospit
buddhist
tzu
chi
medic
foundat
background
ventilatorassoci
pneumonia
vap
commonli
occur
intens
care
unit
patient
tracheal
tube
taiwan
approxim
hospit
patient
contract
vap
mortal
rate
hospit
infect
control
center
report
vap
infect
rate
medic
intens
care
unit
higher
nationwid
medic
center
steadili
increas
accordingli
hospit
day
medic
cost
taiwan
risen
studi
collabor
infect
control
center
respiratori
therapist
team
inform
manag
center
medic
qualiti
manag
center
develop
implement
bundl
care
intervent
reduc
vap
infect
rate
method
medic
intens
care
unit
patient
bed
averag
occup
rate
adopt
studi
crossteam
cooper
brainstorm
analyz
sever
crucial
factor
relat
vap
develop
vap
bundl
care
scale
refer
previou
studi
investig
medic
employe
knowledg
vap
bundl
care
procedur
result
show
knowledg
vari
adopt
consist
care
standard
adequ
daili
assess
tool
respons
invit
extern
infect
control
expert
train
hospit
medic
personnel
provid
bundl
care
modifi
daili
vap
care
standard
eg
rais
bedhead
adopt
daili
sedat
cessat
use
chlorhexidin
glucon
oral
care
drain
ventil
water
wash
hand
provid
train
develop
daili
care
assess
form
establish
inform
share
platform
result
studi
modifi
vap
bundl
care
standard
medic
team
enhanc
knowledg
vap
bundl
care
classroom
learn
digit
train
video
visual
manag
remind
inform
system
accuraci
vap
bundl
care
increas
moreov
vap
infect
rate
reduc
found
bedhead
rais
alert
consciou
patient
could
fall
asleep
experienc
sacrum
pain
accordingli
patient
refus
care
procedur
conclus
bundl
care
inform
system
improv
comprehens
bundl
care
patient
receiv
also
remind
medic
team
member
help
keep
track
task
qualiti
care
provid
effect
medic
team
critic
enhanc
informationshar
platform
use
bundl
care
approach
reduc
icu
vap
cauti
infect
densiti
yuwen
huang
yihgiun
cherng
yafang
wang
yulan
wang
yongch
lau
chun
mah
chienl
su
wen
chuan
lin
infect
control
offic
dean
chamber
infecti
diseas
depart
nurs
respiratori
room
background
implement
invas
medic
intervent
bundl
care
qualiti
improv
program
vap
remark
decreas
incid
rate
cauti
signific
reduct
rel
preintervent
period
method
compar
taiwan
nosocomi
infect
surveil
system
tni
vap
medic
center
region
hospit
respect
icu
incid
cauti
icu
increas
result
hospit
implement
bundl
care
adult
icu
special
focu
vap
cauti
prevent
sever
wrong
intervent
note
qualiti
control
circl
vap
implement
hand
hygien
lack
recognit
appropri
sputum
suction
time
elev
head
bed
angl
drain
discard
condens
collect
tube
cauti
problem
includ
implement
steril
procedur
cathet
insert
hand
hygien
adher
accuraci
moment
audit
cauti
bundl
implement
art
daili
insert
urinari
cathet
five
intervent
measur
video
hand
hygien
hand
hygien
activ
perform
superintend
vice
superintend
director
nurs
depart
particip
video
perform
monthli
audit
done
certif
activ
vap
cauti
bundl
care
prevent
monthi
feedback
result
hand
hygien
adher
accuraci
rate
implement
vap
cauti
incid
rate
vap
cauti
icu
lower
medic
center
region
hospit
conclus
bundl
care
effect
measur
promot
medic
care
qualiti
monthli
meet
surveil
system
appli
evalu
efficaci
use
hepac
lock
flush
reduc
portrel
bloodstream
infect
shujiuan
tsai
chenchi
tsai
chorngjang
lay
huiy
chuang
yalan
chen
linjia
lin
hsiulun
su
background
ventilatorassoci
pneumonia
vap
defin
pneumonia
develop
hour
longer
use
mechan
ventil
accord
previou
studi
oral
hygien
care
use
chlorhexidin
glucon
chg
element
ventil
bundl
suppos
decontamin
mouth
avoid
aspir
contamin
secret
respiratori
tract
prevent
vap
aim
studi
evalu
antiplaqu
efficaci
use
oral
care
chg
gel
adult
intens
care
unit
icu
method
studi
conduct
adult
icu
region
hospit
februari
april
studi
period
vap
bundl
care
implement
includ
headofb
elev
mainten
ventil
circuit
free
accumul
water
daili
interrupt
sedat
daili
assess
readi
extub
hand
hygien
perform
oral
hygien
chg
gel
twice
daili
plaqu
disclos
solut
use
evalu
amount
plaqu
modifi
quigleyhein
plaqu
index
mqhpi
score
record
oral
hygien
care
chg
gel
independ
test
perfomr
evalu
signific
differ
result
patient
enrollw
studi
period
studi
subject
male
mean
age
year
mean
differ
mqhpi
score
ci
p
chg
gel
use
conclus
oral
hygien
care
chg
gel
significantli
lower
mqhpi
score
adult
critic
ill
patient
largesc
investig
warrant
evalu
whether
impact
reduc
incid
vap
evalu
effect
ventilatorassoci
pneumonia
vap
care
bundl
enhanc
ratio
recognit
complianc
district
hospit
chiayun
pan
yuchiao
chen
yujen
chang
huil
tsai
manl
yu
lichu
lee
mingchi
tsai
wenchi
cheng
wenchih
wu
chochin
sun
background
accord
previou
studi
mani
evid
suggest
bundl
care
reduc
healthcar
relat
infect
effect
howev
clinic
staff
nt
know
mean
bundl
care
clearli
nt
obey
measur
well
implement
ventilationassoci
pneumonia
vap
bundl
care
sinc
june
begin
accuraci
bundl
care
may
caus
low
complianc
rate
bundl
care
complianc
rate
vap
mere
respect
lack
recognit
affect
complianc
perform
measur
method
vap
bundl
care
intervent
includ
headofb
elev
degre
twice
oral
hygien
patient
daili
patenc
control
ventil
circuit
daili
assess
sedat
cessat
hand
hygien
evalu
ventil
need
patient
everi
singl
day
made
special
group
led
assist
administr
observ
promot
bundl
care
clinic
unit
found
clinic
staff
poor
recognit
bundl
care
wellknow
measur
elabor
correct
measur
includ
hold
educ
train
activ
benchmark
institut
bundl
care
checklist
demonstr
hold
king
knowledg
respond
game
make
inform
materi
promot
carri
examin
serious
promot
bundl
care
smoothli
result
promot
correct
measur
complianc
rate
vap
bundl
care
respect
improv
rate
test
educ
train
reach
correct
rate
perform
polici
import
vap
achiev
zero
toler
month
continu
conclus
improv
recognit
clinic
staff
enhanc
complianc
rate
bundl
care
lead
reduc
healthcar
relat
infect
still
follow
studi
hope
achiev
goal
zero
toler
cephalosporinglycopeptid
combin
use
clinic
methicillinresist
staphylococcu
aureu
isol
enhanc
vitro
antibacteri
activ
hungjen
tang
chihcheng
lai
chichung
chen
chuncheng
zhang
tzuchieh
weng
wenliang
yu
hungjui
chen
yuhsin
chiu
wenchien
ko
yinch
chuang
background
empir
combin
betalactam
glycopeptid
counter
potenti
staphylococc
pathogen
may
improv
clinic
outcom
case
staphylococcu
aureu
bacteremia
method
report
compar
vitro
studi
combin
effect
differ
cephalosporin
ie
cefazolin
cefmetazol
cefotaxim
cefepim
combin
glycopeptid
randomli
select
methicillinresist
aureu
mrsa
isol
three
method
includ
checkerboard
timekil
combin
mic
measur
method
result
thirteen
sccmec
type
iii
isol
cefazolin
mic
classifi
highcefazolin
mic
hcm
group
wherea
sccmec
type
iv
sccmec
type
v
isol
classifi
lowcefazolin
mic
lcm
group
checkerboard
method
synerg
present
vancomycinbas
combin
well
teicoplaninbas
combin
hcm
lcm
isol
respect
antagon
note
vitro
inhibitori
activ
evid
even
low
concentr
mic
cephalosporin
combin
subinhibitori
concentr
mic
glycopeptid
timekil
assay
synerg
note
suscept
breakpoint
concentr
sbc
cephalosporin
combin
mic
glycopeptid
presenc
sbc
cephalosporin
vancomycin
teicoplanin
mic
decreas
averag
respect
ml
cephalosporin
declin
glycopeptid
mic
obviou
presenc
cefmetazol
conclus
cephalosporinglycopeptid
combin
clinic
achiev
concentr
exhibit
vitro
synergist
antibacteri
activ
clinic
mrsa
isol
combin
requir
clinic
data
support
applic
use
human
mrsa
infect
impact
inoculum
size
activ
cefoperazonesulbactam
chihcheng
lai
chichung
chen
pingchin
chang
yinch
chuang
hungjen
tang
background
studi
perform
assess
vitro
activ
cefoperazon
alon
differ
cefoperazonesulbactam
ratio
differ
inoculum
size
esbl
coli
k
pneumonia
method
minimum
inhibitori
concentr
mic
cefoperazon
cefoperazonesulbactam
fix
ratio
normal
inoculum
size
cfuml
cfuml
high
inoculum
size
cfuml
cfuml
measur
result
addit
sulbactam
ratio
mic
mic
valu
decreas
suscept
rate
cefoperazonesulbactam
ratio
greater
organ
except
p
aeruginosa
p
aeruginosa
suscept
rate
cefoperazonesulbactam
ratio
extendedspectrum
esbl
e
coli
suscept
rate
cefoperazonesulbactam
ratio
decreas
normal
high
inoculum
respect
esbl
k
pneumonia
suscept
rate
cefoperazonesulbactam
ratio
decreas
normal
inoculum
high
inoculum
conclus
cefoperazonesulbactam
ratio
greater
vitro
activ
multidrug
resist
organ
cefoperazonesulbactam
ratio
combin
influenc
inoculum
size
esbl
e
coli
k
pneumonia
could
therapeut
option
treat
sever
infect
clinic
experi
patient
receiv
doripenemcontain
regimen
treatment
healthcareassoci
infect
chienm
chao
chichung
chen
yinch
chuang
chihcheng
lai
hungjen
tang
background
studi
retrospect
review
clinic
experi
patient
receiv
doripenemcontain
regimen
treatment
healthcareassoci
infect
hcai
tertiari
care
center
assess
clinic
use
doripenem
therapi
clinic
set
method
retrospect
studi
medic
record
adult
patient
ever
receiv
doripenemcontain
therapi
treatment
hcai
review
septemb
august
follow
data
extract
age
gender
type
infect
diseas
sever
underli
comorbid
condit
laboratori
result
addit
also
extract
data
regard
rate
mortal
clinic
microbiolog
respons
result
total
adult
patient
hcai
receiv
doripenemcontain
therapi
includ
studi
respiratori
tract
infect
n
common
type
infect
follow
urinari
tract
infect
intraabdomin
infect
skin
soft
tissu
infect
mean
apach
ii
score
rate
clinic
success
overal
inhospit
mortal
rate
among
patient
inhospit
mortal
independ
significantli
associ
apach
ii
score
odd
ratio
ci
achiev
clinic
success
ci
conclus
overal
inhospit
mortal
rate
low
clinic
success
rate
high
among
hcai
patient
receiv
doripenem
treatment
result
suggest
doripenem
may
judici
use
treatment
patient
hcai
combin
cephalosporin
vancomycin
teicoplanin
enhanc
antibacteri
effect
glycopeptid
heterogen
vancomycinintermedi
staphylococcu
aureu
hvisa
visa
chihcheng
lai
chichung
chen
yinch
chuang
hungjen
tang
background
cathet
associ
urinari
tract
infect
cauti
one
common
health
care
associ
infect
imprtant
risk
factor
develop
cauti
prolong
use
urinari
cathet
activ
surveil
infect
control
need
disclos
hospit
deal
problem
effect
method
prospect
surveil
conduct
accord
us
center
diseas
control
prevent
cdc
procedur
major
teach
hospit
fisher
exact
probabl
test
kruskalw
test
ware
perform
result
studi
period
patientday
catheterday
evalu
cauti
occur
overal
rate
cauti
per
catheterday
mean
age
year
femal
gender
account
length
hospit
stay
day
median
part
patient
past
histori
diabet
mellitu
cancer
bedriddern
patient
admit
intens
care
unit
icu
length
icu
stay
day
averag
conclus
case
cauti
distribut
risk
factor
stabl
interven
infect
control
measur
use
comput
remind
reduc
usag
urinari
catheter
attribut
obviou
decreas
rate
urinari
cathet
util
ratio
earli
detect
healthcareassoci
urinari
tract
infect
use
electron
activ
surveil
system
medic
center
huichi
lin
yiju
tseng
hsinhsin
chang
mingyuan
chen
janntay
wang
wanghuei
sheng
yeechun
chen
feipei
lai
shanchwen
chang
center
infect
control
nation
taiwan
univers
hospit
taipei
taiwan
depart
inform
manag
changgung
univers
taoyuan
taiwan
depart
laboratori
medicin
chang
gung
memori
hospit
linkou
taoyuan
taiwan
inform
system
offic
nation
taiwan
univers
hospit
taipei
taiwan
depart
comput
scienc
inform
engin
nation
taiwan
univers
taipei
taiwan
depart
intern
medicin
nation
taiwan
univers
hospit
colleg
medicin
taipei
taiwan
object
appli
hospitalwid
electron
automat
system
earli
detect
intervent
healthcareassoci
urinari
tract
infect
medic
center
method
realtim
inform
techniqu
integr
clinic
laboratori
data
signal
entri
point
user
interfac
assist
infect
control
personnel
make
decis
healthcareassoci
urinari
tract
infect
use
web
servic
techniqu
base
serviceori
architectur
suitabl
integr
heterogen
platform
protocol
applic
result
provid
qualiti
indic
studi
period
episod
icpdetect
hauti
episod
computerdetect
hauti
found
throughout
depart
correl
hai
event
count
without
hauti
surveil
system
differ
depart
display
squar
sampl
correl
coeffici
depart
week
accuraci
detect
rule
total
episod
verifi
june
novemb
episod
computerdetect
hauti
correl
close
infect
control
personnel
detect
p
compar
refer
standard
system
perform
excel
regard
sensit
specif
posit
predict
valu
neg
predict
valu
decreas
delay
hauti
confirm
system
shorten
delay
confirm
hauti
case
averag
day
day
versu
day
p
conclus
electron
activ
hauti
surveil
system
simplifi
workflow
hospit
infect
control
provid
conveni
servic
timesav
detect
hai
allow
specialist
time
deal
ad
hoc
occurr
process
improv
effici
also
manag
strengthen
qualiti
medic
care
well
patient
safeti
shule
chen
chifen
tsou
yingl
chen
hungjen
tang
background
juli
neurosurgeri
resid
inform
infect
control
center
found
increas
number
patient
suspect
postop
infect
neurosurg
outpati
clinic
suspect
relat
construct
work
oper
room
construct
period
oper
room
june
juli
base
chisquar
test
null
hypothesi
oper
neurosurgeri
differ
oper
room
postop
surgic
site
infect
ssi
chanc
construct
method
june
septemb
healthcareassoci
infect
ssi
number
highest
juli
case
ssi
patient
surgeri
divis
distribut
largest
number
neurosurgeri
case
control
chart
difficult
find
ssi
exceed
time
standard
deviat
control
chart
juli
depart
neurosurgeri
knife
time
surgic
number
knife
time
oper
room
knife
time
oper
room
major
rest
oper
room
knive
time
oper
room
ssi
case
oper
room
ssi
case
oper
room
without
infect
base
chisquar
test
event
ssi
signific
construct
work
oper
room
p
result
definit
taiwan
cdc
edit
healthcareassoci
infect
surveil
ssi
followup
survey
divid
implant
implant
implant
track
juli
far
ssi
increas
construct
rang
oper
room
oper
room
adjac
oper
room
oper
room
mainli
perform
neurosurg
surgic
procedur
result
survey
correl
postop
infect
construct
work
oper
room
conclus
suggest
surgeri
room
construct
plan
notic
surgeon
evalu
surgic
schedul
postpon
cancel
make
mandatori
stop
dispos
oper
surgic
committe
moreov
complet
construct
commiss
qualifi
manufactur
dust
detect
bacteria
sampl
normal
environment
test
result
begin
surgeri
order
ensur
qualiti
surgeri
background
incid
carbapenemresist
pseudomona
aeruginosa
crpa
relat
healthcareassoci
infect
hai
increas
recent
year
worldwid
studi
investig
risk
factor
crpa
infect
universityaffili
teach
hospit
taiwan
order
provid
inform
current
infect
control
system
method
retrospect
crosssect
studi
includ
p
aeruginosa
hai
event
januari
june
divid
crpa
infect
case
group
carbapenemsuscept
p
aeruginosa
cspa
infect
refer
group
medic
record
collect
identifi
risk
factor
crpa
hai
mortal
patient
prior
use
antipseudomon
carbapenem
includ
subgroup
analysi
result
p
aeruginosa
infect
case
enrol
total
hai
event
crpa
cspa
preval
crpa
signific
risk
factor
relat
crpa
infect
longer
time
risk
prior
use
antipseudomon
carbapenem
prior
use
aminoglycosid
p
besid
antipseudomon
carbapenem
monotherapi
significantli
increas
risk
crpa
infect
conclus
crpa
preval
tend
elev
worldwid
well
taiwan
antimicrobi
use
monitor
care
especi
carbapenem
aminoglycosid
studi
bigger
popul
carbapenem
use
would
need
confirm
associ
use
carbapenem
monotherapi
risk
get
crpa
infect
implement
care
bundl
prevent
catheterassoci
urinari
tract
infect
cauti
medic
ward
taiwan
region
hospit
hsiao
yungtsung
jian
shumin
lin
yichih
lin
shihua
hsueh
kueihsia
hsu
jiinchyr
taipei
hospit
ministri
health
welfar
background
catheterassoci
urinari
tract
infect
cauti
one
common
health
careassoci
infect
thu
cauti
reduct
metric
includ
health
human
servic
accord
survey
incid
cauti
account
urinari
tract
infect
cathet
util
rate
taiwan
region
hospit
ministri
health
welfar
aim
studi
reduc
incid
cauti
introduct
bundl
care
method
total
bed
place
indwel
cathet
studi
gener
medic
ward
taiwan
region
hospit
januari
may
recruit
analyz
case
receiv
cauti
bundl
care
cauti
bundl
care
includ
compon
first
avoid
unnecessari
urinari
cathet
situ
check
clinic
indic
second
prior
everi
cathet
care
procedur
perform
hand
hygien
wear
glove
apron
third
maintain
qualiti
urinari
cathet
includ
regularli
empti
urinari
drainag
bag
clean
contain
urinari
drainag
bag
place
lower
bladder
level
floor
lastli
physician
check
necess
use
cathet
everi
day
cathet
remov
soon
possibl
requir
addit
intern
audit
team
led
chief
physician
ward
conduct
intern
audit
monthli
use
tabl
specif
design
cauti
bundl
bare
provid
feedback
ward
project
team
regular
meet
check
complianc
intervent
plan
import
index
result
review
improv
result
complianc
rate
cauti
bundl
care
increas
begin
base
urinari
cathet
util
rate
incid
cauti
improv
zero
infect
month
conclus
studi
demonstr
catheterassoci
urinari
tract
infect
effect
reduc
implement
cauti
bundl
bare
coupl
establish
manag
organiz
system
project
improv
ventilatorassoci
pneumonia
bundl
care
respiratori
care
center
zinmin
huang
yisin
lu
shihhan
tung
depart
nurs
buddhist
tzu
chi
gener
hospit
tzu
chi
univers
taipei
taiwan
background
ventilatorassoci
pneumonia
vap
common
nosocomi
infect
respiratori
care
center
rcc
respiratori
care
center
began
implement
ventilatorassoci
pneumonia
bundl
care
march
complianc
rate
bundl
care
intervent
poor
ventil
associatedpneumonia
infect
rate
increas
decemb
led
high
mortal
prolong
hospit
stay
aim
project
upgrad
knowledg
improv
complianc
rate
correct
bundl
care
reduc
infect
rate
patient
unit
method
project
establish
januari
previou
evalu
unit
found
complianc
rate
vap
bundl
care
intervent
nurs
care
care
correct
caus
low
complianc
rate
bundl
care
low
care
correct
lack
recognit
nurs
lack
remind
system
daili
assess
patient
lack
standard
care
guidelin
mouth
care
lack
standard
make
sure
correct
elev
head
bed
shortcom
conduct
educ
elearn
program
vap
bundl
care
develop
remind
system
medic
oper
system
vap
bundl
daili
assess
establish
standard
care
guidelin
mouth
care
check
correct
elev
head
bed
result
implement
intervent
found
project
effect
improv
complianc
rate
vap
bundl
care
intervent
nurs
care
increas
care
correct
upgrad
knowledg
vap
bundl
care
nurs
staff
point
ventil
associatedpneumonia
infect
rate
decreas
reach
zero
toler
februari
april
conclus
effect
implement
ventil
associatedpneumonia
infect
risk
lower
mortal
day
hospit
reduc
protect
patient
diseas
ensur
patient
safeti
system
analysi
bacteria
urinari
tract
infect
risk
factor
imin
che
ningjen
tsai
peiwen
tsai
en
chu
kong
hospit
medic
qualiti
divis
specialist
en
chu
kong
hospit
infect
control
depart
infect
control
practition
background
urinari
tract
infect
uti
common
infect
taiwan
nosocomi
infect
surveil
system
databas
uti
first
infect
hospit
associ
infect
studi
want
analysi
bacteria
uti
risk
factor
accord
previou
studi
bacteria
caus
uti
escherichia
coli
klebsiella
pneumonia
candida
albican
risk
factor
day
foley
use
method
studi
collect
uti
data
analyz
strain
bacteria
risk
factor
otherwis
use
spss
tool
analyz
uti
ratio
day
foley
use
result
analyz
statist
found
top
bacteria
ecoli
candida
spp
enterococcu
spp
uti
case
associ
foley
averag
foley
use
day
day
conclus
accord
analyz
foley
use
would
aris
ratio
haiuti
say
execut
uti
bundl
still
avoid
uti
otherwis
accord
analyz
ecoli
popular
bacteria
uti
prove
ast
data
doctor
doctor
quickli
treat
avoid
bacteremia
final
averag
foley
use
day
higher
tri
reduc
risk
factor
healthcareassoci
elizabethkingia
meningoseptica
infect
taiwan
medic
center
chiap
chen
yinyin
chen
fuder
wang
infect
control
taipei
veteran
gener
hospit
taiwan
background
elizabethkingia
meningoseptica
chryseobacterium
meningosepticum
nonglucosefer
gramneg
aerob
bacillu
incid
e
meningoseptica
healthcareassoci
infect
hai
increas
major
teach
hospit
northern
part
taiwan
past
year
method
jan
dec
total
patient
chryseobacterium
spp
associ
hai
major
medic
center
teach
hospit
northern
taiwan
enrol
host
factor
hospit
servic
surgic
medic
intervent
infect
site
treatment
complic
hai
analyz
retrospect
result
incid
chryseobacterium
spp
associ
hai
increas
episod
per
inpatientday
episod
p
major
infect
site
bloodstream
infect
urinari
tract
infect
secondli
overal
e
meningoseptica
c
indologen
mean
age
year
patient
male
apach
ii
acut
physiolog
chronic
health
evalu
ii
score
admiss
day
prior
hai
day
patient
ever
expos
antibiot
urinari
cathet
median
durat
catheter
day
receiv
central
venou
line
median
placement
durat
day
conclus
secular
trend
increas
number
e
meningoseptica
hai
hospit
past
year
addit
reinforc
standard
infect
measur
hand
hygien
antibiot
stewardship
key
reduc
healthcareassoci
e
meningoseptica
infect
elimin
catheterassoci
urinari
tract
infect
cauti
bundl
yale
shih
hsiangju
chiu
chiawei
yu
depart
nurs
en
chu
kong
hospit
new
taipei
citi
taiwan
background
densiti
cathet
associ
urinari
tract
infect
cauti
surgic
intens
care
unit
quarter
higher
taiwan
clinic
perform
medic
region
hospit
infect
control
unit
medic
qualiti
manag
center
depart
medic
purchas
depart
involv
team
order
reduc
cauti
method
implement
strategi
revis
clear
standard
insert
urin
cathet
interdisciplinari
educ
cauti
prevent
evalu
embrac
bundl
conceptsabcd
asept
insert
b
bag
empti
regularli
individu
collect
contain
c
close
drainag
system
use
indwel
cathet
e
earli
remov
use
remind
system
unschedul
audit
assess
member
three
abil
includ
cognit
affect
technic
skill
result
regard
strategi
gain
three
effect
outcom
follow
cathet
associ
urinari
tract
infect
densiti
reduc
quarter
fourth
quarter
implement
period
complianc
accuraci
rate
proper
handhygien
techniqu
increas
conclus
cauti
densiti
still
maintain
low
sicu
first
quarter
import
lesson
learn
interdisciplinari
team
lead
improv
collabor
outcom
critic
patient
furthermor
even
though
possess
knowledg
execut
individu
profession
respons
realiz
except
outcom
achiev
genuin
teamwork
outbreak
investig
citrobact
koseri
relat
urinari
tract
infect
bed
bath
yiru
hsiao
jenhsien
wang
yawen
chang
shuyen
hsu
shiaoyin
hung
hsiaohui
chen
chiayu
tsai
juihs
wang
background
enterobacteria
import
pathogen
urinari
tract
infect
intern
seriou
problem
regard
antimicrobi
resist
strain
healthcar
system
medic
personnel
keep
go
reduc
healthcar
associ
urinari
tract
infect
medic
institut
cluster
infect
develop
difficult
estim
harm
impact
march
infect
control
center
hospit
found
sever
event
urinari
tract
infect
citrobact
koseri
respiratori
care
ward
microbiolog
laboratori
daili
report
case
number
mean
threshold
initi
outbreak
investig
method
collect
inform
accord
clinic
observ
laboratori
result
medic
record
past
half
year
retrospect
furthermor
perform
item
environment
test
ward
ground
drainag
hole
shift
plate
bath
bed
share
shampoo
bath
gel
result
three
urinari
specimen
one
blood
cultur
three
patient
foley
cathet
reveal
citrobact
koseri
similar
antimicrobi
suscept
test
feb
march
six
patient
citrobact
koseri
infect
sep
jan
develop
sporad
besid
environment
sampl
cultur
report
citrobact
koseri
bath
bed
share
shampoo
subpack
bath
gel
also
intervent
infect
control
measur
educ
caregiv
perform
immedi
shampoo
bath
gel
without
reus
empti
bottl
appli
individu
bath
drainag
system
foley
cathet
must
shut
temporarili
avoid
countercurr
urin
relat
infect
besid
emphas
principl
infect
control
polici
respiratori
care
ward
equip
environ
daili
care
personnel
train
citrobact
koseri
relat
infect
report
follow
environment
test
reveal
neg
result
till
conclus
enterobacteria
induc
outbreak
urinari
tract
infect
healthcar
system
notifi
issu
present
experi
outbreak
citrobact
koseri
relat
urinari
tract
infect
bed
bath
rare
mention
transmiss
enterobacteria
via
equip
environ
remind
effect
bundl
care
intervent
reduc
catheterrel
urinari
tract
infect
share
regin
hospit
taiwan
jenghua
ling
chiahung
liao
peichen
chen
hongchang
hong
liyu
ye
yachin
lee
yushiu
chen
infect
control
center
depart
intern
medicin
background
hospit
urinari
tract
infect
account
healthcareassoci
infect
intens
care
unit
catheterrel
urinari
tract
infect
cauti
account
infect
densiti
literatur
review
hospit
patient
cauti
high
medicalrel
infect
highest
account
accord
empir
medic
literatur
seen
combin
care
measur
effect
reduc
cauti
unit
promot
prevent
urinari
tract
infect
combin
care
measur
hope
reduc
rate
provid
highqual
medic
care
method
start
implement
cauti
care
bundl
januari
patient
cathet
accord
literatur
five
nurs
measur
establish
daili
assess
whether
cathet
remov
hand
hygien
perform
care
cathet
daili
check
cathet
fixat
confirm
cathet
drainag
system
maintain
close
steril
smooth
clean
urethra
soap
water
everi
day
use
checklist
daili
check
whether
care
perform
establish
consensu
oper
standard
revis
improv
care
tool
educ
train
intervent
measur
implement
audit
mechan
cauti
detect
result
feedback
unit
discuss
improv
result
januari
decemb
urinari
tract
infect
still
common
infect
site
intens
care
unit
account
slightli
lower
intervent
case
signific
differ
date
hospit
previou
year
number
indwel
cathet
decreas
day
day
cauti
decreas
conclus
care
bundl
effect
reduc
cauti
improv
health
carerel
infect
improv
patient
safeti
enhanc
intens
care
unit
prevent
healthassoci
infect
tigecyclin
suscept
coagulaseneg
staphylococci
isol
central
taiwan
background
tigecyclin
wide
rang
antibacteri
spectrum
includ
methicillinresist
coagulaseneg
staphylococci
cn
much
known
tigecyclin
resist
cn
studi
aim
explor
tigecyclin
resist
cn
central
taiwan
method
total
isol
cn
collect
central
laboratori
central
region
hospit
allianc
speciat
perform
rrna
gene
sequenc
tigecyclin
suscept
determin
use
vitek
broth
microdilut
method
interpret
done
accord
eucast
standard
result
gene
sequenc
preval
three
speci
found
staphylococcu
epidermidi
isol
staphylococcu
capiti
isol
staphylococcu
haemolyticu
isol
tigecyclin
resist
rate
use
vitek
broth
microdilut
method
respect
mic
consist
within
one
doubl
dilut
rate
among
isol
consist
rate
epidermidi
capiti
haemolyticu
respect
haemolyticu
isol
interpret
suscept
use
broth
microdilut
method
howev
regard
resist
vitek
method
conclus
tigecyclin
resist
toward
cn
central
taiwan
first
reveal
inconsist
mic
use
commerci
vitek
method
standard
broth
microdilut
method
especi
haemolyticu
deserv
continu
studi
background
goal
perform
improv
studi
evalu
effect
target
intervent
decreas
catheterassoci
urinari
tract
infect
cauti
urinari
cathet
util
implement
qualiti
improv
initi
method
cauti
rate
urinari
cathet
util
calcul
adult
intens
care
unit
intervent
studi
conduct
period
month
preintervent
phase
base
line
cathet
associ
cauti
incid
rate
determin
compar
incid
rate
postintervent
phase
complianc
health
care
staff
urinari
cathet
bundl
element
also
measur
implement
cauti
prevent
bundl
includ
set
clear
expect
indic
indwel
urinari
cathet
use
indwel
cathet
polici
includ
criteria
cathet
use
cathet
insert
use
asept
techniqu
steril
equip
acathet
mainten
hand
hygien
document
cathet
placement
daili
assess
continu
need
indwel
urinari
cathet
physician
audit
checklist
check
insert
procedur
review
supervisor
done
multidisciplinari
team
fortnight
result
studi
period
patient
diagnos
cauti
statist
signific
reduct
rate
cauti
icu
per
catheterday
confid
interv
ci
intervent
per
catheterday
ci
p
intervent
urinari
cathet
use
rate
decreas
ci
baselin
ci
p
complianc
rate
icu
nurs
bundl
element
rais
last
month
post
intervent
phase
conclus
increas
complianc
recommend
cathet
associ
urinari
tract
infect
prevent
practic
reduc
incid
cauti
icu
unit
simpl
effect
recommend
part
patient
safeti
cultur
screen
analysi
multidrug
resist
organ
mdro
patient
longterm
care
facil
taiwan
experi
commun
hospit
southern
taiwan
hsaiojung
huang
youyu
shen
yingl
chen
tzuchieh
weng
hansiong
toh
pingyu
chen
chi
mei
medic
center
chiali
chi
mei
medic
center
background
patient
hospit
longterm
care
facil
patient
higher
possibl
multidrug
resist
organ
mdro
infect
commonli
detect
admisss
period
cultur
periond
day
order
earli
detect
special
organ
strain
earli
intervent
includ
contact
isol
start
routin
screen
mdro
hospit
jan
dec
method
assess
inpati
admiss
day
risk
multipl
drugresist
bacteria
longterm
care
facil
hospit
histori
six
month
routin
rectal
swab
vancomycinresist
enterococcu
vre
carbapenemresist
enterobacteriacea
cre
medium
urin
cultur
also
perform
prevent
contact
isol
first
day
admiss
laboratori
staff
receiv
sampl
repor
accord
clsi
norm
background
measl
rubella
vaccineprevent
diseas
accord
guidelin
taiwan
cdc
healthcar
worker
hcw
aim
evalu
boost
efficaci
mmr
vaccin
among
young
hcw
method
jan
dec
eleg
individu
includ
new
junior
staff
intern
work
hospit
least
one
month
antimeasl
virusigg
vida
measl
igg
test
kit
use
result
read
mini
vida
immunoanalyz
express
neg
equivoc
posit
antirubella
virusigg
elecsi
rubella
igg
test
kit
roch
use
coba
analyz
roch
result
express
nonreact
reactiv
second
third
measur
serum
antibodi
perform
one
month
mmr
vaccin
discret
staff
one
two
dose
mmr
vaccin
one
month
interv
freeli
provid
staff
negativeequivoc
nonreact
result
serum
igg
antibodi
result
total
individu
test
measl
rubella
respect
baselin
posit
rate
antimeasl
rubella
igg
intern
staff
respect
number
junior
staff
test
requir
vaccin
measl
rubella
among
vaccin
staff
seroconvers
measl
first
dose
vaccin
among
staff
receiv
second
vaccin
addit
seroconvers
among
seroneg
staff
vaccin
rubella
seroconvers
first
vaccin
among
latter
one
remain
seroneg
second
vaccin
conclus
result
suggest
junior
staff
need
mmr
vaccin
inadequ
serum
igg
titer
measl
rubella
viru
one
dose
mmr
vaccin
vaccine
exhibit
seroconvers
measl
rubella
prevent
occurr
measl
rubella
among
young
hospit
staff
patient
care
mmr
vaccin
advis
seroneg
staff
improv
project
scabi
infect
region
teach
hospit
mengchuan
lu
huiju
hu
hsiuwen
yu
infect
control
depart
cheng
ching
hospit
background
three
nurs
one
caretak
suffer
itchi
skin
continu
januari
januari
medic
ward
infect
control
depart
investig
found
one
nurs
staff
one
caretak
one
patient
diagnos
scabi
infect
assum
infect
patient
transfer
nurs
home
patient
thick
black
crust
two
finger
two
lower
limb
admit
hospit
sinc
januari
consult
dermatologist
diagnos
subacut
dermat
contact
isol
implement
thereaft
refer
hospit
scabi
diagnos
method
spread
scabi
cluster
due
delay
diagnosi
contact
isol
wear
protect
cloth
contact
patient
use
person
medic
equip
infect
control
depart
implement
follow
strategi
organ
educ
train
scabi
formul
rule
patient
transfer
nurs
home
implement
contact
isol
skin
check
finger
palm
wrist
armpit
hip
around
navel
genitourinari
part
abnorm
found
consult
dermatologist
set
comput
inform
system
order
contact
isol
accord
diagnost
code
medic
scabi
use
person
sphygmomanomet
stethoscop
make
sure
clean
disinfect
equip
environ
result
longterm
care
institut
patient
high
risk
scabi
infect
symptom
often
atyp
caus
medic
staff
easi
ignor
isol
measur
result
outbreak
also
increas
risk
infect
medic
staff
order
reduc
spread
scabi
implement
longterm
care
institut
patient
contact
isol
initi
skin
assess
import
set
inform
remind
system
also
help
follow
implement
measur
track
incid
scabi
medic
ward
third
floor
februari
april
found
spread
scabi
show
strategi
effect
experi
report
surveil
vancomycinresist
enterococci
linhui
chao
yawen
chang
ile
chen
ingkit
lee
background
hospit
use
mani
strategi
control
nosocomi
transmiss
vancomycinresist
enterococci
vre
strategi
includ
passiv
surveil
isol
patient
known
previou
current
vre
colon
infect
activ
surveil
use
admiss
cultur
subsequ
isol
patient
found
colon
vre
studi
epidemiolog
featur
risk
factor
intestin
colon
infect
vancomycinresist
enterococci
vre
hospit
patient
method
analyz
surveil
data
januari
decemb
center
vre
endem
clinic
signific
enterococci
test
suscept
vancomycin
intens
care
unit
admiss
screen
admiss
weekli
thereaft
intervent
includ
isol
cohort
vre
patient
monthli
preval
survey
vre
patient
introduct
electron
alert
system
programm
improv
hand
environment
hygien
appoint
antibiot
physician
result
sampl
patient
investig
patient
posit
vre
perform
period
surveil
direct
patient
risk
case
show
posit
result
vre
vre
colon
patient
develop
bsi
vre
central
venou
cathet
insert
well
patient
one
known
risk
factor
associ
colon
vancomycinresist
enterococci
patient
receiv
antibiot
studi
receiv
vancomycin
conclus
colon
vre
mostli
endem
colon
patient
often
infect
howev
cluster
case
colon
occur
associ
increas
rate
infect
routin
surveil
vre
togeth
measur
control
vre
infect
colon
even
vre
endem
facil
constrain
evid
colon
patient
mean
empir
precaut
thu
provid
patient
safeti
minim
risk
nosocomi
infect
influenza
outbreak
investig
control
measur
region
teach
hospit
chunhua
chung
yachi
li
yafang
wang
yungch
liu
wenchuan
lin
infect
control
offic
divis
infecti
diseas
depart
intern
medicin
divis
pediatr
infecti
diseas
depart
pediatr
taipei
medic
univers
background
novemb
year
outbreak
caus
influenza
occur
nurs
home
region
teach
hospit
nineti
resid
total
twenti
four
resid
respiratori
symptom
fever
cough
clinic
attack
rate
method
among
resid
flu
symptom
eight
laboratoryconfirm
influenza
rapid
antigen
test
influenza
viru
chain
reaction
polymeras
nucleic
acid
detect
revers
transcript
polymeras
chain
reaction
rtpcr
viru
isol
cultur
time
applic
epidemiolog
method
investig
collect
suspect
case
determin
clinic
epidemiolog
data
analysi
monitor
result
influenza
confirm
among
patient
one
confirm
swine
confirm
pathogenesi
respiratori
tract
infect
incid
influenza
viru
immedi
take
care
patient
strict
infect
control
measur
epidem
soon
control
conclus
strict
infect
control
measur
appli
includ
isol
infect
resid
earli
rapid
test
flu
symptom
use
mask
staff
famili
member
reinforc
hand
wash
environment
cleans
effect
chemoprophylaxi
given
staff
lessen
impact
infect
strict
infect
control
measur
done
new
case
report
novemb
intervent
program
healthcareassoci
infect
control
teach
hospit
taiwan
frank
lien
yuhong
tsai
wanl
tai
linlin
pan
background
accord
report
healthcar
associ
infect
hai
frequent
advers
event
healthcar
previou
studi
also
show
hai
result
prolong
hospit
stay
increas
medic
cost
lead
signific
mortal
method
case
meet
cdc
criteria
hai
categor
includ
surveil
system
intervent
infect
control
implement
includ
hai
relat
staff
educ
intern
audit
antibiot
stewardship
program
infect
control
method
hand
hygien
remain
one
fundament
critic
part
thu
hand
hygien
complianc
rate
set
threshold
monitor
improv
data
hai
intern
audit
hand
hygien
chiayi
changgung
memori
hospit
region
teach
hospit
southern
taiwan
collect
analyz
pearson
correl
analysi
use
investig
correl
hand
hygien
complianc
rate
overal
icu
hai
incid
per
thousand
inpatientday
linear
regress
method
adopt
reveal
trend
hai
rate
trend
analysi
base
slope
regress
trend
line
result
slope
overal
inpati
icu
inpati
hai
r
r
respect
result
show
period
time
icu
hai
declin
markedli
overal
icu
hai
per
thousand
patientsday
respect
use
linear
regress
model
averag
first
month
overal
icu
hai
rate
approxim
show
larg
portion
hai
reduct
contribut
icu
preliminari
data
first
month
show
overal
icu
hai
rate
respect
result
show
hai
rate
overal
slight
increas
markedli
decreas
icu
first
four
month
compat
assumpt
base
predict
model
pearson
correl
show
hand
hygien
complianc
rate
significantli
strong
correl
icu
hai
rate
r
p
overal
hai
rate
r
p
background
blood
cultur
contamin
bcc
result
increas
workload
lab
staff
overus
abus
antibiot
caus
rais
cost
prolong
hospit
stay
invalid
treatment
therefor
decreas
bcc
rate
import
icu
region
teach
hospit
midland
taiwan
show
averag
bcc
rate
much
higher
threshold
valu
infect
control
team
inspect
procedur
blood
sampl
collect
found
improp
oper
procedur
follow
hand
hygien
conclus
although
bcc
improv
program
reduc
bcc
rate
yet
use
chg
execut
skin
disinfect
decreas
bcc
rate
shorten
wait
time
skin
disinfect
increas
work
effici
medic
staff
elev
qualiti
healthcar
improv
qualiti
ventil
associ
pneumonia
bundl
unit
mean
team
cooper
hsiaoshan
chen
hungjen
tang
iigl
chen
background
innov
progress
medic
technolog
invas
devic
also
import
factor
relat
infect
intens
care
unit
respiratorassoci
pneumonia
one
lead
caus
death
refer
taiwan
clinic
perform
indic
tcpi
incid
respiratorassoci
pneumonia
intens
care
unit
slightli
higher
peer
combin
prevent
respiratoryrel
pneumonia
infect
combin
care
improv
qualiti
combin
care
reduc
rate
respiratoryrel
pneumonia
infect
teambas
mode
cooper
method
hospit
june
decemb
intens
care
unit
use
prevent
breath
apparatusrel
pneumonia
combin
care
checklist
total
five
project
daili
respir
assess
daili
suspens
sed
least
time
day
chlorhexidin
glucon
gel
oral
care
bed
head
rais
drain
ventil
pipe
appli
patient
use
respir
clinic
care
result
correct
rate
combin
respiratorassoci
pneumonia
infect
june
march
increas
infect
rate
decreas
implement
respiratori
tract
although
number
day
reduc
number
case
infect
reduc
averag
case
per
quarter
averag
per
quarter
reduct
implement
vap
bundl
case
vap
reduc
seen
correct
rate
combin
respiratorassoci
pneumonia
infect
associ
decreas
respiratori
rate
conclus
vap
bundl
implement
team
establish
need
crossdepartment
staff
common
particip
cooper
educ
peopl
correct
correct
train
establish
staff
attent
ident
will
put
action
regularli
provid
implement
respiratorassoci
pneumonia
infect
combin
correct
rate
respiratoryrel
pneumonia
infect
rate
relev
inform
feedback
implement
unit
continu
review
effect
implement
multidiment
infect
control
measur
healthcar
associ
infect
intens
care
unit
yale
lee
chiunghui
ho
tzute
kuo
infect
control
offic
da
chien
gener
hospit
background
outbreak
carbapenem
resist
klebsiella
pneumoina
crkp
intens
care
unit
icu
multifacet
intervent
implement
two
stage
sinc
hypothes
infect
control
respons
may
secondari
benefit
reduc
incid
healthcar
associ
infect
hai
method
implement
first
stage
infect
control
measur
sinc
octob
includ
complet
termin
disinfect
cohort
isol
patient
crkp
crpa
vre
second
stage
intervent
start
sinc
april
compris
appli
chlorhexidin
chg
bath
patient
icu
well
find
disinfect
erad
nidus
mdro
cultur
item
nidus
discov
feed
cup
plastic
basket
belong
individu
bed
individu
patient
work
tabl
nurs
two
commun
bedpan
analyz
data
retrospect
prospect
infect
control
databas
sinc
may
icu
bed
calcul
monthli
trend
hai
two
stage
infect
control
measur
icu
adjust
effect
hand
hygien
antibiot
usag
order
assess
chang
hai
period
use
gener
addit
model
gam
fix
effect
period
time
per
month
complianc
accuraci
hand
wash
random
effect
period
time
random
effect
show
chang
hai
intervent
result
implement
trend
uti
show
revers
downward
although
trend
hap
figur
signific
reduct
trend
uti
second
stage
intervent
rr
ci
tabl
result
patient
infect
cre
whose
specimen
includ
sputum
n
urin
n
wound
n
ascit
n
line
n
bile
n
blood
n
group
noncompli
hand
microbi
count
accept
group
microbi
load
close
upper
limit
observ
reveal
thorough
scrub
hh
achiev
reduct
bacteri
load
use
sanit
particip
use
second
hand
wash
recommend
second
report
wash
hand
observ
dirt
found
cohort
crowd
locat
highest
microbi
count
per
individu
lowest
incid
count
staphylococcu
aureu
mrsa
isol
found
particip
hh
remov
use
sanit
coliform
count
compliant
yeast
mould
count
rel
low
claim
employ
agenc
provid
hygien
train
discuss
reveal
welcom
enhanc
hygien
knowledg
job
train
conclus
domest
helper
requir
enhanc
support
hygien
train
special
attent
given
infect
control
carrier
could
risk
spread
mrsaresist
speci
commun
onthejob
train
domest
helper
desir
improv
qualiti
selfmad
ice
consumpt
number
bacteria
improv
qualiti
project
yichia
chen
yuhsiu
lin
yeehuang
ku
jyhjou
chen
infect
control
center
intens
care
depart
medicin
background
hospit
western
restaur
chi
mei
coffe
food
sale
use
selfmad
edibl
ice
octob
januari
chi
mei
coffe
homemad
edibl
ice
number
bacteria
standard
test
addit
temporari
suspens
use
number
addit
raw
bacteria
meet
ice
also
continu
explor
reason
improv
measur
invalid
method
march
nutrit
depart
infect
control
center
safeti
health
room
public
affair
room
jade
meal
compani
improv
project
team
characterist
map
true
verif
qualiti
manag
practic
tool
establish
five
issu
set
target
pass
rate
develop
improv
measur
develop
equip
equip
clean
disinfect
norm
check
mechan
train
method
formul
standard
inspect
oper
standard
check
mechan
train
method
formul
inspect
standard
oper
rule
check
mechan
train
method
updat
water
qualiti
filtrat
equip
four
measur
improv
result
sinc
march
intervent
improv
septemb
pass
rate
complet
develop
three
standard
oper
manual
continu
accord
standard
implement
implement
process
octob
novemb
achiev
selfmad
consumpt
ice
pass
rate
target
decemb
januari
number
bacteria
standard
cfu
ml
may
due
lack
ice
machin
pipelin
steril
equip
ice
machin
surround
environ
pollut
develop
countermeasur
regular
clean
ice
machin
surround
month
ice
machin
line
use
ozon
month
disinfect
quarter
steril
final
februari
april
monitor
result
pass
rate
hospit
provid
safe
food
staff
public
use
teamwork
develop
standard
oper
process
check
extent
problem
staff
match
therefor
continu
monitor
number
bacteria
assess
increas
e
coli
flora
test
ensur
food
safeti
hygien
explor
practic
util
chlorhexidin
gel
clinic
care
unit
shuyuan
kuo
yuhsiu
lin
yee
huangku
pakon
leung
meif
sie
jyhjou
chen
conclus
conclud
addit
earli
art
safe
sex
educ
enhanc
hiv
prevent
campaign
evidencebas
assess
mortal
patient
infect
carbapenemresist
klebsiella
pneumonia
crkp
background
carbapenem
resist
k
pneumonia
crkp
arous
widespread
attent
due
limit
therapeut
option
recent
year
strain
increas
rapidli
though
seem
infer
drug
resist
associ
higher
mortal
gener
studi
found
relationship
util
ebm
method
obtain
critic
apprais
best
evid
estim
mortal
patient
infect
crkp
gener
analyz
factor
mortal
infect
awak
awar
infect
control
work
prevent
strategi
method
term
carbapenem
klebsiella
pneumonia
crkp
motal
associ
synonym
combin
boolean
charact
formul
keyword
search
cochran
librari
pubm
cep
databas
relev
systemat
review
sr
trial
found
cochran
cep
pubm
three
sr
filter
search
result
titl
abstract
sr
subsequ
review
one
latest
srmetaanalysi
select
critic
apprais
analyz
data
retrospect
prospect
infect
control
databas
sinc
may
icu
bed
calcul
monthli
trend
mdro
two
stage
infect
control
measur
icu
adjust
effect
hand
hygien
antibiot
usag
order
assess
chang
mdro
period
use
gener
addit
model
gam
fix
effect
period
time
per
month
complianc
accuraci
hand
wash
random
effect
period
time
random
effect
show
chang
mdro
intervent
result
chang
four
mdro
subtl
period
baselin
intervent
still
nonsignific
period
intervent
tabl
fix
effect
hand
hygien
either
nonsignific
conclus
although
crkp
outbreak
control
infect
control
measur
trend
previous
stationari
mdro
chang
well
pulmonari
tuberculosi
cancer
patient
medic
center
northern
taiwan
chilan
kao
yenp
tsai
hsinyen
chen
wantsui
huang
background
pulmonari
tuberculosi
cancer
two
major
public
health
problem
associ
pulmonari
tuberculosi
cancer
interest
distinct
cancer
known
risk
factor
develop
activ
tuberculosi
retrospect
studi
aim
investig
characterist
activ
tuberculosi
cancer
medic
center
method
data
patient
pulmonari
tuberculosi
retriev
electron
medic
record
januari
decemb
pulmonari
tuberculosi
document
microbiolog
mycobacterium
tuberculosi
infect
defin
sputum
found
posit
cultur
polymeras
chain
reaction
studi
emphasi
patient
characterist
cancer
type
develop
pulmonari
tuberculosi
cancer
patient
result
cancer
patient
pulmonari
tuberculosi
period
studi
twentyon
patient
men
median
age
year
rang
year
twenti
patient
one
solidorgan
tumor
common
site
underli
malign
lung
patient
two
patient
two
kind
solidorgan
tumor
one
patient
gastric
cancer
oral
tongu
cancer
acut
myeloid
leukemia
four
patient
bcell
lymphoma
one
patient
tcell
lymphoma
one
patient
multipl
myeloma
pulmonari
tuberculosi
develop
patient
within
day
diagnosi
cancer
pulmonari
tuberculosi
develop
chemotherapi
patient
conclus
result
physician
awar
risk
develop
pulmonari
tuberculosi
cancer
patient
investig
influenc
antimicrobi
prophylaxi
surgeri
effect
probiot
gut
microbiom
method
patient
underw
spine
surgeri
juli
decemb
includ
studi
twenti
patient
classifi
two
group
accord
permut
block
method
control
n
postop
administr
drugresist
lactic
acid
bacteria
day
treatment
group
n
patient
receiv
surgeri
antimicrobi
prophylaxi
usual
fece
patient
sampl
preoper
postop
day
pod
gut
microbiom
analyz
use
ionpgm
system
clc
genom
workbench
result
signific
differ
control
treatment
group
basic
characterist
age
gender
underli
diseas
surgic
site
antimicrobi
agent
periop
period
control
group
cefazolin
cez
n
clindamycin
n
combin
cez
vancomycin
van
treatment
group
cez
n
combin
cez
van
n
signific
differ
antimicrobi
agent
administr
period
two
group
control
group
two
patient
show
soft
stool
mean
number
oper
taxonom
unit
otu
preoper
control
group
respect
fig
number
otu
control
group
significantli
decreas
compar
preoper
p
mean
number
otu
treatment
group
respect
figur
chang
gut
microbiom
show
figur
permanova
analysi
weight
unifrac
composit
gut
microbiom
significantli
differ
group
p
conclus
gut
microbiom
influenc
antimicrobi
prophylaxi
surgeri
probiot
might
reduc
influenc
evidencebas
efficaci
antibiot
prophylaxi
patient
undergo
elect
laparoscop
cholecystectomi
yich
huang
yuanhsin
chu
divis
infecti
diseas
jenai
hospit
depart
infect
control
jenai
hospit
background
elect
laparoscop
cholecystectomi
may
result
surgic
site
infect
ssi
may
increas
length
hospit
stay
healthcar
cost
antibiot
prophylaxi
form
singl
dose
cephalosporin
still
administ
skin
incis
elect
laparoscop
cholecystectomi
mani
clinic
set
controversi
use
routin
antibiot
prophylaxi
patient
undergo
elect
laparoscop
cholecystectomi
appli
ebm
method
search
systemat
analyz
evid
evalu
safeti
efficaci
routin
antibiot
prophylaxi
patient
undergo
elect
laparoscop
cholecystectomi
method
term
elect
laparoscop
cholecystectomi
antibiot
prophylaxi
surgic
site
infect
synonym
use
formul
pico
engag
keyword
search
cochran
librari
pubm
filter
systemat
review
sr
prioriti
one
relev
sr
metaanalysi
includ
search
result
pubm
afterward
critic
apprais
result
sr
includ
rct
patient
antibiot
prophylaxi
decreas
incid
surgic
site
infect
risk
ratio
rr
confid
interv
ci
p
global
infect
rr
ci
p
hospit
discharg
postop
length
hospit
stay
weight
mean
differ
ci
p
advers
event
report
subgroup
analys
reveal
two
dose
antibiot
dose
antibiot
significantli
reduc
incid
surgic
site
infect
compar
placebo
antibiot
two
dose
rr
ci
dose
rr
ci
singl
dose
antibiot
administr
conclus
antibiot
prophylaxi
safe
effect
decreas
incid
surgic
site
infect
global
infect
hospit
discharg
postop
length
hospit
stay
lowrisk
patient
undergo
elect
laparoscop
cholecystectomi
two
dose
antibiot
prophylaxi
recommend
patient
level
reduc
incid
upper
respiratori
tract
infect
psychiatr
patient
region
teach
hospit
experi
icn
time
remind
given
cohort
care
patient
upper
respiratori
tract
infect
increas
frequenc
interpati
environ
clean
includ
bed
dine
tabl
chair
intervent
event
stop
june
th
conclus
sinc
influenza
transmiss
droplet
contact
especi
psychiatr
patient
alway
share
food
ca
nt
control
healthcar
worker
need
alert
patient
inform
messag
infect
section
immedi
prognost
factor
healthcareassoci
bloodstream
infect
adult
patient
older
year
hsuanyin
ichen
hung
yahuei
huang
yingi
chang
wanghuei
sheng
janntay
wang
weichu
chie
jenpei
liu
yeechun
chen
derchen
women
children
hospit
kaoshiung
taiwan
infect
control
center
nation
taiwan
univers
hospit
taipei
taiwan
depart
intern
medicin
nation
taiwan
univers
hospit
taipei
taiwan
depart
famili
medicin
nation
taiwan
univers
hospit
taipei
taiwan
school
public
health
nation
taiwan
univers
taipei
taiwan
depart
agronomi
nation
taiwan
univers
taipei
taiwan
background
healthcareassoci
bloodstream
infect
habsi
may
worsen
clinic
outcom
among
hospit
patient
especi
geriatr
popul
aim
known
characterist
search
prognost
factor
regard
habsi
geriatr
patient
method
demograph
characterist
comorbid
laboratori
data
mortal
habsi
electron
chart
record
januari
decemb
medic
center
review
retrospect
differ
demograph
characterist
outcom
middl
age
year
geriatr
popul
year
perform
prognost
factor
associ
mortal
identifi
multipl
logist
regress
investig
needl
sharp
injuri
healthcar
worker
region
teach
hospit
taiwan
chien
chen
wang
chiayi
chang
gung
memori
hospit
chiayi
taiwan
background
needl
sharp
injuri
common
occup
injuri
hospit
hepat
b
viru
hbv
hepat
c
viru
hcv
syphili
human
immunodefici
viru
hiv
common
caus
occup
exposur
health
care
worker
infect
caus
physic
psycholog
discomfort
articl
explor
incid
needl
sharp
injuri
hospit
investig
analysi
implement
safeti
needl
method
hospit
standard
staff
injur
needl
sharp
process
includ
wound
treatment
conclus
promot
safeti
needl
belong
taiwan
legisl
polici
provid
year
fulli
use
safeti
needl
investig
behavior
medic
staff
type
item
obvious
use
safeti
needl
reduc
incid
scrap
reduc
safeti
needl
needl
also
contain
special
needl
inspect
promot
safeti
tool
also
includ
chang
use
habit
also
affect
occurr
acupunctur
still
industri
special
safeti
needl
research
develop
medic
staff
habit
period
reduc
incid
needl
sharp
injuri
background
hospit
begin
execut
invas
medic
treatment
care
qualiti
upgrad
program
ministri
health
welfar
depart
diseas
control
agenc
project
need
complet
cathet
placement
checklist
daili
care
tabl
big
burden
clinic
staff
howev
compar
implement
project
arrang
staff
fill
cognit
questionnair
found
implement
cauti
bundl
patient
meaning
recogn
form
inform
reduc
burden
paper
work
increas
implement
combin
care
health
care
worker
implement
wish
method
octob
cauti
bundl
form
compil
particip
unit
nurs
ad
pipelin
familiar
pipe
system
set
tabl
brought
basic
inform
futur
addit
doctor
open
urinari
cathet
surgeon
start
placement
tabl
fill
reason
placement
futur
open
doctor
advic
jump
doctor
account
check
tabl
immedi
know
number
day
place
assess
reason
indwel
substanti
reduct
clinic
staff
fill
time
paper
form
miss
fill
assess
phenomenon
addit
project
give
quarterli
report
inform
program
transfer
materi
physician
care
significantli
reduc
quarterli
report
type
time
paper
consumpt
result
septemb
hospit
start
promot
everi
unit
depart
octob
decemb
particip
unit
began
fill
form
form
complet
rate
doctor
rate
nurs
staff
januari
hospit
began
promot
except
pediatr
depart
unit
educ
train
compet
meet
propaganda
continu
review
improv
project
may
physician
form
complet
rate
high
caregiv
form
complet
rate
substanti
increas
complet
rate
conclus
combin
care
difficult
health
care
worker
difficulti
time
spent
fill
form
time
find
physician
fill
form
effect
use
inform
program
inde
increas
implement
medic
care
health
care
worker
score
system
identifi
hospit
critic
patient
risk
imipenemresist
gramneg
bacilli
septicemia
sepsi
onset
ling
chen
cingl
tai
background
emerg
carbapenem
resist
among
gramneg
bacilli
gnb
increasingli
report
worldwid
matter
great
concern
sinc
complic
empir
guid
treatment
sever
critic
ill
patient
inappropri
administr
empir
antibacteri
may
increas
mortal
rate
septic
patient
aim
deriv
clinic
predict
score
predict
risk
acquisit
imipenemresist
ir
gnb
septicemia
method
retrospect
cohort
studi
enrol
patient
suffer
gnb
bacteremia
hour
admiss
kaohsiung
chang
gung
memori
hospit
kcgmh
bed
tertiarycar
medic
centr
southern
taiwan
januari
decemb
adjust
analys
perform
multivari
analysi
propens
scorebas
match
risk
factor
irgnb
septicemia
evalu
multivari
logist
regress
backward
select
novel
predict
score
irgnb
septicemia
deriv
result
three
hundr
seventi
episod
includ
control
age
charlson
index
sex
follow
independ
risk
factor
obtain
multivari
logist
regress
analysi
prior
extendedspectrum
cephalosporin
exposur
day
youden
index
statist
indic
score
best
cutoff
valu
sensit
specif
conclus
score
might
help
clinician
stratifi
risk
irgnb
septicemia
infect
decid
empir
therapi
patient
sepsi
onset
effect
applic
inform
technolog
improv
tuberculosi
phase
assess
yajhen
ji
yuehi
tsai
yunlin
christian
hospit
tuberculosi
case
manag
yunlin
christian
hospit
supervis
nurs
depart
background
medic
servic
follow
updat
progress
develop
inform
technolog
rate
tuberculosi
assess
stage
region
hospit
may
lead
treatment
failur
drug
resist
occur
patient
assess
chest
xray
examin
bacteriolog
test
time
outpati
messag
list
use
remind
physician
take
chest
xray
examin
bacteriolog
test
rate
tuberculosi
phase
assess
therefor
hope
rate
achiev
improv
applic
inform
technolog
method
develop
electron
messag
board
medic
inform
system
order
remind
physician
order
chest
xray
examin
bacteriolog
test
outpati
medic
system
prescript
stage
continu
improv
appli
mobil
phone
line
contact
public
health
care
divis
commun
august
health
care
divis
enhanc
case
remind
sputum
test
side
effect
medic
result
rate
tuberculosi
assess
phase
three
phase
realli
improv
continu
tuberculosi
assess
use
electron
messag
board
line
inform
softwar
incom
tuberculosi
stage
continu
assess
health
insur
payment
ntd
lose
ntd
low
rate
continu
assess
health
insur
payment
rose
ntd
estim
amount
loss
ntd
amount
loss
reduc
significantli
conclus
applic
inform
technolog
improv
continu
stage
assess
remind
patient
perform
chest
xray
examin
bacteriolog
test
howev
case
take
medicin
regular
although
treatment
failur
occur
three
case
cxr
deterior
sputum
smear
turn
posit
four
case
end
treatment
medic
staff
pay
attent
precaut
line
leak
person
inform
result
whole
data
databas
includ
surgic
schedul
system
medic
system
birth
notif
system
anesthesiolog
system
oper
room
manag
system
nurs
oper
system
book
surgic
schedul
key
point
start
ssi
system
creat
three
tabl
increas
data
collect
integr
found
manag
support
key
point
provid
system
use
accord
studi
result
cover
ratio
ssi
data
juli
octob
januari
surgic
data
automat
supervisor
support
practic
medic
personnel
inde
import
anteced
system
qualiti
inform
qualiti
servic
qualiti
servic
qualiti
depart
posit
signific
influenc
system
qualiti
inform
qualiti
conclus
experi
prove
integr
medic
inform
system
reduc
burden
clinic
staff
automat
bring
inform
avoid
multipl
input
caus
inconsist
genom
pallidum
amoy
strain
own
eight
strainspecif
gene
howev
miss
ten
univers
gene
genom
instanc
amoy
strain
loss
tpr
famili
gene
like
answer
increas
immun
escap
interestingli
also
identifi
rrna
mutat
amoy
stain
first
report
outsid
initi
identif
czech
republ
differ
frequent
mutat
identifi
china
conclus
summari
sequenc
whole
genom
pallidum
amoy
stain
studi
work
aid
better
understand
differ
pathogenesi
syphili
well
geograph
distribut
syphili
epidemiolog
phenotyp
malditof
ms
identif
method
compar
perform
speci
identif
method
fungal
isol
recheck
certifi
authent
mycolog
methodolog
character
gene
sequenc
evalu
region
sequenc
scge
two
malditof
ms
system
vitek
ms
bruker
ms
vitek
compact
system
c
haemulonii
complex
identif
suscept
assay
perform
use
sensititr
yeaston
tm
methodolog
follow
manufactur
instruct
result
twelv
isol
identifi
c
nivariensi
one
c
bracarensi
use
sequenc
refer
method
result
obtain
sequenc
scge
concord
sequenc
result
isol
scge
abl
subtyp
c
nivariensi
four
scge
length
type
lt
isol
fail
identifi
vitek
malditof
ms
system
whilst
bruker
ms
system
bruker
daltonik
correctli
identifi
c
nivariensi
isol
use
lower
cutoff
score
speci
assign
c
bracarensi
isol
identifi
score
vitek
compact
system
could
identifi
c
nivariensi
one
c
bracarensi
isol
misidentifi
remain
c
nivarensi
strain
c
glabrata
isol
low
mic
azol
echinocandin
amphotericin
b
conclus
result
reinforc
need
molecular
differenti
speci
c
nivarensi
c
bracarensi
perform
malditof
may
improv
ad
mass
spectral
profil
msp
current
databas
antifung
suscept
profil
isol
monitor
research
need
studi
effect
role
firstlin
therapi
clinic
manifest
candidemia
caus
uncommon
candida
speci
antifung
suscept
isol
region
hospit
taiwan
background
retrospect
studi
investig
clinic
manifest
candidemia
caus
uncommon
candida
speci
antifung
suscept
isol
region
hospit
taiwan
method
uncommon
candida
speci
initi
defin
candida
speci
c
albican
c
tropicali
c
glabrata
complex
c
parapsilosi
complex
c
krusei
uncommon
candida
isol
identifi
confirm
molecular
method
vitro
suscept
test
uncommon
candida
speci
nine
antifung
agent
conduct
use
broth
microdilut
method
sensititr
yeaston
syo
system
trek
diagnost
system
ltd
east
grimstead
uk
result
twentyon
patient
compris
male
femal
median
age
year
recruit
cancer
n
common
underli
diseas
case
prior
antibiot
exposur
two
patient
prior
antifung
use
overal
inhospit
mortal
rate
c
guilliermondii
n
common
pathogen
follow
c
curvata
n
c
guilliermondii
isol
exhibit
rel
high
rate
azol
minimum
inhibitori
concentr
mic
epidemiolog
cutoff
valu
ecv
wherea
c
pelliculosa
c
lusitania
isol
remain
suscept
azol
three
c
curvata
isol
high
caspofungin
mgl
fluconazol
mic
mgl
could
defin
multidrugresist
conclus
uncommon
candida
speci
frequent
exhibit
high
rate
nonsuscept
antifung
identif
candida
isol
speci
level
blood
sampl
valu
treatment
incid
outcom
cryptococcosi
among
differ
risk
popul
taiwan
background
invas
fungal
diseas
lifethreaten
infect
prolong
neutropen
patient
hematolog
malign
treat
intens
cytotox
chemotherapi
although
liposom
amphotericin
b
lamb
echinocandin
class
agent
administ
emper
antifung
therapi
patient
advers
event
includ
breakthrough
infect
despit
treatment
substanti
drug
toxic
becom
signific
problem
therefor
critic
need
antifung
treatment
strategi
overcom
impedi
conduct
singlearm
multicent
institut
prospect
studi
order
evalu
efficaci
safeti
sequenti
administr
lamb
micafungin
mf
empir
antifung
therapi
antibioticsrefractori
febril
neutropenia
patient
hematolog
malign
receiv
cytotox
chemotherapi
result
total
adult
patient
enrol
patient
fulfil
protocol
defin
criteria
evalu
underli
diseas
consist
acut
leukemia
n
malign
lymphoma
n
myelodysplast
syndrom
n
prior
antifung
prophylaxi
given
patient
treatment
success
achiev
patient
none
patient
show
pulmonari
lesion
radiolog
imag
develop
breakthrough
infect
serum
galactomannan
antigen
increas
one
patient
plasma
glucan
test
posit
patient
test
improv
case
treatment
failur
observ
patient
among
patient
discontinu
studi
drug
due
advers
event
event
drugrel
toxic
hepatotox
nephrotox
hypokalemia
skin
erupt
muscl
stiff
grade
toxic
revers
finish
drug
one
patient
reveal
persist
fever
probabl
due
cytomegaloviru
infect
subsid
ganciclovir
administr
conclus
although
number
patient
studi
limit
sequenti
therapi
mf
lamb
seem
encourag
antifung
treatment
strategi
hematolog
malign
experi
antibioticsrefractori
neutropenia
cytotox
chemotherapi
investig
largescal
studi
need
background
azoleresist
aspergillu
fumigatu
araf
becom
grow
public
health
concern
intern
consensu
suggest
empir
therapi
fumigatu
aspergillosi
guid
local
clinic
environmet
resist
rate
studi
investiagt
current
statu
aozl
resist
among
fumigatu
clinic
isol
taiwan
background
candidemia
becom
emerg
healthcareassoci
infect
signific
mortal
candida
tropicali
common
pathogen
asia
present
studi
aim
identifi
specif
biomark
predict
patient
surviv
metabolom
method
patient
age
candidemia
caus
candida
tropicali
blood
sampl
avail
within
day
onset
day
candidemia
includ
analysi
categor
two
group
depend
surviv
day
metabolom
profil
blood
specimen
collect
day
surviv
death
group
compar
identifi
specif
biomark
predict
patient
surviv
day
partial
least
squarediscrimin
analysi
plsda
perform
score
first
two
compon
plot
visual
well
relev
metabolit
could
identifi
death
surviv
group
statist
differ
death
surviv
group
compar
wilcoxon
rank
sum
test
result
total
patient
c
tropicali
candidemia
includ
median
interv
candidemia
onset
collect
blood
specimen
day
interquartil
rang
day
patient
receiv
antifung
agent
blood
sampl
day
mortal
plsda
score
plot
separ
surviv
death
group
figur
identifi
potenti
marker
predict
day
mortal
phenylalanin
deuteroporphyrin
ix
hippur
area
curv
auc
coeffici
logist
regress
model
result
wilcoxon
rank
sum
test
three
metabolit
shown
tabl
agestratifi
uptak
rate
onceweekli
rifapentin
plu
isoniazid
rate
perman
discontinu
due
intoler
similar
howev
overal
patient
experienc
significantli
lower
rate
perman
discontinu
treatment
compar
evalu
factor
facilit
treatment
complet
ltbi
crucial
achiev
end
tb
goal
reduc
incid
surveil
sever
communityacquir
pneumonia
unknown
etiologyresult
unknown
pathogen
detect
investig
group
updig
taiwan
tsungpei
tsou
wanchin
chen
minnan
hung
sunghsi
wei
hsinchun
lee
chiap
su
jungjung
mu
mingtsan
liu
patient
pathogen
identifi
isol
pcr
respiratori
tract
specimen
blood
seroconvers
classifi
definit
etiolog
patient
pathogen
identifi
mean
antigen
detect
classifi
possibl
etiolog
background
staphylococcu
aureu
import
human
pathogen
also
asymptomat
colon
nare
adult
popul
methicillinresist
strain
mrsa
may
also
display
resist
multipl
drug
major
caus
healthcar
associ
infect
worldwid
increas
concern
strain
aureu
clinic
set
also
harbour
gene
qacab
smr
reduc
suscept
commonli
use
antisept
disinfect
benzalkonium
chlorid
chlorhexidin
well
recognis
elderli
subject
resid
longterm
care
facil
ltcf
act
reservoir
mrsa
littl
known
preval
healthi
elderli
live
commun
aim
determin
preval
mrsa
presenc
biocid
resist
gene
healthi
elderli
subject
attend
commun
centr
elderli
method
elderli
attende
seven
commun
centr
elderli
screen
mrsa
nasal
colon
swab
cultur
chromogen
agar
mrsa
isol
confirm
malditof
suscept
test
perform
follow
eucast
guidelin
qacab
smr
determin
pcr
result
total
elderli
subject
screen
subject
posit
aureu
nasal
carriag
isol
methicillin
resist
overal
isol
posit
qacab
smr
signific
associ
methicillin
resist
presenc
qacab
gene
p
ci
four
mrsa
strain
resist
drug
conclus
overal
carriag
mrsa
subject
margin
higher
figur
report
gener
popul
consider
less
rate
report
elderli
subject
ltcf
presenc
biocid
resist
gene
concern
multidrug
resist
strain
resist
biocid
may
difficult
erad
toler
biocid
may
contribut
persist
mrsa
commun
well
healthcar
set
continu
monitor
strain
essenti
well
educ
proper
use
biocid
antisept
prevent
residu
remain
environ
could
act
facilit
induct
biocid
toler
emphysemat
cystiti
geriatr
patient
escherichia
chihcheng
lu
wenchou
fan
cytoplasm
antibodi
neg
serum
microscop
agglutin
test
leptospirosi
posit
kidney
liver
biopsi
confirm
leptospirosi
immunohistochem
stain
figur
week
admiss
remain
intub
mechan
machin
support
still
intermitt
fever
hemoptysi
despit
transfus
erythrocyt
platelet
antibiot
treatment
start
session
plasma
exchang
plasma
volum
hospit
day
time
plasma
exchang
conscious
pulmonari
hemorrhag
icteru
improv
dramat
extub
admiss
day
recov
well
discharg
day
admiss
conclus
although
role
plasma
exchang
manag
weil
diseas
well
defin
experi
show
combin
antibiot
plasma
exchang
may
help
sever
leptospirosi
pulmonari
renal
syndrom
associ
scabi
psychiatr
disord
childhood
nationwid
populationbas
studi
chienyu
lin
hsin
chi
sheycha
su
chengyin
tseng
pohuang
liu
nanchang
chiu
juim
liu
renjun
hsu
background
streptococcu
sangui
gramposit
anaerob
bacterium
found
oral
caviti
proven
relat
infect
endocard
leptospirosi
scrub
typhu
zoonos
worldwid
distribut
coinfect
report
present
case
sangui
bacteremia
farmer
also
scrub
typhu
leptospirosi
coinfect
yearold
male
farmer
refer
alter
conscious
sepsi
relat
multiorgan
failur
gi
bleed
pneumonia
admit
intens
care
unit
arriv
emerg
depart
blood
cultur
show
sangui
bacteremia
patient
respond
empir
antibiot
tapimycin
multiorgan
failur
got
wors
examin
patient
still
fever
low
blood
pressur
mm
hg
tachycardia
present
symptom
yellowish
skin
color
diffus
petechia
bodi
surfac
oliguria
mlkgday
troponin
ug
l
ecg
reveal
st
elev
consist
nstemi
echocardiogram
reveal
veget
gastrointestin
endoscopi
reveal
bleed
gastric
ulcer
laboratori
studi
reveal
platelet
count
elev
ddimer
fibrinogen
could
explain
dic
caus
bleed
diathesi
also
liver
dysfunct
jaundic
high
blood
level
ammonia
umol
ag
revers
acut
kidney
injuri
hyperkalemia
mmoll
abdomen
sonographi
reveal
ascit
splenomegali
cirrhosi
liver
pictur
show
multipl
petechiea
found
gastric
wall
panedoscop
method
femal
balbc
mice
week
old
infect
approxim
cfu
mrsa
strain
intraperiton
subsequ
mab
vancomycin
hydrochlorid
vcm
daptomycin
dap
inject
intraperiton
alon
combin
anim
monitor
mortal
record
statist
analysi
done
use
logrank
test
determin
differ
treatment
group
result
signific
differ
p
treatment
group
singl
combin
therapi
effect
lifesav
activ
exhibit
dap
combin
find
studi
show
higher
surviv
rate
day
lethal
sepsi
model
combin
mab
mg
singl
mab
use
mg
mg
alon
also
combin
mab
antibiot
mg
vcm
mg
dap
show
higher
surviv
rate
respect
compar
vcm
dap
alon
p
conclus
combin
includ
antibiot
repres
attract
altern
antibiot
monotherapi
current
use
treat
aureu
bacteremia
epidemiolog
sepsi
children
nationwid
cohort
studi
conclus
bcgosteitisosteomyel
strongli
correl
vaccin
newborn
older
infant
question
whether
postpon
bcg
vaccin
could
lead
decreas
risk
bcgosteitisosteomyel
without
increas
tb
mening
bcglymphaden
inject
site
suppur
young
infant
need
care
evalu
preval
bone
loss
short
term
effect
antiretrovir
therapi
bone
miner
densiti
male
japanes
patient
hiv
yusuk
yoshino
keita
misu
kazunori
seo
ichiro
koga
takatoshi
kitazawa
yasuo
ota
depart
intern
medicin
teikyo
univers
school
medicin
tokyo
japan
background
well
known
low
bone
miner
densiti
bmd
preval
hiv
patient
mani
studi
north
america
europ
oceania
reveal
relationship
hiv
low
bmd
still
studi
asian
countri
especi
research
antihiv
drug
earli
impact
bmd
treatment
initi
underrepres
asian
countri
studi
preval
bone
loss
chang
bmd
initi
continu
antiretrovir
therapi
cart
japanes
patient
hiv
method
male
patient
hiv
visit
outpati
clinic
teikyo
univers
hospit
tokyo
japan
april
novemb
enrol
patient
underw
bmd
analys
week
initi
cart
dual
energi
xray
absorptiometori
scan
lumbar
spine
bmd
averag
bilater
femor
neck
bmd
analyz
employ
calcul
zscore
clinic
factor
collect
includ
age
bodi
mass
index
smoke
statu
corticosteroid
use
cart
regimen
laboratori
data
assess
chang
bmd
cart
initi
pair
ttest
determin
risk
factor
low
bone
mass
naiv
patient
influenc
factor
bmd
start
cart
stepwis
multipl
regress
analysi
use
result
thirtyon
patient
follow
median
lumbar
spine
zscore
median
femor
neck
zscore
set
age
serum
ast
level
serum
alt
level
independ
risk
factor
low
bone
mass
patient
chang
bmd
cart
initi
shown
figur
use
tenofovir
disoproxil
fumar
tdf
use
proteas
inhibitor
pi
low
cell
count
independ
risk
factor
bmd
loss
lumbar
spine
ntermin
telopeptidecreatinin
urinari
test
independ
risk
factor
femor
neck
conclus
slight
decreas
bmd
observ
japanes
patient
hiv
bmd
decreas
significantli
cart
initi
lumbar
spine
use
tdf
orand
pi
significantli
increas
risk
bmd
loss
femor
neck
cart
significantli
affect
bmd
patient
higher
bone
metabol
activ
shortterm
longterm
effect
highli
activ
antiretrovir
treatment
incid
tuberculosi
peopl
live
hiv
aid
yungfeng
yen
peihung
chuang
ian
jen
marcelo
chen
yuch
lan
chunyuan
lee
yun
lee
yime
arthur
chen
section
infecti
diseas
taipei
citi
background
shortterm
longterm
effect
highli
activ
antiretrovir
therapi
haart
exposur
incid
tuberculosi
tb
extens
studi
nationwid
populationbas
cohort
studi
aim
determin
shortterm
longterm
effect
haart
incid
tb
peopl
live
hiv
aid
plwha
taiwan
background
highli
activ
antiretrovir
therapi
haart
era
bacteremia
one
import
caus
morbid
mortal
hivinfect
patient
studi
describ
patient
studi
aim
assess
etiolog
pathogen
site
infect
mortal
rate
factor
associ
mortal
hivinfect
patient
bacteremia
method
retrospect
electron
databas
chart
review
hivinfect
patient
bacteremia
vajira
hospit
januari
novemb
perform
result
hivinfect
patient
male
receiv
antiretrovir
drug
cellsmm
among
isol
bacteremia
found
common
organ
salmonella
spp
escherichia
coli
ecoli
ceftriaxon
resist
high
bacteremia
caus
salmonella
group
c
common
site
infect
primari
bacteremia
urinari
tract
infect
mortal
rate
factor
affect
mortal
albumin
level
p
underli
diseas
p
cirrhosi
p
chronic
renal
failur
p
malign
p
focal
site
infect
p
lower
respiratori
tract
infect
p
intraabdomin
infect
p
conclus
salmonella
spp
escherichia
coli
lead
caus
bacteremia
hivinfect
patient
common
site
infect
primari
bacteremia
dengu
viru
nonstructur
protein
induc
platelet
activ
weichueh
wu
trai
ming
yeh
medic
laboratori
scienc
biotechnolog
nation
cheng
kung
univers
tainan
taiwan
background
dengu
viru
denv
mosquitoborn
flaviviru
respons
million
infect
annual
lead
dengu
fever
potenti
lethal
dengu
hemorrhag
fever
dhf
shock
syndrom
dss
dhfdss
patient
often
show
sever
symptom
vascular
leakag
thrombocytopenia
dengu
infect
denv
nonstructur
protein
secret
blood
caus
vascular
leakag
howev
whether
involv
pathogenesi
thrombocytopenia
remain
unclear
studi
hypothes
may
play
critic
role
denvinduc
thrombocytopenia
method
verifi
hypothesi
freshli
isol
platelet
healthi
donor
treat
denv
type
recombin
drosophila
evalu
marker
activ
cytokin
secret
aggreg
result
found
could
bind
tolllik
receptor
platelet
furthermor
pselectin
express
macrophag
migrat
inhibitori
factor
secret
increas
platelet
last
platelet
aggreg
suboptim
dose
adp
enhanc
stimul
conclus
taken
togeth
result
demonstr
could
directli
bind
platelet
induc
platelet
activ
result
suggest
may
contribut
pathogenesi
thrombocytopenia
dengu
infect
act
potent
inhibitor
human
enteroviru
replic
suppress
viral
ire
gunaseelan
saravanan
justin
jang
hann
chu
marva
depart
microbiolog
immunolog
nation
univers
singapor
ctu
imcb
star
background
human
enteroviru
main
caus
agent
hand
foot
mouth
diseas
hfmd
young
children
mani
part
world
especi
asia
neurotrop
natur
caus
sever
infect
complic
includ
enceph
even
death
due
lack
effect
antivir
curb
infect
studi
adopt
approach
identifi
potenti
therapeut
agent
revers
genet
high
throughput
screen
flavonoid
compound
librari
method
flavonoid
deriv
librari
screen
bicistron
ire
construct
identifi
compound
ire
activ
chosen
hit
verifi
cell
viabil
viral
plaqu
assay
result
high
throughput
screen
flavonoid
compound
identifi
potent
inhibitor
downstream
secondari
assay
reaffirm
disrupt
viral
protein
viral
rna
synthesi
reduc
ire
activ
studi
deduc
narrowspectrum
antivir
effect
human
enterovirus
chikungunya
viru
herp
simplex
type
viru
develop
resist
mutant
demonstr
effect
critic
target
name
viral
ire
importantli
abl
show
strong
invivo
efficaci
murin
model
challeng
conclus
conclus
potent
antivir
possibl
human
enterovirus
develop
potenti
clinic
antivir
hfmd
seropreval
human
herpesviru
type
patient
chronic
obstruct
pulmonari
diseas
chengchuan
su
shihm
tsao
chunliang
lai
mingnan
lin
jenpi
tsai
background
seropreval
human
herpesviru
type
high
patient
variou
immunolog
abnorm
patient
chronic
obstruct
pulmonari
diseas
copd
immunocompromis
seropreval
copd
patient
document
method
blood
sampl
collect
copd
patient
ageand
sexmatch
healthi
control
use
determin
lymphocyt
monocyt
count
antibodi
dna
result
copd
patient
lower
lymphocyt
count
higher
monocyt
count
healthi
control
p
respect
seropreval
antibodi
moder
higher
copd
patient
control
vs
p
three
patient
posit
antibodi
also
posit
dna
lymphocyt
count
higher
copd
patient
posit
antibodi
neg
p
copd
patient
posit
dna
neg
p
lymphocyt
count
increas
increas
viral
load
copiesml
conclus
copd
patient
mode
higher
seropreval
healthi
control
lymphocyt
count
significantli
higher
copd
patient
posit
antibodi
dna
neg
lymphocyt
count
increas
increas
viral
load
patient
posit
dna
method
multipl
sequenti
specimen
serum
nasopharynx
swab
sputumtrach
aspir
collect
viru
isol
respiratori
specimen
import
differ
molecular
signatur
compar
previou
virus
investig
result
import
differ
molecular
signatur
viru
includ
insert
three
basic
amino
acid
residu
rkr
cleavag
site
connect
hemagglutinin
peptid
region
antivir
resist
substitut
na
neuraminidas
protein
found
viru
suggest
viru
develop
resist
oseltamivir
amino
acid
length
previou
isol
amino
acid
extend
ctermin
region
amino
acid
contain
pdz
bind
domain
also
contribut
pathogen
conclus
signatur
high
avian
pathogen
oseltamivir
resist
concern
may
implic
clinic
manag
antivir
therapi
current
guidelin
specifi
neuraminidas
inhibitor
nai
drug
choic
treat
patient
infect
avian
influenza
viru
revis
base
geograph
distribut
resist
especi
asiapacif
region
trend
molecular
epidemiolog
hcv
individualpatientand
sequencelevel
analysi
siaoru
lin
minghuei
gu
depart
laboratori
medicin
hualien
tzu
chi
hospit
buddhist
tzu
chi
medic
foundat
taiwan
background
region
genotypespecif
mutat
pattern
hcv
essenti
inform
directact
antivir
agent
daa
design
diagnost
assay
use
region
standard
genotyp
resist
test
afford
tri
understand
molecular
epidemiolog
drugresist
associ
variant
rav
hcvinfect
patient
method
first
set
workflow
specimen
collect
viral
nucleic
acid
extract
perform
pcr
assay
directedsequ
analysi
perform
pcr
assay
sever
specimen
find
hcv
genotyp
patient
investig
preval
rav
daa
treatmentna
hcv
genotyp
patient
amplifi
hcv
viral
region
untranslatedregion
use
bioedit
genotyp
tool
ncbi
websit
analyz
sequenc
data
result
collect
refer
genom
hcv
ncbi
genebank
templat
hcvspecif
primer
set
amplifi
target
silico
submit
genotyp
tool
show
agreement
novemb
may
total
patient
enrol
hcv
genotyp
analysi
genotyp
subtyp
identifi
success
amplifi
case
respect
period
perform
hcv
mutat
analysi
patient
mutat
codon
detect
case
respect
conclus
studi
still
progress
conclut
remain
unclear
howev
natur
occur
rav
daa
preexist
treatmentna
hcv
genotyp
patient
clinician
consid
rav
start
daabas
antivir
therapi
suffer
upper
airway
infect
cough
run
nose
sorethroat
day
prior
admiss
also
fell
onto
ground
brain
ct
show
obviou
intracrani
hemorrhag
suffer
rapid
respir
chest
ct
reveal
subpleur
consolid
lul
bilater
lower
lobe
rll
favour
bilater
pneumonia
admit
intens
care
unit
et
tube
intub
mechan
ventil
use
influenza
rapid
test
show
influenza
oral
oseltamivir
tamiflu
initi
peramivir
rapiacta
ad
use
acut
respiratori
distress
syndrom
ard
develop
use
howev
ard
improv
soon
oseltamivir
tamiflu
intraven
peramivir
rapiacta
continu
use
rtpcr
taiwan
cdc
confirm
influenza
infect
oseltamivir
peramivir
rapiacta
use
day
day
respect
et
tube
could
remov
week
later
becam
stabl
could
discharg
day
discuss
patient
suffer
sever
respiratori
complic
induc
influenza
could
get
well
soon
proper
prompt
use
within
hour
neuraminidas
inhibitor
guidelin
studi
concurr
use
neuraminidas
inhibitor
oseltamivir
peramivir
togeth
patient
fever
subsid
peramivir
use
need
ecmo
use
seem
oseltamivir
peramivir
could
use
togeth
antagon
peramivir
bind
na
enzym
easili
dissoci
peramivir
inhibit
na
activ
longer
period
reactiv
cytomegaloviru
hospit
cours
sepsi
associ
outcom
hsinpai
chen
pingliang
hung
wanhuai
teo
yuanm
lee
yujiun
chan
chengyu
chen
accumul
evid
suggest
cmv
reactiv
critic
ill
patient
sepsi
controversi
exist
respect
associ
cmv
reactiv
outcom
sepsi
viru
reactiv
cours
sepsi
fulli
investig
studi
system
investig
reactiv
pattern
cmv
cours
sepsi
correl
result
outcom
sepsi
method
sepsi
patient
admit
intens
care
unit
blood
sampl
collect
day
hospit
stay
cmv
detect
pcr
viral
load
measur
quantit
pcr
serum
cytokin
cmv
igg
determin
elisa
patient
clinic
characterist
surviv
within
day
record
correl
result
cmv
detect
result
includ
patient
seroposit
cmv
igg
inhospit
followup
cours
cmv
detect
pcr
least
patient
posit
rate
cmv
pcr
increas
initi
day
day
median
viral
load
lower
earli
day
late
day
followup
phase
rel
median
viral
load
vs
p
detect
cmv
day
associ
lower
surviv
rate
compar
whose
blood
neg
cmv
day
p
higher
serum
interleukin
il
level
denot
monocyt
activ
observ
patient
posit
cmv
pcr
especi
day
conclus
frequenc
cmv
reactiv
increas
cours
sepsi
earli
reactiv
cmv
initi
phase
sepsi
associ
poorer
outcom
interact
cmv
host
monocyt
may
play
role
pathophysiolog
sepsi
methanoculleu
taiwanensi
wenhsin
wei
chiehyin
weng
shengchung
chen
meichin
lai
depart
life
scienc
nation
chung
hsing
univers
taichung
taiwan
roc
background
virus
infect
three
domain
life
howev
knowledg
archaeal
virus
limit
late
divers
viru
morpholog
independ
viru
develop
outsid
extrem
thermophilicacidophil
archaeal
host
attract
attent
archaea
viral
investig
current
archaeal
virus
discov
relat
thermophil
crenarchaea
extrem
halophil
euryarchaea
howev
almost
none
methanoarcha
viru
report
past
two
decad
core
sediment
top
ga
hydrat
habitat
deform
front
site
offshor
southwestern
taiwan
methanoculleu
taiwanensi
enrich
isol
character
cell
lysi
observ
stationari
phase
lytic
viru
design
mta
caus
lysi
strain
observ
tem
method
stationari
phase
grown
taiwanensi
cultur
harvest
viru
purifi
peg
precipit
gel
filtrat
sephacryl
column
purifi
viral
dna
obtain
phenolchloroform
extract
ethanol
precipit
whole
genom
sequenc
viru
mta
perform
use
illumina
miseq
function
predict
orf
put
conserv
domain
analyz
blastp
blastx
distant
homolog
search
perform
hhpred
et
al
background
chronic
activ
ebv
diseas
caebv
rare
fatal
complic
ebv
infect
unlik
case
western
countri
ebv
infect
b
cell
major
case
asia
south
american
found
cell
natur
killer
cell
caebv
character
markedli
elev
ebv
antibodi
ebv
dna
blood
histolog
evid
organ
infiltr
virusinfect
cell
detect
ebv
protein
nucleic
acid
tissu
report
fatal
case
ebv
posit
clonal
tcell
lymphoprolif
disord
present
pulmonari
cryptococcosi
method
yearold
farmer
admit
mid
juli
intermitt
fever
cough
whitish
sputum
two
week
cryptococc
pneumonia
confirm
sonoguid
lung
biopsi
march
blood
cryptococc
antigen
titer
ineffect
initi
fluconazol
treatment
replac
combin
liposom
amphotericin
b
later
howev
even
ad
piptazo
treatment
possibl
nosocomi
infect
patient
still
febril
result
admiss
day
diffus
skin
rash
multipl
lymph
node
level
found
chest
abdomen
ct
reveal
multipl
lymphadenopathi
neck
mediastinum
retroperitoneum
skin
rash
biopsi
show
dermi
infiltr
cell
neck
lymph
node
show
necrot
lymphaden
eosinophil
necrot
debri
lymphoid
hyperplasia
immunohistochemistri
stain
perform
fix
paraffinembed
tissu
compar
situ
hybrid
ebvencod
rna
eber
skin
biopsi
lymph
node
posit
eber
confirm
ebv
infect
cell
figur
also
ebv
viral
load
markedli
elev
copiesml
studi
met
characterist
caebv
includ
posit
ebvvcaigg
ebvnaigg
neg
ebvvcaigm
ebveaigg
trimethoprimsulfamethoxazol
initi
prophylaxi
pneumocysti
jiroveci
pneumonia
although
hiv
neg
antiifngamma
antibodi
neg
patient
becam
afebril
tigecyclin
discharg
late
august
complet
year
oral
itraconzol
treatment
die
sepsi
hospit
june
conclus
case
present
pulmonari
cryptococcosi
diagnos
fatal
tcell
lymphoprolif
disord
caebv
character
gener
lymphadenopathi
fever
rash
ebv
detect
cell
immunohistochemistri
studi
tcell
clonal
confirm
diagnosi
topic
use
antimicrobi
surgic
prophylaxi
australian
hospit
rodney
jame
kirsti
buis
karin
thurski
nation
centr
antimicrobi
stewardship
peter
doherti
institut
infect
immun
melbourn
vic
background
mani
studi
support
use
appropri
administ
surgic
antimicrobi
prophylaxi
reduc
surgic
site
postop
infect
guidanc
appropri
use
surgic
antimicrobi
prophylaxi
australia
avail
via
nation
prescrib
guidelin
suggest
principl
antimicrobi
prescrib
regard
surgic
procedur
prescrib
prophylaxi
clear
need
use
topic
antimicrobi
recommend
surgic
prophylaxi
use
topic
antimicrobi
prophylaxi
surgic
procedur
practic
commonli
utilis
surgeon
limit
evid
benefit
current
major
studi
gener
use
australian
hospit
method
pilot
surgic
nation
antimicrobi
prescrib
survey
conduct
april
novemb
use
data
hospit
particip
pilot
procedur
group
topic
antimicrobi
prescrib
appropri
describ
conclus
although
topic
antimicrobi
surgic
prophylaxi
account
small
percentag
intraop
prescrib
threequart
prescript
deem
inappropri
due
report
poor
document
use
topic
antimicrobi
surgic
procedur
would
repres
underestim
true
proport
use
sever
procedur
prophylaxi
prescrib
littl
evid
use
highlight
area
practic
review
experi
share
antibiot
stewardship
four
year
effect
reduc
multidrugresist
organ
huiyun
liang
iigl
chen
hungjen
tang
background
drug
resist
issu
worrisom
concern
world
appropri
use
antibiot
mention
time
howev
face
constantli
detect
variou
multi
drug
resist
microorgan
bring
rigor
examin
control
execut
effect
antibiot
need
review
improv
time
coordin
antibiot
stewardship
databas
system
make
control
effect
hosptial
sinc
begin
implement
antibiot
stewardship
four
year
detect
drugresist
strain
use
antibiot
declin
method
hospit
util
databas
system
assist
execut
antibiot
medic
control
infecti
diseas
specialist
would
follow
laboratori
report
current
medic
order
analysi
system
exam
provid
profession
commend
especi
report
blood
cultur
could
approv
three
day
antibiot
upgrad
downgrad
quick
identif
equip
method
shorten
report
time
clinician
choos
appropri
antiauxiliari
drugresist
bacteria
check
immedi
proceed
isol
immedi
patient
move
implement
disinfect
environment
clean
proceed
joint
audit
result
overview
antibiot
stewardship
studi
period
usag
densiti
antibiot
per
beddayoccup
declin
penicillin
declin
carbapenem
declin
glycopeptid
fluoroquinolon
use
show
stabil
carbapenem
resist
acinetobact
baumannii
methicillinresist
staphylococcu
aureu
report
drop
new
case
conclus
origin
use
antibiot
treatment
bacteri
infect
must
pay
attent
use
period
follow
rule
recommend
avoid
occurr
bacteria
caus
filter
pressur
orthodont
need
pay
attent
monitor
induc
bacteri
resist
follow
sure
monitor
clinic
impact
malditof
mass
spectrometri
combin
antimicrobi
stewardship
intervent
adult
candidemia
nanyao
lee
chinglung
lo
wenliang
lin
jenchieh
lee
mingchi
li
chinshiang
tsai
wenchien
ko
background
candidemia
one
sever
infect
associ
poor
outcom
integr
rapid
speci
identif
via
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditofm
antimicrobi
stewardship
intervent
asi
potenti
earli
custom
appropri
antifung
therapi
improv
patient
outcom
object
studi
assess
impact
approach
outcom
adult
candidemia
method
prepost
quasiexperiment
studi
conduct
medic
center
southern
taiwan
januari
decemb
asi
team
mainli
infect
diseas
specialist
provid
evidencebas
antimicrobi
recommend
receipt
caus
candida
speci
intervent
group
clinic
outcom
compar
histor
control
group
result
total
patient
candidemia
includ
final
analysi
patient
intervent
group
patient
control
group
intervent
group
shorter
time
candida
speci
identif
vs
hour
p
optim
antifung
therapi
vs
day
p
note
sepsisrel
mortal
rate
vs
p
crude
mortal
rate
vs
p
inhospit
crude
mortal
vs
p
lower
intervent
group
conclus
malditofm
adjunct
asi
result
rapid
speci
identif
earli
initi
optim
antifung
therapi
importantli
better
clinic
outcom
adult
candidemia
klebsiella
pneumonia
periren
abscess
complic
endogen
endophthalm
shu
hua
lin
chekim
tan
chimei
medic
center
intens
care
unit
background
endogen
endophthalm
uncommon
sever
ocular
infect
caus
hematogen
bacteri
seed
bacteremia
septicemia
east
asia
increas
incid
diseas
caus
gramneg
organ
klebsiella
pneumonia
kp
common
caus
endogen
endophthalm
kp
produc
infect
varieti
site
risk
increas
patient
impair
host
defens
eg
diabet
mellitu
liver
abscess
kp
main
caus
taiwan
induc
liver
abscess
account
liver
abscess
case
kp
periren
abscess
complic
endogen
endophthalm
endogen
kp
endophthalm
extrem
poor
prognosi
exacerb
delay
diagnosi
yearold
femal
past
histori
type
ii
diabet
mellitu
poor
control
recent
reveal
complain
left
lower
quadrant
pain
sleepi
septic
shock
also
note
abdomen
comput
tomographi
reveal
right
periren
abscess
pigtail
drainag
cathet
insert
blood
cultur
pig
tail
drainag
abscess
cultur
show
kp
emper
antibiot
flomoxef
use
howev
start
red
left
eye
within
hr
sudden
pain
eyelid
swell
conjunctiv
chemosi
found
endogen
kp
endophthalm
suspect
orbit
comput
tomographi
reveal
left
orbit
intraconalextracon
space
left
periorbit
abscess
postsept
cellul
consist
left
endophthalm
result
thu
ophthalmolog
given
intravitr
inject
antibiot
ceftazidim
cc
eye
drop
use
visual
acuiti
left
eye
deterior
light
percept
period
intraocular
pressur
mmhg
adjust
antibiot
meropenem
prescud
mannitol
reduc
intraocular
pressur
left
eye
receiv
intravitr
inject
one
dose
mannitol
intraven
inject
three
dose
meropenem
two
week
therapi
although
left
eye
bacteria
could
cultur
blind
stabl
hemodynam
statu
transfer
ordinari
ward
conclus
acut
endophthalm
medic
emerg
endophthalm
clinic
diagnosi
confirm
posit
aqueou
vitreou
cultur
howev
neg
cultur
exclud
diagnosi
primari
part
specimen
cultur
blood
cultur
high
diagnost
valu
eye
easi
obtain
larg
number
specimen
eye
cultur
posit
rate
low
even
less
usual
long
clinic
symptom
diagnos
decreas
ambulatori
consumpt
cephalexin
cotrimoxasol
period
five
year
observ
follow
signific
declin
antimicrobi
resist
e
coli
two
drug
respect
especi
femal
age
year
p
highest
resist
rate
isolateantimicrobi
combin
particularli
fluoroquinolon
detect
older
male
total
proport
esbl
produc
e
coli
strain
rose
especi
high
resist
rate
older
age
group
p
conclus
decreas
consumpt
certain
antibiot
commun
lead
improv
bacteri
suscept
due
updat
croatian
guidelin
empir
treatment
cauti
chang
ambulatori
use
antibiot
occur
withdraw
amoxicillin
cephalexin
cotrimoxasol
list
first
line
agent
empir
treatment
uncompl
cystiti
elicit
signific
improv
suscept
uropathogen
e
coli
antibiot
sinc
obviou
rise
fluoroquinolon
use
occur
increas
trend
resist
might
caus
spread
highli
epidem
fluoroquinoloneresist
uropathogen
e
coli
clonal
group
particularli
older
men
requir
investig
treatment
escherichia
coli
bacteremia
medic
center
northern
taiwan
tsaiwei
wang
tingch
wu
chilan
kao
wantsui
huang
clinic
outcom
total
durat
antibiot
treatment
etcflomoxef
day
etcquinolon
day
dtcflomoxef
day
dtcquinolon
day
dtccarbapenem
day
mortal
rate
group
etc
dtccarbapenem
wherea
group
relaps
rate
etcflomoxef
etcquinolon
dtcflomoxef
dtcquinolon
dtccarbapenem
dtccarbapenem
higher
rate
mortal
relaps
may
relat
patient
characterist
percentag
dm
malign
immunosuppress
nosocomi
bacteremia
data
clinic
outcom
show
statist
signific
differ
conclus
compar
etcquinolon
etcflomoxef
reveal
tendenc
higher
relaps
rate
definit
therapi
flomoxef
use
hospit
restrict
due
lack
mic
nextstep
take
comorbid
condit
diseas
sever
consider
recruit
patient
valid
charlson
score
done
futur
studi
invas
pulmonari
aspergillu
lung
fibrosi
probabl
sequela
influenza
infect
chiachen
hsu
chi
mei
medic
center
intens
care
medicin
background
fatal
invas
pulmonari
aspergillosi
ipa
may
follow
viral
influenza
infect
superinfect
coinfect
major
caus
morbid
mortal
patient
influenza
conduct
patient
ipa
follow
influenza
infect
refractori
hypoxemia
venoven
mode
extracorpor
membran
oxygen
vv
ecmo
therapi
case
report
man
hypertens
histori
present
ed
accord
famili
visit
friend
day
ago
friend
symptom
common
cold
day
later
fever
frequent
cough
spike
fever
scanti
sputum
sore
throat
develop
short
breath
also
notic
emerg
depart
acut
respiratori
failur
develop
endotrach
intub
perform
patient
admit
intens
care
unit
oseltamivir
intraven
iv
broadspectrum
antibiot
vasopressor
iv
albumin
supplement
initi
howev
refractori
hypoxemia
notic
lung
recruit
therapi
perform
discuss
cardiovascular
surgeon
famili
member
vvecmo
appli
serum
aspergillosi
antigen
posit
therefor
voriconazol
ad
owe
develop
adult
respiratori
distress
syndrom
ard
unstabl
hemodynam
statu
oxygen
improv
anoth
cours
oseltamivir
administr
repeat
real
time
pcr
flua
show
posit
result
anoth
cours
oseltamivir
given
antibiot
shift
imipenem
voriconazol
sulbactam
sodium
intermitt
fever
howev
desatur
profound
shock
develop
despit
vasopressor
aggress
fluid
resuscit
progress
hepat
failur
develop
later
discuss
famili
grave
prognosi
request
hospic
care
remov
ecmo
patient
expir
three
week
later
conclus
summari
aspergillu
potenti
complic
sever
influenza
infect
progress
pulmonari
infect
initi
diagnosi
influenza
rais
suspicion
superinfect
includ
aspergillu
import
take
heed
posit
sputum
microscopi
cultur
aspergillu
set
follow
appropri
diagnost
procedur
earli
diagnosi
treatment
key
fatal
complic
influenza
diseas
empir
caspofungin
sever
influenza
suspect
invas
pulmonari
aspergillosi
huichun
chao
wenliang
yu
recent
year
rise
incid
invas
pulmonari
aspergillosi
ipa
critic
ill
patient
report
ipa
diagnos
critic
ill
patient
viru
infect
day
intens
care
unit
icu
admiss
render
vulner
fungal
infect
mortal
ipa
remain
high
backbon
manag
prophylaxi
earli
diagnosi
earli
initi
antifung
reduct
invas
aspergillosi
relat
mortal
case
report
year
old
man
major
past
histori
hyperuricemia
gout
dyslipidemia
chronic
kidney
diseas
ckd
stage
suffer
progress
dyspnea
recent
week
brought
emerg
room
laboratori
data
reveal
anemia
hyperkalemia
acut
ckd
uremia
elev
cardiac
enzym
sever
metobol
acidosi
rapid
influenza
viru
antigen
reveal
posit
chest
xray
show
acut
respiratori
distress
syndrom
ard
due
respiratori
failur
intub
done
emerg
hemodialysi
perform
empir
antibiot
tazobactam
caspofungin
oseltamivir
cultur
reveal
neg
find
meanwhil
result
serum
aspergilu
galactomannan
gm
antigen
assay
index
kept
antifungu
use
clinic
signific
region
multicent
surveil
antimicrobi
consumpt
resist
japanes
acut
care
hospit
arufumi
shiota
aichi
prefectur
infect
control
network
depart
infect
control
prevent
aichi
medic
univers
hospit
background
region
continu
monitor
antimicrobi
consumpt
import
prevent
develop
drug
resist
region
aichi
prefectur
infect
control
network
led
region
administr
japan
perform
surveil
antimicrobi
consumpt
resist
herewith
present
result
region
multicent
evalu
antimicrobi
consumpt
resist
within
seven
year
conclus
clarifi
region
transit
antimicrobi
consumpt
seven
year
notabl
although
analysi
carbapenem
consumpt
show
increas
base
valu
measur
aud
dot
increas
note
carbapenem
resist
p
aeruginosa
auddot
ratio
carbapenem
might
contribut
decreas
carbapenem
resist
p
aeruginosa
previou
studi
also
show
high
plasma
concentr
linezolid
may
induc
thrombocytopenia
studi
demonstr
relationship
plasma
concentr
clinic
outcom
knowledg
research
conduct
han
chines
popul
studi
aim
investig
associ
concentr
linezolid
ae
clinic
outcom
method
prospect
observ
studi
perform
tertiari
teach
hospit
decemb
may
adult
patient
therapeut
drug
monitor
tdm
linezolid
includ
linezolid
peak
trough
concentr
measur
hplc
use
calcul
hour
areaunderthecurv
auc
patient
data
collect
via
electron
medic
chart
safeti
clinic
outcom
assess
throughout
treatment
cours
day
complet
linezolid
mortal
also
record
ae
evalu
naranjo
score
definiteprob
ae
defin
linezolidrel
advers
event
analysi
result
among
patient
enrol
studi
mean
age
year
old
male
linezolid
tdm
collect
perform
within
day
median
trough
peak
auc
standard
dose
mg
twice
daili
reduc
dose
mg
daili
mgl
mgl
mglhr
mgl
mgl
mglhr
respect
plasma
concentr
fold
higher
prescrib
inform
similar
result
japanes
studi
thrombocytopenia
common
advers
event
peripher
neuropathi
appear
infrequ
median
trough
concentr
significantli
higher
patient
thrombocytopenia
total
ae
vs
mgl
p
relat
ae
vs
mgl
p
median
trough
level
also
significantli
higher
relat
leukopenia
ae
vs
mgl
p
associ
identifi
plasma
concentr
anemia
lactic
acidosi
peripher
neuropathi
clinic
outcom
includ
mortal
conclus
linezolid
plasma
concentr
standard
dose
fold
higher
prescrib
inform
similar
result
japanes
studi
higher
trough
concentr
associ
thrombocytopenia
leukopenia
howev
signific
differ
observ
linezolid
concentr
ae
clinic
outcom
dose
adjust
tailor
tdm
may
consid
prevent
linezolid
associ
thrombocytopenia
leukopenia
investig
outcom
patient
infect
mdr
multidrug
resist
pathogen
one
region
hospit
southern
taiwan
cultur
site
clinic
specimen
sputum
urin
blood
wound
distribut
age
yearold
male
predomin
note
outcom
cohort
refer
medic
center
still
admiss
die
discharg
conclus
mdr
pathogen
isol
clinic
specimen
morbid
mortal
increas
elderli
patient
curd
mortal
rate
cohort
mrsa
crab
predomin
mdr
pathogen
limit
staff
equip
avail
mani
patient
refer
medic
center
transfer
back
long
term
care
facil
later
respiratori
urinari
tract
infect
two
major
site
infect
hospit
especi
elderli
patient
target
group
elderli
long
term
care
focu
infect
control
well
antibiot
stewardship
need
effect
antimicrobi
stewardship
programm
reduc
incid
esbl
case
lau
hui
wong
ke
juin
fong
siew
moy
depart
pharmaci
infect
control
unit
infect
control
unit
hospit
wanita
dan
kanak
kanak
sabah
background
sinc
first
report
case
extend
spectrum
beta
lactamas
esbl
resist
betalactamas
report
worldwid
presenc
ubiquit
cefuroxim
one
cephalosporin
implic
emerg
esbl
gram
neg
organ
esbl
rate
paediatr
surgic
ward
hospit
wanita
kanakkanak
sabah
hwkk
alarmingli
high
surveil
studi
could
link
common
usag
cefuroxim
object
studi
describ
effect
antimicrobi
stewardship
am
programm
reduc
incid
esbl
produc
escherichia
coli
ecoli
klebsiella
pneumonia
kleb
pneumonia
method
studi
conduct
juli
decemb
peadiatr
surgic
ward
hwkk
first
six
month
usag
intraven
iv
cefuroxim
mg
describ
number
vial
total
number
esbl
case
calcul
posit
esbl
cultur
specimen
includ
start
januari
am
team
suggest
iv
ampicilinsulbactam
g
altern
cefuroxim
peadiatr
surgic
ward
intervent
monthli
post
intervent
audit
done
occur
rate
esbl
case
pre
post
intervent
compar
mean
score
iv
cefuroxim
usag
result
two
hundr
fortyseven
patient
includ
studi
signific
differ
variat
clcr
vancomycin
treatment
daili
dose
mgkg
day
vs
mgkgday
durat
treatment
day
vs
day
howev
creatinin
clearanc
decreas
vancomycin
treatment
compar
baselin
treatment
signific
differ
total
dose
vancomycin
treatment
g
g
vancomycin
trough
level
mgl
ml
conclus
studi
demonstr
higher
vancomycin
cumul
dosag
trough
level
associ
higher
incid
kidney
injuri
studi
perform
evalu
correl
dosag
trough
level
treatment
respons
assess
applic
high
dose
regimen
vancomycin
taiwanes
popul
base
idsa
guidelin
impact
antibiot
stewardship
rapid
diagnost
test
coagulaseneg
staphylococcu
blood
cultur
wenliang
lin
nanyao
lee
huihung
yu
wenchien
ko
phengi
yeh
background
part
escherichia
coli
frequent
isol
caus
agent
urinari
tract
infect
strain
call
upec
uropathogen
escherichia
coli
upec
involv
chronic
refractori
urinari
tract
infect
due
adhes
invas
urotheli
cell
surfac
type
pili
format
biofilm
elucid
previou
studi
proanthocyanidin
pac
cranberryspecif
compon
influenc
adhes
invas
upec
urotheli
cell
addit
report
pac
affect
quorumsens
mechan
contribut
format
biofilm
decreas
pathogen
factor
method
strain
use
strain
uropathogen
escherichia
coli
upec
standard
strain
e
coli
pseudomona
aeruginosa
standard
strain
blood
deriv
pseudomona
aeruginosa
strain
first
microtit
plate
assay
perform
evalu
biofilm
format
compar
nonaddit
pac
addit
pac
second
express
csga
csgd
crl
fimh
biofilm
relat
gene
escherichia
coli
examin
polymeras
chain
reaction
assay
moreov
inhibitori
effect
pac
express
biofilm
associ
gene
also
investig
result
biofilm
format
decreas
case
addit
pac
case
nonaddit
pac
express
gene
csga
csgd
crl
fimh
howev
even
pac
ad
affect
express
biofilm
gene
e
coli
conclus
studi
show
pac
suppress
biofilm
format
prove
caus
inhibit
express
biofilm
associ
gene
addit
infer
caus
inhibit
biofilm
format
pac
gene
mutat
pac
influenc
intermolecular
relationship
quorumsens
mechan
therefor
need
investig
pac
affect
quorumsens
intermolecular
chihhao
hung
tienyuan
wu
chihua
chen
depart
pharmaci
taichung
tzu
chi
hospit
buddhist
tzu
chi
medic
foundat
taichung
taiwan
depart
pharmacolog
school
medicin
tzu
chi
univers
hualien
taiwan
background
colistin
polymyxin
class
antibiot
bactericid
properti
excel
bactericid
abil
mani
nosocomi
infect
includ
acinetobact
speci
enterobact
speci
escherichia
coli
klebsiella
speci
pseudomona
aeruginosa
stenotrophomona
maltophilia
due
limit
antibiot
select
multidrug
resist
gramneg
bacteria
mdrg
infect
pneumonia
risk
infect
mortal
high
case
colsitn
common
use
antibiot
mdrg
infect
except
convent
intraven
iv
inject
colistin
inhal
colistin
increas
concentr
lung
tissu
new
administr
rout
offlabel
use
howev
uncertainti
effect
safeti
need
investig
therefor
effect
inhal
colistin
compar
inject
colistin
studi
method
patient
januari
decemb
use
iv
inject
inhal
colistin
hour
enrol
studi
assess
criteria
includ
bacteri
cultur
result
downgrad
withdraw
colistin
treatment
averag
length
hospit
stay
mortal
rate
result
total
number
patient
treat
colistin
iv
vs
inhal
vs
respect
mean
age
year
old
vs
year
old
day
drug
use
day
vs
day
respect
downgrad
withdraw
colistin
treatment
case
vs
case
respect
averag
hospit
stay
day
vs
day
treatment
mortal
rate
vs
conclus
studi
iv
inject
colistin
patient
complex
infect
still
better
inhal
present
iv
inject
colstin
treat
hospit
acquir
pneumonia
hap
ventil
acquir
pneumonia
vap
still
recommend
primari
rout
sinc
patient
use
colistin
complic
infect
effect
safeti
may
need
largescal
clinic
studi
approv
futur
hypersensit
betalactam
antibiot
result
studi
base
clinic
histori
skin
challeng
test
adnen
toumi
karim
aouam
moham
chakroun
amel
chaaban
infecti
diseas
depart
ur
monastir
univers
hospit
tunisia
pharmacolog
depart
monastir
univers
hospit
tunisia
background
betalactam
hypersensit
remain
overestim
lack
object
diagnosi
tool
lead
unjustifi
therapeut
altern
studi
perform
order
analyz
epidemiolog
clinic
chronolog
featur
betalactam
hypersensit
evalu
skin
test
valu
establish
practic
approach
explor
drug
hypersensit
method
includ
advers
effect
suspect
induc
betalactam
notifi
pharmacovigil
unit
monastir
year
drug
imput
establish
accord
begaud
et
al
method
skin
test
perform
recommend
enda
result
betalactam
hypersensit
retain
case
notif
almost
reaction
cutan
mainli
maculapapular
rash
sever
estim
delay
reaction
occur
case
reaction
resolv
drug
withdraw
identifi
posit
rechalleng
skin
test
perform
case
posit
penicillin
implic
case
almost
immedi
reaction
induc
penicillin
hypersensit
select
one
betalactam
nearli
half
case
crossreact
objectifi
among
penicillin
cephalosporin
case
involv
piperacillintazobactam
two
case
imipenem
one
case
conclus
present
studi
determin
betalactam
hypersensit
reaction
featur
develop
explor
practic
approach
diagnosi
confirm
use
skin
test
possibl
dreg
rechalleng
improv
find
drug
provoc
test
would
reliabl
tool
ps
atp
antimicrobi
activ
base
chelat
action
ferric
ion
show
combin
effect
antimycobacterium
avium
complex
drug
yutaka
tatano
yuichi
kanehiro
seiko
yamab
chiaki
sano
toshiaki
shimizu
hideki
yagi
haruaki
tomioka
depart
pharmaceut
scienc
intern
univers
health
welfar
faculti
medicin
shiman
univers
depart
nutrit
scienc
yasuda
women
univers
depart
basic
medic
scienc
nurs
depart
primari
educ
yasuda
women
univers
background
atp
upregul
macrophag
antimycobacteri
activ
depend
manner
howev
whether
atp
directli
exhibit
antimicrobi
effect
intracellular
mycobacteria
still
unknown
sinc
recogn
direct
antibacteri
activ
atp
bacteria
includ
mycobacteria
studi
mechan
antimicrobi
effect
addit
examin
detail
profil
antimycobacterium
avium
complex
mac
activ
antimicrobi
agent
combin
atp
method
use
mycobacteria
includ
mac
mycobacterium
tuberculosi
common
bacteria
like
staphylococcu
aureu
confirm
mediat
antibacteri
activ
atp
ironchel
effect
establish
enterobactindefici
mutant
strain
klebsiella
pneumonia
delet
entb
gene
bacteri
siderophor
product
measur
ca
chrome
azurol
assay
use
clarithromycin
ethambutol
rifampin
rifabutin
evalu
combin
effect
atp
antimac
drug
mac
organ
result
speci
strain
depend
common
bacteria
examin
atp
suscept
atp
markedli
inhibit
growth
intracellular
meanwhil
avium
moder
suscept
resist
atp
aureu
moder
highli
suscept
atp
antimac
activ
significantli
reduc
mgcl
fecl
atpresist
escherichia
coli
k
pneumonia
produc
signific
level
siderophor
cultiv
presenc
atp
atp
exhibit
moder
level
antimicrobi
effect
mutant
k
pneumonia
strain
moreov
found
antimac
activ
select
drug
markedli
potenti
straindepend
manner
case
onset
regrowth
antimicrobi
agenttr
mycobacteria
cultiv
significantli
delay
presenc
atp
conclus
studi
atp
antibacteri
activ
found
attribut
ironchel
abil
also
found
atp
inhibit
growth
variou
bacteria
includ
mycobacteria
without
damag
bacteri
surfac
structur
thu
atp
promis
adjunct
agent
chemotherapi
mycobacteri
infect
use
antimac
drug
current
examin
chang
antimac
activ
increas
intramacrophag
atp
concentr
evalu
synergist
antibacteri
mechan
natur
product
methicillinresist
staphylococcu
aureu
chuihian
lim
chiamin
yuan
chungwai
shaiu
haochieh
chiu
background
emerg
antibiot
resist
impos
seriou
challeng
public
health
worldwid
unit
state
methicillinresist
staphylococcu
aureu
mrsa
infect
claim
nearli
live
year
convent
antibiot
suffici
treat
mrsa
infect
new
antibiot
novel
action
mechan
highli
need
previous
group
show
smallmolecul
compound
exhibit
synergist
antibacteri
activ
natur
product
mrsa
aim
uncov
synergist
antibacteri
mechan
combin
method
antibacteri
activ
combin
mrsa
assess
mic
assay
mbc
assay
timekil
assay
cell
toxic
combin
examin
differ
epitheli
cell
line
use
mtt
cell
viabil
assay
furthermor
vivo
efficaci
combin
evalu
mous
model
mrsa
skin
infect
result
screen
natur
product
identifi
capabl
potenti
antibacteri
activ
time
combin
also
display
fastkil
activ
mrsa
demonstr
erad
bacteria
broth
within
minut
contrast
effect
cytotox
toward
human
epitheli
cell
observ
subsequ
experiment
result
indic
short
exposur
mrsa
increas
bacteri
suscept
combinatori
effect
reduc
antioxid
long
acylchain
includ
astaxanthin
alphatocopherol
dosedepend
manner
addit
phenol
antioxid
butyl
hydroxytoluen
bht
contrast
stabliz
increas
antibacteri
activ
combin
current
studi
evalu
efficaci
combin
mrsa
skin
infect
underway
conclus
find
provid
strong
evid
prooxid
activ
play
import
role
synergist
bactericid
effect
combin
could
develop
topic
medic
mrsa
skin
infect
vitro
activ
ceftolozanetazobactam
pseudomona
aeruginosa
enterobacteriacea
isol
medic
center
taiwan
background
pseudomona
aeruginosa
enterobacteriacea
lead
nosocomi
gramneg
pathogen
often
multidrug
resist
ceftolozanetazobactam
toltaz
antipseudomon
cephalosporin
inhibitor
approv
treatment
complic
intraabdomin
infect
combin
metronidazol
complic
urinari
tract
infect
fda
unit
state
european
medicin
agenc
method
antimicrobi
suscept
toltaz
ten
compar
cefepim
cefoperazonesulbactam
ceftazidim
ciprofloxacin
colistin
imipenem
levofloxacin
meropenem
piperacillintazobactam
piptaz
tigecyclin
evalu
isol
collect
medic
center
taiwan
test
minimum
inhibitori
concentr
mic
follow
clsi
guidelin
central
laboratori
ihma
inc
result
interpret
use
clsi
guidelin
drug
except
colistin
eucast
tigecyclin
fda
qualiti
control
strain
use
day
test
background
antibiot
therapi
recommend
choic
nontubercul
mycobacteria
ntm
infect
current
multidrug
therapi
standard
practic
treatment
option
exist
solut
intrins
acquir
antibiot
resist
major
difficulti
treatment
sever
previou
studi
suggest
singl
extract
formul
tradit
chines
medicin
tcm
alon
combin
antibiot
may
treat
common
bacteri
infect
therefor
synergist
combin
therapi
antibiot
plu
tcm
could
effect
solut
studi
provid
evid
combin
tcm
antibiot
may
yield
synergi
treatment
ntm
infect
method
two
standard
mycobacteri
strain
mycobacterium
abscessu
colleg
american
pathologist
cap
rgm
mycobacterium
avium
subsp
avium
serotyp
sgm
chosen
studi
three
scientif
tcm
formul
extract
subtli
granul
includ
scute
cimicifuga
combin
scc
dandelion
wild
chrysanthemum
combin
dwcc
gleditsia
combin
gc
appli
experi
three
step
minim
inhibitori
concentr
mic
measur
preset
concentr
mycobacteria
perform
monotherapi
clsi
recommend
antibiot
monotherapi
tcm
formul
serial
dilut
concentr
combin
antibiot
plu
scc
step
repeatedli
perform
estim
averag
mic
result
bacteriostat
effect
tcm
formul
observ
abscessu
avium
inhibitori
concentr
scc
dwcc
gc
mgml
mgml
respect
signific
reduct
mic
abscessu
avium
also
measur
scc
ad
concentr
mgml
onto
commerci
antibiot
well
mic
abscessu
clarithromycin
tigecyclin
ciprofloxacin
moxifloxacin
trimethoprimsulfamethoxazol
doxycyclin
cefoxitin
avium
clarithromycin
ethambutol
significantli
decreas
combin
mgml
scc
conclus
tcm
formul
alon
yield
similar
bacteriostat
effect
antibiot
ntm
observ
combin
treatment
tcm
formul
plu
antibiot
could
synergist
antibacteri
effect
ntm
machan
tcm
formul
antibiot
resist
ntm
explor
antimicrobi
resist
variou
antibiot
escherichia
coli
western
part
japan
year
studi
tetsuro
muratani
haruhisa
saku
tomoko
kobayashi
junichi
ohno
ihibiki
amr
laboratori
kitakyushu
japan
hibiki
research
group
clinic
microbiolog
kyurin
medic
laboratori
background
although
escherichia
coli
one
bacteria
consist
human
intestin
normal
flora
e
coli
bacteria
abl
caus
infecti
diseas
variou
site
urinari
tract
intestin
tract
respiratori
tract
wound
biliari
tract
blood
stream
etc
e
coli
suscept
variou
antibiot
major
problem
multi
drug
resist
e
coli
emerg
increas
investig
suscept
variou
antibiot
e
coli
isol
western
part
japan
method
total
nondupl
e
coli
isol
urinein
period
japan
use
studi
divid
isol
isol
period
everi
year
durat
durat
b
durat
c
mic
variou
antimicrobi
isol
determin
twofold
serial
agar
dilut
method
describ
clsi
resist
isol
antimicrobi
basic
interpret
accord
clsi
breakpoint
result
e
coli
isol
urinari
tract
respiratori
tract
wound
blood
stream
account
inpatientsoutpati
respect
tabl
show
ratio
esbl
produc
quinoloneresist
esbl
produc
increas
inpati
outpati
ratio
quinoloneresist
inpati
chang
howev
ratio
outpati
increas
ovious
background
increas
resist
neisseria
gonorrhoea
ceftriaxon
ctrx
global
problem
conduct
molecular
epidemiolog
analysi
n
gonorrhoea
isol
japan
purpos
examin
ctrx
resist
mechan
method
antimicrobi
suscept
cefixim
cfix
ctrx
measur
use
n
gonorrhoea
isol
japan
thirti
two
isol
analyz
amino
acid
sequenc
penicillinbind
protein
furthermor
molecular
epidemiolog
similar
analyz
neisseria
gonorrhoea
multiantigen
sequenc
type
ngmast
result
thirti
two
isol
classifi
three
group
group
cfix
susceptiblectrx
suscept
group
b
cfix
resistancectrx
suscept
group
c
cfix
resistancectrx
resist
base
suscept
record
common
mutat
group
pattern
v
group
b
pattern
x
group
c
pattern
xxxiv
pattern
x
xxxiv
mosaiclik
mutat
amino
acid
sequenc
common
sequenc
type
st
mgmast
group
group
b
group
c
group
characterist
st
ngmast
confirm
addit
isol
highlevel
ctrx
resist
strain
franc
confirm
howev
detect
strain
sensit
ctrx
conclus
indic
mutat
significantli
associ
decreas
susceptibilii
cfix
mutat
confer
clear
influenc
decreas
susceptibilii
ctrx
studi
suggest
resist
mechan
ctrx
due
mutat
also
complic
mechan
plasmid
carri
bla
carbapenem
resist
gene
transfer
acinetobact
baumannii
acinetobact
nosocomiali
hsingyu
chen
hungsheng
shang
junren
sun
background
acinetobact
nosocomiali
found
serv
reservoir
resist
determin
health
care
set
hospit
carbapenem
nonsuscept
rate
acinetobact
nosocomiali
approxim
howev
carbapenem
resist
mechan
acinetobact
nosocomiali
rare
studi
main
object
work
investig
resist
mechan
molecular
epidemiolog
imipenem
nonsuscept
acinetobact
nosocomiali
taiwan
method
fortyon
imipenem
nonsuscept
acinetobact
nosocomiali
isol
collect
bloodstream
infect
identifi
use
autom
vitek
system
confirm
rrna
intergen
spacer
sequenc
antibiot
suscept
test
perform
broth
microdilut
method
imipenem
nonsuscept
isol
examin
pcr
assay
presenc
carbapenemaseencod
gene
plasmid
sequenc
transform
acinetobact
baumannii
assess
transfer
abil
result
carbapenemas
gene
detect
fortyon
isol
common
carbapenemas
gene
n
furthermor
six
five
one
detect
gene
product
sequenc
gene
conform
plasmid
plasmid
sequenc
one
copi
gene
previou
studi
plasmid
transmit
acinetobact
baumannii
rather
acinetobact
nosocomiali
plasmid
extract
clinic
acinetobact
nosocomiali
transform
acinetobact
baumannii
minimum
inhibitori
concentr
imipenem
meropenem
doripenem
ertapenem
increas
mgl
mgl
mgl
mgl
mgl
mgl
mgl
mgl
respect
conclus
conclus
found
plasmid
carri
domin
imipenem
nonsuscept
acinetobact
nosocomiali
isol
plasmid
contribut
carbapenem
resist
may
spread
acinetobact
baumannii
acinetobact
nosocomiali
background
carbapenem
resist
seriou
global
concern
effort
find
novel
resist
mechan
ongo
wellknown
mechan
includ
loss
porin
derepress
esbl
product
along
loss
either
one
porin
studi
isol
two
klebsiella
pneumonia
strain
singl
patient
meropenem
treatment
two
strain
show
ident
pfge
pattern
differ
carbapenem
suscept
method
hodg
test
dd
sdspage
wg
along
rnaseq
perform
get
holist
view
chang
allel
express
develop
k
pneumonia
network
system
klebsiellanet
cover
code
gene
klebsiella
pneumonia
strain
cofunct
link
put
candid
gene
shortlist
compar
wg
transcriptom
analysi
use
klebsiellanet
plasmid
carri
zeocin
marker
use
complement
gene
disk
diffus
use
meropenem
ertapenem
perform
check
diffus
pattern
result
strain
lack
present
isol
suscept
meropenem
highli
resist
put
candid
gene
shortlist
analysi
p
among
put
candid
transport
protein
exhibit
tendenc
toward
meropenem
suscept
complement
tabl
conclus
put
candid
gene
select
gene
use
klebsiellanet
protein
belong
mf
famili
transport
protein
obtain
gene
complement
interestingli
transport
specif
meropenem
alon
first
report
contribut
protein
meropenem
resist
profil
transport
protein
mostli
act
efflux
pump
result
contrari
identif
new
plasmidmedi
ampc
clinic
isol
citrobact
freundii
chihm
chen
hwajen
wu
liitzu
wu
background
citrobact
freundii
recent
year
demonstr
resist
tradit
agent
ampicillin
carbenicillin
cephalothin
also
newer
agent
thirdgener
cephalosporin
monobactam
even
produc
carbapenemas
studi
perform
character
c
freundii
isol
collect
taiwanes
hospit
carri
novel
ampctyp
gene
method
use
antibiot
suscept
test
plasmid
analysi
transconjug
clonimg
sequenc
analysi
ampctyp
gene
genecontain
recombin
plasmid
transform
escherichia
coli
select
use
ampicillin
result
resist
phenotyp
found
produc
confer
resist
oxyiminocephalosporin
cephamycin
resist
aris
product
betalactamas
could
transfer
conjug
incw
plasmid
e
coli
substrat
inhibit
profil
enzym
resembl
ampc
betalactamas
resist
gene
prove
contain
open
read
frame
show
amino
acid
ident
plasmidmedi
enzym
c
freundii
dna
sequenc
analysi
also
identifi
gene
upstream
ampc
whose
sequenc
ident
ampr
gene
c
freundii
addit
fumar
operon
frdabcd
outer
membran
lipoprotein
blc
surround
amprampc
gene
c
freundii
identifi
insert
sequenc
element
observ
one
side
sequenc
identifi
conclus
result
clearli
show
new
plasmidencod
ampc
gene
ampr
gene
c
freundii
presenc
resist
region
isol
divers
genet
determin
resist
mobil
element
may
contribut
emerg
spread
gene
chromosom
orand
plasmid
level
hiroshi
hasegawa
keita
noguchi
yoko
mano
katsumi
fujitani
nobuhiko
furuya
background
uropathogen
escherichia
coli
upec
respons
urinari
tract
infect
uti
addit
women
treat
uti
experi
recurr
least
within
month
initi
infect
despit
proper
antibacteri
treatment
recurr
uti
secondari
infect
caus
strain
e
coli
caus
primari
infect
firstlin
agent
treatment
uti
fluoroquinolon
fq
howev
recent
year
fqresist
e
coli
increasingli
report
worldwid
proanthocyanidin
pac
abund
cranberri
use
prevent
uti
centuri
howev
mechan
underli
effect
unknown
studi
atyp
pac
use
prevent
recurr
upec
infect
via
differ
mechan
convent
antibacteri
therapi
method
e
coli
strain
upec
strain
use
studi
checkerboard
method
use
evalu
effect
combin
antibacteri
pac
e
coli
swarm
twitch
motil
assess
use
platebas
assay
pac
ad
concentr
test
abil
inhibit
adhes
e
coli
human
bladder
epitheli
cell
cell
invas
inhibit
also
test
similar
manner
result
combin
pac
caz
show
synergist
effect
pac
treatment
significantli
reduc
mean
spread
rang
swarm
twitch
motil
upec
strain
result
inhibit
attach
upec
strain
cell
show
statist
signific
differ
p
pac
convers
pac
inhibit
adher
strain
cell
mean
valu
cell
invas
pactreat
upec
strain
significantli
smaller
untreat
upec
furthermor
show
invas
cell
conclus
combin
pac
caz
inhibitori
effect
flagellamedi
motil
suggest
essenti
upec
dissemin
upper
urinari
tract
propos
inhibit
flagellamedi
motil
may
key
mechan
pac
prevent
uti
vitro
antiadhes
antiinvas
activ
cranberryderiv
pac
upec
suggest
presenc
urin
reduc
bacteri
colon
uti
advanc
food
clinic
manifest
includ
gastroenter
cellul
soft
tissu
infect
seri
clinic
syndrom
appear
immunocompromis
patient
due
extens
use
antibiot
clinic
practic
isol
multidrugresist
aeromona
strain
increas
pump
resistancenodulationcel
divis
rnd
superfamili
ubiquit
gramneg
bacteria
broadest
substrat
rang
increas
express
chromosom
gene
rndtype
efflux
system
play
major
role
multidrug
resist
gramneg
bacteria
howev
contribut
rnd
efflux
gene
develop
multidrug
resist
aeromona
strain
evalu
clinic
set
method
minimum
inhibitori
concentr
mic
use
determin
pattern
resist
antibiot
presenc
absenc
efflux
inhibitor
multidrug
resist
antimicrobi
drug
class
aeromona
strain
select
analysi
bactericid
effect
treatment
combin
efflux
inhibitor
antibiot
evalu
surviv
rate
realtim
pcr
use
investig
express
level
rnd
efflux
gene
experi
done
triplic
result
present
analyz
student
ttest
result
multidrug
resist
aeromona
strain
resist
antibiot
includ
sulfonamid
quinolon
aminoglycosid
mic
piperacillintasobactam
erythromycin
imipenem
significantli
reduc
multidrug
resist
clinic
isol
presenc
efflux
pump
inhibitor
express
level
rnd
efflux
gene
elev
multidrug
resist
aeromona
strain
conclus
rnd
efflux
system
contribut
drug
resist
aeromona
strain
higher
level
rnd
efflux
gene
found
multidrug
resist
clinic
isol
studi
need
elucid
whether
express
efflux
system
confer
intrins
resist
antibiot
aeromona
hydrogen
peroxid
enhanc
bactericid
effect
toluidin
bluemedi
photodynam
therapi
methicillin
resist
staphylococcu
aureu
yich
tsai
shinbei
wu
yafang
tsai
yuchen
hsu
chialun
yu
takwah
wong
background
emerg
multipledrug
resist
bacteria
includ
salmonella
seriou
threat
public
health
worldwid
top
salmonella
capabl
avoid
antibiot
attack
invad
host
cell
lead
problem
treatment
thu
novel
therapeut
intervent
erad
intracellular
bacteria
well
reduc
incid
resist
highli
need
previous
identifi
smallmolecul
anticanc
agent
show
potent
activ
salmonella
typhimurium
macrophag
salmonellosi
mice
model
dissoci
antibacteri
activ
antiprolif
activ
focus
librari
synthes
screen
antibacteri
activ
intracellular
typhimurium
macrophag
cytotox
toward
host
cell
method
antibacteri
activ
cytotox
deriv
first
assess
use
imagebas
highcont
system
compound
show
good
select
antibacteri
activ
cytotox
analys
intracellular
infect
assay
mtt
cell
viabil
assay
effect
compound
bacteri
growth
broth
evalu
use
mic
assay
result
among
compound
test
exhibit
better
antibacteri
activ
show
antibacteri
activ
equal
much
lower
cytotox
toward
host
cell
result
mic
assay
indic
compound
inhibitori
activ
bacteria
growth
medium
suggest
suppress
intracellular
bacteria
via
hosttarget
mechan
current
studi
evalu
efficaci
select
deriv
salmonellainfect
mice
underway
conclus
find
provid
proofofconcept
antibacteri
activ
dissoci
antiprolif
activ
via
structur
optim
repres
promis
scaffold
develop
novel
hosttarget
antibacteri
agent
treatment
salmonellosi
background
clinic
antibiot
failur
may
result
bacteri
resist
also
persist
form
infect
intracellular
bacteria
protect
host
immun
defenc
partli
also
antibiot
action
studi
activ
moxifloxacin
model
intracellular
infect
aureu
local
phagolysosom
compar
refer
strain
clinic
isol
collect
patient
persist
infect
method
refer
strain
clinic
isol
collect
bachmai
hospit
hanoi
patient
still
infect
day
treatment
activ
antibiot
recurr
previou
infect
mic
microdilut
clsi
recommend
suscept
accord
eucast
intracellular
infect
human
monocyt
h
phagocytosi
elimin
nonintern
bacteria
exposur
gentamicin
intracellular
activ
chang
cfu
initi
inoculum
h
use
wide
rang
extracellular
concentr
mic
static
concentr
c
maxim
efficaci
e
max
calcul
hill
equat
fit
concentrationrespons
data
see
antimicrob
agent
chemoth
result
shown
tabl
moxifloxacin
c
alway
close
mic
strain
whatev
suscept
broth
e
max
significantli
lower
less
neg
clinic
isol
compar
refer
strain
conclus
intracellular
form
clinic
isol
obtain
patient
persist
infect
significantli
less
erad
refer
strain
suggest
state
less
respons
moxifloxacin
phagolysosom
environ
potenti
link
therapeut
failur
vivo
remain
establish
hsiowyun
hsue
wenpo
tseng
hueiy
chen
shyme
lee
wychan
lee
chung
hospit
infect
control
committe
leader
depart
medicin
laboratori
depart
chairman
committe
chung
hospit
superintend
background
antimicrobi
resist
amr
major
global
public
health
problem
hospit
commun
acquir
infect
knowledg
attitud
public
toward
use
antibiot
key
factor
influenc
antibiot
prescript
consequ
antibiot
resist
antibiot
educ
intervent
program
design
deliv
correct
knowledg
regard
appropri
use
antibiot
order
reduc
possibl
antibiot
resist
method
intervent
conduct
educ
intervent
group
selfconstruct
survey
list
cronbach
alpha
valu
result
evalu
use
test
pair
ttest
random
particip
locat
around
daan
district
taipei
particip
period
march
june
result
suggest
particip
correct
knowledg
educ
intervent
result
particip
still
prefer
take
antibiot
way
rather
follow
doctor
prescript
mostli
nt
realiz
import
consequ
antibiot
resist
importantli
educ
intervent
improv
knowledg
antibiot
use
limit
influenc
attitud
behavior
particip
studi
suggest
suitabl
way
deliv
correct
knowledg
regard
use
antibiot
public
still
issu
concern
author
method
strain
e
coli
k
pneumonia
p
aeruginosa
expos
ciprofloxacin
dc
rang
organ
suspens
plate
ciprofloxacin
contain
agar
plate
follow
incub
hour
coloni
select
drug
contain
plate
test
determin
mic
compar
predrug
exposur
mic
valu
mic
valu
ident
within
doubl
dilut
taken
indic
impact
test
strain
kill
cfuml
organ
expos
ciprofloxacin
dc
log
reduct
kill
measur
minut
drug
exposur
result
mic
valu
follow
e
coli
k
pneumonia
p
aeruginosa
instanc
regardless
ciprofloxacin
dc
post
exposur
mic
valu
within
doubl
dilut
preexpos
mic
valu
kill
experi
log
reduct
percent
kill
viabl
cell
differ
organ
test
without
drug
organ
growth
minim
first
minut
drug
exposur
organ
growth
observ
follow
minut
follow
drug
exposur
differ
drug
expos
without
drug
assay
conclus
ciprofloxacin
dc
msw
select
resist
subpopul
e
coli
k
pneumonia
p
aeruginosa
similarli
exposur
organ
kill
assay
ciprofloxacin
show
differ
drug
expos
bacteria
without
drug
low
ciprofloxacin
dc
observ
cipro
dpi
administr
appear
select
resist
organ
test
background
fluoroquinolon
commonli
prescrib
antimicrobi
agent
user
regist
advers
gastroenterolog
symptom
aim
evalu
associ
use
fluoroquinolon
gastrointestin
tract
perfor
method
conduct
nest
casecontrol
studi
nation
health
insur
claim
databas
use
fluoroquinolon
classifi
current
day
past
day
prior
index
date
prior
year
use
fluoroquinolon
use
condit
logist
regress
model
estim
rate
ratio
rr
adjust
match
diseas
risk
score
dr
result
identifi
cohort
individu
diagnos
gastrointestin
perfor
match
control
current
use
fluoroquinolon
associ
greatest
increas
risk
gastrointestin
perfor
dr
score
adjust
rr
ci
risk
gastrointestin
perfor
attenu
past
rr
ci
prior
year
use
rr
ci
current
use
macrolid
activ
compar
associ
signific
increas
risk
gastrointestin
perfor
rr
ci
mitig
select
bia
also
exclud
peopl
never
use
fluoroquinolon
peopl
infecti
coliti
enter
gastroenter
analysi
higher
risk
gastrointestin
perfor
still
associ
use
fluoroquinolon
conclus
found
use
fluoroquinolon
associ
nonneglig
increas
risk
gastrointestin
perfor
physician
awar
possibl
associ
background
drugresist
tuberculosi
drtb
especi
multidrugand
extens
drugresist
mxdr
tb
emerg
menac
world
recent
year
shorten
time
drug
suscept
test
dst
molecular
diagnost
becom
popular
accuraci
method
depend
reliabl
dst
data
compar
whole
genom
sequenc
wg
data
dst
result
tuberculosi
mtb
isol
includ
mdr
xdr
detect
mutat
evalu
use
allinon
webbas
wg
analys
tool
identifi
novel
resist
respons
mutat
method
mtb
collect
basic
drtb
patient
osaka
habikino
medic
center
osaka
japan
conduct
wg
analysi
isol
use
miseq
illumina
tgstb
http
gphniidgojptgstb
use
predict
mutat
respons
gene
phenotyp
dst
result
obtain
use
proport
method
welpack
kyokuto
antituberculosi
drug
minimum
inhibitori
concentr
mic
drug
result
drtb
includ
mdr
xdr
result
dst
consist
lineag
eastasian
lineag
euroamerican
date
analys
isol
drug
potenti
amr
predict
program
tgstb
site
june
predict
mxdrtb
correctli
proport
discrep
phenotyp
predict
dst
isoniazid
kanamycin
rifampicin
ethambutol
fluoroquinolon
increas
qualiti
molecular
dst
need
establish
high
qualiti
genom
databas
drtb
strain
reliabl
phenotyp
dst
show
detail
result
drtb
gene
analysi
includ
mic
data
lili
liu
shaogang
zhu
yonglin
ningn
zhang
manli
tong
huilin
zhang
lirong
lin
jianghua
yan
tianci
yang
method
analysi
lncrna
express
profil
identifi
differenti
express
lncrna
cell
respons
pallidum
infect
neurosyphili
patient
cell
isol
peripher
blood
mononuclear
cell
rna
extract
perform
conduct
experi
express
profil
mrna
lncrna
cell
isol
neurosyphili
patient
healthi
control
analyz
use
microarray
assay
four
lncrna
select
conduct
valid
use
real
timequantit
polymeras
chain
reaction
express
level
mention
lncrna
neurosyphili
patient
healthi
control
compar
result
total
lncrna
mrna
found
differenti
express
compar
cell
neurosyphili
patient
healthi
control
individu
transcript
lncrna
mrna
significantli
express
respect
compar
healthi
control
fold
chang
fold
chang
overexpress
underexpress
lncrna
neurosyphili
patient
major
differenti
express
lncrna
intergen
region
intron
antisens
proteincod
loci
natur
antisens
proteincod
loci
worth
note
lncrna
signific
differ
along
significantli
differ
mrna
among
pair
gene
mrna
posit
correl
lncrna
respect
mrna
posit
correl
lncrna
respect
follow
five
mrna
correl
two
differenti
lncrna
name
go
analysi
reveal
differenti
express
code
gene
mainli
involv
biolog
process
among
signific
associ
observ
defens
respons
fungu
defens
respons
bacterium
kill
cell
organ
disrupt
cell
organ
subsequ
pathway
analysi
also
conduct
cell
receptor
signal
pathway
mapk
signal
pathway
tgfbeta
signal
pathway
etc
found
associ
differenti
express
mrna
conclus
present
studi
reveal
differenti
express
profil
lncrna
cell
respons
pallidum
infect
neurosyphili
patient
lncrna
involv
key
biolog
process
cell
respons
pallidum
infect
cov
regul
express
rgg
differenti
phosphoryl
level
covr
chihyuan
kao
chuan
chiangni
addit
inactiv
rgg
enhanc
abil
resist
stress
condit
thought
provid
surviv
advantag
bacteria
host
immun
system
previou
studi
found
express
rgg
downregul
cov
mutant
studi
aim
elucid
whether
cov
particip
regul
rgg
express
modul
level
covr
phosphoryl
method
cov
shown
kinas
phosphatas
activ
elucid
cov
influenc
covr
phosphoryl
statu
regul
rgg
kinas
phosphatas
activ
inactiv
sitedirect
mutagenesi
respect
phostag
western
blot
analysi
perform
detect
covr
phosphoryl
level
cov
mutant
addit
express
rgg
cov
isoallel
strain
analyz
rtqpcr
result
present
studi
found
nonphosphoryl
covr
inhibit
rgg
express
strongli
phosphoryl
covr
addit
express
rgg
regul
isoallel
strain
cov
cov
strain
result
show
express
rgg
decreas
significantli
cov
strain
howev
express
rgg
increas
gradual
cov
strain
compar
wildtyp
strain
result
suggest
cov
regul
express
rgg
differenti
phosphoryl
level
covr
conclus
cov
regul
express
rgg
differenti
phosphoryl
level
covr
campylobact
jejuni
cytoleth
distend
toxin
suppress
mobil
rage
lipid
raft
respons
inflammatori
respons
zhipei
jiang
meizi
huang
yuan
chen
chihho
lai
background
cytoleth
distend
toxin
cdt
produc
campylobact
jejuni
contain
three
subunit
cdta
cdtb
cdtc
interact
cdta
cdtc
membran
lipid
raft
deliv
cdtb
nucleu
follow
induct
inflamm
cell
death
highmobl
group
box
one
damageassoci
molecular
pattern
damp
nuclear
dnabind
protein
stabil
nucleosom
promot
dna
repair
activ
signal
mediat
receptor
advanc
glycat
endproduct
rage
import
defend
bacteri
infect
aim
studi
explor
cdt
regul
autophagi
damp
trigger
rage
mobil
lipid
raft
induc
inflammatori
method
molecular
mechan
underli
cdt
regul
autophagi
process
confer
cell
death
cell
cycl
arrest
investig
biochem
analys
conduct
explor
dampmedi
trigger
rage
mobil
lipid
raft
respons
cdtinduc
inflamm
result
studi
show
cdt
induc
rage
express
suppress
indic
damp
trigger
rage
activ
inflammatori
respons
intracellular
avail
activ
autophagi
result
reveal
cdt
control
import
regul
autophagi
also
found
damp
mobil
rage
lipid
raft
respons
cdtinduc
inflamm
conclus
find
demonstr
cdt
suppress
autophagi
trigger
damprageinflamm
axi
import
pathogenesi
c
jejuni
comparison
intraven
anesthet
inhibit
secret
ro
product
aureu
infect
cell
wenchun
lin
mingshan
chen
shewmeei
sheu
background
one
key
pathway
employ
opportunist
pathogen
p
aeruginosa
establish
pathogenesi
format
biofilm
apart
biofilm
format
bacterium
abl
produc
differ
virul
factor
help
drug
resist
nutrit
uptak
overcom
problem
need
establish
altern
antimicrobi
henc
studi
taken
investig
antibacteri
antivirul
properti
flavonoid
quercetin
cathet
associ
p
aeruginosa
method
select
p
aeruginosa
strain
use
evalu
effect
quercetin
differ
concentr
bactericid
biofilm
viabil
elastas
siderophor
pyocyanin
twitch
motil
biofilm
result
bactericid
assay
show
except
one
clinic
strain
isol
complet
inhibit
quercetin
concentr
mgml
quercetin
show
signific
effect
siderophor
pyocyanin
elastas
product
motil
assay
show
concentr
strain
form
microbi
coloni
unabl
spread
plate
quercetin
show
signific
inhibitori
effect
biofilm
format
concentr
mgml
except
od
strain
form
weak
biofilm
od
highest
concentr
two
clinic
isol
form
weak
biofilm
od
strain
unabl
form
biofilm
conclus
studi
reveal
quercetin
good
antibacteri
antibiofilm
activ
suggest
compound
use
treat
p
aeruginosa
either
food
supplement
develop
new
antibiot
combin
background
colistin
resist
cr
gram
neg
bacteria
worldwid
concern
increas
recent
discoveri
spread
plasmidmedi
gene
activ
efflux
mechan
known
variou
bacteria
confer
resist
variou
antibiot
includ
tigecyclin
fluoroquinolon
carbapenem
recent
one
efflux
pump
inhibitor
epi
carbonyl
cyanid
cccp
show
abil
revers
colistin
resist
colistin
resist
gram
neg
bacteria
klebsiella
pneumonia
pseudomona
aeruginosa
stenotrophomona
maltophilia
acinetobact
baumannii
unknown
mechan
action
object
studi
evalu
effect
epi
collect
well
defin
colistinresist
strain
isol
laboratori
includ
naturallyresist
gram
neg
bacteria
acquiredresist
bacteria
mgrb
method
compar
diamet
inhibit
colistin
disk
minimum
inhibitori
concentr
mic
realiz
etest
method
muellerhinton
medium
mh
mh
supplement
mgl
cccp
statist
analysi
perform
use
student
test
risk
studi
collect
strain
includ
cr
strain
escherichia
coli
k
pneumonia
enterobact
cloaca
known
mechan
resist
pmra
pmrb
mgrb
associ
unknown
mechan
enterobact
spp
e
coli
klebsiella
spp
salmonella
enterica
intrins
resist
enterobacteriacea
serratia
marcescen
proteu
spp
providencia
spp
morganella
morganii
result
preliminari
result
show
mean
increas
colistin
diamet
mm
posit
strain
cccp
ad
medium
diamet
colistin
disk
alon
mm
diamet
colistin
disk
ccp
pvalu
marcescen
mic
colistin
decreas
mgl
mean
mgl
pvalu
genom
analysi
ongo
identifi
efflux
pump
could
involv
mechan
action
due
cccp
conclus
show
cccp
efflux
pump
inhibitor
abl
revers
resist
colistin
colistinresist
gram
neg
bacteria
phenomenon
independ
mechan
resist
involv
sinc
gene
resist
implic
resist
colistin
bacteria
mean
efflux
pump
play
addit
role
resist
colistin
genom
analys
ongo
identifi
pump
could
target
specif
epi
futur
work
open
new
area
research
develop
adjunct
therapi
cr
bacteri
infect
two
lysin
gene
abla
methanoarchaea
function
compat
solut
synthesi
gene
translat
modif
yishan
wu
chuanchuan
hung
chengyu
chen
meichin
lai
depart
life
scienc
nation
chung
hsing
univers
taichung
taiwan
roc
background
n
ubiquit
compat
solut
osmolyt
among
methanoarchaea
counter
osmot
stress
synthes
lysin
lysin
abla
form
acetyl
group
transfer
acetyltransferas
ablb
whole
genom
sequenc
halophil
methanoarchaeon
methanohalophilu
portucalensi
reveal
two
abla
gene
cotranscrib
ablb
respons
n
synthesi
wherea
locat
within
translat
associ
protein
without
ablb
method
rnaseq
perform
illumina
hiseq
phylogenet
relationship
rrna
gene
methanogen
archaea
bacteria
construct
neighborjoin
method
mega
program
heterolog
overexpress
e
coli
ril
purifi
nickel
affin
chromatographi
maintain
overexpress
protein
reduct
state
dihydrolipo
acid
sodium
dithionit
buffer
enzymat
activ
assay
determin
product
ultra
perform
liquid
chromatographi
result
transcriptom
anslysi
show
transcript
express
higher
optim
growth
condit
also
salt
stress
fold
temperatur
stress
fold
indic
demand
higher
compat
n
phylogenet
analysi
base
amino
acid
archaea
bacteria
indic
halophil
methanoarcha
may
horizont
transfer
deltaprotebacteria
amino
acid
sequenc
similar
lysin
desulfuromonadal
bacterium
homolog
model
structur
contain
fe
cluster
sam
bind
domain
plp
bind
site
ctermin
zinc
bind
site
found
investig
enzym
activ
gene
transform
overexpress
e
coli
ril
respect
protein
maintain
reduct
state
addit
dihydrolipo
acid
sodium
dithionit
uplc
system
use
identifi
end
product
establish
futur
enzym
kinet
investig
conclus
genom
transcriptom
phylogenet
analysi
identifi
two
lysin
gene
abla
methanoarchaea
function
compat
solut
synthesi
gene
may
function
translat
modif
involv
methanoarchaea
commun
cold
seep
area
four
way
closur
ridg
offshor
southwestern
taiwan
culturedepend
method
shengchung
chen
meichin
lai
depart
life
scienc
nation
chung
hsing
univers
taichung
taiwan
background
widespread
accumul
methan
hydrat
within
accretionari
prism
offshor
sw
taiwan
postul
occur
base
presenc
intens
bottom
simul
reflect
four
way
closur
ridg
fwcr
one
site
intens
methan
seepag
chemosynthet
commun
highli
dens
mussel
bed
found
carbon
isotop
composit
flux
methan
indic
biogen
methan
sourc
known
produc
methanoarchaea
domin
area
describ
methanoarchaea
commun
cold
seep
area
culturedepend
method
method
use
videoguid
multicor
vcorer
collect
sediment
sampl
cold
seep
area
station
fwcr
cruis
rv
nov
methanoarchaea
sediment
sampl
enrich
room
temperatur
use
rich
media
mbw
mix
substrat
includ
acet
format
methanol
growth
methanoarchaea
monitor
methan
product
use
ga
chromatographi
pure
partial
pure
methanoarcha
isol
purifi
rolltub
techniqu
identifi
use
phylogenet
analysi
rrna
gene
sequenc
result
total
sediment
core
methanoarchaea
enrich
retriev
coldseep
region
fwcr
month
incub
bottl
methanoarchaea
enrich
contain
methan
product
indic
methanoarchaea
grew
insid
anaerob
rolltub
techniqu
perform
obtain
singl
coloni
methan
produc
enrich
sampl
conclus
culturedepend
method
reveal
domin
methanoarchaea
methanoculleu
strain
occur
rel
abund
cold
seep
region
fwcr
offshor
sw
taiwan
may
indic
methanoculleu
strain
prevail
methan
produc
cold
seep
addit
endem
potenti
new
speci
methanoarchaea
cold
seep
region
collect
studi
inhibitori
effect
ganoderma
neojaponicum
water
extract
osteoclast
differenti
via
upregul
heme
downregul
express
chinhuei
lee
haiwei
cheng
jiintsuey
chen
chiliang
chern
depart
biolog
scienc
nation
sun
yatsen
univers
kaohsiung
taiwan
depart
orthoped
surgeri
fooyin
univers
hospit
pingtung
taiwan
depart
medic
laboratori
scienc
biotechnolog
fooyin
univers
kaohsiung
taiwan
background
osteoclast
multinucl
boneresorb
cell
differenti
receptor
activ
nuclear
factor
kappab
ligand
rankl
macrophag
colonystimul
factor
mcsf
reactiv
oxygen
speci
ro
gener
nadph
oxidas
upon
rankl
stimul
demonstr
play
key
role
osteoclast
differenti
previou
studi
shown
ganoderma
neojaponicum
water
extract
gne
increas
heme
protein
express
decreas
hydrogen
peroxideinduc
oxid
stress
murin
macrophag
method
gne
isol
water
extract
ganoderma
neojaponicum
use
test
osteoclastogenesi
inhibit
effect
ranklstimul
bone
marrowderiv
macrophag
bmm
murin
monocyt
cell
line
vitro
result
show
gne
could
inhibit
ranklinduc
ro
product
format
osteoclast
moreov
gne
treatment
decreas
express
nuclear
factor
activ
cell
master
regul
osteoclast
differenti
osteoclast
marker
cathepsin
k
addit
gne
impair
activ
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
cjun
ntermin
kinas
jnk
conclus
data
suggest
gne
inhibit
osteoclastogenesi
downregul
ranklinduc
ro
product
upregul
amino
acid
residu
novel
enzymeiia
affect
product
klebsiella
pneumonia
novaria
sari
dewi
panjaitan
yutz
horng
pochi
soo
institut
medic
scienc
colleg
medicin
tzuchi
univers
hualien
taiwan
depart
laboratori
medicin
biotechnolog
tzuchi
univers
hualien
taiwan
also
known
trimethylen
glycol
multifunct
valuabl
organ
compound
recent
use
variou
industri
field
synthesi
biodegrad
polyest
polyurethan
polyeth
besid
chemic
method
produc
ferment
process
glycerol
certain
bacteria
includ
klebsiella
pneumonia
glycerol
metabol
ferment
bacteri
aerob
anaerob
metabol
pathway
aerob
glycerol
uptaken
bacteri
cell
glycerol
facilit
protein
glpf
phosphoryl
glycerol
kinas
glpk
becom
metabol
enterobacteriacea
phosphotransferas
system
pt
protein
enzymeiia
glc
also
call
crr
catabolit
repress
resist
found
central
regul
carbon
metabol
unphosphoryl
crr
protein
bind
glpk
inhibit
function
previou
studi
found
novel
kpeiia
could
inhibit
product
klebsiella
pneumonia
direct
bind
glpk
base
proteinprotein
interact
site
predict
amino
acid
residu
predict
import
residu
bind
sever
mutat
design
order
mimic
either
unphosphoryl
phosphoryl
protein
found
unphosphoryl
could
bind
stronger
kpglpk
phosphoryl
form
result
higher
nonuptaken
glycerol
concentr
use
medium
lower
product
background
proteu
mirabili
common
human
pathogen
caus
urinari
tract
infect
uti
especi
patient
indwel
urinari
cathet
mani
regulatori
mechan
evolv
bacteria
adapt
chang
divers
environ
type
vi
secret
system
known
contribut
bacteri
pathogen
exert
toxic
effect
host
cell
compet
bacteri
speci
involv
broad
varieti
function
biofilm
format
stress
sens
larg
array
function
reflect
divers
regulatori
mechan
regul
p
mirabili
remain
unclear
recent
transcriptom
analysi
reveal
p
mirabili
regul
mani
regul
method
first
confirm
regul
regul
use
realtim
rtpcr
promot
report
assay
identifi
one
main
structur
operon
four
hcpvgrg
effector
operon
p
mirabili
use
sequenc
specif
rt
pcr
investig
whether
regul
bind
directli
promot
region
use
dnasei
footprint
assi
overexpress
effector
toxin
perform
disclos
function
growth
predomin
test
kill
assay
use
observ
competit
wild
type
regul
mutant
contruct
vipab
encod
sheath
mutant
confirm
regulatormedi
kill
also
purifi
possibl
toxin
assess
function
e
coli
kill
result
mani
regul
posit
regul
bind
directli
promot
region
also
posit
regul
express
effector
toxin
overexpress
effector
toxin
wildtyp
p
mirabili
result
increas
kill
regul
mutant
e
coli
accordingli
growth
predomin
test
kill
assay
demonstr
p
mirabili
confer
growth
predomin
wildtyp
regul
mutant
e
coli
conclus
express
p
mirabili
posit
regul
mani
regul
affect
kill
function
contribut
growth
predomin
regul
mutant
e
coli
suggest
p
mirabili
antibacteri
weapon
background
rapid
diagnosi
bacteremia
critic
sepsi
patient
new
gener
blood
cultur
system
possess
fulli
automat
function
includ
signin
load
unload
bottl
reduc
hand
time
easi
oper
hospit
staff
improv
delayentri
blood
cultur
system
specimen
even
night
shift
lack
manpow
run
microbiolog
servic
introduc
emerg
room
er
taiwan
hospit
allow
nurs
staff
load
blood
cultur
bottl
immedi
collect
day
even
nigh
shift
benefit
intervent
turnaround
time
tat
blood
cultur
investig
method
studi
conduct
hospit
efficaci
introduc
er
compar
exist
procedur
blood
cultur
specimen
load
bact
alert
system
dayshift
microbiolog
lab
regard
tat
medic
order
detect
time
even
night
shift
specimen
result
applic
er
achiev
follow
result
first
time
medic
order
blood
cultur
bottl
load
incub
shorten
hour
averag
second
tat
medic
order
posit
detect
posit
cultur
er
within
hr
tat
posit
cultur
previou
procedur
bactalert
microbiolog
laboratori
within
hr
third
bottl
posit
hour
previou
bactalert
procedur
posit
hour
conclus
autom
blood
cultur
system
easi
oper
er
staff
introduc
er
solv
problem
delay
entri
includ
time
transport
blood
cultur
bottl
er
microbiolog
room
avoid
need
manpow
transport
even
night
shift
load
blood
specimen
blood
cultur
system
perform
immedi
intervent
result
faster
blood
cultur
result
therefor
would
help
treatment
sepsi
patient
antibiot
stewardship
background
tedizolid
phosphat
oncedaili
treatment
demonstr
noninferior
linezolid
mg
twicedaili
treatment
patient
absssi
investig
multicentr
phase
studi
predominantli
asian
popul
method
adult
patient
absssi
ie
cellulitiserysipela
major
abscess
wound
infect
due
suspectedconfirm
gramposit
pathogen
randomis
receiv
intraven
oral
ivpo
oncedaili
tedizolid
phosphat
mg
day
iv
po
twicedaili
linezolid
mg
day
primari
endpoint
earli
clinic
respons
rate
base
lesion
size
reduct
hour
treatment
initi
intenttotreat
itt
randomis
popul
noninferior
predefin
lower
limit
confid
interv
ci
betweentreat
differ
greater
result
patient
n
mainland
china
taiwan
philippin
usa
randomis
n
n
tedizolid
linezolid
arm
respect
baselin
characterist
similar
tedizolid
linezolid
arm
regard
mean
age
year
year
proport
asian
patient
male
cellulitiserysipela
respect
primari
endpoint
treatment
differ
ci
modifi
itt
popul
mitt
exclud
patient
without
take
dose
studi
drug
tedizolid
n
linezolid
n
treatment
differ
lower
upper
limit
ci
secondari
endpoint
includ
clinic
respons
rate
endoftherapi
eot
investig
assess
clinic
success
posttherapi
evalu
pte
show
high
clinic
efficaci
itt
clinic
evalu
ce
popul
microbiolog
erad
rate
favour
treatment
includ
mrsa
infect
tedizolid
linezolid
treatmentemerg
advers
event
teae
rate
tedizolid
linezolid
drugrel
teae
respect
drugrel
inject
site
phlebiti
slightli
frequent
tedizolid
n
linezolid
n
discontinu
due
teae
arm
death
report
conclus
noninferior
day
ivtoor
oncedaili
mg
tedizolid
phosphat
day
ivtoor
twicedaili
linezolid
earli
clinic
respons
inconclus
hour
treatment
initi
tedizolid
show
consist
high
clinic
efficaci
later
timepoint
eot
pte
compar
pivot
establish
tedizolid
highli
efficaci
mrsa
infect
well
toler
tigecyclin
treatment
sever
c
difficil
infect
cdi
tsehao
chen
soonhian
teh
lihshinn
wang
weiyi
lei
hueijen
chao
siaoru
lin
school
medicin
buddhist
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
background
clostridium
difficil
infect
cdi
common
caus
iatrogen
diarrhea
hypervirul
toxinotyp
iii
strain
c
difficil
easili
found
north
america
three
case
previous
describ
taiwan
metronidazol
vancomycin
use
firstlin
treatment
cdi
refractorysever
cdi
becom
frequent
drug
choic
fidaxomicin
avail
hospit
mani
countri
may
need
consid
altern
treatment
tigecyclin
strain
cdi
method
retrospect
review
patient
diagnosi
cdi
confirm
stool
cultur
ag
test
pcr
januari
march
tertiari
hospit
eastern
taiwan
genexpert
c
difficileepi
assay
use
identifi
strain
cdi
select
case
physician
charg
felt
necessari
result
total
case
diagnos
cdi
among
two
identifi
strain
cdi
genexpert
also
confirm
cultur
case
classifi
sever
complic
cdi
conscious
chang
accompani
sever
bandemia
fail
convent
combin
treatment
metronidazol
vancomycin
result
intraven
tigecyclin
treatment
prescrib
adjunct
therapi
patient
recov
unev
hypervirul
strain
success
result
shown
sigmoidoscopi
tigecyclin
treatment
one
patient
figur
conclus
studi
advantag
ad
tigecyclin
standard
treatment
strain
cdi
clearli
manifest
tigecyclin
combin
either
metronidazol
vancomycin
appear
reason
therapi
sever
severecompl
cdi
clinic
characterist
bacteremia
caus
vancomycinsuscept
enterococcu
faecali
enterococcu
feacium
tertiari
hospit
casecontrol
studi
alert
enterococcu
faecium
strain
high
minimum
inhibitori
concentr
daptomycin
hiroki
namikawa
hiroshi
kakeya
koichi
yamada
wataru
shibata
hiroki
fujimoto
yukihiro
kaneko
infect
control
scienc
bacteriolog
osaka
citi
univers
graduat
school
medicin
asahimachi
abenoku
osaka
japan
background
mortal
bacteremia
due
enterococcu
faecium
high
e
faecium
strain
high
minimum
inhibitori
concentr
mic
daptomycin
dap
recent
problem
clinic
practic
studi
aim
assess
predictor
factor
prognosi
patient
bacteremia
due
e
faecium
antimicrobi
suscept
focus
dap
e
faecium
isol
method
medic
record
patient
e
faecali
bacteremia
patient
e
faecium
bacteremia
admit
osaka
citi
univers
hospit
januari
march
retrospect
review
patient
background
predictor
factor
infect
prognosi
antimicrobi
suscept
isol
bacteremia
evalu
result
mean
sequenti
organ
failur
assess
sofa
score
mortal
differ
two
group
howev
independ
predictor
associ
e
faecium
bacteremia
multivari
analysi
use
quinolon
p
malign
p
prolong
hospit
p
cardiovascular
diseas
opposit
predictor
p
number
e
faecium
isol
dap
mic
e
faecali
p
conclus
care
use
dap
crucial
administ
therapi
e
faecium
bacteremia
background
fitzhughcurti
syndrom
first
describ
defin
perihepat
concomit
pelvic
inflammatori
diseas
chlamydia
trachomati
consid
culprit
pathogen
syndrom
usual
featur
right
upper
quadrant
abdomin
pain
mimick
hepatobiliari
diseas
pose
clinic
diagnost
challeng
case
report
femal
admit
fever
chill
persist
right
upper
quadrant
abdomin
pain
vagin
discharg
laboratori
data
reveal
leukocytosi
neutrophil
predomin
admiss
abdomin
ct
reveal
mild
right
side
pelur
effus
mass
lesion
cecum
transvagin
ultrasound
indic
fluid
accumul
pelvic
cul
de
sac
bilater
adnexa
mass
favour
endometrioma
serum
serolog
reveal
chlamydia
trachomati
iga
posit
clinic
laboratori
find
suggest
fitzhughcurti
syndrom
two
week
treatment
intraven
flumarin
clinicin
patient
show
signific
clinic
improv
conclus
fitzhughcurti
syndrom
includ
differenti
diagnosi
women
right
upper
quadrant
pain
especi
reproduct
age
posit
aspergillu
galactomannan
assay
sever
influenza
patient
coinfect
fungal
curvularia
speci
wenliang
yu
depart
intens
care
medicin
chi
mei
medic
center
tainan
taiwan
depart
medicin
taipei
medic
univers
taipei
taiwan
background
invas
pulmonari
aspergillosi
ipa
might
occur
sever
influenza
patient
taiwan
case
sever
influenza
ipa
increasingli
report
aspergillu
galactomannan
gm
antigen
assay
greatli
facilit
earli
diagnosi
highrisk
patient
howev
gm
antigen
could
posit
infect
caus
filament
fungi
penicillium
curvularia
speci
care
clinic
correl
advis
method
yo
man
copd
fever
product
cough
day
deni
system
diseas
dyspnea
exert
like
climb
stair
wheez
sound
mild
chest
tight
note
brought
er
temperatur
degre
celsiu
bp
mm
hg
emerg
intub
mechan
ventil
perform
impend
respiratori
failur
lab
data
reveal
leukocytosi
elev
lactat
level
mmolel
mix
respiratori
metabol
acidosi
influenza
antigen
posit
pcr
method
confirm
flua
differ
cxr
show
emphysemat
chang
mild
infiltr
lung
hypotens
occur
er
fluid
resuscit
inotrop
agent
infus
use
impress
septic
shock
copd
acut
exacerb
influenza
infect
admit
intens
care
unit
icu
manag
result
icu
piperacillintazobactam
oseltamivir
use
sputum
cultur
yield
mold
speci
curvularia
blood
aspergillu
gm
antigen
index
normal
index
therefor
voriconazol
initi
anoth
sputum
cultur
yield
pseudomona
aeruginosa
elizabethkingia
meningoseptica
antibiot
shift
imipenem
tigecyclin
howev
dyspnea
becam
airhung
pattern
cxr
show
bilater
consolid
progress
compat
acut
respiratori
distress
syndrom
develop
profound
shock
statu
expir
day
hospit
conclus
aspergillu
gm
posit
found
patient
sever
influenza
taiwan
first
report
posit
aspergillu
gm
test
sever
influenza
patient
curvularia
infect
earli
diagnosi
manag
ipa
import
treatment
curvularia
infect
usual
consist
amphotericin
b
itraconazol
voriconazol
also
appear
promis
case
highlight
posit
aspergillu
gm
test
could
occur
invas
fungal
infect
therefor
gm
assay
must
interpret
caution
due
cross
reaction
fungi
might
need
differ
antifung
therapi
background
invas
pulmonari
aspergillosi
ipa
might
compris
sever
influenza
patient
taiwan
epidemiolog
associ
sever
influenza
ipa
report
meanwhil
prior
highlevel
ambient
fine
particul
matter
diamet
micrometr
pm
influenza
epidem
also
notic
howev
detail
evid
epidemiolog
linkag
pm
ipa
limit
therefor
compar
correl
pm
monthli
averag
level
differ
exposur
period
critic
level
develop
ipa
among
sever
influenza
noninfluenza
patient
method
retrospect
review
adult
patient
sever
influenza
tertiari
medic
center
taiwan
januari
march
definit
probabl
ipa
requir
abnorm
radiolog
find
posit
aspergillu
galactomannan
gm
antigen
andor
aspergillu
isol
platelia
aspergillu
ag
eia
biorad
laboratori
marneslacoquett
franc
use
detect
gm
blood
posit
cutoff
valu
index
pm
index
ambient
air
pollut
tainan
citi
obtain
taiwan
air
qualiti
monitor
network
spearman
correl
use
measur
strength
epidemiolog
associ
two
variabl
result
total
patient
sever
influenza
found
studi
period
monthli
averag
pm
level
exposur
monthli
critic
level
within
previou
month
signific
correl
develop
ipa
sever
influenza
patient
signific
correl
ipa
noninfluenza
patient
tabl
influenza
case
significantli
increas
averag
pm
exceed
critic
level
prior
month
conclus
pm
exposur
within
previou
month
particularli
critic
level
may
posit
correl
develop
ipa
set
sever
influenza
result
among
case
one
patient
year
old
patient
femal
clinic
manifest
includ
life
threaten
enceph
pneumon
gener
lymphadenopathi
multiorgan
involv
two
patient
receiv
pcr
toxoplasma
one
show
posit
result
two
patient
confirm
hiv
infect
two
patient
fever
sepsi
cours
one
present
brain
lesion
four
patient
present
multipl
lymphadenopathi
three
patient
cn
involv
icu
stay
one
two
month
one
mortal
alsotoxoplasma
antibodi
undetect
two
three
case
two
case
take
profil
studi
autoantibodi
detect
plasma
howev
level
whole
blood
lower
compar
control
group
might
indic
immun
defici
conclus
patient
multipl
site
lymphadenopathi
could
control
well
medic
excis
howev
cn
involv
may
caus
complic
clinic
cours
need
intens
medic
care
may
even
caus
mortal
lab
test
toxoplasma
antibodi
usual
rapid
tool
detect
limit
especi
patient
immunodefici
profil
could
provid
inform
patient
immun
statu
dissemin
toxoplasmosi
chunyu
chang
lihshinn
wang
tsunglang
chiu
pauyuan
chang
chihm
hu
chiach
j
conclus
previou
public
report
ischem
stroke
complic
meningococc
mening
howev
knowledg
first
report
subdur
effus
secondari
meningococcemia
mening
adult
earli
detect
appropri
treatment
may
improv
outcom
streptococcu
acidominimu
endocard
present
acut
coronari
syndrom
yenchen
lin
lihshinn
wang
background
filament
basidiomycet
emerg
fungal
pathogen
immunocompromis
host
volvariella
volvacea
nonsporul
filament
basidiomycet
commonli
known
straw
mushroom
describ
case
invas
fungal
infect
volvariella
volvacea
patient
tcell
acut
lymphoblast
leukaemia
chemotherapi
infect
involv
brain
lung
skin
eventu
fatal
method
male
chines
singaporean
resid
diagnos
tcell
octob
treat
first
cycl
hypercvad
regimen
intrathec
cytarabin
fluconazol
prophylaxi
treatment
complic
linerel
bloodstream
infect
intermitt
confus
mri
brain
show
sever
ringenhanc
lesion
ct
thorax
show
nodul
cavit
start
empir
iv
ceftriaxon
gm
daili
switch
posaconazol
prophylaxi
underw
bronchoalveolar
lavag
lumbar
punctur
brain
biopsi
diagnost
week
later
repeat
mri
brain
ct
thorax
demonstr
improv
lesion
continu
second
cycl
hypercvad
decemb
unfortun
deterior
day
later
anoth
linerel
infect
new
nodul
repeat
mri
brain
brain
biopsi
yield
diagnosi
patient
becam
progress
obtund
commenc
empir
pyrimethamin
clindamycin
folin
acid
meropenem
liposom
amphotericin
b
develop
new
skin
nodul
biopsi
histolog
reveal
broadappear
fungal
hypha
patient
succumb
infect
day
later
result
skin
biopsi
cultur
grew
coloni
light
browncolour
mould
identifi
volvariella
volvacea
molecular
sequenc
conclus
patient
may
partial
respond
switch
prophylaxi
fluconazol
posaconazol
paradox
may
made
diagnosi
difficult
patient
infect
resembl
form
invas
fungal
infect
lungbrain
syndrom
skin
involv
histopatholog
examin
difficult
distinguish
volvariella
volvacea
invas
mould
key
manag
infect
obtain
tissu
diagnosi
microbiolog
assist
molecular
sequenc
techniqu
volvariella
volvacea
emerg
potenti
fatal
caus
invas
fungal
infect
patient
haematolog
malign
prompt
diagnosi
treatment
crucial
staphylococcu
warneri
bacteremia
complic
periton
patient
hypertherm
intraperiton
chemotherapi
hipec
wensen
lee
fulun
chen
shioshin
jean
tsongyih
ou
erythromycin
mgl
oxacillin
mgl
gentamicin
mg
l
tetracyclin
mgl
suscept
vancomycin
mgl
linezolid
mgl
moxifloxacin
mgl
ciprofloxacin
mgl
clindamycin
mgl
examin
transesophag
echocardiographi
tee
show
neg
find
pulsefield
gel
electrophoresi
pfge
staphylococcu
warneri
strain
peripher
blood
strain
ascit
show
ident
pattern
figur
figur
pulsefield
gel
electrophoresi
pfge
staphylococcu
warneri
strain
peripher
blood
strain
ascit
show
ident
pattern
conclus
pulmonari
aspergillosi
prove
howev
tissu
prove
brain
liver
perform
due
patient
complic
howev
patient
condit
imag
studi
show
improv
voriconazol
prescrib
henc
invas
aspergillosi
involv
lung
liver
brain
highli
suspect
background
gastrointestin
gi
bleed
common
patient
end
stage
renal
diseas
esrd
associ
higher
mortal
cytomegaloviru
cmv
infect
cmv
diseas
may
occur
esrd
patient
without
presenc
overt
immunodefici
gastrointestin
tract
common
site
involv
clinician
awar
possibl
esrd
patient
gi
symptom
report
case
esrd
regular
hemodialysi
hd
accompani
sever
gi
bleed
cmv
coliti
case
report
year
old
femal
past
histori
esrd
regular
hd
time
suffer
coffe
ground
vomit
tonight
husband
said
reciv
hd
program
weight
loss
one
kilogram
yesterday
due
reason
sent
emerg
room
er
help
er
laboratori
data
show
sever
hyperkalemia
atrial
flutter
coffe
ground
emerg
hd
done
admit
intens
care
ward
due
coronari
arteri
diseas
three
vener
diseas
cad
intermitt
tachybradycardia
icu
blood
transfus
perform
high
dose
protonpump
inhibitor
ppi
infus
also
perform
upper
gastrointestin
endoscopi
ugi
endoscopi
done
show
gastric
ulcer
antrum
bleed
post
hemoclip
duoden
ulcer
electrocardiogram
reveal
wave
invers
echocardiographi
cardiologist
consult
due
cad
suspici
non
stelev
myocardi
infarct
due
anemia
howev
echocardiographi
show
evid
hypokineas
medic
use
clinic
condit
improv
chest
xray
show
right
upper
lobe
consolid
sputum
cultur
acinetobact
baumannii
ad
antibiot
ceftazidim
plu
vancomycin
infect
control
inform
condit
famili
repeat
ugi
endoscopi
due
high
risk
rebleed
due
easi
bleed
posit
cmvpolymeras
chain
reaction
gastric
fluid
note
gi
bleed
stop
ganciclovir
infus
two
day
gener
condit
got
much
better
shift
iv
form
ganciclovir
valganciclovir
discharg
discuss
cmv
establish
potenti
infect
lead
reactiv
immunosuppress
affect
almost
organ
system
gastrointestin
tract
involv
common
rare
occurr
cmvassoci
fatal
multipl
gastric
duoden
bleed
high
index
suspicion
need
immunocompromis
patient
gastrointestin
bleed
earli
diagnosi
possibl
benefici
outcom
histoplasma
blood
stream
infect
bone
marrow
involv
aid
patient
dachuan
yeh
yu
huai
ho
lihshinn
wang
minghuei
gu
hueijen
chao
yunghsiang
hsu
divis
infecti
diseas
depart
intern
medicin
depart
laboratori
medicin
depart
patholog
buddhist
tzu
chi
gener
hospit
hualien
taiwan
background
histoplasma
capsulatum
rare
seen
taiwan
report
case
dissemin
histoplasmosi
aid
patient
method
man
admit
onemonth
histori
high
fever
abdomin
pain
newli
diagnos
aid
two
week
transfer
hospit
treatment
physic
examin
patient
appear
weak
thin
temperatur
puls
beat
per
minut
respir
rate
per
minut
laboratori
studi
reveal
hemoglobin
gdl
leukocyt
count
platelet
count
ast
iul
alt
iul
count
hiv
viral
load
copiesml
abdomin
pelvic
ct
show
splenomegali
enlarg
retroperiton
mesenter
ln
massiv
amount
ascit
lung
ct
show
consolid
left
lower
lung
field
pleural
effus
opportunist
infect
survey
neg
except
pcr
assay
herp
simplex
viru
cytomegaloviru
blood
bronchial
alveolar
lavag
posit
lymph
node
biopsi
feasibl
due
sever
thrombocytopenia
manag
perform
bone
marrow
aspir
biopsi
platelet
transfus
show
hypocellular
marrow
marrow
content
less
neg
malign
patient
condit
deterior
transfer
hospic
care
result
six
week
later
tb
cultur
peripher
blood
show
growth
mold
microorgan
subsequ
identifi
h
capsulatum
pcr
assay
blood
cultur
fungal
cultur
report
steril
one
two
week
incub
period
bone
marrow
biopsi
revis
gm
stain
show
numer
intracellular
yeastlik
microorgan
consist
histoplasmosi
figur
conclus
histoplasmosi
rare
seen
taiwan
limit
number
case
report
could
miss
laboratori
incub
recoveri
fungi
shorter
four
six
week
would
advis
laboratori
review
cultur
polici
extend
fungal
cultur
incub
least
four
week
slow
grow
mold
would
underestim
short
incub
time
fungu
servic
laboratori
noncirrhot
portal
hypertens
hiv
patient
yuhuai
ho
lei
wei
yi
yunghsiang
hsu
lihshinn
wang
base
find
liver
biopsi
perform
histolog
analysi
biopsi
figur
reveal
focal
spotti
necrosi
swell
hepatocyt
lymphocyt
satellitosi
compat
mild
acut
hepat
mild
portal
area
fibrosi
noncirrhot
portal
hypertens
diagnos
background
voriconazol
antifung
medicin
kill
growth
fungi
caus
infect
usual
use
treatment
patient
invas
aspergillosi
especi
chemotherapi
patient
infecti
diseas
voriconazol
nonlinear
pharmacokinet
profil
wide
interand
intra
individu
variabl
high
total
voriconazol
concertr
also
induc
toxic
live
unbound
form
poison
sepsi
patient
hypoalbuminemia
patient
use
fomula
adjust
total
voriconazol
concertr
therapeut
drug
monitor
import
patient
avoid
toxic
liver
studi
intend
establish
liquid
chromatographytandem
mass
spectrometri
method
clinic
diagnost
purpos
method
use
multipl
reaction
mornitor
mrm
tandem
mass
analysi
masstocharg
mz
precursor
product
ion
voriconazol
intern
standard
ketocozol
use
calibr
basi
quantit
measur
mz
ketocozol
also
use
highthroughput
equilibrium
dialysi
method
quantit
analysi
unbound
voriconazol
concertr
result
accord
preliminari
result
withinrun
betweenrun
precis
method
respect
recoveri
tandem
mass
assay
background
immunodefici
known
risk
factor
cerebr
toxoplasmosi
caus
immunodefici
includ
usag
immunosuppress
method
man
right
kidney
transplant
prednisolon
tacrolimu
cellcept
treatment
brought
anoth
hospit
ataxia
urinari
incontin
week
brain
comput
tomographi
scan
arrang
hospit
famili
told
patient
might
cerebrovascular
accid
transfer
tzu
chi
gener
hospit
physic
examin
bodi
temperatur
puls
rate
respiratori
rate
blood
pressur
mmhg
laboratori
test
reveal
leukocytosi
normocyt
anemia
brain
magnet
reson
imag
show
least
four
lobul
nodular
lesion
frontal
right
tempor
lobe
mark
perifoc
edema
rimenhanc
admiss
stereotact
brain
biopsi
perform
result
patholog
result
brain
biopsi
show
necrosi
brain
tissu
neutrophil
macrophag
nuclear
debri
biopsi
tissu
show
neg
bacteri
cultur
acidfast
stain
tuberculosi
fungal
cultur
biopsi
tissu
also
done
discuss
infecti
diseas
doctor
toxoplasmosi
nocardiosi
fungal
infect
suspect
long
term
immunosuppress
previou
kidney
transplant
pair
toxoplasma
immunoglobulin
immunoglobulin
g
neg
brain
magnet
reson
imag
reveal
enlarg
right
frontal
lesion
whole
bodi
positron
emiss
tomographi
show
multipl
brain
lesion
mainli
right
cerebrum
mass
effect
tini
nodul
posterior
segment
right
upper
lung
sulfamethoxazoletrimethoprim
treatment
initi
possibl
cerebr
toxoplasmosi
patient
hyperkalemia
transfer
surgic
intens
care
unit
sulfamethoxazoletrimethoprim
treatment
immedi
discontinu
patient
craniotomi
remov
tumor
hemodialysi
oper
howev
patient
septic
shock
condit
went
downhil
discharg
due
termin
statu
day
later
hospit
day
tachyzoit
found
necrot
brain
tissu
special
stain
includ
period
acidschiff
stain
grocott
methenamin
silver
stain
toxoplasma
immunohistochemistri
stain
confirm
toxoplasmosi
figur
conclus
long
term
immunosuppress
kidney
transplant
led
immunodefici
patient
becam
risk
factor
infect
toxoplasma
gondii
neg
result
toxoplasma
immunoglobulin
immunoglobulin
g
level
could
exclud
diagnosi
toxoplasma
infect
correl
previou
studi
mycobacterium
celatum
pulmonari
infect
patient
aid
cryptococcosi
multipl
std
lihshinn
wang
tzuyu
tsai
jenjyh
lee
tengyi
lin
hueijen
chao
chiach
jacki
wang
result
year
old
man
diagnosi
hiv
admit
hospit
due
bilater
pneumonia
septic
shock
august
inotrop
agent
use
unstabl
oxygen
rapid
acut
respiratori
distress
syndrom
receiv
endotrach
intub
mechan
ventil
laborartoy
data
reveal
hiv
viral
load
test
copiesml
ratio
mycoplasma
pneumonia
ab
titer
chest
xray
show
illdefind
groundglass
opac
bilater
lung
field
predominantli
central
lung
zone
upper
lobe
pjassoci
pneumocysti
pneumonia
pcp
condier
admiss
antibiot
therapi
use
includ
piperacillintazobactam
levofloxacin
possibl
bacteri
pneumonia
tmpsmz
initi
probabl
pcp
intens
care
continu
thrombocytopenia
around
ul
persist
even
pneumonia
seem
better
piperacillintazobactam
chang
cefpirom
howev
persist
thrombocytopenia
still
note
check
blood
cmvpcr
result
posit
sputum
cmvpcr
also
posit
cmv
viral
load
iuml
ganciclovir
ad
cmv
infect
treatment
thrombocytopenia
improv
solumedrol
taper
solucortef
oral
prednisolon
standard
dose
regimen
extub
perform
august
recov
well
antibiot
therapi
shift
oral
form
levofloxacin
tmpsmz
valganciclovir
discharg
unev
septemb
conclus
pcp
remain
common
disord
onset
acquir
immunodefici
syndrom
hiv
patient
coinfect
cmv
poor
prognost
sign
set
pcp
cmvrelat
organ
diseas
suspect
patient
cell
number
lower
suscess
antipneumocysti
treatment
steroid
therapi
patient
still
present
sever
thrombocytopenia
led
secondari
diagnosi
cmv
syndrom
case
may
experi
worsen
pulmonari
infect
due
cmv
pneumon
use
steroid
therapi
care
patient
high
hiv
viral
load
low
count
howev
tachypnea
fever
note
postop
day
addit
astalt
tbidbl
elev
two
fold
reintub
imipenem
administr
empir
antibiot
agent
day
later
seizur
attack
twice
imipenem
shift
meropenem
follow
lab
exam
show
dic
ct
scan
reveal
portal
vein
thrombosi
occup
lumen
massiv
pleural
effus
sputum
blood
cultur
sampl
grew
candida
initi
impress
hepat
failur
candidiasi
patient
expir
two
week
later
due
multipl
organ
failur
autopsi
liver
show
central
cholestasi
bile
canalicular
cholestasi
liver
specimen
token
via
surgeri
hepatocellular
carcinoma
portal
area
inflamm
without
cholestasi
indic
post
hepatectomi
liver
failur
leptospirosi
confirm
sampl
liver
kidney
bone
marrow
lung
brain
soft
tissu
base
strongli
postiv
warthin
starri
stain
leptospira
antibodi
conclus
case
demonstr
leptospiriosi
may
progress
weil
diseas
acut
dissemin
encephalomyel
accord
previou
public
incid
leptospirosi
cn
involv
around
mostli
diagnos
lumbar
punctur
earli
diagnosi
may
challeng
case
cn
symptom
may
confus
druginduc
seizur
weil
diseas
sever
form
leptospirosi
character
jaundic
hemorrhag
renal
failur
cholestasi
leptospir
invad
intercellular
junction
hepatocyt
patient
diagnosi
solid
conclus
patient
multipl
organ
failur
major
oper
weil
diseas
adem
consid
differenti
diagnosi
coinfect
mycobacterium
tuberculosi
nontubercul
mycobacterium
difficulti
diagnosi
treatment
lihshinn
wang
chiach
jacki
wang
xinyi
zheng
jenjyh
lee
tengyi
lin
yunghsiang
hsu
chenglung
ku
background
mycobacterium
abscessu
subspeci
massiliens
one
three
subspeci
abscessu
complex
mabc
import
caus
nontubercul
mycobacteria
ntm
infect
rapidli
grow
mycobacteria
rgm
mabc
consid
highli
drugresist
extrem
difficult
treat
often
incur
prosthet
joint
infect
due
abscessu
subsp
massiliens
rare
optim
therapi
remain
unknown
method
male
histori
gout
prolong
corticosteroid
treatment
present
left
hip
pain
instabl
limit
rang
motion
one
month
sep
hip
xray
comput
tomographi
ct
scan
anoth
hospit
reveal
find
consist
avascular
necrosi
left
femor
head
underw
left
total
hip
arthroplasti
requir
reduct
sublux
prosthesi
next
day
admit
two
week
later
open
repair
recurr
sublux
prosthesi
within
one
month
first
surgeri
underw
third
surgeri
trochant
advanc
osteotomi
prothesi
disloc
one
year
later
patient
one
month
histori
bulg
cyst
left
hip
left
hip
cyst
felt
hematoma
ntm
isol
cultur
cyst
fluid
isol
grew
subcultur
within
day
inocul
consid
rgm
antintm
treatment
start
empir
azithromycin
ciprofloxacin
sulfamethoxazoletrimethoprim
doxycyclin
result
isol
later
identifi
abscessu
subsp
massiliens
suscept
clarithromycin
tigecyclin
autoantibodi
neg
patient
stop
antintm
treatment
onemonth
therapi
discharg
medic
advic
patient
experienc
recurr
pain
left
hip
month
later
develop
drain
sinu
tract
pu
grew
abscessu
subsp
massiliens
remov
prosthesi
antintm
treatment
restart
intraven
tigecyclin
clarithromycin
clofazimin
amikacin
patient
stop
antintm
therapi
due
nausea
malais
anorexia
weight
loss
acut
kidney
injuri
liver
dysfunct
symptom
improv
discontinu
clofazimin
tigecylin
symptom
appear
rechalleng
clofazimin
tigecyclin
final
patient
place
oral
suppress
antintm
treatment
result
serotyp
ia
common
patient
less
hour
old
wherea
iii
common
patient
older
hour
earlyonset
diseas
day
ia
iii
caus
infect
follow
ib
lateonset
diseas
day
serotyp
iii
predomin
follow
ia
ib
thirtyon
episod
complic
cultureconfirm
mening
compar
serotyp
ia
iii
patient
found
serotyp
ia
patient
significantli
younger
median
age
day
higher
male
percentag
perinat
matern
fever
higher
mortal
surviv
curv
patient
serotyp
iii
infect
significantli
better
nontyp
iii
infect
exclus
found
serotyp
iii
compris
serotyp
ia
conclus
serotyp
ia
caus
invas
infect
younger
infant
higher
mortal
serotyp
iii
trival
ia
ib
iii
gb
vaccin
might
prevent
earlyonset
diseas
lateonset
diseas
gb
mening
taiwan
sphenoid
sinus
complic
cavern
sinu
thrombosi
yunhu
wang
poyen
chen
peiju
ting
fangliang
huang
depart
pediatr
taichung
veteran
gener
hospit
taichung
taiwan
chung
medic
univers
taichung
taiwan
hung
kuang
univers
taichung
taiwan
background
cavern
sinu
thrombosi
cst
rare
infect
diseas
associ
high
mortal
rate
cst
result
infect
tissu
drain
cavern
sinu
purpos
studi
review
rare
case
cst
secondari
sphenoid
sinus
underresearch
children
method
report
girl
diagnos
cavern
sinu
thrombosi
sphenoid
sinus
present
fever
nuchal
pain
one
week
also
review
literatur
cavern
sinu
thrombosi
secondari
sphenoid
sinus
clinic
manifest
laboratori
data
imag
find
pathogen
medic
surgic
treatment
clinic
outcom
analyz
result
eight
case
headach
five
case
fever
case
one
ophthalm
symptom
four
case
comput
tomographi
magnet
reson
imag
find
reveal
isol
sphenoid
sinus
three
case
evid
streptococcu
infect
blood
cultur
two
case
staphylococcu
aureu
blood
sinu
cultur
seven
case
surgic
intervent
follow
antibiot
therapi
case
receiv
antibiot
therapi
administ
intraven
ceftriaxon
metronidazol
six
case
receiv
intraven
oral
form
anticoagul
therapi
case
corticosteroid
treatment
case
good
prognosi
except
three
case
morbid
manag
cst
use
intraven
antibiot
therapi
combin
endonas
sinu
surgeri
earli
use
anticoagul
reduc
morbid
mortal
cst
corticosteroid
treatment
cst
remain
controversi
background
acut
febril
ill
afi
common
syndrom
also
repres
frequent
admiss
diagnos
servic
even
though
syndrom
alway
convent
includ
major
indic
infecti
diseas
sometim
take
big
effort
estabilish
etiolog
diagnos
therefor
mani
patient
afi
empir
diagnos
accord
clinic
manifest
certain
epidemiolog
like
sesson
stroke
proffesion
exposur
travel
wonder
clinician
alway
focus
clinicalepidemiologicalbinom
consid
dynam
chang
infecti
nosolog
global
era
method
patient
hospit
infecti
disesas
hospit
patient
inclus
pattern
also
astandard
clinicaland
laboratori
evalu
patient
met
follow
case
criteria
year
age
admit
particip
institut
histori
fever
least
two
day
temperatur
admiss
oral
rectal
identifi
caus
fever
physician
instruct
exclud
caus
fever
diarrhea
hepat
cough
andor
symptom
respiratori
tract
infect
urinari
tract
infect
cellul
rheumat
fever
abscess
andor
known
caus
fever
admit
patient
afi
provid
anamnest
data
epidemiolog
detail
blood
sampl
bacteri
cultur
serolog
analysi
risk
factor
includ
anim
contact
consumpt
raw
dairi
product
significantli
associ
brucellosi
exposur
vector
endem
area
profession
exposur
travel
outsid
countri
result
case
definit
base
laboratori
result
patient
evalu
posit
brucella
posit
hemocultur
bacteri
endocard
predomin
staphyloccouccu
aureu
riketcia
tick
born
pathogen
hemorrhag
fever
infecti
mononucleosi
malaria
leishmaniasi
leptospirosi
conclus
survey
identifi
sever
import
pathogen
one
import
specif
percentag
correl
pathogen
specif
clinic
manifest
epidemiolog
data
allow
better
recognit
infecti
nosolog
featur
countri
may
also
lead
develop
target
prevent
strategi
background
acinetobact
baumannii
import
pathogen
nosocomi
bloodstream
infect
pneumonia
account
high
morbid
mortal
rate
howev
studi
regar
optim
treatment
acinetobact
baumannii
bacterem
pneumonia
limit
method
conduct
retrospect
studi
januari
decemb
medic
centr
taiwan
compar
efficaci
colistinbas
sulbactambas
therapi
baumannii
bacterem
pneumonia
clinic
featur
outcom
patient
investig
result
studi
period
patient
receiv
either
colistinbas
sulbactambas
treatment
among
patient
receiv
concomit
treatment
colistin
sulbactam
exclud
twentyf
patient
receiv
colistinbas
therapi
receiv
sulbactambas
therapi
includ
final
analysi
differ
baselin
characterist
mortal
mortal
overal
inhospit
mortal
group
ventilatorassoci
pneumonia
like
receiv
colistinbas
treatment
rather
sulbactambas
treatment
odd
ratio
confid
interv
ci
p
risk
factor
independentlyassoci
higher
mortal
baumannii
bacterem
pneumonia
higher
apach
ii
score
ci
p
ci
p
respect
result
conclud
patient
baumannii
bacterem
pneumonia
treat
either
colistinbas
sulbactambas
therapi
similar
clinic
outcom
sever
diseas
higher
apach
ii
score
independ
associ
higher
mortal
largescal
prospect
studi
need
investig
clinic
efficaci
two
regimen
treatment
baumannii
bacterem
pneumonia
comparison
cultureneg
cultureposit
necrot
fasciiti
clinic
characterist
outcom
treatment
tsungyu
huang
yaohung
tsai
chingyu
lee
weihsiu
hsu
background
necrot
fasciiti
rapidli
progress
lifethreaten
surgic
intervent
broadspectrum
antibiot
usag
import
bacteri
proven
patient
necrot
fasciiti
studi
undertaken
ascertain
whether
clinic
present
outcom
patient
diseas
differ
infect
cultureneg
compar
cultureposit
pathogen
method
onehundr
fortythre
patient
necrot
fasciiti
examin
prospect
april
may
patient
receiv
prompt
radic
debrid
adequ
broadspectrum
antibiot
therapi
aggress
resuscit
thirtyeight
patient
infect
cultureneg
pathogen
group
patient
cultureposit
pathogen
group
result
group
male
predomin
group
character
lower
incid
tachypnea
local
paintend
lower
sequenti
organ
failur
assess
sofa
score
lower
rate
bandemia
bacteremia
lactat
acidosi
hypoalbuminemia
lower
preval
alcohol
plu
diabet
mellitu
higher
rate
acut
respiratori
failur
acut
renal
failur
higher
admiss
rate
intens
care
unit
icu
admiss
common
group
multivari
analysi
male
odd
ratio
confid
interv
ci
local
paintend
ci
tachypnea
ci
identifi
infect
cultureposit
pathogen
conclus
cultureposit
necrot
fasciiti
mostli
present
local
paintend
tachypnea
men
predomin
differ
mortal
rate
limb
amput
rate
hospit
stay
icu
stay
still
need
data
confirm
find
hospit
cirrhosi
diabet
howev
rare
caus
spontan
bacteri
periton
sbp
cirrhot
patient
method
man
alcohol
liver
cirrhosi
childpugh
class
c
type
diabet
mellitu
develop
abdomin
pain
fever
abdomen
distend
shift
dull
laboratori
examin
show
white
blood
cell
wbc
count
neutrophil
paracentesi
ascit
reveal
wbc
count
neutrophil
base
patient
histori
physic
examin
result
paracentesi
spontan
bacteri
periton
suggest
blood
cultur
posit
campylobact
coli
intraven
ciprofloxacin
administ
patient
recoveri
treatment
result
sbp
caus
campylobact
rare
first
case
report
sbp
caus
campylobact
present
targan
et
al
sinc
five
case
report
literatur
three
five
patient
associ
periton
bacteremia
present
case
main
underli
condit
relat
liver
diseas
includ
alcohol
abus
cirrhosi
cancer
diabet
chemotherapi
present
case
patient
high
risk
campylobact
infect
sever
alcohol
liver
cirrhosi
report
case
sbp
caus
c
coli
campylobacterrel
sbp
mainli
occur
patient
sever
underli
alcohol
liver
cirrhosi
mimic
fungal
ball
urinari
bladder
caus
tissu
invas
c
glabrata
complic
acut
obstruct
uropathi
linfang
chen
fulun
chen
divis
infecti
diseas
depart
intern
medicin
wan
fang
medic
center
taipei
medic
univers
taipei
taiwan
femal
patient
underli
asthma
type
diabet
mellitu
decad
month
histori
cspine
injuri
central
cord
syndrom
consequ
left
hemiparesi
neurogen
bladder
statu
post
foley
cathet
insert
episod
urinari
tract
infect
extend
spectrum
betalactamas
esbl
e
coli
k
pneumonia
suspect
bilater
chronic
nephriti
periren
effus
found
comput
tomographi
admit
sepsi
recurr
urinari
tract
infect
howev
day
antibiot
therapi
doripenem
mg
everi
hour
empir
therapi
esbl
coli
target
therapi
p
aeruginosa
light
yellow
turbid
urin
lot
necrot
debri
lowgrad
fever
increas
dose
insulin
control
hyperglycemia
aggrav
leukocytosi
foley
urin
cultur
yield
c
glabrata
high
dose
fluconazol
mgkgday
foley
cathet
obstruct
develop
partial
reliev
manual
irrig
foley
cathet
revis
amphotericin
b
continu
irrig
mg
everi
day
via
foley
cathet
appli
salvag
therapi
frequenc
foley
cathet
obstruct
caus
necrot
debri
progress
everi
day
everi
sever
hour
acut
obstruct
uropathi
complic
retrograd
vancomycin
resist
e
faecium
septicemia
daptomycin
mgkgday
therapi
vancomycin
resist
efaecium
septicemia
resolv
without
infect
endocard
amphotericin
b
continu
irrig
replac
system
fluconazol
mgkgday
combin
flucytosin
mgkgday
divid
dose
therapi
urologist
perform
urethrobladd
cystoscop
irrig
found
larg
area
thicken
necrot
tissu
coat
anterior
rightposterior
urinari
bladder
wall
mimic
lot
separ
fungal
ball
transurethr
resect
bladder
debrit
tissu
found
yeast
form
fungu
bud
phenomenon
without
hypha
pseudohypha
tissu
cultur
prove
mix
invas
c
glabrata
esblk
pneumonia
infect
extens
surgic
cauter
foley
cathet
obstruct
necrot
debri
grossli
rare
case
report
talk
candida
fungal
ball
urinari
bladder
sever
complic
mainli
candidemia
first
case
acknowledg
discuss
invas
urinari
bladder
cglabrata
mix
infect
sever
complic
aggress
invas
procedur
perform
treat
select
c
glabrata
urinari
bladder
infect
role
doxycyclin
mous
model
clostridium
difficil
infect
chunwei
chiu
yuanpin
hung
peijan
tsai
wenchien
ko
background
clostridium
difficil
infect
cdi
major
caus
nosocomi
antibioticassoci
diarrhea
metronidazol
vancomycin
therapeut
choic
cdi
use
associ
colon
vancomycinresist
enterococci
high
recurr
rate
doxycyclin
show
promis
vitro
antibactier
activ
clinic
c
difficil
isol
achiev
high
concentr
bowel
tissu
howev
efficaci
doxycyclin
treat
cdi
clear
method
clinic
c
difficil
isol
tainan
hospit
ministri
health
welfar
test
suscept
doxycyclin
agar
dilut
method
evalu
whether
doxycyclin
facili
prolifer
c
difficil
intestin
ex
vivo
assay
perform
growth
c
difficil
cocultur
cecum
content
mice
oral
doxycyclin
administr
therapeut
effect
doxycyclin
therapi
cdi
examin
establish
cdi
mous
model
result
clinic
c
difficil
isoalt
mic
doxycyclin
clinic
c
difficil
growth
c
difficil
cocultur
cecum
content
show
decreas
mice
doxycyclin
administr
mice
clindamycin
use
clindamycin
vs
doxycyclin
cfuml
vs
cfuml
p
meanwhil
mice
oral
challeng
c
difficl
doxycyclin
administr
excret
less
c
difficil
face
cfuml
vs
cfuml
p
less
bodi
weight
loss
kg
vs
kg
p
mice
clindamycin
use
mice
treat
doxycyclin
show
less
bodi
weight
loss
control
mice
kg
vs
kg
p
besid
doxycyclin
therapi
show
noninferior
metronidazol
vancomycin
therapi
accord
bodi
weight
loss
mice
cdad
doxycyclin
vs
metronidazol
kg
vs
hospit
center
mother
theresa
servic
infecti
diseas
univers
hospit
center
mother
theresa
servic
reanim
anesthesia
univers
hospit
center
mother
theresa
sid
background
although
tetanu
current
rel
rare
infecti
diseas
remain
high
mortal
diseas
high
manag
cost
reason
sever
form
complic
requir
applic
therapeut
protocol
intens
care
unit
studi
protocol
import
analyz
patient
prognosi
also
treatment
cost
effect
method
collect
case
group
gender
age
therapeut
protocol
group
classif
accord
therapeut
protocol
adapt
graviti
case
mild
moder
sever
sever
use
method
consist
case
group
age
gener
tetanu
hospit
reanim
infecti
diseas
hospit
period
januari
result
data
sex
male
femal
age
group
preval
age
group
accord
therapeut
protocol
first
group
patient
underw
paralysi
curar
artifici
ventil
case
second
group
patient
undergo
tracheostomi
third
group
patient
use
sedat
alon
diazepam
opiat
fourth
group
deep
sedat
anesthesia
adrenerg
blockad
case
death
case
caus
death
mainli
due
paralysi
artifici
ventil
complic
appli
sever
form
sever
brain
damag
consequ
side
effect
treatment
cerebr
thrombosi
case
pneumothorax
case
staphylococc
pneumonia
case
pulmonari
embol
case
complic
sed
procedur
deep
sedat
endotrach
intub
bradycardia
cardiac
arrest
case
hypoxia
vagal
stimul
durat
paralysi
day
day
lighter
form
period
mechan
ventil
shorter
sever
form
longer
conclus
overal
tetanu
mortal
adult
result
case
death
caus
cerebr
thrombosi
case
spontan
pneumothorax
case
staphylococc
pneumonia
case
pulmonari
thromboembol
case
cardiac
arrest
case
applic
malditof
ms
clinic
diagnost
anaerob
blood
cultur
shinwei
wang
peifang
tsai
ya
hui
liu
peijan
tsai
background
inform
regard
use
malditof
ms
altern
convent
laboratori
method
rapid
reliabl
identif
anaerob
blood
isol
still
limit
aim
studi
assess
perform
malditof
ms
identif
anaerob
blood
cultur
method
retrospect
surveil
studi
juli
march
conduct
nation
cheng
kung
univers
hospit
southern
taiwan
identif
result
malditof
ms
compar
obtain
rrna
sequenc
result
studi
malditof
ms
evalu
anaerob
isol
previous
identifi
rrna
gene
sequenc
biochem
test
rapid
id
system
total
genu
speci
identifi
strain
confirm
rrna
gene
sequenc
among
isol
identifi
malditof
ms
speci
level
vs
use
rapid
id
system
agreement
method
rrna
gene
sequenc
isol
discrep
result
show
malditof
api
correctli
identifi
isol
respect
discrep
malditof
ms
probabl
mainli
among
nonfragili
bacteroid
spp
gpac
could
identifi
use
method
result
show
malditof
ms
robust
reliabl
tool
identif
anaerob
blood
isol
microbiolog
laboratori
extens
develop
databas
frequent
isol
anaerob
speci
also
newli
recogn
taxonom
rearrang
genera
speci
well
continu
establish
techniqu
realli
reduc
turnaround
time
final
identif
number
isol
requir
rrna
sequenc
weihan
huang
minghuei
gu
siaoru
lin
chiach
j
wang
lihshinn
wang
background
myeloma
patient
may
present
clinic
sign
hypercalcemia
anemia
renal
dysfunct
bone
disabl
init
diagnosi
howev
infect
still
signific
caus
morbid
lead
caus
death
patient
myeloma
increas
suscept
patient
myeloma
infect
result
antineoplast
therapi
also
ageand
diseas
relat
immunodefici
method
businessperson
inform
stage
ii
chronic
renal
impair
possibl
due
uncontrol
hypertens
two
year
suffer
bilater
flank
pain
urinari
urgenc
one
week
prior
admiss
treat
oral
antibiot
impress
urinari
tract
infect
local
clinic
fever
chill
alter
mental
statu
one
day
prior
admiss
present
patient
unclear
conscious
confus
stupor
brain
ct
reveal
mild
cortic
brain
atrophi
csf
studi
show
slightli
turbid
appear
orang
color
low
sugar
csf
glucos
mgdl
vs
normal
blood
sugar
mgdl
high
protein
total
proteincsf
mgdl
pleocytosi
wbc
wbc
count
segment
neutrophil
lymphocyt
monocyt
crp
mgdl
pathogen
identifi
gram
stain
afb
stain
india
ink
stain
even
cultur
impress
bacteri
mening
admit
antibiot
treatment
result
admiss
lab
data
show
hypercalcemia
correct
calcium
mmoll
renal
impair
creatinin
mg
dl
ag
revers
albuminglobulin
gdl
treatment
serum
protein
electrophoresi
immunofix
electrophoresi
disclos
igg
kappa
monoclon
gammopathi
quantit
igg
mgdl
serum
free
light
chain
ratio
kappa
lambda
mgl
bone
marrow
biopsi
flow
cytometri
analysi
confirm
multipl
myeloma
igg
immunohistochemistri
stain
patient
treat
standard
therapi
vtd
regimen
velcad
thalidomid
dexamethason
strigent
complet
remiss
conclus
present
myeloma
patient
initi
mimick
meining
sinc
myeloma
patient
higher
suscept
infect
ignor
gener
evalu
integr
clinic
inform
patient
repeat
infect
serratia
marcescen
lung
abscess
present
pseudohemoptysi
hsin
yu
lu
li
hsinn
wang
chih
pin
lin
si
shiuan
peng
pao
yaun
chang
yung
hsiang
hsu
school
medicin
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
divis
chest
medicin
depart
intern
medicin
depart
laboratori
medicin
depart
radiolog
depart
patholog
buddhist
tzu
chi
gener
hospit
hualien
taiwan
background
serratia
marcescen
produc
red
pigment
prodiogiosum
regard
harmless
gramneg
bacillu
recent
recogn
nosocomi
opportunist
infect
method
patient
male
histori
pulmonari
tuberculosi
tb
resolut
year
ago
often
hemoptysi
sinc
admit
due
progress
hemoptysi
gener
sore
laboratori
data
show
influenza
b
antigen
aspergillu
antigen
acidfast
stain
neg
mycoplasma
igm
posit
chest
comput
tomographi
ct
show
sporad
fibroinfiltr
lung
ball
cage
featur
right
upper
lung
treat
clarithromycin
tranesam
acid
bronchoscopi
reveal
activ
bleed
figur
bronchial
alveolar
lavag
show
aspergillu
antigen
posit
therefor
voriconazol
treatment
ad
howev
day
discharg
came
back
due
massiv
hemoptysi
ml
associ
symptom
dyspnea
dizzi
right
upper
chest
pain
result
marcescen
grown
sputum
cultur
admiss
still
treat
aspergillosi
chest
x
ray
show
right
upper
lung
atelectasi
right
upper
lobectomi
perform
patholgi
reveal
chronic
abscess
granuloma
surprizingli
evid
fungal
infect
activ
tuberculosi
voriconazol
shift
piperacillintazobactam
howev
fever
tachycardia
leukocytosi
marcescen
grown
sputum
cultur
mix
flora
marcescen
lung
abscess
final
diagnosi
hemoptysi
consid
pseudohemoptysi
repeat
sputum
grew
organ
could
produc
prodiogiosum
mimick
fresh
blood
repeat
chest
ct
show
sever
adhes
without
adequ
expans
therefor
piperacillintazobactam
shift
levofloxaxin
patient
right
lower
lung
superior
segmentectomi
bronchopleur
fistula
found
air
leakag
without
improv
patient
final
cure
thoracoplasti
right
nd
th
rib
discharg
conclus
hemoptysi
common
patient
tb
aspergillosi
rare
lung
abscess
marcescen
lung
abscess
rare
present
symptom
hemoptysi
could
red
pigment
prodiogiosum
produc
marcescen
splenic
abscess
uncommon
entiti
potenti
life
threaten
meichun
lee
chienhung
lu
weiy
lee
chunm
lee
background
splenic
abscess
rare
potenti
life
threaten
scanti
publish
studi
avail
aim
studi
review
clinic
featur
microbiolog
etiolog
treatment
outcom
patient
splenic
abscess
recent
year
method
review
admit
patient
suspect
splenic
abscess
made
diagnosi
splenic
abscess
clinic
characterist
underli
diseas
treatment
cours
organ
spectra
abscess
number
size
therapeut
method
clinic
outcom
tertiari
medic
center
northern
taiwan
period
year
jan
dec
analyz
result
patient
splenic
abscess
male
femal
ratio
mean
age
year
rang
day
year
common
present
fever
patient
diffus
abdomin
pain
patient
left
upper
quadrant
pain
tender
patient
splenomegali
patient
leftsit
pleural
effus
patient
leukocytosi
note
antimicrobi
therapi
administ
patient
fourteen
patient
recov
medic
treatment
one
patient
underw
splenectomi
four
patient
perform
percutan
drainag
splenic
abscess
patient
receiv
antimicrobi
therapi
alon
conclus
note
mortal
may
relat
patient
underli
immunodefici
rel
high
proport
patient
splenic
abscess
receiv
antimicrobi
therapi
alon
got
good
prognosi
especi
patient
small
multipl
abscess
background
associ
psoriasi
leptospirosi
previous
mention
seldom
case
report
describ
case
method
woman
histori
hypertens
medic
control
psoriasi
admit
tzu
chi
gener
hospit
itch
erythmat
plaqu
whole
bodi
four
extrim
month
diagnos
psoriasi
fifteen
year
flare
intermitt
previous
work
breakfast
stand
engag
farm
young
upon
admiss
multipl
psoriat
lesion
trunk
extrem
stiff
neck
arthriti
finger
toe
joint
also
note
result
ten
year
ago
came
hospit
control
psoriasi
condit
phototherapi
acitretin
calcipotriol
methotrex
prescrib
dermatologist
skin
biopsi
done
show
superfici
perivascular
lymphocyt
infiltr
elong
rete
ridg
consist
psoriasi
urin
pcr
comfirm
leptospir
infect
penicillin
g
rifampicin
ad
skin
lesion
dramat
control
week
patient
discharg
home
oral
penicillin
g
rifampin
time
admiss
antibiot
leptospirosi
chang
ceftriaxon
fosfomycin
due
unavail
penicillin
g
skin
biopsi
ten
year
ago
also
taken
immunochem
stain
leptospira
reveal
posit
figur
conclus
psoriasi
fundament
inflammatori
skin
condit
reactiv
abnorm
epiderm
differenti
hyperprolifer
current
research
suggest
inflammatori
mechan
immun
base
like
initi
maintain
primarili
cell
dermi
reactiv
cell
dermi
epidermi
local
effect
cytokin
tumor
necrosi
factor
lead
inflamm
cellmedi
immun
respons
epiderm
hyperprolifer
observ
person
psoriasi
cytokin
produc
respons
infect
propos
involv
pathogenesi
leptospirosi
clinic
impact
sputum
isol
extendedspectrum
betalactamaseproduc
escherichia
coli
klebsiella
pneumonia
maki
shikata
naoki
iwanaga
yosuk
nagayoshi
shinnosuk
takemoto
tadayoshi
oono
keiko
hisatomi
seiji
nagashima
depart
infecti
diseas
nation
hospit
organ
nagasaki
medic
center
depart
respiratori
medicin
nation
hospit
organ
nagasaki
medic
center
background
infect
caus
extendedspectrum
betalactamas
esbl
produc
organ
emerg
problem
recent
broadspectrum
antibiot
need
treatment
esblproduc
organ
reveal
characterist
bacterem
pneumonia
caus
esblproduc
organ
extrem
import
clinician
yet
studi
effect
achiev
aim
studi
evalu
correl
sputum
isol
esblproduc
escherichia
coli
klebsiella
pneumonia
outcom
bacterem
pneumonia
method
retrospect
analyz
patient
bacterem
pneumonia
caus
e
coli
k
pneumonia
includ
esblproduc
object
januari
decemb
nagasaki
medic
center
bacterem
pneumonia
defin
case
e
coli
k
pneumonia
isol
sputum
cultur
clinic
suspect
respiratori
symptom
fever
cough
sputum
dyspnea
elev
inflammatori
respons
laboratori
data
chest
abnorm
shadow
clinic
inform
outcom
adult
bacterem
pneumonia
caus
esblproduc
e
coli
k
pneumonia
analyz
result
total
patient
bacterem
pneumonia
includ
esblproduc
caus
e
coli
patient
k
pneumonia
patient
identifi
classifi
hospitalacquir
pneumonia
healthcareassoci
pneumonia
communityacquir
pneumonia
mean
age
esbl
nonesbl
year
year
male
patient
respect
disclos
risk
factor
sputum
isol
esblproduc
e
coli
k
pneumonia
follow
low
bmi
p
antibiot
use
histori
p
esbl
isol
histori
p
high
charlson
comorbid
index
p
high
quick
sofa
p
impact
sputum
isol
esblproduc
e
coli
k
pneumonia
clinic
cours
inappropri
empir
therapi
initi
often
p
associ
mortal
p
conclus
esblproduc
bacterem
pneumonia
associ
comorbid
sever
diseas
appropri
empir
therapi
could
lead
improv
prognosi
liu
yaochang
wang
lihshinn
chang
huairen
chen
yite
lin
tengyi
school
medicin
buddhist
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
divis
cardiolog
depart
intern
medicin
depart
intens
care
medicin
depart
laboratori
medicin
buddhist
tzu
chi
gener
hospit
hualien
taiwan
background
myocard
lifethreaten
diseas
leptospirosisassoci
myocard
often
underestim
method
previou
healthi
man
present
histori
gener
malais
patient
work
supermarket
contact
frozen
meat
frequent
sinc
day
initi
present
began
experi
gener
malais
chest
tight
mild
fever
report
dyspnea
abdomin
pain
recent
travel
histori
similar
symptom
among
famili
friend
due
persist
symptom
brought
emerg
room
anoth
hospit
examin
hypotens
mmhg
note
laboratori
examin
report
bandemia
creactiv
protein
mgdl
troponini
ngml
immedi
transfer
hospit
emerg
depart
afebril
tachycardia
beat
min
hypotens
mmhg
physic
examin
report
promin
find
except
cm
knife
cut
wound
left
hand
happen
work
week
ago
ecg
reveal
normal
sinu
rhythm
chest
x
ray
show
congest
statu
cardiac
echographi
report
diffus
poor
wall
motion
tent
diagnosi
acut
myocard
septic
shock
patient
admit
result
adequ
hydrat
vasopressor
carri
empir
treat
vancomycin
meropenem
hospit
day
mycoplasma
pneumonia
igm
antibodi
posit
titer
antibiot
switch
levofloxacin
oral
penicillinv
ad
infecti
diseas
doctor
suggest
consid
leptospirosi
accord
patient
occup
exposur
hydrocortison
colchicin
prescrib
myocard
patient
improv
dramat
follow
day
blood
cultur
steril
evid
activ
viral
infect
discharg
week
admiss
unev
one
month
initi
present
microscop
agglutin
test
leptospirosi
reveal
signific
rise
compar
pair
sera
leptospira
santarosai
serovar
shermani
posit
titer
confirm
leptospirosi
conclus
previou
studi
report
myocard
result
pneumonia
leptospirosi
howev
antigen
mimicri
leptospir
mycoplasma
could
play
role
biolog
fals
posit
reaction
physician
care
patient
present
risk
factor
leptospira
infect
mycobacterium
abscessu
complex
pneumonia
possibl
progress
multifoc
leukoencephalopathi
pml
present
aid
yuhui
lin
soonhian
teh
lihshinn
wang
chiajung
chiang
yiwen
wu
school
medicin
buddhist
tzu
chi
univers
hualien
taiwan
divis
infecti
diseas
depart
intern
medicin
buddhist
tzu
chi
gener
hospit
hualien
taiwan
ministri
health
welfar
chest
hospit
tainan
taiwan
background
abscessu
complex
mabc
group
rapidli
grow
nontubercul
mycobacteria
ntm
speci
caus
pulmonari
infect
aid
method
bisexu
man
present
product
cough
month
start
fever
accompani
product
cough
fever
subsid
spontan
patient
still
intermitt
cough
yellowish
sputum
without
hemoptysi
night
sweat
weight
loss
kg
patient
went
anoth
hospit
one
month
prior
admiss
chest
x
ray
cxr
reveal
multipl
nodul
cavit
bilater
lung
field
figur
chest
comput
tomographi
ct
show
multipl
nodul
cystic
lesion
bilater
lung
figur
b
three
set
sputum
acid
fast
stain
show
neg
result
one
three
set
sputum
cultur
show
ntm
patient
admit
treat
possibl
ntm
pneumonia
result
admiss
complet
blood
count
show
pancytopenia
white
blood
cell
count
lymphocytopenia
hiv
agab
posit
elisa
western
blot
hiv
viral
load
copiesul
haart
initi
abacavirlamivudin
nevirapin
hospit
day
test
show
sputum
pneumocysti
jiroveci
blood
aspergillu
posit
pcr
sputum
tuberculosi
complex
undetect
pcr
ntm
pulmonari
diseas
confirm
second
expector
sputum
sampl
ethambutol
clarithromycin
prescrib
treat
possibl
avium
complex
mac
common
ntm
infect
hivaid
rifabutin
levofloxacin
ad
hospit
day
clarithromycin
shift
azithromycin
intoler
studi
sputum
cultur
confirm
mabc
offici
mycobacterium
laboratori
progress
lower
limb
pain
blur
vision
difficult
speak
note
brain
magnet
reson
imag
mri
show
mass
effect
pml
suspect
patient
discharg
week
hospit
stay
hiv
viral
load
lower
copiesul
within
month
seizur
happen
per
month
followup
mri
show
aggrav
pml
took
ethambut
azithromycin
rifambutin
outpati
treatment
year
followup
cxr
show
improv
conclus
mabc
infect
difficult
treat
multidrug
resist
mac
mabc
coinfect
possibl
mac
may
need
treat
empir
count
extrem
low
aid
uniqu
physiolog
properti
toxigen
clostridium
difficil
ribotyp
chengju
tseng
yungchieh
fu
boyang
tsai
ya
hui
liu
peijan
tsai
background
sporeform
microorgan
clostridium
difficil
enabl
toler
extrem
environ
lot
strain
enclos
toxin
gene
gener
toxin
damag
host
lead
variou
diseas
mild
diarrhea
sever
pseudomembran
megacolon
two
c
difficl
genotyp
ribotyp
found
possess
three
toxin
gene
tcda
tcdb
cdtab
demonstr
harm
ribotyp
creatur
impli
import
immedi
recognit
proper
treatment
method
retrospect
surveil
studi
januari
januari
conduct
medic
ward
district
hospit
southern
taiwan
molecular
character
isol
perform
use
pcr
ribotyp
result
ribotyp
frequent
identifi
focus
zoonot
seen
uniqu
perform
compar
convent
c
difficil
includ
ribotyp
coloni
morpholog
agar
cellular
aggreg
broth
reveal
dissimilar
behavior
rather
ribotyp
highli
aggreg
cell
examin
shown
neither
correl
growth
rate
bacteri
popul
format
biofilm
result
studi
suggest
c
difficil
distinct
physiolog
phenotyp
could
observ
easili
without
molecular
type
klebsiella
pneumonia
liver
abscess
associ
syndrom
first
case
taiwan
background
anteced
infect
common
syndrom
gb
thought
trigger
immun
respons
lead
acut
polyneuropathi
campylobact
jejuni
human
immunodefici
viru
hiv
zika
viru
wellknown
common
specimen
anteced
infect
howev
report
klebsiella
pneumonia
primari
liver
abscess
could
also
lead
gb
case
report
retir
male
patient
undeyli
diseas
type
ii
diabet
mellitu
chronic
kidney
diseas
stage
v
discharg
week
ago
due
biliari
tract
infect
bacteremia
proven
k
pneumonia
infect
admit
fever
chill
hour
abdomin
echo
arrang
show
bile
duct
dilat
abdomin
mri
reveal
lobul
lesion
liver
restrict
diffus
favor
liver
abscess
flomocef
everi
hour
prescrib
impress
liver
abscess
blood
cultur
admiss
show
growth
howev
bilater
lower
leg
muscl
power
deep
tendon
reflex
dtr
decreas
quickli
distal
proxim
progress
difficulti
defec
urin
hospilit
cerebrospin
fluid
studi
show
albuminocytolog
dissoci
electromyogram
emg
indic
sensorimotor
polyneuropathi
axon
degener
indirect
prove
impress
gb
intraven
immunoglubumin
inject
final
discharg
sinc
symptom
progress
anymor
three
month
later
could
walk
defec
normal
came
back
patient
depart
follow
discuss
bilater
leg
weak
dtr
decreas
spread
distal
proxim
emg
indic
sensorimotor
polyneuropathi
axon
degener
albuminocytolog
dissoci
truli
correspond
gb
patient
besid
typic
symptom
present
cjejuni
hiv
zika
viru
thu
could
boldli
associ
gb
kpneumonia
liver
abscess
first
report
case
syndrom
taiwan
associ
kpneumonia
liver
abscess
kept
mind
make
diagnosi
acut
onset
bilater
leg
weak
method
admiss
intermitt
high
fever
persist
lab
data
show
leukocytosi
persist
elev
crp
level
howev
respiratori
urinari
symptom
lab
data
show
pct
level
refer
level
chemotherapi
done
major
complic
note
howev
wateri
diarrhea
note
sinc
night
crp
level
elev
mgl
furthermor
stool
examin
show
posit
toxin
b
suspect
clostridium
difficil
infect
prescrib
flagyl
sinc
also
prescrib
trancolon
smecta
symptom
reliev
collect
rectal
swab
cultur
clostridium
difficil
identif
order
keep
contact
isol
result
intermitt
fever
still
note
intermitt
diarrhea
still
note
kept
oral
flagyl
use
furthermor
sever
electrolyt
imbal
persist
week
hyponatremia
hypokalemia
hypomagnesemia
hypophosphatemia
frequent
electrolyt
supplement
need
especi
hypokalemia
wateri
diarrhea
improv
semifluidsolid
like
stool
decreas
frequenc
therefor
discontinu
contact
isol
sinc
conclus
clostridium
difficil
kind
normal
bacteria
human
intestin
tract
use
antibiot
lead
intestin
bacteria
reduc
normal
therefor
caus
lot
breed
caus
diseas
sever
electrolyt
imbal
cancer
patient
elderli
immun
function
defici
longterm
hospit
use
antibiot
treatment
suscept
infect
clostridium
difficil
infect
hand
bodi
surfac
contact
hand
wash
patient
chemotherapi
medic
team
prevent
clostridium
difficil
particularli
import
epidemiolog
urinari
tract
infect
singapor
teach
hospit
result
pilot
audit
goh
yi
suan
vivian
low
wei
ting
gabriel
aw
liang
cheng
park
chang
joon
low
taoyang
isaac
sarah
bint
mohd
sidek
paul
anantharajah
tambyah
yong
loo
lin
school
medicin
nation
univers
singapor
singapor
divis
infecti
diseas
nation
univers
hospit
singapor
coauthor
background
urinari
tract
infect
uti
among
preval
infect
worldwid
howev
limit
data
southeast
asia
method
conduct
clinic
audit
describ
epidemiolog
uti
nation
univers
hospit
teach
hospit
cover
western
sector
singapor
patient
data
extract
patient
chart
electron
medic
record
demograph
clinic
microbiolog
featur
outcom
defin
uti
posit
urin
cultur
cfu
bacteriaml
definit
follow
intern
standard
statist
analysi
perform
use
fisher
exact
test
student
ttest
result
overal
patient
urin
cultur
posit
urin
cultur
neg
urin
cultur
bacteriuria
cfuml
common
femal
male
p
posit
urin
cultur
fever
alter
mental
state
lower
urinari
tract
symptom
combin
symptom
patient
asymptomat
bacteriuria
signific
differ
symptom
frequenc
patient
posit
neg
cultur
ci
p
fever
ci
p
exclud
patient
concomit
infect
presenc
fever
hour
cultur
also
associ
bacteriuria
cfuml
ci
p
urin
wbc
count
significantli
rais
patient
posit
urin
cultur
p
compar
neg
urin
cultur
suggest
urin
microscopi
use
screen
urin
cultur
even
hospitalis
patient
hospitalonset
uti
account
uti
communityonset
uti
account
length
hospit
houti
patient
day
significantli
higher
couti
patient
day
ci
p
otherwis
differ
two
group
commonest
caus
organ
cultur
e
coli
n
follow
klebsiella
pneumonia
n
high
degre
antimicrobi
resist
detect
e
coli
ampicillinresist
ciprofloxacinresist
resist
thirdgenerationcephalosporin
conclus
pilot
audit
limit
small
sampl
size
presenc
concomit
infect
larger
studi
need
confirm
find
effect
target
therapi
patient
uti
without
exacerb
problem
antimicrobi
resist
develop
improv
inhous
protocol
fast
reliabl
identif
directli
posit
blood
cultur
use
malditof
ms
menglan
zhou
qiwen
yang
yingchun
xu
background
bloodstream
infect
major
caus
morbid
mortal
hospit
patient
worldwid
applic
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
directli
blood
cultur
bc
broth
potenti
identifi
bloodstream
infect
earlier
facilit
time
manag
method
develop
inhous
ih
protocol
direct
malditof
ms
base
identif
posit
bc
compar
perform
commerci
kit
protocol
initi
evalu
improv
known
select
posit
bc
sampl
studi
parallel
perform
protocol
coloni
ms
identif
posit
clinic
bc
sampl
discrep
investig
gold
standard
gene
sequenc
result
spike
bc
sampl
ih
method
show
compar
result
appli
modifi
cutoff
valu
accur
speci
genu
level
identif
achiev
clinic
monomicrobi
bc
show
superior
perform
gram
neg
bacteria
gram
posit
bacteria
versu
anaerob
yeast
accuraci
speci
identif
achiev
respect
polymicrobi
mix
cultur
malditof
ms
correctli
report
singl
speci
present
polymicrobi
bc
standard
mode
use
mix
method
two
speci
correctli
identifi
sampl
comparison
differ
bottl
type
result
indic
lytic
anaerobicf
cultur
vial
exhibit
best
perform
among
three
bactectm
plu
aerobicf
bactectm
anaerobicf
bactectm
mycof
lytic
conclus
develop
novel
simpl
costeffect
sampl
prepar
method
direct
identif
pathogen
posit
bc
evidencebas
comparison
diagnost
accuraci
xpert
mtbrif
assay
smear
microscopi
pulmonari
tuberculosi
rifampicin
resist
detect
evalu
yich
huang
yuanhsin
chu
divis
infecti
diseas
jenai
hospit
depart
infect
control
jenai
hospit
background
accur
earlier
detect
tb
tb
drug
resist
critic
tb
control
mycobacteri
cultur
consid
best
refer
standard
rel
complex
slow
thu
taiwan
cdc
recommend
develop
rapid
techniqu
xpert
mtbrif
cepheid
assay
introduc
diagnosi
tb
rif
rifampicin
resist
herein
compar
diagnost
accuraci
pulmonari
tuberculosi
smear
microscopi
assess
assay
rifampicin
resist
adult
method
diagnost
question
acquir
systemat
review
sr
crosssect
studi
refer
standard
blind
prioriti
ppulmonari
tuberculosi
ixpert
mtbrif
csmear
microscopi
odiagnost
accuraci
pico
term
respect
synonym
engag
boolean
charact
search
cochranelibrari
sr
filterd
search
result
cochran
one
relev
sr
select
pubm
includ
sr
result
initi
test
replac
smear
microscopi
xpert
mtb
rif
pool
sensit
pool
specif
addon
test
follow
neg
smear
microscopi
result
xpert
mtbrif
pool
sensit
pool
specif
smearposit
cultureposit
tb
xpert
mtbrif
pool
sensit
compar
smear
microscopi
xpert
mtbrif
increas
tb
detect
among
cultureconfirm
case
rifresist
detect
xpert
mtbrif
pool
sensit
pool
specif
conclus
compar
smear
microscopi
xpert
mtbrif
substanti
increas
tb
detect
among
cultureconfirm
case
xpert
mtbrif
higher
sensit
tb
detect
smearposit
smearneg
patient
adult
nonetheless
test
may
valuabl
addon
test
follow
smear
microscopi
patient
previous
found
smearneg
rifampicin
resist
detect
xpert
mtbrif
provid
accur
result
allow
rapid
initi
mdrtb
treatment
level
clinic
aspect
rhodotorula
fungemia
region
teach
hospit
yi
ching
huang
divis
infect
diseas
jenai
hospit
dali
branch
background
rhodotorula
speci
common
environment
pigment
basidiomycet
yeast
also
present
skin
nail
respiratori
gastrointestin
urinari
tract
human
rhodotorula
speci
infrequ
yeast
pathogen
increasingli
caus
invas
infect
fungemia
mening
ocular
infect
periton
endocard
risk
factor
includ
immunocompromis
patient
presenc
central
venou
cathet
propos
studi
review
case
rhodotorula
fungemia
period
year
determin
risk
factor
outcom
method
record
microbiolog
laboratori
jenai
hospit
dali
branch
region
teach
hospit
taiwan
review
identifi
patient
posit
blood
cultur
rhodotorula
speci
januari
decemb
follow
inform
collect
age
gender
underli
diseas
presenc
type
central
venou
cathet
parenter
nutrit
use
corticosteroid
exposur
broadspectrum
antibiot
result
cultur
blood
sampl
obtain
patient
grew
rhodotorula
speci
mainli
rhodotorula
mucilaginosa
median
age
year
femal
patient
predomin
central
venou
cathet
present
patient
includ
patient
hickman
cathet
broadspectrum
antibiot
administ
patient
patient
receiv
antifung
therapi
mortal
conclus
common
predispos
factor
presenc
central
venou
cathet
use
broadspectrum
antibiot
result
case
collect
may
april
singl
tertiari
teach
hospit
men
age
year
old
msm
common
acut
syndrom
includ
fever
skin
rash
coinfect
syphili
hiv
agab
eia
elisa
show
posit
hiv
rna
viral
load
rang
log
copyml
count
less
time
show
neg
western
blot
show
indetermin
result
repeat
western
blot
done
reveal
posit
result
final
time
interv
month
conclus
although
indetermin
western
blot
may
present
acut
earli
hiv
infect
confirm
hiv
infect
still
need
inform
hiv
rna
viral
load
pcr
seroconvers
clinician
neg
western
blot
usual
exclud
hivaid
may
ignor
fact
window
period
present
acut
hiv
infect
high
risk
popul
diagnosi
acut
earli
hiv
infect
made
obtain
exposur
histori
present
std
experi
share
use
system
alert
mechan
clostridium
difficil
toxin
detect
metropolitan
hospit
chiungyin
chuang
chinhsiung
kao
background
clostridium
difficil
infect
cdi
associ
longterm
multipl
use
antibiot
disrupt
normal
gut
flora
result
diarrhea
pseudomembran
coliti
megacolon
etc
difficulti
diagnosi
strain
divers
make
earli
treatment
isol
challeng
bacteri
cultur
identif
timeconsum
use
confirm
virul
strain
introduc
inspect
equip
activ
set
molecular
analysi
mechan
toxinproduc
strain
detect
toxin
carrier
receiv
time
treatment
infect
control
implement
method
gene
xpert
dx
system
use
detect
toxin
gene
clostridium
difficil
strain
highli
pathogen
set
alert
mechan
hospit
inform
system
provid
daili
list
inpati
meet
inclus
criteria
time
diarrhea
equal
five
time
weight
wateri
diarrhea
equal
g
day
also
advic
item
code
automat
result
among
sampl
posit
toxin
strain
detect
laboratori
sent
inform
physician
infect
control
depart
immedi
posit
outcom
releas
also
medic
inform
system
nurs
inform
system
reveal
alert
signal
isol
remind
conclus
patient
suspect
infect
clostridium
difficil
diagnos
treat
rapid
molecular
biolog
analysi
time
contact
precaut
antibiot
evalu
environment
clean
rule
establish
carri
control
nosocomi
clostridium
difficil
infect
improv
medic
care
qualiti
perform
assess
autom
icub
platform
identif
gramposit
cocci
flag
blood
cultur
includ
drugsuscept
resist
isol
tai
vancomycin
vanavanb
resist
associ
gene
use
multiplex
pcr
technolog
method
total
consecut
flag
blood
cultur
bottl
gramposit
cocci
evalu
use
icub
platform
nation
taiwan
univers
hospit
result
platform
compar
final
result
combin
culturebas
malditofm
identif
minimum
inhibitori
concentr
oxacillin
vancomycin
rrna
speci
identif
resistanceassoci
gene
sequenc
meca
vanavanb
result
exclus
sampl
process
error
overal
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
platform
identif
gramposit
cocci
speci
background
multidrugresist
gramneg
bacteria
particularli
e
coli
produc
extend
spectrum
betalactamas
esbl
andor
carbapenemas
caus
global
public
health
concern
date
limit
data
avail
genet
studi
multidrug
resist
e
coli
myanmar
method
total
nondupl
consecut
isol
e
coli
collect
north
okkalapa
gener
hospit
yangon
myanmar
januari
decemb
analyz
presenc
bla
ctxm
bla
tem
bla
shv
confirm
multiplex
pcr
subtyp
assign
sequenc
sequenc
type
st
determin
base
achtman
scheme
mlst
carbapenemas
gene
virul
factor
gene
allel
aac
ibcr
detect
pcr
mic
antimicrobi
determin
broth
microdilut
test
result
among
isol
esbl
product
confirm
isol
isol
resist
carbapenem
among
esblproduc
e
coli
domin
phylogroup
n
follow
n
n
n
half
isol
gene
wherea
allel
detect
phylogroup
isol
total
isol
carri
ctxm
andor
ctxm
gene
classifi
group
n
group
n
identifi
dminant
type
minor
type
isol
gene
mostli
classifi
phylogroup
ndm
gene
detect
n
carbapenemresist
isol
among
gene
predomin
follow
gene
ndm
geneposit
isol
classifi
variou
phylogroupsgenotyp
includ
variant
detect
one
isol
urin
wound
swab
belong
phylogroup
clone
poccess
virul
factor
ndm
geneposit
isol
conclus
studi
reveal
high
rate
esblproduc
e
coli
classifi
emerg
carbapenemresist
isol
variou
ndm
gene
myanmar
analysi
distribut
featur
drug
resist
clinic
isol
stenotrophomona
maltophilia
region
hospit
central
taiwan
anchi
chen
yaoshen
tung
yuiyein
yang
background
maltophilia
natur
resist
mani
broadspectrum
antibiot
opportunist
pathogen
capabl
caus
respiratori
bloodstream
urinari
infect
hospit
patient
receiv
treatment
condit
may
suscept
infect
especi
sever
impair
immun
system
purpos
studi
collect
sampl
stenotrophomona
maltophilia
order
determin
drug
sensit
epidemiolog
featur
method
epidemiolog
data
obtain
strain
stenotrophomona
maltophilia
collect
januari
decemb
region
hospit
central
taiwan
fullyautomat
microorgan
identif
drug
sensit
analysi
conduct
use
phoenix
system
bd
result
total
strain
maltophilia
obtain
outpati
gener
ward
intens
care
unit
term
gender
patient
male
remain
patient
femal
sourc
sampl
sputum
n
wound
n
blood
n
urin
n
bile
n
n
resist
stenotrophomona
maltophilia
isol
ceftazidim
caz
levofloxacin
lvx
sulfamethoxazol
sxt
resist
rate
respect
fig
result
show
maltophilia
high
rate
separ
hospit
prevent
focu
cleanli
hospit
disinfect
equip
handwash
staff
order
reduc
infect
rate
nosocomi
infect
drug
sensit
maltophilia
monitor
analyz
assist
clinic
physician
choos
reason
treatment
antibiot
demograph
characterist
patient
infect
carbapenem
suscept
acinetobact
baumannii
csab
carbapenem
resist
acinetobact
baumannii
crab
without
multipl
drug
resist
mdr
isol
region
teach
hospit
southern
taiwan
yipe
chen
poliang
lu
chunchi
huang
jengyih
wu
chenmin
kuo
tungnan
liao
ko
background
overus
antibiot
healthcar
institut
led
emerg
resist
pathogen
taiwan
preval
multidrug
resist
organ
close
monitor
hospit
taiwan
preval
colon
organ
commun
especi
among
adult
larg
unknown
studi
aim
investig
preval
colon
methicillinresist
staphylococcu
aureu
mrsa
extendedspectrum
esbl
produc
carbapenemresist
escherichia
coli
klebsiella
pneumonia
vancomycinresist
enterococci
vre
among
healthi
adult
commun
taiwan
method
march
may
prospect
observ
studi
conduct
nation
taiwan
univers
hospit
hsinchu
branch
nasal
swab
anal
swab
stool
collect
healthi
adult
volunt
bacteri
cultur
identif
perform
use
select
cultur
medium
assist
bacteri
identif
system
standard
case
record
form
use
collect
demograph
data
paricip
result
total
paricip
includ
averag
age
year
old
male
femal
ratio
common
chonic
cormobid
paricip
hepatitri
b
paricip
travel
abroad
expos
antibiot
previou
one
year
among
prevel
nasal
carriag
mrsa
prevel
stool
carriag
cefotaxim
nonsuscept
esblproduc
escherichia
coli
respect
carbapenemresist
enterobacterecia
vre
isol
conclus
high
rate
colon
escherichia
coli
carri
cefotaxim
nonsuscept
esbl
found
among
taiwanes
adult
commun
contrari
carbapenemresist
enterobacterecia
vre
detect
prevel
rate
nasal
carriag
mrsa
remain
stationari
plasmidmedi
fosfomycin
resist
determin
synergi
fosfomycin
meropenem
carbapenemresist
klebsiella
pneumonia
isol
taiwan
tsungi
yang
tingyin
wang
sungpin
tseng
method
crkp
clinic
isol
collect
nationwid
surveil
studi
hospit
taiwan
antimicrobi
suscept
determin
pfge
mlst
determin
clonal
related
carbapenemas
fosfomycinas
gene
detect
pcr
flank
region
determin
pcr
sequenc
synergist
activ
meropenem
fosfomycin
examin
checkerboard
method
result
total
crkp
isol
taiwan
conclus
clone
pulsotyp
xxiii
found
prevail
among
fosfomycinresist
crkp
taiwan
accord
vitro
data
combin
fosfomycin
meropenem
potenti
altern
choic
antimicrobi
suscept
variou
antibiot
staphylococcu
saprophyticu
isol
urin
japan
koichi
takahashi
tetsuro
muratani
junichi
ohno
ihibiki
amr
laboratori
kitakyushu
japan
fukuoka
shin
mizumaki
hospit
background
staphylococcu
saprophyticu
one
major
uropathogen
caus
acut
uncompl
urinari
tract
infect
howev
data
antimicrobi
suscept
saprophyticu
isol
japan
report
investig
suscept
variou
antibiot
saprophyticu
isol
japan
method
total
nondupl
saprophyticu
isol
urin
period
japan
use
studi
mic
variou
antimicrobi
isol
determin
twofold
serial
agar
dilut
method
describ
clsi
resist
isol
antimicrobi
basic
interpret
accord
clsi
breakpoint
mecaposit
isol
determin
pcr
use
specif
primer
result
isol
femal
patient
account
isol
male
patient
isol
howev
account
isol
femal
patient
isol
patient
less
year
old
contrast
isol
male
patient
less
year
old
account
monomicrobi
infect
account
femal
male
betalactamas
detect
isol
mecaposit
isol
account
ratio
mecaposit
isol
ratio
mecaposit
isol
femal
patient
male
patient
mic
oxacillin
mecaposit
neg
isol
rang
mgl
mgl
isol
mic
mgl
oxacillin
exist
strain
one
mecaneg
mecaposit
isol
resist
levofloxacin
mgl
minocyclin
mgl
vancomycin
mgl
teicoplanin
mgl
resist
ratio
clarithromycin
azithromycin
clindamycin
fofomycin
sufamethoxazoletrimethoprim
conclus
japan
mecaposit
saprophyticu
emerg
increas
ratio
account
especi
account
japan
increas
mecaposit
saprophyticu
isol
clinic
problem
chemotherapi
fluoroquinol
resist
howev
consid
continu
survey
antimicrobi
suscept
saprophyticu
epidemiolog
analysi
drug
resist
bacteria
experi
region
teach
hospit
hsinchu
hui
min
fan
ya
hsiao
yu
tin
cheng
yu
huang
yi
shun
chen
laboratori
medicin
depart
depart
intern
medicin
nation
taiwan
univers
hospit
hsinchu
branch
roc
background
sinc
hospit
join
antibiot
stewardship
program
focus
reduc
contamin
rate
clinic
specimen
monitor
preval
multidrug
resist
bacteria
promot
proper
use
antibiot
purpos
set
qualiti
indic
underw
intern
discuss
staff
train
analyz
isol
rate
drugresist
bacteria
past
two
year
evalu
effect
infect
control
hospit
investig
drugresist
bacteria
clinic
signific
healthcareassoci
infect
includ
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococcu
vre
carbapenemresist
acinetobact
baumannii
crab
carbapenemresist
enterobactoriacea
cre
use
whonet
system
work
inform
technolog
depart
statist
report
format
construct
could
analyz
isol
rate
trend
drugresist
pattern
bacteria
januari
februari
analyz
result
report
track
group
meet
regularli
held
infect
control
committe
provid
time
effect
clinic
inform
infect
control
practition
physician
result
isol
rate
multidrug
resist
bacteria
follow
respect
mrsa
mean
crab
reduc
mean
annual
isol
rate
mrsa
crab
declin
significantli
isol
rate
cre
drop
mean
flat
trend
howev
vre
increas
mean
show
upward
trend
conclus
trend
analysi
mrsa
crab
cre
indic
success
infect
control
howev
increas
isol
rate
vre
highlight
need
reinforc
monitor
vre
infect
key
point
infect
control
hospit
epidemiolog
analysi
multidrug
resist
pathogen
could
assist
clinician
choos
appropri
antibiot
analysi
decreas
multidrug
resist
microorgan
improv
patient
surviv
better
qualiti
care
well
reduct
medic
expens
would
expect
antimicrobi
resist
staphylococcu
aureu
pseudomona
aeruginosa
otorrhea
chronic
suppur
otiti
media
patient
yeehyuk
kim
depart
otorhinolaryngologyhead
neck
surgeri
school
medicin
cathol
univers
daegu
daegu
korea
background
know
bacteria
caus
chronic
suppur
otiti
media
csom
antimicrobi
suscept
caus
bacteria
import
use
antibiot
primari
treatment
method
studi
conduct
retrospect
march
februari
tertiari
hospit
korea
use
medic
record
patient
otorrhea
caus
csom
result
commonli
identifi
bacteria
staphylococcu
aureu
particip
case
case
methicillinresist
staphylococcu
aureu
mrsa
mrsa
case
resist
vancomycin
case
suscept
seven
case
resist
trimethoprimsulfamethoxazol
tmpsmx
case
suscept
mrsa
highest
sensit
tmpsmx
except
vancomycin
second
frequent
identifi
bacteria
pseudomona
aeruginosa
patient
case
case
ciprofloxacinresist
pseudomona
aeruginosa
crpa
crpa
highli
suscept
ceftazidim
amikacin
meropenem
patient
case
remain
bacteria
detect
except
two
bacteria
growth
found
patient
may
due
antibiot
use
arriv
tertiari
hospit
conclus
mrsa
suscept
tmpsmx
among
oral
medicin
therefor
tmpsmx
may
preferenti
treatment
mrsa
outpati
set
crpa
show
lowest
resist
ceftazidim
suitabl
oral
antibiot
exist
crpa
inpati
treatment
consid
case
background
previou
studi
suggest
sequenc
type
predomin
among
borderlineoxacillin
resist
mecaposit
staphylococcu
aureu
borsa
minimum
inhibitori
concentr
oxacillin
isol
clinic
data
relat
bacteremia
caus
borsa
isol
limit
method
patient
age
year
bacteremia
due
borsa
admit
emerg
depart
tertiari
hospit
januari
decemb
evalu
clinic
characterist
patient
bacteremia
caus
borsa
methicillinsuscept
aureu
mrsa
bacteremia
compar
antimicrobi
suscept
test
determin
use
agar
dilut
method
genet
characterist
borsa
isol
analyz
use
type
sccmec
gene
multilocu
sequenc
type
mlst
pulsedfield
gel
electrophoresi
perform
identifi
clonal
emerg
st
type
isol
promot
region
sequenc
quinoloneresist
gene
also
analyz
borsa
isol
major
ciprofloxacin
resist
clone
respect
result
among
patient
bacteremia
due
borsa
inhospit
mortal
significantli
lower
bacterem
patient
caus
mrsa
p
underli
condit
similar
borsa
mrsa
patient
less
dialysi
former
p
multivari
analysi
reveal
septic
shock
odd
ratio
confid
interv
ci
bacteremia
origin
lower
respiratori
tract
infect
ci
two
independ
risk
factor
mortal
multidrug
resist
highlevel
ciprofloxacin
resist
mic
rang
replac
predomin
clone
sinc
major
cluster
isol
detect
conclus
clinic
present
underli
condit
borsa
mrsa
bacteremia
patient
similar
lower
inhospit
mortal
emerg
multidrug
resist
clone
replac
common
borsa
isol
repeat
hiv
test
earli
hiv
diagnosi
among
client
attend
voluntari
counsel
test
vct
clinic
wuxi
china
retrospect
cohort
studi
xiaojun
meng
wenjuan
xuan
zhang
hao
cheng
jing
gu
andrew
grulich
huachun
zou
inject
drug
use
ever
test
hiv
overal
rate
incid
hiv
diagnosi
among
vct
client
per
personyear
incid
hiv
diagnosi
associ
male
gender
adjust
hazard
ratio
ahr
ci
attend
hospitalbas
vct
clinic
malemal
sexual
behavior
higher
cell
count
observ
among
case
diagnos
vct
clinic
base
local
center
diseas
control
prevent
compar
base
clinic
servic
median
versu
copiesmm
p
background
japan
pneumococc
vaccin
introduc
replac
pneumococc
vaccin
previou
studi
noninvas
pneumococc
diseas
nonipd
outpati
among
children
demonstr
increas
serotyp
period
nov
nov
present
studi
aim
investig
serotyp
distribut
antimicrobi
suscept
pneumonia
among
children
method
may
novemb
total
pneumococc
isol
collect
noninvas
infect
pediatr
outpati
year
visit
variou
hospit
clinic
throughout
hokkaido
northern
main
island
japan
isol
serotyp
sequenti
multiplex
pcr
method
pcr
addit
genet
subtyp
serogroup
perform
report
previous
suscept
antimicrobi
measur
broth
microdilut
method
use
dri
plate
eiken
isol
domin
serotyp
result
among
isol
prevail
serotyp
serotyp
account
isol
total
isol
serotyp
nonsuscept
rate
penicillin
among
serotyp
respect
isol
serotyp
nonsuscept
erythromycin
tetracyclin
high
rate
cefotaxim
nonsuscept
found
serotyp
isol
examin
suscept
vancomycin
quinolon
conclus
present
studi
indic
increas
nonvaccin
serotyp
follow
use
conjug
vaccin
associ
increas
antimicrobi
resist
domin
serotyp
background
cellul
usual
caus
indigen
flora
colonz
skin
appendag
staphylococcu
streptococcu
howev
absenc
abscess
open
wound
difficult
establish
bacteri
etiolog
usual
prescrib
antibiot
base
local
epidemiolog
data
recent
year
communityacquir
mrsa
methicillinresist
staphylococcu
aureu
increas
gradual
taiwan
whether
antibiot
mrsa
mssa
methicillinsuscept
staphylococcu
aureu
prescrib
time
becom
clinic
dilemma
herein
conduct
studi
establish
epidemiolog
data
evalu
associ
treatment
respons
nasal
carriag
statu
adult
patient
cellul
method
patient
age
diagnosi
cellul
enrol
nasal
swab
clinic
sampl
inform
collect
sent
microbiolog
cultur
suscept
test
result
total
patient
includ
twoyear
consecut
prospect
observ
studi
nasal
swab
surveil
show
patient
without
aureu
colon
patient
aureu
colon
patient
colon
mrsa
specif
background
factor
age
underli
diseas
patient
sourc
identifi
predict
carriag
statu
four
patient
mrsa
colon
none
given
antimrsa
antibiot
empir
clinic
respons
includ
day
antibiot
day
hospit
differ
mssa
colon
without
aureu
colon
howev
pu
format
note
pu
cultur
result
correl
nasal
carriag
statu
limit
studi
small
case
number
patient
group
nasal
mrsa
colon
conclus
taiwan
mrsa
nasal
carriag
rate
high
adult
patient
cellul
specif
factor
identifi
predict
mrsa
nasal
carrier
group
patient
howev
whether
patient
nasal
mrsa
carrier
differ
treatment
respons
antibiot
empir
antibiot
mrsa
need
background
carbapenem
resist
klebsiella
pneumonia
crkp
recogn
healthcar
set
pose
seriou
threat
hospit
patient
crkp
resist
almost
avail
antimicrobi
agent
mechan
resist
carbapenem
involv
product
carbapenemas
loss
porin
howev
type
carbapenemas
involv
vari
countri
countri
previous
crkp
isol
tertiari
hospit
malaysia
character
low
et
al
studi
aim
determin
chang
trend
genotyp
characterist
crkp
compar
isol
publish
data
method
total
crkp
isol
collect
diagnost
lab
hospit
presenc
carbapenemas
gene
outer
membran
protein
omp
isol
determin
use
polymeras
chain
reaction
pcr
isol
subject
multilocu
sequenc
type
mlst
result
obtain
isol
compar
publish
data
crkp
isol
hospit
isol
isol
publish
low
et
al
first
isol
per
patient
addit
studi
clonal
complex
relat
isol
defin
eburst
base
assign
sequenc
type
isol
studi
sequenc
type
isol
previou
studi
low
et
al
result
ndm
common
carbapenemas
gene
detect
among
isol
major
ndm
produc
isol
coproduc
carbapenemas
loss
porin
detect
isol
compar
previou
studi
number
ndm
hospit
significantli
increas
isol
isol
overal
increas
number
carbapenemas
coproduc
isol
period
observ
addit
sequenc
type
new
sequenc
type
st
identifi
among
isol
similar
previou
find
isol
predomin
follow
final
base
eburst
analysi
isol
group
two
clonal
complex
sequenc
type
isol
appear
singleton
conclus
high
heterogen
among
isol
crkp
observ
increas
case
crkp
hospit
might
due
emerg
crkp
harbor
variou
carbapenemas
coupl
loss
porin
analysi
salmonella
strain
hospit
experi
chiachun
tsaz
lichiu
weng
peil
lien
chich
chen
background
salmonella
one
main
caus
diarrheal
diseas
gener
human
contract
consumpt
contamin
food
manur
anim
origin
egg
meat
poultri
milk
veget
implic
transmiss
usual
character
acut
onset
fever
abdomin
pain
diarrhea
nausea
vomit
case
salmonellosi
mild
howev
sometim
lifethreaten
salmonella
gram
neg
rod
genu
belong
enterobactericea
famili
genu
salmonella
serotyp
current
recogn
antimicrobi
resist
public
health
concern
salmonella
one
microorgan
resist
emerg
analyz
strain
salmonella
understand
serum
group
specimen
sourc
antimicrobi
drug
resist
method
total
strain
salmonella
isol
clinic
specimen
patient
analysi
done
sampl
salmonella
group
analysi
strain
salmonella
type
b
strain
type
c
strain
type
strain
e
type
strain
unidentifi
nonpolyai
vi
type
strain
strain
salmonella
isol
bile
blood
pu
fece
urin
account
fece
blood
urin
analyz
routin
antibiot
suscept
test
ampicillinsulbactam
ceftriaxon
ertapenem
imipenem
levofloxacin
trimethoprimsulfam
ampicillinsulbactam
suscept
ceftriaxon
suscept
ertapenem
suscept
imipenem
suscept
levofloxacin
suscept
trimethoprimsulfam
suscept
conclus
antigen
group
salmonella
found
variou
type
often
type
separ
mainli
isol
fece
antibiot
suscept
test
part
carbapenem
class
imipenem
imipenem
susceptibil
fluoquinolon
drug
levofloxacin
susceptibil
drug
also
susceptibil
test
salmonella
one
common
caus
food
poison
symptom
salmonellosi
mild
patient
recov
without
specif
treatment
case
howev
children
elderli
patient
associ
dehydr
becom
sever
lifethreaten
antimicrobi
resist
salmonella
emerg
right
antibiot
choic
import
improv
condit
oper
room
fuchieh
chang
hsuehwen
wu
lilin
kuo
changpan
liu
background
hocl
weak
acid
product
anion
interact
cell
wall
cell
membran
acid
interact
pathogen
destroy
structur
pathogen
osmol
chang
final
pathogen
die
studi
want
know
realli
effect
hocl
kill
pathogen
vitro
method
studi
use
acinetobact
baumannii
pathogen
beg
transfer
acinetobact
baumannii
normal
salin
check
macfaland
use
suspens
add
hocl
use
tsa
agar
cultur
accord
previou
studi
bacteria
live
surfac
hospit
month
staff
touch
surfac
would
chanc
infect
patient
action
say
easi
infect
crab
imperfect
infect
control
report
found
error
hospit
occur
action
bronchoscopi
oper
method
investig
collect
five
strain
crab
patient
bal
cultur
check
action
staff
oper
bronchoscopi
use
puls
field
gel
electrophoresi
check
strain
result
investig
found
staff
use
dispos
gel
bronchoscopi
wound
anoth
risk
infect
otherwis
found
staff
nt
wash
hand
correctli
thank
pfge
result
show
crab
say
crab
could
live
surfac
one
train
present
icu
conclus
case
even
crab
still
found
possibl
chanc
would
caus
infect
staff
nt
take
care
besid
suggest
better
use
dispos
gel
bronchoscopi
tabl
ward
environ
clean
monitor
took
month
result
show
even
clean
disinfect
implement
mdro
still
exist
ward
environ
thu
provid
sanitari
unit
data
educ
train
ask
improv
practic
environ
clean
besid
tabl
also
show
nonhighrisk
ward
section
free
mdro
indic
highrisk
ward
section
regularli
monitor
supervis
implement
environ
clean
disinfect
ensur
better
cleanli
hospit
environ
better
healthcar
qualiti
trend
carbapenemresist
acinetobact
baumannii
pseudomona
aeruginosa
region
teach
hospit
among
drugresist
speci
crab
crpa
major
therefor
articl
aim
analyz
trend
crab
crpa
recent
year
method
statist
data
antibiot
suscept
gramneg
bacteria
regard
acinetobact
baumannii
pseudomona
aeruginosa
collect
medic
inform
system
hospit
carbapenem
seen
index
percentag
carbapenemresist
strain
depend
highest
percentag
either
ertapenem
imipenemresist
strain
result
statist
result
show
year
acinetobact
baumannii
strain
total
crab
averag
pseudomona
aeruginosa
strain
total
crpa
averag
found
sinc
crab
crpa
decreas
year
year
suddenli
rais
yet
infect
control
intervent
crab
decreas
result
list
figur
conclus
crab
show
highest
percentag
antibiot
resist
mdro
hospit
addit
promot
antibiot
stewardship
program
attent
paid
mdro
monitor
monitor
data
count
result
report
infect
control
meet
quarterli
therefor
abl
find
predescrib
trend
rais
crab
immedi
took
intervent
includ
contact
precaut
arrang
area
place
treat
mdro
patient
besid
auto
messag
system
establish
remind
healthcar
staff
implement
contact
precaut
facilit
prevent
mdro
transmiss
clean
efficaci
contamin
mobil
nurs
cart
tunchieh
chen
chunfeng
chiu
jennif
naihwa
shih
background
mobil
nurs
cart
trend
modern
nurs
practic
enhanc
work
effici
reduc
process
mistak
mobil
devic
might
becom
media
transmiss
multidrug
resist
organ
studi
aim
investig
adequaci
access
surfac
disinfect
process
nurs
cart
provid
experi
establish
standard
oper
process
environment
cleanli
disinfect
method
perform
surfac
cultur
everi
mobil
nurs
cart
highli
frequent
touch
point
test
disinfect
efficaci
differ
agent
alcohol
quaternari
ammonium
base
spray
tissu
determin
surfac
atp
bioluminesc
conduct
questionnair
healthcar
worker
conveni
access
differ
disinfect
agent
result
yield
microorgan
total
point
clinic
signific
bacteria
follow
frequenc
enterococcu
faecium
stenotrophomona
maltophilia
enterobact
cloaca
enterococcu
faecali
acinetobact
baumannii
efficaci
differ
disinfect
agent
well
determin
signific
declin
atp
valu
surfac
cleani
healthcar
worker
report
similar
conveni
access
diffec
disinfect
agent
conclus
mobil
medic
devic
wide
use
modern
healthcar
servic
demonstr
devic
could
media
bacteri
transmiss
might
result
healthcar
associ
infect
alcohol
quaternari
ammonium
base
agent
suitabl
agent
purpos
small
part
automat
endoscop
reprocessor
may
caus
posit
result
repeat
microbiolog
monitor
gastrointestin
endoscop
highlevel
disinfect
cheyi
hung
shushia
chang
kuang
tien
gener
hospit
kuang
tien
gener
hospit
dajia
branch
background
contamin
endoscop
link
outbreak
healthcareassoci
infect
medic
devic
microbiolog
surveil
may
help
monitor
effect
gi
endoscop
disinfect
studi
caus
gi
endoscop
clean
disinfect
standard
procedur
still
test
posit
bacteri
growth
discuss
method
oeraw
autom
endoscop
repressor
aer
aizu
olympu
co
ltd
tokyo
japan
use
endoscop
reprocess
one
one
oeraw
aer
use
endoscop
use
colonoscop
monitor
qualiti
gastrointestin
endoscop
reprocess
two
endoscop
one
colonoscop
randomli
select
obtain
surveil
cultur
monthli
cultur
obtain
ad
ml
steril
water
biopsi
channel
endoscop
wash
collect
steril
contain
plate
onto
blood
eosinmethylen
blue
agar
incub
examin
bacteri
growth
fishbon
diagram
use
identifi
possibl
caus
problem
sort
idea
use
categori
result
total
cultur
obtain
januari
novemb
year
cultur
posit
endoscop
fishbon
diagram
show
root
caus
posit
cultur
may
job
rotat
old
equip
reprocess
procedur
alter
improv
howev
posit
cultur
obtain
endoscop
process
fact
found
joint
waterair
channel
instrumentsuct
channel
aer
damag
could
allow
circul
fluid
pressur
channel
differ
method
use
monitor
environ
clean
hospit
includ
direct
observ
bacteri
cultur
atp
adenosin
triphosph
bioluminesc
assay
purpos
termin
disinfect
patient
discharg
ensur
environ
clean
ward
keep
next
patient
infect
caus
pollut
environ
thu
region
teach
hospit
appli
atp
evalu
efficaci
monitor
environ
clean
termin
disinfect
method
two
medic
ward
surgic
ward
obstetr
ward
intens
care
ward
section
select
accord
number
bed
ten
high
contact
surfac
ward
section
chosen
atp
test
sanitari
staff
clean
ward
environ
ppm
hypochlor
acid
patient
discharg
clean
surfac
minut
hour
later
surfac
rub
sampl
atp
swab
environ
monitor
result
total
sampl
rlu
valu
sampl
thu
unqualifi
rate
ward
environ
clean
refriger
door
handl
surgeri
ward
show
highest
rlu
next
ekg
monitor
keyboard
rlu
bedsid
cabinet
tabl
surfac
rlu
medic
intens
care
ward
ccu
desk
drawer
besid
bed
rlu
closet
door
handl
rlu
medic
ward
besid
surfac
surgic
intens
care
ward
icu
show
rlu
valu
indic
high
efficaci
termin
disinfect
rlu
valu
show
tabl
conclus
environment
surfac
monitor
show
unqualifi
cleanli
mean
clean
work
thoroughli
implement
provid
sanitari
unit
data
educ
train
ask
improv
practic
highrlu
environment
surfac
help
make
environ
clean
better
clean
environ
associ
better
healthcar
qualiti
gener
regularli
monitor
environ
clean
necessari
either
method
use
correl
first
line
antituberculosi
drug
hepat
background
accord
american
societi
microbiolog
blood
cultur
contamin
rate
lower
bacteriolog
laboratori
region
teach
hospit
set
threshold
monitor
blood
cultur
contamin
rate
everi
month
averag
blood
cultur
contamin
rate
juli
septemb
higher
threshold
analyz
caus
made
critic
examin
possibl
caus
follow
result
blood
cultur
contamin
rate
novemb
decemb
respect
lower
monthli
monitor
quarterli
evalu
collect
blood
cultur
sampl
carri
conclus
blood
cultur
report
provid
import
basi
physician
recogn
pathogen
result
blood
infect
prescrib
drug
effect
treatment
oper
appropri
sampl
collet
skill
help
reduc
blood
cultur
contamin
rate
provid
correct
result
ensur
accuraci
laboratori
report
increas
healthcar
qualiti
applic
fluoresc
marker
quantit
bioburden
method
cleanli
assess
ichen
hung
haoyuan
chang
anchi
chen
ling
ting
yeurhur
lai
wanghuei
sheng
nation
taiwan
univers
hospit
nation
taiwan
univers
background
improv
environment
clean
hospit
shown
decreas
crosstransmiss
pathogen
sever
object
method
includ
aerob
coloni
count
acc
adenosin
triphosph
atp
bioluminesc
assay
fluoresc
marker
develop
cleanli
assess
howev
publish
data
avail
regard
interpret
fluoresc
marker
method
studi
conduct
prospect
survey
stratifi
sampl
hospit
hightouch
surfac
test
termin
clean
use
fluoresc
marker
atp
assay
acc
surfac
fluoresc
marker
evalu
defin
total
clean
partial
clean
residu
gel
clean
benchmark
clean
criteria
atp
acc
rel
light
unit
rlu
coloni
form
unit
cfu
cm
respect
result
hightouch
surfac
surfac
total
clean
accord
fluoresc
marker
surfac
partial
clean
surfac
clean
respect
atp
acc
assess
consid
clean
accord
test
standard
surfac
fluoresc
marker
total
clean
group
signific
lower
atp
valu
acc
valu
partial
clean
group
clean
group
tabl
total
clean
group
signific
higher
atp
clean
rate
acc
clean
rate
group
total
clean
vs
clean
signific
p
evalu
provid
surfac
fluoresc
marker
total
clean
could
offer
object
standard
hospit
cleanli
strengthen
reliabl
wipe
hightouch
surfac
improv
clean
qualiti
studi
necessari
establish
associ
cleanli
microbi
transmiss
healthcareassoci
infect
background
hand
hygien
use
alcohol
hand
rub
extens
promot
hospit
sinc
adopt
element
multimod
promot
strategi
hand
hygien
includ
prepar
resourc
obtain
baselin
complianc
rate
formal
kickoff
ceremoni
serial
educ
program
continu
monitor
feedback
also
develop
ongo
action
plan
promot
hand
hygien
everi
year
complianc
rate
risen
howev
found
complianc
rate
reach
plateau
period
object
program
empow
engag
educ
train
infect
control
link
nurs
icln
hand
hygien
promot
supervis
recruit
icln
ward
unit
appoint
observ
hand
hygien
practic
reinforc
hand
hygien
complianc
enhanc
safeti
cultur
method
observ
period
divid
two
part
part
part
icln
recruit
hand
hygien
observ
introduct
hand
hygien
observ
provid
infect
control
nurs
icn
icn
provid
orient
coach
day
observ
everi
observ
till
icln
abl
perform
observ
independ
icln
assign
observ
ward
except
ward
order
avoid
bia
observ
session
last
minut
icln
selfrespond
questionnair
use
evalu
programm
afterward
ict
would
collect
duli
complet
questionnair
perform
data
analysi
result
total
number
hand
hygien
opportun
observ
icln
part
part
respect
signific
variat
vs
p
hand
hygien
complianc
rate
first
part
hand
hygien
observ
observ
perform
icn
previou
quarter
studi
overal
hand
hygien
complianc
rate
significantli
improv
p
staff
group
icln
complet
evalu
questionnair
background
tuberculosi
tb
common
legal
infecti
diseas
taiwan
lesion
tuberculosi
sometim
nonclass
lead
difficulti
make
clinic
diagnosi
thu
tuberculosi
easili
caus
nosocomi
infect
reason
behind
worth
explor
diagnosi
tuberculosi
mainli
depend
chest
xray
tbafb
tbcultur
patient
diagnos
receiv
treatment
time
juli
anoth
hospit
notifi
us
one
patient
tuberculosi
june
patient
admit
hospit
day
found
contact
estim
communic
period
month
patient
diagnos
patient
neither
present
classic
symptom
tuberculosi
receiv
chest
xray
inspect
result
want
analyz
reason
make
improv
method
use
root
caus
analysi
rca
implement
intervent
includ
add
inpati
chest
xray
inspect
routin
standard
oper
procedur
announc
infect
control
committe
visit
staff
meet
provid
inservic
educ
follow
contact
chest
xray
inspect
regularli
result
intervent
chest
xray
inspect
one
routin
admiss
inspect
inpati
also
two
regular
cours
relat
tuberculosi
year
cours
complet
rate
health
care
profession
conclus
patient
tuberculosi
may
spread
mycobacterium
tuberculosi
hospit
diagnosi
confirm
thu
increas
risk
exposur
infect
staff
patient
necessari
make
convinc
diagnosi
time
implement
infect
control
intervent
provid
care
experi
refer
medic
nurs
manag
investig
treatment
abnorm
increas
mdro
surgic
intens
care
unit
medic
center
chifen
tsou
yingl
chen
hung
jen
tang
result
control
measur
success
case
vre
colon
identifi
vre
isol
environ
surfac
bed
rail
ambu
bag
patient
bucket
urin
curtain
isol
sent
refer
laboratori
type
confirm
environment
sampl
strain
patient
isol
vre
first
occas
conclus
although
vre
known
persist
environ
concern
vre
persist
despit
clean
icu
investig
reveal
ward
cleaner
respons
clean
bed
nurs
staff
respons
clean
medic
instrument
cot
side
bed
may
move
unclear
whose
role
clean
cot
side
transmiss
patient
howev
like
occur
nearpati
area
hospit
bed
patient
equip
clean
soil
linen
room
floor
usual
done
ward
cleaner
clean
nearpati
area
greyer
may
carri
nurs
staff
ward
cleaner
healthcar
assist
depend
natur
equip
clean
importantli
nearpati
area
import
nich
transmiss
multidrug
resist
organ
investig
control
outbreak
impetigo
infect
among
newborn
matern
nurseri
region
teach
hospit
yulan
wang
yuwen
huang
yafang
wang
yongch
lau
wenchuan
lin
infect
control
offic
infecti
diseas
pediatr
infect
diseas
background
five
new
born
report
pustul
skin
arm
eye
impetigo
suspect
octob
year
matern
nurseri
implement
infect
control
measur
appli
order
control
outbreak
method
environment
laboratori
investig
start
studi
interview
healthcar
worker
work
matern
nurseri
five
neonat
present
pustul
day
admiss
found
worker
chang
protect
cloth
medic
file
locat
patient
room
worker
fail
clean
hand
repeat
use
babi
towel
clean
stuff
locat
patient
room
environment
sampl
specimen
frequent
use
neonat
care
equip
radiant
warmer
weight
scale
babi
incub
nurs
ward
keyboard
collect
bacteri
cultur
nasal
swab
sampl
background
accur
diagnosi
bloodstream
infect
reli
result
blood
cultur
especi
emerg
room
er
emerg
critic
patient
taken
care
reli
heavili
rapid
correct
blood
cultur
result
case
hospit
contamin
rate
blood
cultur
constantli
remain
high
clsi
would
influenc
physician
make
correct
diagnosi
choos
suitabl
antimicrobi
agent
therefor
reduc
contamin
rate
blood
cultur
becom
critic
issu
method
interdisciplinari
team
set
qualiti
control
approach
team
analyz
caus
blood
cultur
contamin
realtim
observ
site
certain
infect
control
strategi
implement
includ
new
trial
chg
deterg
prepar
procedur
newlytest
soak
time
sec
disinfect
cotton
swab
chg
revis
disinfect
procedur
feedback
blood
cultur
contamin
consequ
reeduc
train
result
januari
april
contamin
rate
blood
cultur
decreas
addit
wait
time
evapor
deterg
decreas
three
minut
less
one
minut
averag
blood
cultur
er
per
month
minut
hour
save
one
month
weight
medic
wast
per
sampl
decreas
gram
gram
total
gram
indic
cost
save
wast
handl
neali
per
month
er
conclus
implement
infect
polici
toward
blood
cultur
procedur
benefici
physician
make
precis
therapeut
decis
demonstr
effect
approach
reduc
wait
time
cost
er
background
hand
hygien
lead
measur
prevent
spread
antimicrobi
resist
reduc
healthcareassoci
infect
howev
healthcar
worker
complianc
optim
practic
remain
low
set
evalu
impact
multifacet
hand
hygien
hh
intervent
adher
hh
isol
rate
antibiot
resist
organ
method
multifacet
hh
intervent
conduct
isol
resist
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
mrsa
compar
convent
intervent
period
intervent
consist
multidisciplinari
hh
campaign
encourag
moment
hh
monitor
consumpt
hh
product
feedback
use
report
benchmark
direct
observ
hh
practic
mrsa
high
risk
ward
antimicrobi
use
densiti
antimicrobi
heterogen
index
also
evalu
antibiot
class
evalu
tazobactampiperacillin
carabapenem
th
gener
cephalosporinsceftazidim
fluoroquinolon
result
particip
rate
hh
campaign
increas
p
number
hh
episod
per
patient
day
calcul
consumpt
alcohol
hand
rub
increas
p
signific
differ
isol
rate
hospit
onset
mrsa
intervent
period
patient
day
p
isol
rate
p
aeruginosa
reveal
resist
class
antibiot
also
significantli
decreas
patient
day
p
addit
direct
hh
observ
reloc
new
ward
benefici
effect
mrsa
high
risk
ward
rate
antimicrobi
use
densiti
carbapenem
decreas
antimicrobi
heterogen
index
improv
conclus
parallel
introduct
multifacet
hh
intervent
strategi
appropri
use
antimicrobi
signific
impact
isol
antimicrobi
resist
organ
infect
control
experi
suspect
gastrointestin
tract
cluster
incid
psychiatr
center
rehabilit
ward
shiunyin
jeng
yupin
liu
hueilan
lu
tsojen
wang
chungshin
liao
jianan
psychiatr
center
chang
hua
hospit
background
psychiatr
patient
poor
self
hygien
selfcar
infecti
diseas
occur
easi
lead
cluster
event
psychiatr
rehabilit
ward
implement
gastrointestin
monitor
system
earli
intervent
import
low
function
close
rehabilit
ward
background
order
maintain
qualiti
bacteri
cultur
trace
infect
control
medic
staff
regularli
particip
infect
control
train
cours
implement
clinic
relat
busi
notif
posit
result
bacteri
cultur
signific
abnorm
legal
infecti
pathogen
patient
receiv
effect
treatment
immedi
annual
collect
drug
sensit
test
result
statist
analysi
group
discuss
regularli
infect
control
team
member
discuss
collabor
meaning
case
promot
clinic
interact
method
bacteri
cultur
notif
mechan
pathogen
bacteria
includ
monitor
system
pathogen
bacteria
strain
monitor
infect
case
avoid
spread
infect
avoid
cluster
infect
occur
tni
system
provid
report
function
hospit
analyz
medic
carerel
infect
result
bacteri
cultur
antibiot
resist
distribut
hospit
refer
intern
review
improv
assist
hospit
develop
appropri
monitor
mechan
method
enhanc
qualiti
nosocomi
infect
control
long
patient
test
report
presenc
bacteri
cultur
posit
laboratori
inform
send
newslett
infect
control
center
medic
pharmaci
abnorm
cultur
result
tabul
sens
meet
review
whether
absenc
neglig
result
januari
may
one
abnorm
inform
data
three
set
sputum
cultur
sent
laboratori
march
data
found
abnorm
march
report
regist
march
send
messag
doctor
pharmaceut
infect
control
center
relev
report
sent
infect
control
center
notifi
ward
provid
district
area
care
immedi
receiv
abnorm
report
famili
medicin
consult
medic
use
follow
xray
blood
examin
march
conclus
establish
mechan
prevent
bacteri
cultur
prevent
spread
infecti
diseas
hospit
speed
diagnosi
infecti
diseas
physician
expertis
understand
domest
epidem
rapid
correct
diagnosi
patient
condit
accord
sever
diseas
infecti
patient
provid
appropri
treatment
isol
measur
requir
relev
medic
staff
take
appropri
protect
measur
avoid
caus
nosocomi
infect
experi
share
applic
fluoresc
agent
detect
person
protect
equip
puton
takeoff
train
ents
yang
jann
tay
conclus
applic
fluoresc
agent
detect
evalu
skill
puttingon
takingoff
ppe
increas
learn
motiv
traine
also
provid
object
indic
realtim
feedback
addit
analyz
contamin
part
refer
prior
puton
takeoff
procedur
better
procedur
instruct
manual
could
figur
effect
activ
screen
vancomycin
resist
enterococci
vre
intens
care
unit
region
hospit
wanl
tai
chiayi
chang
gung
memori
hospit
background
preval
vancomycin
resist
enterococcu
vre
healthcareassoci
infect
significantli
increas
intens
care
unit
chg
bath
patient
icu
well
find
disinfect
erad
nidus
multipl
drug
resist
organ
mdro
cultur
item
nidus
discov
feed
cup
plastic
basket
belong
individu
bed
individu
patient
work
tabl
nurs
two
commun
bedpan
analyz
data
retrospect
prospect
infect
control
databas
sinc
may
icu
bed
calcul
monthli
trend
crkp
two
stage
infect
control
measur
icu
adjust
effect
hand
hygien
antibiot
usag
order
assess
chang
crkp
period
use
gener
addit
model
gam
fix
effect
period
time
per
month
complianc
accuraci
hand
wash
random
effect
period
time
random
effect
show
chang
crkp
intervent
result
upward
trend
crkp
turn
downward
second
stage
intervent
significantli
figur
second
stage
intervent
show
signific
effect
rr
ci
tabl
fix
effect
hand
hygien
nonsignific
result
show
signific
differ
incid
mdro
occurr
two
abnorm
event
first
occurr
mdro
mdro
sudden
chang
caus
kpc
analysi
caus
abnorm
event
contact
isol
measur
environment
cleanli
infect
control
intervent
measur
addit
origin
hand
hygien
contact
isol
measur
environment
clean
highrisk
case
identifi
case
central
care
second
occurr
mdro
abnorm
event
suspect
burst
bacteria
crab
monitor
caus
event
may
due
unit
space
clean
bed
equip
care
area
bed
abnorm
process
infect
control
measur
collect
origin
collect
area
collect
strengthen
detect
room
increas
noncrab
environment
clean
frequenc
result
second
use
mdro
abnorm
first
use
bundl
care
hand
hygien
contact
isol
protect
measur
environment
clean
highrisk
partit
isol
second
use
bundl
care
hand
hygien
contact
isol
protect
measur
environ
clean
found
combin
mdro
suspect
group
time
mdro
detect
unit
analysi
abnorm
event
discuss
care
unit
main
reason
occurr
event
possibl
combin
care
work
still
effect
solv
outbreak
event
conclus
taiwan
medic
care
environ
clinic
care
worker
often
fail
clarifi
care
area
patient
area
immedi
work
busi
result
complianc
rate
hand
hygien
contact
isol
reach
therefor
reduc
care
worker
due
hand
hygien
contact
isol
measur
implement
lead
migrat
caus
infect
addit
detect
mdro
must
concentr
receiv
two
abnorm
event
handl
still
need
consid
staff
infect
control
requir
holist
manner
consid
effici
way
solv
problem
experi
use
refer
deal
suspect
mdro
outbreak
event
background
follow
pilot
studi
alcoholbas
hand
gel
ttsh
chosen
extens
evalu
apriljun
method
inpati
ward
outpati
occup
physiotherapi
clinic
chosen
base
alcoholbas
handrub
util
studi
period
hand
gel
place
ward
clinic
begin
week
exist
handrub
remov
trial
period
healthcar
worker
handwash
handrub
accord
moment
per
hospit
polici
week
trial
washout
period
week
hand
gel
replac
exist
handrub
healthcar
worker
invit
particip
survey
nine
attribut
product
use
likertscal
trial
period
mean
score
comput
attribut
student
ttest
use
compar
differ
staff
told
report
advers
reaction
studi
team
monitor
record
skin
reaction
trial
result
particip
nurs
alliedhealth
profession
doctor
particip
thought
product
c
work
better
current
product
rate
best
overal
satisfact
comparison
two
mean
product
c
current
handrub
eight
attribut
signific
examplesplash
mean
score
vs
p
conclus
product
c
prefer
hand
gel
consid
altern
current
hand
hygien
product
phase
model
share
phase
juli
septemb
hold
experi
share
confer
regular
meet
help
eight
hospit
southern
taiwan
improv
cauti
result
phase
cauti
rate
declin
three
icu
phase
cauti
rate
reduc
six
icu
phase
total
hospit
overal
cauti
rate
improv
conclus
multimod
intervent
nursingdriven
base
essenti
reduc
cauti
point
extens
make
success
experi
duplic
unit
hospit
epidemiolog
predictor
mortal
bloodstream
infect
among
patient
temporari
hemodialysi
cathet
mengch
chen
yinyin
chen
fuder
wang
infect
control
divis
infecti
diseas
depart
medicin
taipei
veteran
gener
hospit
taipei
taiwan
nation
yangm
univers
taipei
taiwan
background
bloodstream
infect
bsi
common
patient
temporari
hemodialysi
cathet
result
prolong
hospit
increas
medic
expens
increas
risk
mortal
studi
aim
explor
profil
recogn
pathogen
predict
prognost
factor
mortal
bloodstream
infect
method
retrospect
studi
perform
medic
center
epidemiolog
investig
conduct
patient
temporari
hemodialysi
cathet
report
bsi
inclued
except
individu
age
chisquar
test
use
categor
variabl
mannwhitney
u
test
use
data
nonnorm
distribut
logist
regress
analysi
use
assess
predict
prognost
factor
mortal
result
total
patient
bsi
includ
studi
period
patient
predominantli
male
mean
age
year
median
length
stay
day
common
isol
organ
staphylococcu
aureu
acinetobact
baumannii
klebsiella
pneumonia
common
isol
antimicrobialresist
pathogen
methicillinresist
coagulaseneg
staphylococcu
carbapenemresist
acinetobact
baumannii
methicillinresist
staphylococcu
aureu
crude
rate
inhospit
mortal
rate
mortal
rate
death
logist
regress
analysi
identifi
shock
odd
ratio
confid
interv
ci
bedridden
ci
use
continu
venoven
hemofiltr
cvvh
ci
antibiot
ci
mechan
ventil
ci
independ
predictor
mortal
conclus
common
isol
organ
bsi
staphylococcu
aureu
patient
temporari
hemodialysi
cathet
shock
bedridden
use
cvvh
antibiot
mechan
ventil
independ
predict
prognost
factor
mortal
use
vap
bundl
prevent
ventil
associ
pneumonia
medic
center
intens
care
unit
yach
huang
chunhs
liao
meil
fang
chingjung
tsai
peichi
tu
shuchuan
huang
far
eastern
memori
hospit
background
mechan
intub
essenti
part
critic
patient
ventil
associ
pneumonia
vap
import
complic
intub
increas
hospit
cost
prolong
hospit
stay
potenti
threaten
patient
life
bundl
intervent
propos
effect
decreas
incid
vap
order
reduc
occurr
vap
vap
care
bundl
care
implement
intens
care
unit
sinc
method
intens
care
unit
provid
care
medic
case
mainli
bed
vap
bundl
includ
educ
enhanc
vap
bundl
care
awar
background
mani
critic
ill
patient
surviv
use
mechan
ventil
howev
patient
seriou
clinic
condit
immunecompromis
statu
mani
health
care
associ
infect
like
ventilatorassoci
pneumonia
vap
major
complic
vap
defin
pneumonia
hour
use
ventil
mainli
due
bacteri
infect
accord
us
nosocomi
infect
surveil
system
data
incid
vap
also
import
indic
qualiti
control
critic
care
unit
incid
vap
relat
length
hospit
stay
durat
mechan
ventil
incid
increas
everi
one
day
hospit
stay
peak
incid
occur
seventh
day
averag
day
ventil
use
thu
ventil
use
longer
durat
increas
patient
hospit
stay
mortal
hospit
incid
vap
intens
care
unit
expect
achiev
zero
toler
come
year
howev
mani
new
health
care
personnel
year
multipl
health
care
measur
fulfil
target
central
diseas
control
depart
implement
program
bundl
care
invas
health
care
procedur
fortun
particip
program
strengthen
prevent
vap
applic
bundl
care
method
appli
health
care
personnel
train
basic
knowledg
bundl
care
sinc
februari
implement
vap
bundl
care
includ
elev
head
bed
oral
cleans
use
tooth
clean
spong
small
tooth
brush
chlorhexidin
contain
mouthwash
set
clean
steril
steam
inhal
therapi
equip
chang
tube
regularli
addit
set
bottl
facilit
remov
fluid
insid
ventil
circuit
avoid
contamin
environ
standard
infect
control
measur
ad
intens
care
unit
manual
keep
health
care
personnel
follow
result
follow
februari
june
vap
case
period
continu
health
care
provid
educ
train
appli
bundl
care
vap
thu
incid
vap
effect
reduc
conclus
evid
base
strategi
bundl
care
seem
simpl
develop
promot
implement
strategi
counter
check
measur
signific
implement
vap
bundl
care
prevent
reduc
vap
incid
decreas
durat
ventil
use
averag
length
hospit
stay
decreas
patient
morbid
mortal
experi
reduc
catheterrel
urinari
tract
infect
medic
center
hueiwen
lai
ilun
hou
yulin
lee
tsunjung
liu
doctor
order
foley
insert
chang
stand
order
instead
stat
order
catheter
hour
system
remind
doctor
remov
foley
everi
day
skin
disinfect
foley
insert
use
aqua
chg
chang
size
catheterrecommend
addit
urin
sediment
hematuria
surgeri
bph
etc
recommend
use
size
rest
situat
consid
use
fr
expand
asept
area
preconnect
cathet
urin
bag
prevent
comtamin
use
bladder
scan
avoid
repeat
foley
insert
train
specialist
check
bundl
care
foley
insert
daili
care
catheterrel
urinari
tract
infect
intervent
reduc
pvalu
conclus
infect
control
committe
identifi
effect
measur
infect
control
manual
reduc
catheterrel
urinari
tract
infect
continu
monitor
qualiti
indic
survey
effect
vap
ventilatorassoci
pneumonia
prevent
implement
care
bundl
icu
region
hospit
taiwan
background
icu
within
bed
belong
gener
adult
intens
care
unit
start
implement
care
bundl
vap
prevent
june
realiz
effect
analyz
densiti
infect
use
rate
ventil
two
period
preintervent
nov
may
postintervent
jun
dec
result
refer
continu
improv
qualiti
medic
care
method
infect
control
practition
collect
case
base
surveil
definit
vap
formul
cdc
case
reconfirm
minist
critic
care
medicin
follow
intervent
propos
cdc
jct
item
lift
head
bed
ceas
sed
daili
daili
evalu
extub
drain
water
ventil
empti
perform
oral
nurs
care
mouthwash
contain
chlorhexidin
least
time
per
day
keep
record
check
list
result
statist
show
densiti
infect
period
preintervent
postintervent
respect
use
rate
ventil
conclus
densiti
infect
increas
month
postintervent
stage
valu
chisquar
test
p
use
rate
ventil
increas
rate
higher
rate
equival
icu
identifi
tni
taiwan
analyz
case
found
case
per
season
individu
occur
everi
differ
month
zero
infect
maintain
latest
season
show
daili
evalu
extub
put
effect
definit
abl
improv
qualiti
medic
care
explor
effect
urinari
cathet
care
bundl
system
shawshin
wu
huimei
huang
weipin
lai
taichung
veteran
gener
hospit
regist
nurs
taichung
taiwan
taichung
veteran
gener
hospit
supervisor
taichung
taiwan
taichung
veteran
gener
hospit
engin
taichung
taiwan
background
establish
inform
system
onlin
cathet
remov
assess
tool
urinari
cathet
bundl
care
improv
bundl
care
complianc
thu
reduc
urinari
cathet
indwel
day
usag
infect
densiti
method
patient
comprehens
ward
medic
centr
select
studi
object
purpos
sampl
studi
period
januari
april
program
design
set
onlin
cathet
remov
assess
tool
realtim
queri
system
mobil
app
program
mobil
app
program
includ
placement
check
daili
care
evalu
result
studi
period
patient
urinari
cathet
total
day
cathet
indwel
program
set
cathet
placement
check
done
patient
cathet
insert
complianc
rate
util
program
total
staff
preform
urin
cathet
daili
assess
use
program
complianc
rate
increas
averag
length
cathet
indwel
decreas
day
day
cathet
util
rate
decreas
catheterrel
urinari
tract
infect
densiti
decreas
satisfact
rate
informat
conclus
system
first
implant
initi
complianc
rate
reason
physician
complet
daili
assess
cathet
remov
program
ad
evalu
path
remind
window
physician
order
system
complianc
rate
increas
combin
implant
informat
onlin
realtim
inquir
system
mobil
devic
usercent
program
design
achiev
purpos
simplifi
process
increas
effici
data
process
integr
enhanc
complianc
result
significantli
improv
complianc
rate
care
bundl
user
satisfact
reduc
use
cathet
length
indwel
infect
densiti
effect
ventilatorassoci
pneumonia
bundl
intervent
region
hospit
yuhsiu
lin
siaopei
guo
pakon
leung
meif
sie
yeehuang
ku
jyhjou
chen
background
nebul
devic
wide
use
deliv
aerosol
therapi
especi
pediatr
patient
respiratori
diseas
howev
nebul
potenti
sourc
microbi
contamin
respiratori
tract
smallvolum
nebul
medic
administ
bronchodil
includ
handheld
nebul
produc
bacteri
aerosol
ultrason
handheld
nebul
associ
nosocomi
pneumonia
method
order
understand
suitabl
influenc
ultrason
nebul
use
treatment
respiratori
diseas
paediatr
patient
conduct
systemat
literatur
review
articl
publish
april
keyword
chines
english
enter
search
engin
compris
medic
databas
select
articl
match
standard
review
result
hour
usag
burkholderia
cepacia
complex
bcc
isol
ultrason
nebul
bcc
isol
obtain
nebul
drain
tube
oper
water
chamber
oscil
nebul
solut
evidencebas
medicin
literatur
suggest
appropri
mainten
ultrason
nebul
crucial
prevent
bcc
contamin
nebul
subsequ
respiratori
tract
blood
infect
new
contamin
control
measur
implement
follow
avail
ultrason
nebul
strictli
limit
time
devic
return
medic
engin
section
mainten
nebul
drain
tube
oscil
complet
disinfect
everi
h
use
ethanol
use
nebul
survey
diaphragm
breakag
pinhol
use
devic
measur
electr
resist
addit
observ
children
breath
pattern
avoid
cold
high
dens
fog
caus
respiratori
spasm
problem
conclus
literatur
evid
show
use
ultrasound
nebul
risk
nosocomi
respiratori
infect
moreov
addit
mainten
procedur
requir
instrument
mainten
recommend
use
singl
use
dispos
jet
nebul
regard
patient
safeti
cost
consider
therapeut
effect
recommend
implement
clean
disinfect
procedur
order
make
best
treatment
spray
therapi
right
equip
mouth
tube
mask
chosen
fit
children
age
cognit
abil
effect
deploy
care
bundl
precaut
catheterassoci
urinari
tract
infect
ward
orthoped
belong
region
hospit
locat
southern
taiwan
lichun
liu
likuan
chih
chihlin
liu
suchen
liu
chihhsuan
cheng
wenhan
chang
yingsheng
pan
infect
control
committe
tainan
municip
hospit
taiwan
nurs
depart
tainan
municip
hospit
taiwan
orthoped
tainan
municip
hospit
taiwan
background
hospit
bed
acut
patient
bed
laid
ward
orthoped
bed
appli
place
cure
patient
depart
orthoped
neurosurgeri
urolog
densiti
urinari
tract
infect
ward
occupi
rd
place
rank
ward
hospit
becam
ward
particip
measur
care
bundl
catheterassoci
urinari
tract
infect
propos
cdc
jct
june
st
start
collect
number
patient
use
cathet
per
day
realiz
effect
sheet
discuss
depth
method
case
catheterassoci
urinari
tract
infect
collect
base
surveil
definit
healthcareassoci
infect
second
edit
revis
cdc
follow
measur
propos
cdc
jct
item
place
inspect
execut
hand
hygien
insert
cathet
use
asept
techniqu
steril
insert
cathet
cathet
proper
fix
way
execut
hand
hygien
immedi
insert
cathet
measur
daili
care
evalu
take
precaut
catheterassoci
urinari
tract
infect
evalu
extub
hand
hygien
fix
posit
asept
fluent
urethr
orific
clean
result
statist
show
densiti
first
half
year
junnov
deploy
care
bundl
second
half
year
dec
may
third
half
year
junnov
use
rate
respect
conclus
compar
measur
deploy
one
half
year
first
half
densiti
infect
obvious
declin
valu
fisher
exact
test
p
show
deploy
care
bundl
lower
densiti
still
room
improv
rate
use
cathet
rise
possibl
reason
relat
specif
patient
receiv
cure
inform
provid
medic
profess
refer
investig
treatment
abnorm
increas
bloodstream
infect
peripher
blood
stem
cell
transplant
hsiaoshan
chen
hungjen
tang
yinhsun
feng
yale
hsien
chinyi
li
iigl
chen
background
ventilatorassoci
pneumonia
vap
common
healthcareassoci
infect
intens
care
unit
caus
patient
sever
morbid
mortal
jan
execut
ventil
care
bundl
vcb
reduc
vap
hospit
includ
daili
assess
readi
extub
daili
sedat
vacat
elev
patient
head
bed
use
chlorhexidin
oral
care
exhaust
water
ventil
circuit
everi
two
hour
vap
incid
reduc
surgic
intens
care
unit
sicu
still
higher
sicu
teach
hospit
order
reduc
vap
incid
sicu
use
qualiti
control
circl
reinforc
efficaci
vcb
method
hospit
region
teach
hospit
sicu
use
qualiti
control
circl
find
disadvantag
vcb
program
includ
poor
cognit
vcb
sicu
member
lack
intern
audit
carri
vcb
misarrang
suction
tube
aerosol
therapi
apparatu
inaccur
angl
elev
bed
head
execut
improv
plan
includ
regular
train
program
vcb
sicu
develop
audit
system
adequ
storag
suction
tube
aerosol
therapi
apparatu
ad
angl
scale
bedsid
result
intervent
vap
incid
sicu
reduc
accuraci
vcb
increas
conclus
qualiti
control
circl
good
way
reinforc
efficaci
vcb
explor
effect
cauti
bundl
care
southern
region
hospit
yan
ru
chen
yeehuang
ku
infect
control
center
chi
mei
medic
center
liouy
background
urinari
tract
infect
uti
one
common
medic
carerel
infect
account
associ
use
cathet
hospit
involv
depart
health
welfar
medic
treatment
care
qualiti
improv
program
promot
catheterrel
urinari
tract
combin
care
measur
clinic
field
audit
found
problem
feedback
unit
improv
reduc
urinari
tractrel
urinari
tract
infect
improv
medic
qualiti
protect
patient
safe
method
intern
control
cathet
carri
intern
care
manag
extern
control
infect
control
nurs
monthli
audit
statist
feedback
male
catheter
competit
held
technolog
standard
actual
applic
clinic
practic
result
promot
program
januari
june
gener
hospit
cauti
densiti
intens
care
unit
juli
start
field
audit
cathet
placement
care
complianc
cauti
infect
densiti
tabl
show
although
audit
complianc
rate
increas
intens
care
unit
cauti
densiti
increas
gener
ward
cauti
densiti
flat
plan
promot
januari
march
complianc
rate
nurs
practition
perform
male
patient
catheter
april
male
catheter
competit
held
cours
intern
medicin
surgeri
rate
complianc
complianc
rate
increas
april
august
complianc
rate
conclus
lead
catheterassoci
urinari
tract
infect
may
larg
number
factor
soon
possibl
remov
cathet
asept
techniqu
oper
daili
care
necessari
perform
ring
audit
regular
feedback
unit
staff
inservic
educ
evalu
indic
continu
track
period
effect
reduc
catheterassoci
urinari
tract
infect
densiti
applic
diversifi
strategi
improv
qualiti
cathet
care
yumei
ho
wenyin
huang
wenjen
yau
tsungyen
yang
powen
yang
nanp
yang
key
element
cauti
bundl
consist
hand
hygien
wear
person
protect
equip
use
dispos
glove
cleans
urethr
meatu
prior
cathet
insert
use
steril
salin
daili
assess
cathet
need
asept
urin
sampl
techniqu
make
sure
drain
bag
cathet
right
posit
multidisciplinari
team
led
deputi
superintend
regular
educ
program
committe
held
incid
cauti
cost
compar
preand
postintervent
phase
result
patient
suffer
cauti
preand
postintervent
phase
incid
rate
cauti
per
catheterday
preand
postintervent
phase
respect
p
establish
standard
process
cathet
care
educ
train
standard
cathet
placement
process
daili
care
process
besid
keep
monitor
sop
product
cathet
flow
chart
remind
earli
assess
possibl
remov
cathet
remind
card
catheter
bedsid
remind
day
catheter
chart
remind
day
catheter
system
implement
standard
cathet
care
design
new
cathet
fix
sticker
bed
patient
use
conveni
pant
could
hide
urin
bag
hook
affix
keep
urin
bag
smoothli
place
rubyr
tape
ml
urin
bag
check
drainag
system
maintain
close
avoid
distort
compress
chang
posit
result
implement
intervent
measur
recheck
septemb
uncomplet
care
indwel
urinari
cathet
rate
indwel
cathet
associ
urinari
tract
infect
rate
averag
number
day
indwel
cathet
drop
significantli
day
januari
august
conclus
unit
indwel
cathet
associ
urinari
tract
infect
rate
last
year
check
problem
analysi
found
caus
problem
creativ
strategi
interven
intervent
includ
sop
indwel
cathet
associ
urinari
tract
infect
rate
decreas
transdisciplin
enhanc
care
implement
infect
control
interprofession
collabor
practic
reduc
incid
ventil
associ
pneumonia
day
mechan
ventil
use
intens
care
unit
waner
jang
hsinyu
cheng
yu
lin
taipei
hospit
ministri
health
welfar
jang
waner
background
ventil
associ
pneumonia
common
hospit
infect
critic
ill
patient
also
import
indic
healthcar
qualiti
infect
rate
ventil
associ
pneumonia
increas
establish
project
interprofession
collabor
practic
reduc
incid
ventil
associ
pneumonia
day
mechan
ventil
use
intens
care
unit
therebi
reduc
mortal
hospit
day
health
care
cost
method
research
larger
cohort
studi
could
help
clarifi
characterist
impact
bundl
care
prevent
healthcareassoci
infect
intens
care
unit
local
hospit
taiwan
bundl
care
prevent
hai
intens
care
unit
icu
local
hospit
taiwan
method
qualityimprov
intervent
includ
educ
vap
bundl
central
venou
cathet
cvc
insert
bundl
cauti
bundl
process
outcom
surveil
sequenti
introduc
sinc
intervent
period
implement
multidisciplinari
care
bundl
consist
hand
hygien
use
maximum
barrier
precaut
use
chlorhexidin
scrub
insert
site
headofb
elev
educ
provid
dedic
line
cart
checklist
oral
care
chlorhexidin
solut
twice
daili
daili
consider
need
cathet
mani
measur
incid
rate
hai
bundl
intervent
measur
compar
result
incid
rate
overal
hai
bundl
intervent
episod
vap
record
studi
period
rate
ventil
use
icu
significantli
declin
incid
rate
bsi
cauti
bundl
intervent
respect
background
purpos
studi
compar
effect
chlorhexidin
glucon
chg
oral
rins
normal
salin
reduc
number
oral
bacteria
incid
rate
ventilatorassoci
pneumonia
vap
order
establish
standard
procedur
clinic
practic
method
doubleblind
random
clinic
trial
conduct
intens
care
unit
icu
district
hospit
patient
randomli
assign
experiment
group
n
receiv
chg
control
group
n
receiv
normal
salin
mouth
care
studi
initi
educ
train
carri
icu
nurs
staff
oral
care
oropharyng
swab
sampl
chisquar
ttest
use
analyz
differ
two
group
surviv
time
analyz
show
whether
differ
occurr
vap
result
signific
differ
age
sex
type
artifici
airway
day
artifici
airway
use
two
group
signific
differ
coloni
growth
x
p
abnorm
bodi
temperatur
x
p
incid
vap
experiment
control
group
x
p
respect
incid
vap
experiment
control
group
x
p
respect
surviv
analysi
show
mean
durat
vap
day
experiment
group
day
control
group
conclus
comparison
effect
normal
salin
oral
care
patient
artifici
airway
ventil
use
chg
significantli
reduc
oral
bacteria
growth
reduc
abnorm
rate
temperatur
delay
time
vap
occurr
recommend
futur
studi
may
necessari
increas
sampl
size
determin
effect
chg
reduc
incid
vap
find
suggest
chg
use
oral
care
reduc
patient
oral
bacteria
delay
time
vap
occurr
coexist
clinic
carbapenemresist
escherichia
coli
isol
chihcheng
lai
chichung
chen
yinch
chuang
hungjen
tang
background
sinc
new
delhi
first
detect
sever
variant
identifi
differ
one
two
amino
acid
substitut
novel
first
identifi
sequenc
type
klebsiella
pneumonia
strain
like
ndm
variant
confer
high
level
resist
compromis
effect
antibiot
includ
carbapenem
although
polymyxin
b
colistin
polymyxin
e
offer
limit
treatment
option
multidrugresist
mdr
organ
carri
emerg
plasmidmedi
colistin
resist
gene
mobilis
colistin
resist
gene
confer
resist
colistin
polymyxin
e
may
attenu
util
colistin
method
antimicrobi
suscept
test
clinic
isol
test
agar
dilut
method
genet
background
detect
includ
multilocu
sequenc
type
mlst
drug
resist
gene
pcr
sequenc
result
femal
patient
histori
colon
cancer
chronic
kidney
diseas
undergon
radic
left
hemicolectomi
month
prior
current
hospit
admiss
admit
intens
care
unit
periton
septic
shock
clinic
condit
haemodynam
statu
gradual
improv
follow
antibiot
treatment
piperacillintazobactam
tzp
day
result
laboratori
examin
follow
white
blood
cell
count
mm
platelet
count
creatinin
mgdl
aspart
aminotransferas
iul
creactiv
protein
mgl
refer
valu
mgl
despit
tzp
resum
uti
complic
sepsi
syndrom
clinic
condit
rapidli
deterior
patient
famili
request
support
care
final
patient
die
day
hospit
meanwhil
urinari
cathet
specimen
grew
carbapenemresist
e
coli
molecular
diagnosi
identifi
e
coli
isol
carri
conclus
present
case
indic
possibl
coproduct
among
clinic
isol
indic
import
surveil
colistinand
carbapenemresist
enterobacteriacea
isol
associ
gene
human
special
refer
background
studi
intend
investig
impact
implement
catheterassoci
urinari
tract
infect
cauti
bundl
care
incid
cauti
highrisk
unit
taiwan
method
thirteen
highrisk
unit
includ
medic
n
surgic
n
cardiac
intens
care
unit
n
respiratori
care
center
n
respiratori
care
ward
n
includ
qualityimprov
project
stud
period
divid
preintervent
phase
januari
juli
postintervent
phase
august
octob
result
incid
cauti
decreas
per
catheterday
ci
p
introduct
cauti
bundl
among
episod
cultureproven
cauti
candida
spp
common
pathogen
n
seven
element
insert
bundl
complianc
lowest
clean
perineum
follow
hand
hygien
overal
complianc
rate
insert
bundl
medic
center
region
hospit
district
hospit
respect
six
element
mainten
bundl
complianc
lowest
daili
review
need
foley
cathet
overal
complianc
rate
mainten
bundl
medic
center
region
hospit
district
hospit
respect
conclus
implement
cauti
bundl
care
reduc
cauti
process
surveil
checklist
help
understand
part
bundl
care
requir
improv
role
doxycyclin
therapi
multidrugresist
e
colian
vitro
studi
chihcheng
lai
chichung
chen
yinch
chuang
hungjen
tang
background
studi
assess
vitro
antibacteri
activ
combin
amikacin
doxycyclin
tigecyclin
multidrugresist
e
coli
isol
method
twentyfour
differ
pulsotyp
includ
extendedspectrum
esbl
carbapenemresist
new
delhi
metallobetalactamas
ndm
klebsiella
pneumonia
carbapenemas
kpc
e
coli
isol
collect
combin
effect
detect
two
method
includ
checkerboard
timekil
result
isol
suscept
amikacin
tigecyclin
esbl
carbapenemresist
e
coli
suscept
doxycyclin
ndme
coli
mic
checkerboard
method
show
esbland
carbapenemresist
e
coli
synergist
effect
amikacindoxycyclin
respect
two
kpcand
two
ndme
coli
fic
index
amikacindoxycyclin
respect
esbland
carbapenemresist
e
coli
isol
combin
amikacin
doxycyclin
exhibit
synergist
activ
vs
isol
concentr
respect
synergist
effect
seem
similar
doxycyclin
tigecyclin
base
combin
amikacin
conclus
antibacteri
activ
doxycyclin
enhanc
addit
amikacin
observ
multidrugresist
e
coli
isol
impact
mortal
central
venou
cathet
associ
bloodstream
infect
medic
center
shu
mei
sun
yin
yin
chen
fu
der
wang
infect
control
taipei
veteran
gener
hospit
nation
yangm
univers
medic
depart
taipei
veteran
gener
hospit
background
central
venou
cathet
signific
risk
factor
healthcar
associ
bloodstream
infect
often
increas
mortal
risk
method
retrospect
surveil
studi
conduct
nearli
medic
center
taiwan
hospit
patient
older
develop
healthcar
associ
bloodstream
infect
admit
includ
includ
first
episod
bloodstream
infect
patient
experienc
one
episod
healthcar
associ
bloodstream
infect
univari
analysi
use
chisquar
test
ttest
mannwhitney
u
test
identifi
signific
risk
factor
cabsi
finali
logist
regress
use
explor
impact
prognost
factor
mortal
cabsi
result
total
healthcar
associ
bloodstream
infect
enrol
studi
central
venou
cathet
associ
patient
experienc
cabsi
high
mortal
rate
noncabsi
group
vs
p
well
mortal
vs
p
univari
analysi
result
control
potenti
confound
factor
use
logist
regress
model
analysi
identifi
cabsi
independ
risk
factor
mortal
confid
interv
ci
p
conclus
result
demonstr
central
venou
cathet
associ
bloodstream
infect
led
higher
mortal
medic
center
remov
cathet
reduc
usag
urinari
catheter
urinari
tract
infect
hospit
patient
wan
tsuei
huang
yin
yin
chen
fu
der
wang
infect
control
taipei
veteran
gener
hospit
nation
yangm
univers
background
studi
appli
remov
cathet
evalu
effect
evalu
measur
rate
catheterassoci
urinari
tract
infect
catheter
day
urinari
cathet
use
method
prospect
followup
studi
perform
medic
center
approach
indwel
urinari
cathet
presenc
hour
jul
jun
sinc
juli
intervent
cathet
catheter
urinari
catheter
evalu
measur
observ
use
cathet
catheterrel
urinari
tract
infect
rate
chang
result
total
patient
recruit
util
rate
indwel
urinari
cathet
intervent
decreas
significantli
p
durat
catheter
increas
day
day
p
averag
rate
catheterassoci
urinari
tract
infect
p
chisquar
trend
test
signific
differ
conclus
evalu
urinari
cathet
extract
provid
physician
nurs
assess
remov
cathet
soon
possibl
mani
factor
affect
cauti
recommend
futur
continu
promot
multifacet
measur
teamwork
reduc
unnecessari
cathet
indwel
attent
bladder
function
assess
continu
reduc
cathet
use
resuscit
rate
hope
abl
reduc
cauti
final
region
hospit
use
bundl
care
lower
ventilatorassoci
pneumonia
infect
icu
hsiaopei
kuo
yeehuang
ku
infect
control
center
chi
mei
medic
center
liouy
tainan
taiwan
background
respiratoryrel
pneumonia
increas
patient
mortal
prolong
hospit
day
medic
expens
serious
affect
patient
prognosi
intervent
respiratorassoci
pneumonia
combin
complianc
rate
complianc
audit
effect
reduc
respiratori
rate
pneumonia
associ
method
five
adult
intens
care
unit
district
hospit
south
combin
respiratorassoci
pneumonia
base
intrus
care
dispos
qualiti
improv
program
julydecemb
first
phase
implement
januaryjun
second
phase
implement
juli
decemb
third
stage
implement
result
statist
first
phase
complianc
daili
extub
assess
stabil
agent
oral
care
bedsid
empti
due
bedsid
elev
complianc
low
respiratori
therapist
unit
care
chief
enhanc
remind
feedback
second
stage
audit
effect
bedsid
elev
complianc
rate
third
stage
audit
result
bedsid
complianc
complianc
rate
oral
care
first
stage
complianc
rate
upgrad
third
stage
complianc
respiratori
associ
pneumonia
infect
rate
decreas
intervent
third
stage
conclus
establish
regular
feedback
audit
mechan
import
teamwork
effect
improv
complianc
rate
therebi
reduc
respir
rate
respiratoryrel
pneumonia
third
phase
hospit
complianc
rate
reduc
respir
pneumonia
improv
ventilatorassoci
pneumonia
bundl
care
teamwork
intens
care
unit
yuhsia
wang
lihsueh
chen
naizhen
hou
depart
nurs
tainan
municip
hospit
background
mortal
rate
approach
ventilatorassoci
pneumonia
vap
account
health
careassoci
infect
hcai
patient
receiv
mechan
assist
ventil
risk
acquir
pneumonia
compar
patient
receiv
ventilatori
support
risk
acquir
pneumonia
increas
per
day
prevent
better
cure
therefor
care
patient
mechan
ventil
especi
import
expect
implement
care
bundl
improv
hcai
rate
ensur
high
care
qualiti
method
care
bundl
includ
care
ventil
circuit
daili
assess
sedat
oral
hygien
head
bed
elev
intermitt
subglott
secret
drainag
drain
ventil
circuit
implement
januari
incid
vap
higher
hospit
initi
implement
stage
caus
lack
knowledg
care
bundl
strategi
low
implement
rate
lack
unifi
mouthwash
ingredi
lack
standard
audit
practic
low
correct
rate
care
practic
strengthen
implement
infect
control
measur
chang
institut
manag
human
behavior
need
henc
measur
includ
educ
program
evidencebas
research
innov
approach
vap
guidelin
audit
multidisciplinari
team
work
result
care
qualiti
improv
addit
staff
knowledg
vap
increas
accuraci
implement
care
achiev
via
audit
analysi
control
chart
monitor
rate
vap
indic
process
control
dramat
improv
comparison
hospit
benefit
includ
higher
rate
ventil
wean
lower
infect
rate
conclus
use
teamwork
build
safeti
cultur
contribut
promot
complianc
care
bundl
chang
institut
manag
staff
behavior
improv
qualiti
health
care
also
assur
patient
safeti
benefit
hospit
health
worker
govern
reduc
ventilatorassoci
pneumonia
surgic
intens
care
unit
upgrad
integr
care
peiyu
taeng
fangyu
shih
nurs
buddhist
tzu
chi
medic
foundat
taipei
tzu
chi
hospit
background
incid
ventil
associ
pneumonia
surgic
intens
care
ward
higher
other
integr
care
carri
howev
found
poorli
practic
program
familiar
lack
relev
educ
train
april
incid
respiratoryrel
pneumonia
high
result
nurs
care
qualiti
great
challeng
method
intens
care
unit
physician
nurs
respiratori
therapist
compos
special
committe
juli
use
innov
method
produc
vap
bundl
care
poster
standard
elev
bed
degre
modifi
oral
care
daili
teamwork
hand
document
sustain
train
job
enhanc
colleagu
realiz
integr
care
result
later
unitintegr
care
increas
improv
cognit
test
increas
point
point
ventilatorassoci
pneumonia
rate
decreas
conclus
implement
integr
care
respiratori
caus
relev
pneumonia
reduc
infect
caus
ventil
also
reduc
number
day
patient
use
respir
shorten
length
patient
stay
mortal
intens
care
unit
efficaci
care
bundl
improv
catheterassoci
urinari
tract
infect
siyin
lin
chihjen
liu
chenszu
chin
addit
formal
program
start
protocol
recruit
patient
famili
member
particip
care
bundl
cauti
order
improv
care
qualiti
reduc
rate
cauti
method
hospit
task
group
start
program
intervent
juli
primari
survey
staff
perform
urinari
catheter
reveal
although
knowledg
cauti
correct
perform
correct
sinc
introduc
care
bundl
program
urinari
catheter
medic
surgic
ward
program
inservic
educ
medic
team
member
includ
handon
teach
onlin
learn
independ
risk
factor
mortal
stratifi
patient
critic
ill
noncrit
ill
group
found
appropri
antimicrobi
therapi
associ
surviv
benefit
group
conclus
host
factor
predictor
mortal
patient
crkp
bacteriuria
antimicrobi
treatment
associ
surviv
benefit
either
critic
ill
noncrit
ill
patient
find
may
provid
insight
futur
antibiot
stewardship
intervent
influenc
chang
frequenc
patient
urinari
drainag
bag
cleanli
urinari
tract
infect
chuchun
lin
yinyin
chen
fuder
wang
background
indwel
urinari
cathet
one
commonest
clinic
treatment
evid
base
replac
time
foley
cathet
urinari
drainag
bag
rang
week
two
week
per
month
cilin
standard
oper
procedur
research
motiv
come
oper
differ
guidelin
us
center
diseas
control
prevent
method
observ
studi
june
juli
patient
alloc
studi
case
inpati
foley
day
infect
ward
central
hospit
taipei
citi
risk
factor
contamin
qualiti
urinari
drainag
bag
binari
outcom
analyz
logist
regress
observ
two
group
chang
urinari
drainag
bag
day
result
found
patient
foley
clean
contamin
chang
bag
group
chang
bag
group
clean
dirti
p
two
group
urinari
drainag
bag
cleanli
signific
differ
p
silicon
materi
latex
cathet
coat
silicon
coat
materi
train
microorgan
p
compar
two
group
chang
bag
group
microorgan
cultur
data
patient
chang
group
patient
signific
statist
analysi
p
logist
regress
use
analyz
adjust
variabl
chang
group
shelter
effect
howev
whether
chang
urinari
drainag
bag
would
signific
bacteria
cultur
p
conclus
patient
indwel
cathet
day
group
chang
urinari
drainag
bag
everi
day
cathet
significantli
dirti
signific
differ
urinari
drainag
bag
microbi
cultur
replac
urinari
drainag
bag
group
background
resid
ltcf
survivor
acut
medic
condit
frequent
harbor
multidrug
resist
organ
result
previou
treatment
cours
therefor
infect
colon
methicillinresist
staphylococcu
aureu
mrsa
becom
import
issu
studi
plan
investig
antimicrobi
agent
suscept
molecular
type
methicillinresist
staphylococcu
aureu
mrsa
resid
environ
six
longterm
care
facil
ltcf
taiwan
method
prospect
investig
exist
mdro
includ
mrsa
resid
six
ltcf
environ
januari
decemb
activ
surveil
colon
mdro
perform
cultur
nasal
rectal
swab
sampl
everi
three
month
resid
msa
identifi
swab
specimen
environment
sourc
collect
cultur
minim
inhibitori
concentr
mic
common
antimicrobi
agent
test
sccmec
genotyp
multilocu
sequenc
type
mlst
select
mrsa
isol
analyz
result
total
isol
mrsa
identifi
studi
period
among
isol
identifi
ltcf
resid
gener
isol
number
ltcf
resid
surveil
cultur
correl
number
isol
environ
predomin
sccmec
genotyp
type
iv
v
predomin
mlst
type
belong
predomin
mlst
strain
vari
facil
facil
howev
mlst
type
environ
cultur
could
correl
cultur
resid
minim
inhibitori
concentr
mic
isol
mrsa
variou
commonli
use
antibiot
determin
isol
suscept
vancomycin
nitrofurantoin
quinopristindalfoprestin
linezolid
mupirocin
teicoplanin
daptomycin
rifampicin
fucid
acid
also
exert
excel
vitro
activ
isol
mrsa
howev
mic
valu
tetracyclin
trimethoprimsulfamethoxazol
ciprofloxacin
significantli
lower
compar
conclus
mrsa
wide
distribut
longterm
care
facil
taiwan
singl
clonal
expans
found
differ
facil
howev
mlst
type
environment
stain
highli
correl
colon
strain
ltcf
resid
individu
environment
cleans
polici
adopt
facilit
ltcf
reduc
environment
colon
mrsa
commonli
use
antimicrobi
agent
hospitalacquir
strain
mrsa
remain
highli
activ
isol
ltcf
fangchen
hung
chunhs
liao
far
eastern
memori
hospit
infect
control
center
background
oncolog
patient
central
artifici
venou
cathet
increas
risk
bloodstream
infect
patient
oncolog
ward
use
central
venou
cathet
chemotherapi
incid
bloodstream
infect
due
high
incid
bloodstream
infect
unit
seri
improv
program
carri
sinc
method
unit
bed
averag
hospit
stay
day
task
forc
form
oncologist
nurs
infect
control
staff
serial
intervent
enforc
includ
use
prefil
heparin
syring
reduct
nonessenti
use
artifici
blood
vessel
background
ventilatorassoci
pneumonia
vap
frequent
hospit
acquir
infect
among
intens
care
unit
patient
goal
studi
appli
bundl
ventilatorassoci
pneumonia
prevent
process
qualiti
improv
singl
surgic
intens
care
unit
method
consist
implement
evidencebas
ventilatorassoci
pneumonia
prevent
bundl
adapt
surgic
icu
use
plandostudyact
cycl
strategi
qualiti
improv
care
bundl
implement
includ
headofb
elev
daili
sedat
vacat
assess
extub
peptic
ulcer
diseas
prophylaxi
oral
care
chlorhexidin
prevent
tube
condens
enter
airway
mainten
endotrach
tube
cuff
pressur
mmhg
bundl
complianc
vap
rate
follow
studi
analys
sicu
util
ventil
util
vap
incid
januari
june
assess
impact
vap
bundl
clinic
set
result
total
sicu
patient
analyz
studi
mean
age
older
control
group
vs
year
old
ventil
day
longer
control
group
vs
day
compar
control
group
patient
vap
higher
incid
underlin
copd
vs
higher
rate
blocker
ppi
use
vs
higher
rate
use
inotrop
agent
immedi
ventil
support
higher
rate
tpn
use
vs
mean
interv
intub
diagnosi
vap
day
mean
interv
intub
mortal
day
respons
vap
bundl
intervent
differ
sicu
util
p
prevap
postvap
bundl
phase
note
wherea
ventil
util
decreas
ventil
day
ventil
day
p
monthli
vap
densiti
remark
decreas
background
worldwid
increas
incid
carbapenemaseproduc
enterobacteriacea
cpe
cpe
contain
plasmidborn
genet
materi
capabl
spread
rapidli
bacteria
individu
render
carbapenem
import
group
broad
spectrum
antibiot
useless
detect
signific
increas
cpe
includ
three
outbreak
convalesc
hospit
although
standard
infect
control
measur
like
hand
hygien
audit
regular
environment
decontamin
place
cpe
incid
increas
rose
henc
cpe
reduct
program
formul
method
cpe
reduct
program
start
juli
focus
three
area
activ
surveil
screen
patient
complain
diarrheal
symptom
stay
day
antimicrobi
therapi
screen
cpe
enabl
earli
identif
isol
cpe
carrier
focus
hand
hygien
complianc
improv
program
napkin
care
enter
feed
concurr
feedback
given
frontlin
result
report
senior
manag
monthli
basi
patient
environment
care
improv
environment
cleanli
maxim
regular
ward
decontamin
central
cleans
team
ad
hoc
clean
cre
detect
staff
cleans
techniqu
assess
regular
procedur
hand
hygien
audit
uv
fluoresc
marker
also
util
appli
high
touch
area
includ
pantri
sink
monitor
perform
environment
measur
initi
includ
sink
decontamin
revis
bodi
fluid
dispos
procedur
revis
handl
enter
feed
milk
equip
patient
utensil
result
incid
nosocomi
cpe
drop
cpe
outbreak
launch
cpe
reduct
program
hand
hygien
complianc
improv
particular
hand
hygien
enter
feed
increas
hand
hygien
napkin
care
uv
fluoresc
marker
assess
show
percentag
mark
environ
effect
clean
increas
conclus
cpe
reduct
program
control
nosocomi
spread
cpe
hospit
earli
identif
isol
cpe
carrier
enhanc
environment
hygien
focus
hand
hygien
essenti
element
success
final
good
commun
cooper
frontlin
infect
control
team
indispens
mdro
reduct
program
method
conduct
retrospect
studi
patient
treat
mechan
ventil
equal
calendar
day
april
octob
compar
mechan
ventil
patient
defin
vae
patient
defin
vae
also
analyz
risk
factor
clinic
outcom
vae
statist
analysi
perform
chisquar
test
signific
differ
determin
p
result
among
episod
mechan
ventil
episod
complic
vae
ventilatorassoci
condit
vac
infectionrel
vac
ivac
possibl
vap
pvap
chest
xp
find
follow
pleural
effus
pulmonari
edema
pneumothrax
find
vae
occur
frequent
medic
icu
surgic
icu
p
length
icu
stay
becam
longer
vae
p
mortal
rate
vae
group
significantli
higher
vae
group
p
signific
differ
vae
group
vae
group
intraven
volum
overload
nutrit
manag
patient
defin
vae
show
hypoalbuminemia
gdl
conclus
sinc
vae
affect
patient
qol
prognosi
might
also
import
improv
malnutrit
vae
patient
nutrit
support
team
prevent
vae
excel
infect
control
polici
zero
infect
staphylococcu
aureu
bacteremia
hemodialysi
roomon
teach
hospit
experi
hanchuan
chuang
jenzon
chen
yuarnjang
lee
divis
infecti
diseas
depart
intern
medicin
taipei
medic
univers
hospit
depart
infect
control
taipei
medic
univers
hospit
background
patient
regular
hemodialysi
risk
staphylococcu
aureu
bacteremia
risk
factor
includ
vascular
access
comorbid
mortal
rate
staphylococcu
aureu
high
aureu
caus
infect
endocard
septic
arthriti
osteomyel
bacteremia
inhospit
mortal
infect
endocard
import
issu
prevent
episod
staphylococcu
aureu
bacteremia
accord
previou
studi
staphylococcu
aureu
nasal
carrier
would
follow
staphylococcu
aureu
bacteremia
therefor
wonder
know
decreas
nasal
carrier
rate
staphylococcu
aureu
hemodialysi
room
would
reduc
incid
staphylococcu
aureu
bacteremia
method
one
infect
control
polici
implement
sinc
may
dec
hemodialysi
room
one
teach
hospit
taiwan
includ
patient
polici
includ
two
step
activ
surveil
staphylococcu
aureu
nasal
swab
everi
month
decolon
staphylococcu
aureu
carrier
result
polici
rate
staphylococcu
aureu
nasal
carrier
diminish
three
sequenti
screen
incid
staphylococcu
aureu
bacteremia
near
zero
except
one
patient
methicillinsensit
staphylococcu
aureu
bacteremia
conclus
studi
support
activ
surveil
give
good
infect
control
patient
regular
hemodialysi
outbreak
influenza
psychiatr
hospit
taiwan
yuchen
lin
kuansheng
chung
hsiuchu
liu
juisui
wang
chihlung
hsieh
iyen
lee
kueich
lin
kaohsiung
municip
kaisyuan
psychiatr
hospit
background
studi
investig
process
influenza
transmiss
infect
control
intervent
appli
psychiatr
hospit
addit
weak
point
infect
control
intervent
fomit
transmiss
effect
time
tamiflu
oseltamivir
phosphat
use
discuss
studi
method
action
research
method
use
order
offer
suitabl
intervent
infect
control
time
psychiatr
hospit
inform
influenza
vaccin
rate
way
tamiflu
oseltamivir
phosphat
use
symptom
influenza
result
influenza
rapid
screen
epidem
curv
diseas
transmiss
collect
result
first
patient
influenzalik
ill
ili
report
critic
intens
care
unit
jan
six
case
influenzalik
ill
report
one
night
acut
ward
pediatr
adolesc
ward
report
outbreak
event
within
day
patient
health
care
profession
suffer
season
influenza
three
psychiatr
ward
influenza
vaccin
rate
among
health
care
profession
averag
unfortun
season
influenza
vaccin
rate
among
psychiatr
patient
averag
besid
morbid
season
influenza
averag
unfortun
posit
influenza
rapid
screen
result
higher
expect
even
though
type
influenza
viru
detect
quantit
realtim
rtpcr
tamiflu
oseltamivir
phosphat
appli
psychiatr
patient
also
health
care
profession
result
dose
rate
tamiflu
oseltamivir
phosphat
averag
averag
day
isol
day
three
psychiatr
ward
conclus
conclus
infect
control
intervent
psychiatr
ward
easi
medic
surgic
ward
due
movement
abil
among
psychiatr
patient
season
influenza
vaccin
could
see
health
prevent
intervent
protect
patient
influenza
season
come
tamiflu
oseltamivir
phosphat
dose
could
suggest
outbreak
event
occur
ward
environ
clean
disinfect
highli
suggest
order
stop
drop
infect
transform
contact
infect
psychiatr
patient
hand
evalu
qualiti
hand
hygien
skill
use
fluoresc
lotion
ultraviolet
test
wanch
wu
polin
chen
chiawen
li
wenchien
ko
naiy
ko
center
infect
control
nation
cheng
kung
univers
hospit
tainan
taiwan
divis
infecti
diseas
depart
intern
medicin
nation
cheng
kung
univers
hospit
tainan
taiwan
nurs
depart
nation
cheng
kung
univers
hospit
tainan
taiwan
background
promot
qualiti
hand
hygien
skill
sever
innov
teach
program
initi
sinc
order
evalu
qualiti
hand
hygien
skill
employe
studi
hospit
investig
ultraviolet
light
uv
light
test
underw
march
method
total
staff
member
includ
administr
worker
healthcar
provid
differ
specialti
enrol
qualiti
hand
hygien
skill
evalu
use
fluoresc
lotion
uv
light
test
briefli
fluoresc
lotion
smear
evenli
hand
handwash
uv
light
use
check
light
spot
hand
indic
fluoresc
lotion
remov
handwash
cleaness
seven
main
area
includ
palm
back
hand
gap
finger
knuckl
thumb
finger
nail
wrist
hand
measur
section
score
hand
result
total
employe
nurs
member
hospit
administr
medic
technician
doctor
mainten
worker
janitor
staff
medic
center
particip
evalu
result
show
particip
pass
test
perfectli
miss
area
hand
miss
point
finger
gap
left
hand
left
hand
finger
gap
right
hand
score
nurs
administr
member
medic
technician
doctor
mainten
worker
janitor
staff
p
staff
examin
roomsdepart
got
highest
score
follow
intens
care
unit
administr
station
p
conclus
abil
perform
good
hand
hygien
skill
vari
differ
station
depart
signific
differ
observ
among
employe
differ
specialti
fluoresc
lotion
uv
light
test
reveal
miss
point
hand
hygien
skill
individu
help
staff
improv
skill
accordingli
use
qualiti
control
circl
reduc
posit
surveil
cultur
rate
intestin
endoscop
meiyu
wu
peichin
hung
chenshuan
chung
hsinyen
tsai
chunhs
liao
infect
control
center
ultrasound
endoscopi
center
infecti
diseas
divis
gastroenterolog
hepatolog
divis
far
eastern
memori
hospit
new
taipei
citi
taiwan
background
posit
surveil
cultur
endoscop
disinfect
uncommon
overal
posit
rate
surveil
bacteri
cultur
rate
endoscop
disinfect
endoscop
center
sever
problem
includ
incorrect
manual
clean
inappropri
storag
lack
autom
wash
devic
qualiti
control
circl
form
staff
endoscop
center
depart
endoscop
improv
qualiti
endoscop
disinfect
method
qualiti
control
circl
implement
meausr
includ
clean
perform
qualifi
personnel
educ
train
annual
educ
workshop
traing
poster
standard
oper
process
clean
room
insepct
correct
manual
clean
use
disinfect
agent
circl
leader
procur
wash
machin
storag
cabinet
circl
member
meet
quarterli
inspect
particip
unit
regularli
result
total
peopl
receiv
educ
train
onsit
audit
unit
perform
everi
six
month
includ
use
autom
wash
machin
process
manual
clean
storag
endoscop
regular
check
concentr
opa
etc
common
defect
incorrect
manual
clean
process
inappri
endoscop
storag
expir
opa
test
stripe
effort
qualiti
control
circl
number
defect
decreas
total
march
decemb
posit
surveil
cultur
rate
reduc
first
quarter
top
three
isol
organ
pseudomona
aeruginosa
pseudomona
putida
enterobact
cloaca
conclus
qualiti
control
circl
perform
regular
check
intervent
qualiti
endoscop
disinfect
could
improv
significantli
outbreak
sever
respiratori
tract
infect
due
human
metapneumoviru
infect
one
region
hospit
southern
taiwan
wanl
chen
baochen
chen
yehsuan
jao
miaoci
cai
yingchen
hsu
yeuhju
chen
wenhsin
tsai
hungchin
tsai
august
deviat
rang
age
staff
member
patient
year
old
common
present
upper
respiratori
tract
infect
patient
pneumonia
besid
patient
hypoxia
fatal
rate
patient
among
confirm
case
patient
among
patient
possibl
case
outbreak
confirm
case
viral
cultur
polymeras
chain
reaction
possibl
case
clinic
diagnosi
phylogenet
tree
analysi
show
high
degre
strain
similar
indic
origin
sourc
conclus
hmpv
import
pathogen
invad
elderli
person
health
care
worker
outbreak
region
hospit
survey
dispos
crekpc
region
hospit
taiwan
chihlin
liu
likuan
chih
lichun
liu
wenhan
chang
shuchen
wang
chaotai
li
paochen
chen
yingsheng
pan
background
hospit
own
bed
march
juli
st
case
prove
posit
crekpc
result
reconfirm
cdc
taiwan
compar
one
case
occur
result
obvious
higher
order
prevent
spread
diseas
relat
intervent
implement
immedi
experi
would
share
medic
profess
refer
method
bacteria
cultur
laboratori
isol
specimen
fit
cre
drug
resist
condit
defin
cdc
activ
notif
proceed
infect
control
intervent
activ
june
discuss
staff
divis
laboratori
medicin
relat
intervent
adopt
clarifi
whether
individu
case
relav
one
anoth
intervent
adopt
investig
ward
proceed
sampl
inspect
environ
ward
patient
live
well
hand
staff
work
revis
standard
oper
procedur
multipledrug
resist
strain
result
analyz
case
one
patient
healthcareassoci
infect
nt
juli
specimen
includ
collect
ward
well
hand
staff
rectalswab
specimen
crkp
case
sent
inspect
specimen
verifi
crekp
drug
resist
kpc
drug
resist
case
identifi
cdc
specimen
collect
bedsid
bar
bedsid
tabl
rectalswab
crkp
case
conclus
colon
often
occur
infect
event
specimen
one
inpati
surround
verifi
crkp
environment
collect
inspect
although
sourc
infect
ca
nt
confirm
investig
contin
proceed
final
found
result
insuffici
concentr
bleach
formul
staff
improv
kept
follow
august
found
case
follow
two
month
environment
clean
disinfect
key
point
epidem
prevent
studi
would
provid
medic
profess
refer
implement
intervent
deal
multipledrug
resist
strain
key
word
follow
citrat
tiab
cathet
lock
cancer
malign
result
synthesi
paper
paper
met
inclus
criteria
distinguish
pico
chaftari
level
enrol
patient
hematolog
malign
peripher
insert
central
cathet
picc
use
lock
consist
ml
nitroglycerin
combin
sodium
citrat
ethanol
lumen
lock
least
h
daili
prior
flush
reduc
central
lineassoci
bloodstream
infect
clabsi
rate
cathet
day
cathet
day
advers
event
one
headach
one
rash
mild
transient
rosenblatt
j
level
report
synergi
glyceryl
trinitr
gtn
citrat
ethanol
rapidli
erad
methicillinresist
staphylococcu
aureu
methicillinresist
staphylococcu
epidermidi
pseudomona
aeruginosa
candida
albican
biofilm
vitro
model
cathet
biofilm
colon
conclus
sodium
citrat
may
effect
central
venou
cathet
lock
solut
hematolog
malign
antimicrobi
antithrombot
effect
evid
suffici
need
prospect
trail
confirmli
effect
prevent
needlestick
injuri
bodi
fluid
exposur
implement
safetyengin
devic
medic
center
taiwan
shufen
chien
juchun
lo
yule
lai
janntay
wang
wanghuei
sheng
yeechun
chen
shanchwen
chang
center
infect
control
occup
safeti
health
offic
depart
intern
medicin
nation
taiwan
univers
hospit
taipei
taiwan
background
sinc
increasingli
complic
medic
environ
threat
emerg
infecti
diseas
issu
workplac
safeti
health
promot
get
import
needlestick
injuri
nsi
bodi
fluid
exposur
common
occup
hazard
medic
institut
besid
continu
enhanc
train
educ
personnel
protect
well
continu
improv
tool
equip
workplac
also
expect
avoid
occurr
accident
nsi
use
safetyengin
devic
sed
import
reform
step
prevent
nsi
taiwan
allow
law
usag
promot
sed
daili
practic
hospit
set
necessari
investig
effect
use
sed
term
reduc
incid
nsi
method
studi
conduct
medic
center
bed
sinc
start
promot
usag
sed
hospit
phase
phase
train
educ
program
prevent
healthcar
personnel
nsi
also
conduct
close
monitor
incid
analysi
underli
mechan
nsi
implent
simutan
intervent
improv
medic
practic
understand
factor
result
nsi
perform
result
overal
incid
nsi
decreas
decreas
especi
obviou
intern
nurs
addit
rate
nsi
caus
convent
devic
includ
syring
intraven
cathet
wing
needl
insulin
syring
etc
decreas
result
convent
syring
declin
howev
occurr
nsi
made
incorrect
oper
safeti
devic
safeti
devic
activ
increas
conclus
use
sed
effect
prevent
nsi
must
work
correctli
standard
oper
procedur
train
educ
usag
sed
necessari
promot
use
sed
keep
make
safeti
workplac
environ
sustain
effort
ongo
promot
occup
health
diffus
rectum
ulcer
bleed
sever
cytomegaloviru
infect
patient
case
report
ching
ting
wen
lian
yu
chimei
medic
center
intens
care
unit
background
cytomegaloviru
cmv
usual
caus
asymptomat
infect
produc
mild
flulikesymptom
afterward
remain
latent
throughout
life
may
reactiv
immunocompromis
individu
symptomat
diseas
usual
manifest
mononucleosi
syndrom
symptomat
cmv
diseas
affect
almost
everi
organ
bodi
rare
manifest
cmv
infect
immunocompet
individu
includ
thrombocytopenia
hemolyt
anemia
present
case
colon
cancer
reciv
chemotherapi
ufur
howev
massiv
bloodi
stool
passag
found
pandoscopi
reveal
esophag
ulcer
patholog
confirm
cmv
infect
ganciclovir
therapi
perform
stop
bleed
surgic
intervent
case
report
yo
male
patient
admit
due
left
femor
intertrochant
comminut
fractur
admiss
surgic
treatment
perform
aspir
pneumonia
develop
fever
dyspnea
condit
oper
due
unstabl
vital
sign
dyspnea
transfer
icu
intub
due
respiratori
failur
broad
spectrum
antibiot
septic
workup
fluid
resuscit
perscrib
patient
much
bloodi
stool
passag
note
gs
consult
anal
fissur
bleed
suspect
howev
recurr
bloodi
stool
note
colonoscopi
reveal
multipl
rectal
ulcer
sp
biopsi
patholog
rectal
ulcer
show
favor
cmv
coliti
thu
ganciclovir
ad
combin
antibiot
tazobactampiperacilin
pneumonia
treatment
repeat
colonoscopi
due
persist
intermitt
bloodi
stool
passag
repeat
cmvpcr
antigenemia
repeat
colonscopi
show
rectal
ulcer
ooz
antibiot
adjust
infect
men
suggest
diflucan
ad
funguria
patient
condit
becam
get
stabl
due
neg
antigenemia
neg
stool
cmvpcr
oral
form
ganciclovir
discontinu
discuss
id
man
due
improv
clinic
symptom
patient
discharg
rel
stabl
condit
discuss
gastrointestin
cmv
infect
respond
well
ganciclovir
treatment
independ
caus
underli
immunosuppress
therefor
patient
offer
antivir
treatment
soon
possibl
earli
diagnosi
suspect
cmv
infect
immunosuppress
patient
gastrointestin
symptom
utmost
import
repeat
endoscopi
may
consid
previou
studi
meet
conclu
gastrointestin
cmv
diseas
kept
mind
immunocompromis
patient
compat
clinic
symptom
evalu
effect
clean
product
action
care
work
car
region
hospit
chunfeng
chiu
minhan
hsieh
tunchieh
chen
infect
control
offic
kaohsiung
municip
tatung
hospit
depart
nurs
kaohsiung
municip
tatung
hospit
depart
intern
medicin
kaohsiung
medic
univers
background
region
hospit
south
taiwan
enurs
cart
nurs
staff
daili
medic
work
order
evalu
mobil
enurs
cart
becam
media
multidrug
resist
organ
mdro
transmiss
atpbioluminesc
cultur
perform
assess
efficaci
surfac
clean
hightouch
surfac
mobil
enurs
cart
mean
valu
atpbioluminesc
surfac
rlu
cultur
grew
isol
microorgan
result
reveal
clean
insuffici
univers
regul
investig
clean
questionnair
correl
conveni
clean
tool
therefor
studi
tri
assess
efficaci
clean
four
differ
clean
tool
studi
also
evalu
medic
staff
clean
mobil
enurs
cart
differ
clean
tool
analysi
tri
find
increas
medic
staff
clean
mobil
enurs
cart
make
sure
clean
avoid
healthcareassoci
infect
method
mobil
enurs
cart
clean
four
differ
tool
assess
outcom
clean
ten
hightouch
surfac
cart
check
atpbioluminesc
clean
questionnair
design
medic
staff
evalu
satisfact
medic
staff
differ
clean
tool
result
use
four
differ
clean
tool
enurs
cart
vehicl
clean
found
differ
clean
product
make
surfac
clean
mean
valu
atpbioluminesc
surfac
rlu
total
questionnair
fill
medic
staff
questionnair
includ
item
conveni
oper
clean
effect
odor
stimul
skin
result
show
medic
staff
satisfi
antisept
wet
tissu
b
conclus
clean
tool
conveni
oper
effect
clean
lower
stimul
skin
smell
increas
frequenc
clean
medic
staff
medic
staff
implement
clean
import
clean
mobil
enurs
cart
therefor
establish
standard
procedur
mobil
enurs
cart
clean
system
audit
essenti
improv
integr
oral
care
nurs
prevent
ventilatorassoci
pneumonia
shwuhwa
leu
meiju
su
liyao
shuchun
chang
yuehchen
fu
hsial
wu
lichu
li
chinyu
chen
tzupe
shih
wenchih
wu
choch
sun
background
use
ventilatorassoci
pneumonia
vap
intens
care
unit
qualiti
indic
monitor
import
item
extend
hospit
stay
increas
cost
medic
care
ashraf
ostroskyzeichn
systemat
introduct
prevent
combin
care
remodel
correct
concept
staff
care
implement
unifi
effect
care
measur
combin
care
also
respir
patient
oral
care
import
expect
effect
prevent
vap
improv
patient
clean
comfort
order
enhanc
profession
care
servic
qualiti
april
team
use
technic
audit
observ
method
averag
correct
rate
nurs
staff
integr
oral
care
first
newli
transfer
personnel
protect
lack
awar
second
lack
appropri
care
product
use
third
relev
care
oper
check
mechan
standard
oper
practic
purpos
project
improv
integr
oral
care
method
order
improv
integr
oral
care
nurs
staff
improv
measur
made
everi
month
june
septemb
particip
trm
competit
extern
expert
clinic
guidanc
improv
care
product
equip
use
multifunct
aspir
toothbrush
oral
dentur
chlorhexidin
oral
clean
gel
mouthwash
system
prevent
prevent
vap
care
standard
revis
special
oral
care
technolog
develop
use
breath
apparatu
oper
instruct
implement
vap
care
check
reward
intern
check
outsid
hospit
inspect
counsel
bundl
protect
angel
recognit
implement
incent
system
result
june
vap
care
integr
check
result
care
integr
nurs
knowledg
oral
care
increas
maintain
vap
zero
case
conclus
sinc
introduct
modular
care
unit
effect
prevent
infect
significantli
improv
peer
awar
care
skill
effect
teamwork
increas
effici
work
process
care
buy
use
new
improv
care
product
conveni
effect
current
hospit
promot
implement
respiratori
care
ward
share
unit
promot
implement
experi
order
achiev
purpos
maintain
patient
safeti
improv
qualiti
medic
servic
role
cytomegaloviru
pneumonia
contributor
bystand
huil
huang
wenliang
yu
depart
intens
care
medicin
chi
mei
medic
center
tainan
taiwan
depart
medicin
taipei
medic
univers
taipei
taiwan
background
influenza
may
caus
sever
diseas
need
care
intens
care
unit
icu
viral
infect
icu
often
involv
respiratori
system
caus
signific
morbid
mortal
especi
immunocompromis
patient
meanwhil
critic
ill
patient
admit
icu
predispos
mani
nosocomi
infect
due
underli
ill
variou
invas
procedur
prolong
hospit
stay
report
detect
cytomegaloviru
cmv
morganella
morganii
patient
prolong
icu
stay
pathogen
often
ignor
might
clinic
signific
method
case
studi
result
yo
man
histori
hypertens
chronic
kidney
diseas
brain
stroke
medic
control
acut
respiratori
distress
requir
immedi
intub
admit
icu
hemodialysi
use
increas
metabol
acidosi
progress
pulmonari
edema
polymeras
chain
reaction
pcr
test
nasopharyng
sampl
posit
influenza
complet
cours
oseltamivir
therapi
piperacillin
use
pneumonia
caus
klebsiella
pneumonia
day
icu
stay
transfer
respiratori
care
center
rcc
difficulti
wean
ventil
howev
septic
shock
note
stay
rcc
cultur
blood
sputum
yield
morganii
blood
aspergillu
galactomannan
antigen
index
normal
addit
cmvpcr
result
sputum
blood
sampl
posit
cmv
viral
load
iuml
imipenem
use
day
without
anticmv
treatment
condit
improv
therebi
success
extub
wean
ventil
day
stay
rcc
transfer
ward
discharg
unev
day
hospit
stay
conclus
cmv
antigenemia
uncommon
find
icu
patient
immunocompromis
statu
although
associ
higher
morbid
mortal
clinic
signific
cmv
icu
patient
unknown
meanwhil
organ
morganii
proven
pathogen
could
potenti
danger
overlook
thu
morganii
infect
vigor
treat
wherea
cmv
reactiv
ignor
current
case
difficult
discern
whether
cmv
play
role
pneumonia
statu
cmv
might
bystand
anticmv
therapi
given
might
contributor
associ
prolong
hospit
stay
clinic
characterist
patient
infect
vancomycinresist
enterococci
hsiulun
su
yalan
chen
chenchi
tsai
shujuan
tsai
jialin
lin
huiy
chuang
meilan
shen
chorngjang
lay
infect
control
committe
nurs
depart
divis
infecti
diseas
depart
medicin
method
hospit
region
teach
hospit
studi
retrospect
caseanalysi
studi
review
medic
record
patient
infect
vre
jan
dec
result
patient
infect
vre
whose
specimen
includ
urin
n
wound
n
blood
n
stool
n
ascit
n
bile
n
cvp
line
n
drain
tube
n
n
pleural
effusio
n
pu
n
patient
year
old
common
comorbid
disord
includ
hypertens
diabet
mellitu
bedridden
statu
patient
readmit
half
year
one
time
readmiss
anoth
time
readmiss
vre
isol
two
patient
everi
readmiss
conclus
studi
show
patient
infect
vre
elderli
peopl
comorbid
disord
one
half
patient
bedridden
found
vre
could
found
readmiss
patient
infect
vre
use
bundl
care
reduc
ventil
associ
pnumonia
densitycas
region
teach
hospit
taiwan
chiachi
liu
chunchih
yeh
siangru
syu
infect
control
committe
icu
ten
chan
gener
hospit
chungli
taoyuan
taiwan
introduct
prevent
infect
count
intens
care
critic
ill
patient
ventil
associ
pneumonia
vap
one
prolong
time
ventilatior
usag
also
increas
durat
hospit
medic
cost
even
count
one
import
caus
mortal
patient
method
ventil
associ
pneumonia
reach
icu
ten
chan
gener
hospit
chungli
taoyuan
taiwan
seem
rise
compar
follow
two
year
review
bundl
care
caus
ineffect
execut
care
profession
short
understand
care
method
lack
stand
oper
procedur
nt
lift
bedhead
measur
instrument
short
evalu
chart
therefor
follow
infect
control
contain
measur
introduc
includ
consclus
effect
way
reduc
vap
remov
tube
earlier
chime
medic
quliti
demand
object
implement
idea
bundl
care
lower
medic
care
associ
infect
shorten
hospit
day
patient
stay
away
deseas
make
sure
safeti
medic
care
ps
icar
intervent
reduc
catheterassoci
urinari
tract
infect
adult
intens
care
medic
center
yuehju
chen
chengho
chang
juikuang
chen
infect
control
committe
nurs
depart
background
hospit
earli
implement
nursegener
remind
physician
remov
cathet
day
insert
abl
effect
reduc
cathet
durat
mean
day
lower
rate
cauti
unfortun
remind
intervent
also
easili
ignor
cathet
may
remain
place
without
action
sinc
rate
cauti
began
increas
recent
year
reach
case
per
urinari
cathet
day
method
icar
intervent
perform
august
coordin
strategi
compris
icar
slogan
poster
indic
clean
asept
removeearli
easi
smooth
team
work
focu
nurs
driven
cathet
remov
potoca
background
ambient
air
may
contamin
carri
signific
level
varieti
potenti
detriment
microorgan
exogen
flora
primarili
aerob
especi
gramposit
organ
microbi
concentr
indoor
oper
room
one
extrins
influenc
factor
surgic
site
infect
aim
studi
assess
microbi
coloni
count
work
or
tertiari
referr
medic
center
method
prospect
observ
studi
conduct
or
medic
center
taiwan
equip
ventil
system
high
effici
particul
air
filter
ventil
system
or
produc
minimum
approxim
air
chang
filter
air
per
hour
vertic
laminar
airflow
system
use
move
particlefre
air
asept
oper
field
uniform
veloc
microbiolog
air
count
measur
use
impactor
air
sampler
month
result
overal
mean
number
bacteri
coloni
or
cfum
mean
number
coloni
highest
transplant
surgeri
follow
pediatr
surgeri
fungi
cultur
air
sampl
total
contain
pathogen
isol
air
or
coagulaseneg
staphylococcu
common
pathogen
follow
micrococcu
spp
staphylococcu
conclus
studi
demonstr
free
fungi
number
mean
bacteri
coloni
far
suggest
level
surgic
activ
despit
wellcontrol
ventil
system
hepa
filter
air
flow
condit
hospit
or
control
regul
remov
airborn
microorgan
help
control
infect
method
ic
team
visit
bacteriolog
lab
inform
cotton
battinglik
materi
receiv
abnorm
result
next
visit
compani
head
nurs
investig
see
whether
number
surgic
site
infect
case
show
abnorm
increas
past
month
result
found
green
cotton
fiber
top
surfac
oper
lampshad
visit
green
cotton
fiber
green
cloth
use
wrap
surgic
instrument
specul
cotton
fiber
scatter
surgic
instrument
parcel
open
also
found
sanitari
staff
oper
procedur
routin
clean
floor
oper
tabl
wall
nt
includ
oper
lampshad
therefor
result
fiber
accumul
environment
clean
disinfect
implement
air
qualiti
monitor
follow
subsequ
result
normal
also
abnorm
increas
surgic
site
infect
ssi
rate
signific
differ
p
compar
mean
valu
preinfect
stage
conclus
oper
room
import
environ
surgeri
perform
save
live
ensur
environ
clean
free
pollut
import
case
recheck
revis
sanitari
staff
sop
ad
work
clean
top
locker
oper
lampshad
avoid
accumul
cotton
fiber
dust
caus
environment
pollut
evidencebas
assess
effect
antibiot
prophylaxi
prevent
burn
wound
infect
fangch
liu
yuanhsin
chu
divis
infecti
diseas
jenai
hospit
depart
infect
control
jenai
hospit
background
burn
injuri
associ
signific
death
disabl
multipl
surgic
procedur
prolong
hospit
high
cost
taiwan
icst
french
burn
associ
suggest
antibiot
prophylaxi
given
soon
sever
burn
rather
local
infect
burn
patient
infect
assur
herein
perform
search
provid
evidencebas
recommend
prophylact
treatment
burn
patient
method
use
relev
term
keyword
prophylaxi
antibiot
burn
search
cochran
librari
pubm
electron
databas
acquir
cochran
systemat
review
critic
apprais
result
thirtysix
rct
includ
trial
metaanalyz
particular
antibiot
silver
sulfadiazin
show
signific
increas
burn
wound
infect
longer
hospit
stay
compar
dressingsskin
substitut
ci
md
day
respect
evid
effect
system
antibiot
prophylaxi
nonsurg
patient
burn
infect
rate
trial
system
antibiot
trimethoprimsulfamethoxazol
relat
signific
reduct
pneumonia
one
trial
rr
limit
evid
effect
antibiot
unabl
draw
reliabl
conclus
therefor
antibiot
prophylaxi
suggest
routin
administr
burn
patient
consist
taiwan
icst
suggest
french
burn
associ
guidelin
hour
antibiot
prophylaxi
intervent
appropri
drug
usag
reassess
prefer
result
bacteria
cultur
adjust
applic
antibiot
burn
patient
experi
share
amblyopia
caus
emb
drug
region
hospit
yajhen
ji
shufan
lin
yuehi
tsai
yunlin
christian
hospit
tuberculosi
case
manag
yunlin
christian
hospit
thorac
surgeon
background
tuberculosi
oldest
diseas
standard
treatment
includ
four
kind
medic
combin
treatment
inh
rmp
pza
emb
treatment
process
vari
person
person
differ
side
effect
emb
relat
blur
vision
like
confus
degen
diseas
elderli
method
mr
person
histori
type
dm
cataract
tuberculosi
found
septemb
patient
began
use
fourinon
standard
treatment
regimen
treatment
left
eye
blur
vision
mention
right
eye
vision
normal
color
discrimin
public
health
center
patient
complain
blur
vision
deterior
januari
diagnos
deneg
glaucoma
local
clinic
januari
inform
doctor
chest
opd
next
day
patient
told
inform
dot
observ
patient
receiv
oper
cataract
right
eye
local
clinic
jan
abnorm
color
discrimin
found
januari
therefor
stop
antitb
treatment
januari
famili
question
deterior
vision
due
emb
refer
patient
ophthalmolog
author
case
appli
phytosanitari
relief
patient
transfer
tuberculosi
hospit
pch
method
visual
checklist
print
automat
patient
take
emb
comput
set
check
simpl
vision
test
includ
color
discrimin
case
manag
treatment
everi
month
treatment
emb
record
result
simpl
vision
test
use
questionnair
tuberculosi
diagnosi
treatment
case
occurr
abnorm
keep
record
case
manag
public
health
depart
result
implement
program
includ
case
sinc
sep
new
onset
occurr
due
take
emb
caus
visionrel
medic
disput
conclus
everi
medic
disput
process
learn
improv
hope
provid
better
qualiti
servic
event
want
earli
prevent
drug
induc
side
effect
therefor
could
put
end
medic
disput
support
winwin
strategi
patient
medic
caregiv
combin
care
reduc
respiratori
care
center
catheterrel
urinari
tract
infect
effect
ping
yang
chiayi
chang
gung
memori
hospit
infect
control
commiss
background
respiratori
care
center
januari
catheterrel
urinari
tract
infect
densiti
compar
previou
month
averag
ductrel
urinari
tract
infect
densiti
high
chisquar
test
statist
valu
p
field
audit
found
implement
hand
health
implement
catheter
process
urethr
disinfect
process
disinfect
time
enough
set
urin
bag
exit
bed
along
situat
recent
year
found
import
activ
combin
infect
control
measur
help
reduc
catheterrel
infect
project
explor
method
begin
collect
inform
statu
quo
analysi
solut
accord
plan
period
implement
period
evalu
period
implement
plan
period
plan
educ
train
cours
investig
cathet
placement
care
process
revis
placement
checklist
care
assess
form
audit
plan
implement
period
revis
oper
process
includ
time
hand
wash
newli
revis
indwel
cathet
checklist
care
assess
tabl
publish
unit
bulletin
board
public
know
conduct
educ
train
perform
technic
audit
use
catheter
care
checklist
evalu
period
unifi
teach
correct
catheter
care
process
repli
teach
plan
audit
catheterrel
urinari
tract
infect
densiti
increas
reduct
cathet
placement
complianc
rate
increas
result
cathet
relat
urinari
tract
infect
densiti
plan
period
implement
evalu
period
drop
cathet
complianc
complianc
increas
improv
conclus
uti
bundl
list
catheter
care
standard
educ
train
audit
system
organ
make
cathet
placement
care
concept
effect
accord
literatur
point
remov
cathet
prevent
urinari
tract
main
caus
infect
relationship
patient
respiratori
care
center
implement
cathet
earli
remov
difficult
also
resist
project
due
januari
catheterrel
urinari
tract
infect
densiti
rise
time
analysi
improv
achiev
desir
result
impact
analysi
hemodialysisrel
bloodstream
infect
bundl
care
intervent
chiahung
liao
jenghua
ling
zongfang
jhung
hungni
lee
background
taiwan
endstag
renal
failur
patient
receiv
hemodialysi
replac
treatment
healthcar
associ
bloodstream
infect
may
result
elev
morbid
mortal
prolong
admiss
higher
cost
conduct
previou
evidencebas
procedur
identifi
great
effect
rate
bloodstream
infect
bundl
care
hemodialysi
unit
final
compar
hemodialysi
associ
bloodstream
infect
rate
intervent
method
project
conduct
stepbystep
staff
educ
perform
june
use
doublelumen
hemodialysi
cathet
insert
check
list
doublelumen
hickman
hemodialysi
cathet
care
check
list
arterioven
fistula
care
check
list
standard
procedur
sinc
june
calcul
analyz
complianc
correct
rate
gave
feedback
hemodialysi
unit
everi
month
final
analyz
hemodialysi
associ
bloodstream
infect
rate
intervent
result
educ
coars
conduct
evidencedbas
procedur
identifi
lower
rate
bloodstream
infect
check
list
intervent
complianc
correct
rate
improv
gradual
hemodialysi
associ
bloodstream
infect
also
improv
januari
may
june
octob
conclus
evidencebas
bundl
care
intervent
hemodialysi
unit
may
result
improv
complianc
correct
rate
medic
staff
reduc
hemodialysi
associ
bloodstream
infect
rate
use
educ
programm
encourag
hand
hygien
alcoholbas
handrub
reduc
nearpati
environment
contamin
elderli
resid
longterm
care
odonoghu
margaret
yang
lin
siu
gilman
kithang
lee
paul
hong
boost
maureen
valeri
ho
jacquelin
mei
chi
suen
lorna
kwai
ping
school
nurs
hong
kong
polytechn
univers
depart
health
technolog
informat
hong
kong
polytechn
univers
background
elderli
resid
longterm
care
facil
ltcf
colon
infect
multidrug
resist
organ
act
import
reservoir
lead
crosscontamin
within
ltcf
well
transfer
hospit
upon
admiss
colon
mrsa
well
recogn
major
risk
factor
subsequ
infect
role
patient
hand
neglect
hospit
ltcf
even
though
suggest
may
repres
underrecogn
reservoir
pathogen
aim
determin
educ
regular
remind
improv
avail
alcohol
base
hand
rub
abhr
would
increas
frequenc
hand
hygien
elderli
resid
long
term
care
capabl
perform
hand
hygien
without
assist
method
nasal
swab
collect
elderli
subject
attend
commun
centr
social
activ
swab
cultur
chromogen
agar
speci
identif
perform
use
malditof
antimicrobi
suscept
test
perform
result
interpret
accord
eucast
guidelin
presenc
ar
gene
detect
pcr
figur
hand
nearpati
environment
contamin
beforeand
onemonth
hand
hygien
intervent
involv
use
abhr
ltcf
elderli
resid
data
test
subject
result
particip
compli
time
abl
demonstr
signific
reduct
hand
nearpati
environment
contamin
patient
previous
highest
level
organ
present
figur
frequenc
hand
hygien
event
per
day
also
increas
significantli
period
signific
chang
frequenc
quartil
p
conclus
adopt
directli
observ
hand
hygien
subject
capabl
use
abhr
without
assist
possibl
resid
ltcf
achiev
improv
hand
hygien
three
occas
introduc
methodolog
main
mealtim
elderli
unabl
perform
hand
hygien
propos
hcw
physic
assist
patient
rub
abhr
hand
preliminari
studi
show
promis
approach
reduc
mdro
problem
ltcf
set
background
order
monitor
infecti
diseas
avoid
potenti
epidem
outbreak
taiwan
hospit
particip
epidem
prevent
cloud
project
driven
center
diseas
control
cdc
develop
establish
automat
laboratori
data
deliv
platform
connect
cdc
server
provid
prompt
sustain
data
diseas
surveil
method
sever
strategi
launch
hospit
achiev
assign
first
medic
technologist
inform
technician
particip
train
cours
loinc
logic
observ
identifi
name
code
relma
regenstrief
loinc
map
assist
map
organ
laboratori
raw
data
laboratori
inform
system
databas
inform
technician
develop
automat
data
exchang
program
base
loinc
standard
laboratori
report
inform
data
analys
audit
medic
technologist
upload
daili
addit
upload
data
sampl
investig
cdc
test
period
confirm
accuraci
result
could
success
transfer
twenti
kind
regul
organ
mycobacterium
tuberculosi
hepat
c
viru
streptococcu
agalactia
total
submit
design
item
august
novemb
cdc
increas
overal
upload
pathogen
observ
compar
baselin
conclus
summari
finish
automat
data
exchang
program
transfer
platform
provid
data
public
health
surveil
gover
could
immedi
monitor
hospit
report
data
taiwan
effect
analyz
recent
trend
kind
infecti
diseas
epidem
prevent
cloud
project
continu
surveil
infecti
diseas
perform
popular
futur
adopt
gatekeep
model
enhanc
qualiti
portacath
hsinhsu
chen
huip
sun
tainan
municip
hospit
background
portacath
often
use
chemotherapi
regimen
nurs
play
central
role
patient
cathet
care
qualiti
cathet
care
directli
influenc
patient
safeti
patient
famili
member
incorpor
gatekeep
model
portacath
care
enhanc
commun
healthcar
profession
patient
qualiti
care
share
decisionmak
sdm
strategi
method
team
use
matern
health
booklet
refer
formul
portacath
care
booklet
contain
inform
selfassess
postop
wound
care
infus
note
principl
care
discharg
home
infus
record
discuss
allow
patient
understand
use
manag
portacath
result
patient
condit
home
present
condit
admiss
would
understood
selfassess
brochur
admiss
hospit
therefor
nurs
could
provid
patient
time
access
relev
inform
nurs
intervent
sinc
implement
studi
region
hospit
februari
found
complet
rate
portacath
care
guidanc
reach
addit
patient
satisfact
score
increas
signific
improv
suitabl
nurs
procedur
timeli
nurs
care
conclus
although
worri
give
inform
regard
portacath
patient
famili
member
increas
probabl
disput
occurr
patient
hospit
staff
staff
member
nt
follow
standard
care
necessari
incorpor
patient
famili
number
gatekeep
mode
better
understand
clinic
qualiti
therebi
enhanc
educ
train
practic
staff
improv
patient
safeti
background
effect
control
tuberculosi
tb
requir
close
partnership
privat
public
healthcar
provid
integr
webbas
inform
system
vital
crucial
engag
relev
healthcar
provid
prevent
diagnosi
treatment
tb
method
monitor
inform
system
establish
taiwan
center
diseas
control
tcdc
singl
entryway
enhanc
capac
flexibl
main
purpos
system
promot
rapid
respons
provid
decis
support
inform
tb
epidemiolog
case
manag
treatment
dot
rate
contact
trace
coverag
tb
cluster
tb
statist
laboratori
data
includ
system
inform
without
person
data
view
onlin
access
permiss
daili
laboratori
data
includ
afbsmear
cultur
identif
drug
suscept
test
interferongamma
releas
assay
igra
automat
enter
differ
interfac
divers
inform
system
clinic
set
public
health
sector
system
provid
time
warn
drugresist
case
igraposit
case
highrisk
popul
manag
staff
accord
respons
addit
daili
schedul
analys
laboratori
qualiti
indic
turnaround
time
visual
profil
updat
automat
result
current
inform
system
cover
tb
patient
manag
highrisk
popul
need
rapidli
diagnos
drugresist
tb
autom
data
transfer
reduc
workload
prevent
entri
error
caus
firstlin
staff
observ
increas
timeli
accuraci
data
autom
realtim
analysi
indic
enhanc
laboratori
qualiti
manag
facilit
prompt
respons
occurr
moreov
central
monitor
effect
laboratori
servic
case
manag
conduct
tcdc
period
system
improv
mobil
tb
control
activ
outbreak
respons
conclus
find
indic
effect
time
comprehens
inform
share
webbas
monitor
system
improv
tb
care
control
assess
effect
differ
process
procedur
yield
treponema
pallidum
dna
blood
lirong
lin
jinyi
fan
xiaozhen
zhu
zhengxiang
gao
xu
shen
kun
gao
dan
liu
jianjun
niu
lili
liu
tianci
yang
background
blood
conveni
extract
treponema
pallidum
dna
pcr
sensit
pallidum
dna
detect
unsatisfactori
investig
effect
differ
process
procedur
yield
pallidum
dna
blood
improv
sensit
method
employ
realtim
pcr
target
evalu
pallidum
dna
yield
seri
simul
experi
infect
rabbit
blood
test
differ
centrifug
forc
process
time
storag
temperatur
red
cell
lysi
pretreat
also
conduct
result
pallidum
dna
yield
follow
red
cell
lysi
pretreat
time
greater
whole
blood
time
greater
residu
hematocyt
without
pretreat
wholeblood
simul
experi
pallidum
dna
yield
lower
layer
time
upper
layer
centrifug
forc
g
respect
howev
pallidum
dna
yield
clot
differ
centrifug
forc
infect
rabbit
blood
experi
similar
result
mention
addit
sampl
process
time
within
h
storag
temperatur
affect
pallidum
dna
extract
effici
conclus
pallidum
dna
yield
significantli
improv
red
cell
lysi
pretreat
appropri
centrifug
furthermor
dna
extract
yield
pallidum
greater
whole
blood
residu
hematocyt
compar
plasma
serum
clot
comparison
three
prepar
method
direct
identif
microorgan
posit
blood
cultur
malditofm
jeong
su
park
da
yeong
song
taek
soo
kim
kyoung
un
park
euichong
kim
depart
laboratori
medicin
seoul
nation
univers
bundang
hospit
seongnamsi
korea
depart
laboratori
medicin
seoul
nation
univers
hospit
seoul
korea
depart
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
korea
background
direct
identif
microorgan
posit
blood
cultur
bottl
use
matrixassist
laser
desorpt
ioniz
time
offlight
mass
spectrometri
malditofm
report
effect
treatment
septic
patient
howev
addit
cost
commerci
maldi
sepsityp
kit
bruker
dalton
may
burden
clinic
laboratori
studi
evalu
three
prepar
method
simpl
centrifug
ethanolform
acid
prepar
sepsityp
method
posit
blood
cultur
method
studi
perform
septemb
march
seoul
nation
univers
bundang
hospit
seongnam
republ
korea
bottl
show
posit
blood
cultur
bactalert
test
cultur
subject
malditofm
vitek
ii
microscan
siemen
healthcar
analysi
pellet
three
direct
prepar
method
identifi
malditofm
cutoff
score
fisher
exact
test
mcnemar
chisquar
test
use
pvalu
less
consid
statist
signific
simpl
centrifug
method
ml
broth
tube
centrifug
rpm
one
minut
supernat
discard
ethanol
formic
acid
prepar
simpl
prepar
nonsepsityp
pellet
aerob
bottl
suspend
ml
saponin
wash
pellet
treat
ethanol
formic
acid
acetonitril
sepsityp
prepar
perform
accord
manufactur
instruct
result
total
number
identifi
patient
cultur
aerob
anaerob
bottl
fungi
mix
bacteria
polymicrobi
sampl
exclud
sampl
sepsityp
method
identifi
better
method
p
especi
simpl
centrifug
gram
posit
bacteria
significantli
less
identifi
gram
neg
bacteria
echinocandin
agent
prefer
c
glabrata
infect
suggest
echinocandin
start
empir
antifung
therapi
blood
cultur
turn
posit
h
aerob
incub
efficaci
safeti
echinocandin
prevent
invas
fungal
infect
patient
hematolog
malign
meichuan
lee
hansiong
toh
depart
pharmaci
chimei
medic
center
tainan
taiwan
depart
intens
care
medicin
chimei
medic
center
tainan
taiwan
background
patient
hematolog
malign
high
risk
invas
fungal
infect
ifi
associ
high
mortal
rate
past
azol
avail
antifung
prophylact
agent
novel
antifung
agent
echinocandin
found
strong
antifung
activ
isol
candida
spp
aspergillu
spp
aim
studi
evalu
effect
echinocandin
prevent
invas
fungal
infect
patient
hematolog
malign
method
follow
databas
search
medlin
pubm
may
cochran
databas
cochran
librari
without
languag
restrict
also
handsearch
relat
refer
random
control
trial
rct
compar
azol
echinocandin
includ
analys
echinocandin
micafungin
caspofungin
anidulafungin
compar
effect
statist
analysi
perform
review
manag
version
metaanalysi
synthes
use
randomeffect
model
result
express
rel
risk
rr
confid
interv
ci
heterogen
test
use
cochran
q
statist
gener
test
result
qualiti
assess
review
evid
rct
enrol
patient
hematolog
malign
receiv
antifung
agent
prophylaxi
ifi
rct
compar
micafungin
azol
rct
compar
caspofungin
azol
rct
compar
anidulafungin
antifung
agent
overal
incid
ifi
signific
differ
two
echinocandin
azol
ci
howev
subgroup
analysi
show
micafungin
effect
azol
prevent
ifi
ci
caspofungin
similar
effect
azol
ci
figur
conclus
metaanalysi
show
micafungin
might
better
choic
ifi
prophylaxi
patient
hematolog
malign
howev
effect
caspofungin
might
mitig
due
smaller
sampl
size
studi
data
safeti
still
insuffici
rct
requir
consid
cost
efficaci
micafungin
could
suggest
first
choic
ifi
prophylaxi
distribut
drug
suscept
candida
speci
cancer
patient
candidemia
cancer
center
yihsuan
chen
tingmei
liu
depart
patholog
laboratori
medicin
koo
foundat
sun
yatsen
cancer
center
taiwan
background
candida
common
caus
invas
fungal
infect
immunocompromis
cancer
patient
knowledg
antibiot
suscept
differ
candida
speci
may
help
clinician
treatment
plan
method
retriev
data
candida
speci
patient
candidemia
period
yeast
identif
method
includ
window
test
chromagar
candida
ureas
pellicl
c
aux
vitek
yst
also
perform
yeast
drug
suscept
test
atb
fungu
interpret
guidelin
vitro
suscept
test
candida
speci
appli
accord
clsi
result
coloni
candida
speci
candidemia
c
albican
n
commen
speci
follow
c
parapsilosi
n
c
glabrata
n
c
tropicali
n
c
guiliermondii
complex
n
c
krusei
n
c
inconspicua
n
c
haemilonii
n
c
lusitania
n
also
perform
antifung
drug
suscept
test
includ
flucytosin
amphotericin
b
voriconazol
fluconazol
intraconazol
candida
coloni
isol
asept
specimen
c
albican
n
c
tropicali
n
suscept
intraconazol
sensit
respect
speci
suscept
antifung
agent
howev
c
glabrata
n
indiscern
suscept
fluconazol
intraconazol
suscept
rate
amphotericin
b
flucytosin
voriconazol
respect
c
parapsilosi
n
c
lusitania
n
suscept
antifung
agent
c
krusei
n
speci
intrins
resist
fluconazol
suscept
c
krusei
flucytosin
intermedi
suscept
rate
voriconazol
amphotericin
b
respect
c
guiliermondii
complex
n
suscept
antifung
agent
except
intermedi
suscept
intraconazol
c
inconspicua
n
intermedi
suscept
fluconazol
intraconazol
suscept
antifug
agent
conclus
c
albican
remain
common
speci
found
patient
candidemia
similar
report
countri
nevertheless
incid
decreas
less
c
tropicali
second
common
speci
c
parapsilosi
c
glabrata
knowledg
distribut
antifung
drug
suscept
differ
candida
speci
hospit
may
help
clinician
prescript
plan
ocular
candidiasi
patient
candidemia
takashi
ueda
yoshio
takesu
kazuhiko
nakajima
kaoru
ichiki
kaori
ishikawa
yasunao
wada
toshi
tsuchida
yoshiko
takahashi
mika
ishihara
takeshi
kimura
depart
infect
control
prevent
hyogo
colleg
medicin
nishinomiya
japan
depart
pharmaci
hyogo
colleg
medicin
nishinomiya
japan
background
ocular
candidiasi
major
complic
candidemia
institut
ophthalmolog
examin
routin
perform
patient
candidemia
base
bundl
approach
takesu
et
al
jac
method
incid
ocular
candidiasi
among
patient
candidemia
time
diagnosi
vitreou
bodi
involv
rate
antifung
use
clinic
outcom
review
nonneutropen
adult
patient
ocular
candidiasi
reat
april
decemb
result
among
candidemia
patient
underw
ophthalmolog
examin
ocular
candidiasi
detect
patient
twentyon
patient
diagnos
initi
examin
median
day
cultur
blood
sampl
posit
patient
diagnos
followup
examin
median
day
vitreou
bodi
involv
detect
patient
among
consciou
patient
complain
visual
abnorm
candida
albican
commonli
detect
caus
agent
patient
blood
specimen
c
albican
isol
rate
patient
without
ocular
candidiasi
differ
significantli
vs
p
patient
ocular
candidiasi
significantli
higher
valu
pgml
vs
pgml
p
treatment
success
improv
patient
clinic
data
resolut
ocular
diseas
confirm
ophthalmolog
examin
achiev
patient
visual
recoveri
obtain
patient
mortal
rate
patient
fluconazol
voriconazol
liposom
amphotericin
b
administ
initi
antifung
patient
respect
altern
select
voriconazol
use
liposom
amphotericin
b
patient
stepdown
oral
therapi
introduc
patient
none
patient
receiv
intravitr
inject
antifung
underw
vitrectomi
mean
durat
intraven
antifung
therapi
significantli
longer
patient
vitreou
bodi
involv
compar
patient
chorioretin
day
vs
day
p
conclus
incid
candidiasi
concomit
previou
report
howev
higher
frequenc
vitreou
bodi
involv
experienc
addit
consider
number
patient
diagnos
ocular
candidiasi
initi
examin
exhibit
condit
followup
ophthalmolog
examin
outcom
fluconazol
dose
candidemia
caus
differ
candida
speci
chingyao
shih
huishan
tsai
wenliang
lin
fengi
yeh
depart
pharmaci
nation
cheng
kung
univers
hospit
tainan
taiwan
background
fluconazol
amongst
first
line
antifung
agent
invas
candidiasi
taiwan
differ
candida
speci
show
variou
suscept
fluconazol
dosedepend
sensit
fluconazol
pose
concern
efficaci
method
retrospect
studi
includ
adult
patient
candidemia
treat
antifung
agent
least
hour
juli
june
record
patient
medic
histori
laboratori
data
treatment
mortal
day
end
treatment
pathogen
erad
rate
primari
secondari
endpoint
respect
logist
regress
mantelhaenszel
test
util
analysi
variant
might
influenc
clinic
outcom
result
mortal
rate
pathogen
distribut
candida
albican
c
tropicali
c
parapsilosi
c
glabrata
candida
speci
respect
overal
mortal
rate
c
tropicali
infect
higher
mortal
rate
statist
signific
overal
erad
rate
c
albican
infect
higher
proport
clear
median
day
c
glabrata
median
day
p
fluconazol
use
initi
treatment
almost
case
fluconazol
dose
adjust
renal
function
weight
accordingli
gave
load
dose
logist
regress
found
continu
treatment
anoth
week
document
clearanc
signific
associ
surviv
rate
odd
ratio
ci
howev
give
fluconazol
load
dose
keep
mainten
dose
fluconazol
mgkg
show
signific
associ
mortal
rate
pathogen
erad
conclus
studi
adequ
treatment
cours
fluconazol
associ
patient
surviv
even
differ
candida
speci
reveal
poor
clinic
outcom
new
treatment
strategi
candidemia
increas
fluconazoleresist
candida
pathogen
necessari
pulmonari
fungal
infect
due
basidiomycet
speci
ceriporia
lacerata
hiv
patient
lihshinn
wang
chiach
jacki
wang
hueijen
chao
siaoru
lin
chihbin
lin
yunghsiang
hsu
background
basidiomycet
rare
report
caus
invas
respiratori
infect
despit
airborn
spore
abund
environ
immunocompromis
individu
suscept
method
msm
admit
histori
fuo
aug
complain
fever
dizzi
sore
throat
purul
sputum
cough
myalgia
deni
abdomin
pain
diarrhea
receiv
antipyret
resolv
fever
treat
entecavir
hbv
infect
year
found
hivinfect
admiss
cellsul
start
zidovudin
lamivudin
nevirapin
chest
xray
cxr
reveal
bilater
pulmonari
infiltr
also
reactiv
rpr
posit
tppa
serum
csf
intraven
penicillin
treatment
administ
neurosyphili
patient
partial
improv
sulfamethoxazoletrimethoprim
treatment
patient
develop
gener
erythemat
patch
plaqu
attribut
sulfamethoxazoletrimethoprim
nevirapin
nevirapin
chang
kaletra
sulfamethoxazoletrimethoprim
clindamycin
diagnos
pcp
sputum
pcr
cxr
improv
toxoplasma
serolog
iha
ameba
neg
result
patient
febril
hospit
day
blood
pcr
confirm
cmv
infect
whole
bodi
gallium
scan
show
increas
uptak
bilater
lung
without
focu
infect
becam
afebril
initi
intraven
ganciclovir
treatment
still
cxr
improv
chest
hrct
reveal
mix
alveolar
interstiti
lesion
bilater
lung
patchi
consolid
hilar
region
patholog
bronchoscop
biopsi
reveal
fungal
infect
amphotericin
b
amb
ad
patient
could
toler
convent
amb
due
rigor
fever
replac
liposom
formul
week
liposom
amb
treatment
antifun
therapi
chang
oral
itraconazol
treatment
cultur
bronchoalveolar
lavag
grew
filament
fungu
figur
pcr
confirm
isol
basidiomycota
sp
ceriporia
lacerata
patient
treat
oral
itraconazol
month
recurr
found
year
followup
conclus
fungal
infect
account
larg
number
aidsindex
diagnos
complic
cours
mani
patient
hiv
infect
clinic
suspicion
broader
recognit
diseas
caus
filament
fungi
among
clinician
microbiologist
would
improv
therapeut
experi
select
better
treatment
strategi
background
candida
glabrata
speci
complex
includ
candida
glabrata
sensu
stricto
two
major
cryptic
speci
candida
nivariensi
candida
bracarensi
distinct
speci
relev
epidemiolog
purpos
antifung
manag
phenotyp
identif
method
frequent
misidentifi
speci
c
glabrata
henc
identif
depend
molecular
method
malditof
ms
although
dna
sequenc
fungal
rdna
intern
transcrib
spacer
region
region
rrna
gene
accur
molecular
analysi
timeconsum
expens
present
studi
sought
examin
abil
vitek
ms
burker
ms
system
differenti
speci
within
c
glabrata
complex
use
varieti
softwar
includ
clinprotool
method
two
commerci
malditof
ms
system
vitek
ms
system
bruker
ms
system
bruker
daltonik
employ
vitek
ms
ruo
bruker
clinprotool
program
respect
evalu
identif
isol
c
glabrata
complex
c
glabrata
c
nivarensi
c
bracarensi
result
c
glabrata
sensu
stricto
identifi
correctli
system
distinct
principl
compon
compar
two
cryptic
speci
c
nivariensi
c
bracarensi
could
identifi
speci
level
vitek
ms
ivd
bruker
biotyp
ms
correctli
identifi
vitek
ms
ruo
gener
algorithm
model
clinprotool
softwar
show
recognit
capabl
cross
valid
discrimin
c
nivariensi
c
bracarensi
spectra
peak
statist
reveal
five
marker
reliabl
distinguish
c
nivariensi
c
bracarensi
area
curv
auc
valu
respect
small
inhous
bruker
spectral
databas
establish
incorpor
spectra
two
clinic
isol
repres
c
nivariensi
c
bracarensi
identifi
studi
complement
inhous
databas
remain
c
nivariensi
c
bracarensi
isol
correctli
identifi
speci
level
score
conclus
malditof
ms
enabl
rapid
reliabl
identif
c
glabrata
complex
isol
use
vitek
ms
ruo
system
bruker
clinprotool
softwar
addit
msp
bruker
ms
databas
repres
local
divers
isol
assist
achiev
differenti
cryptic
speci
within
c
glabrata
complex
background
gramposit
bacterium
enterococcu
faecali
fungu
candida
albican
common
opportunist
pathogen
human
bodi
oral
caviti
gastrointestin
tract
estim
nosocomi
c
albican
bloodstream
infect
polymicrobi
top
three
commonli
coisol
bacteri
speci
staphylococcu
epidermidi
enterococcu
spp
staphylococcu
aureu
previou
vitro
studi
show
e
faecali
could
inhibit
c
albican
hyphal
morphogenesi
reduc
biofilm
format
furthermor
coinfect
e
faecali
c
albican
mice
result
less
mortal
infect
either
speci
alon
howev
clinic
mix
bloodstream
infect
associ
candida
enterococcu
rare
caus
wors
clinic
outcom
immun
compromis
cancer
patient
interact
two
microb
mixedtyp
infect
bloodstream
ie
plankton
form
investig
studi
method
epidemiolog
bloodstream
infect
e
faecali
c
albican
mix
infect
case
collect
chimei
hospit
analyz
medium
use
cocultur
two
microb
test
interact
growth
vitro
biofilm
assay
use
studi
influenc
yeast
form
c
albican
mix
infect
e
faecali
drug
suscept
antibiot
ampicillin
gentamicin
antifung
caspofungin
amphotericin
b
microb
analyz
check
phenotyp
chang
associ
virul
result
candidaassoci
mix
bloodstream
infect
incid
infect
case
e
faecali
significantli
higher
gut
bacteria
similar
previou
report
decreas
biofilm
format
c
albican
prove
vitro
biofilm
assay
resist
antibiot
enhanc
e
faecali
cocultur
c
albican
conclus
interact
e
faecali
c
albican
might
alter
antibiot
suscept
e
faecali
patient
matter
present
biofilm
plankton
form
special
attent
must
gener
acut
hepat
caus
ltbi
treatment
isoniazid
quit
rare
present
exact
mechan
isoniazid
relat
hepatotox
still
unclear
might
relat
age
slow
acetyl
toxic
hydrazin
metabolit
homozyg
wild
type
genotyp
conclus
advers
event
acut
hepat
induc
ltbi
treatment
isoniazid
recommend
trace
liver
function
time
everi
week
close
especi
patient
whose
liver
function
fail
recov
quit
medic
conclus
treatment
pay
highli
attent
patient
clinic
symptom
close
track
biochem
test
blood
treat
advers
event
time
import
ensur
complet
treatment
achiev
purpos
cure
spatiotempor
analys
mild
sever
influenza
ill
associ
air
pollut
taiwan
pinwei
shih
tachien
chan
chwanchuen
king
institut
epidemiolog
prevent
medicin
nation
taiwan
univers
ntu
research
center
human
social
scienc
academia
sinica
institut
epidemiolog
prevent
medicin
colleg
public
health
ntu
background
epidem
influenza
taiwan
usual
vari
differ
year
exampl
earli
epidem
sever
led
massiv
crowd
emerg
room
mani
teach
hospit
shortag
human
resourc
intens
care
unit
icu
insuffici
avail
ecmo
hand
sinc
exchang
crossstrait
taiwan
mainland
china
becom
frequent
divers
influenza
viru
increas
therefor
understand
spatiotempor
distribut
mild
sever
case
influenza
associ
factor
method
use
softwar
satscan
discov
area
suffer
high
incid
influenzalik
ill
ili
went
understand
epidemiolog
ill
area
figur
risk
factor
weather
condit
popul
densiti
air
pollut
poultri
farm
densiti
final
confirm
strength
associ
risk
factor
diseas
use
regress
model
result
air
qualiti
index
aqi
refer
impact
daili
concentr
six
substanc
includ
co
aqi
impli
degre
effect
air
pollut
health
also
welldocu
respiratori
system
becom
sensit
period
poor
air
qualiti
addit
condit
local
weather
interact
weather
air
pollut
may
help
us
observ
case
respiratori
ill
increas
certain
time
lag
therefor
higher
incid
influenzalik
ill
would
occur
frequent
time
period
poor
air
qualiti
area
sever
problem
air
pollut
conclus
hope
result
studi
involv
aqi
local
weather
implic
epidemiolog
mild
sever
influenza
case
altogeth
provid
earli
warn
harm
reduct
influenzalik
ill
implement
appropri
prevent
measur
compar
assess
guidelin
individu
risk
infect
endocard
takahiko
fukuchi
divis
gener
medicin
jichi
medic
univers
saitama
medic
center
background
infect
endocard
sever
diseas
high
morbid
mortal
rate
health
care
provid
worldwid
consid
mean
prevent
diseas
howev
guidelin
relat
topic
differ
among
industri
countri
author
make
close
examin
guidelin
method
guidelin
unit
kingdom
nation
institut
health
care
excel
nice
notabl
contain
prescript
recommend
prophylact
antibiot
european
societi
cardiolog
esc
recommend
antibiot
highestrisk
individu
dental
procedur
american
heart
associ
aha
recommend
antibiot
highestrisk
individu
dental
urolog
gastroenterolog
dermatolog
invas
procedur
contrast
japanes
societi
cardiolog
recommend
antibiot
broader
rang
individu
includ
lower
risk
procedur
almost
congenit
valvular
heart
diseas
addit
recommend
nice
guidelin
chang
slightli
english
populationbas
studi
reveal
higher
incid
endocard
introduct
aggress
new
guidelin
one
reason
mani
differ
among
guidelin
might
random
control
trial
conduct
prophylact
effect
antibiot
individu
risk
endocard
therefor
guidelin
formul
committe
access
concret
evid
term
caus
pathogen
endocard
staphylococc
endocard
unprevent
oral
amoxicillin
increas
worldwid
find
studi
east
asia
includ
japan
show
one
third
endocard
case
caus
streptococcu
spp
moreov
state
major
guidelin
oral
hygien
import
dental
procedur
prevent
streptococcu
infect
result
histor
cohort
studi
reveal
indirect
evid
prevent
endocard
amoxicillin
indic
uk
guidelin
might
insuffici
japanes
guidelin
implement
standard
practic
driven
local
polit
climat
scientif
evid
basi
current
evid
neither
aha
esc
guidelin
consid
superior
conclus
primari
care
physician
dentist
consid
prophylaxi
endocard
dental
procedur
recommend
aha
esc
establish
assess
chemotherapi
order
templat
side
effect
huip
sun
huangpin
liang
tainan
municip
hospit
background
side
effect
chemotherapi
got
wors
dose
accumul
time
length
chemotherapi
nurs
staff
play
vital
role
maintain
patient
qualiti
life
effect
treat
prevent
reduc
distress
side
effect
due
chemotherapi
reinforc
knowledg
relat
chemotherapi
selfcar
behavior
current
staff
often
focus
possibl
side
effect
separ
chemotherapi
drug
howev
chemotherapi
templat
vari
type
cancer
side
effect
depend
type
chemotherapi
offer
purpos
studi
establish
assess
form
chemotherapi
order
templat
side
effect
method
retrospect
chart
review
perform
collect
six
chemotherapi
order
templat
breast
cancer
colorect
cancer
hepatocellular
carcinoma
top
three
common
cancer
region
hospit
side
effect
regard
everi
chemotherapi
order
templat
assess
identifi
common
specif
side
effect
base
literatur
review
reaction
chemotherapi
result
offer
inform
potenti
side
effect
treatment
start
chemotherapi
could
reduc
discomfort
deterior
qualiti
life
furthermor
process
informationgiv
improv
nurs
care
qualiti
reinforc
strong
nursepati
relationship
conclus
chemotherapi
side
effect
patient
sometim
differ
record
literatur
staff
record
chemotherapi
side
effect
patient
assess
process
analyz
assess
form
data
use
establish
guidelin
educ
common
side
effect
chemotherapi
order
templat
reduc
incid
needlestick
injuri
clinic
staff
yi
fang
hsieh
ya
fang
wang
wen
chuan
lin
yong
ching
lau
conclus
needlestick
injuri
long
second
abl
chang
life
medic
worker
educ
strengthen
awar
reduc
staff
due
lack
habit
lack
cognit
use
safeti
needl
expect
effect
prevent
injuri
blood
bodi
fluid
exposur
event
train
everi
clinic
medic
staff
develop
safe
cultur
preval
risk
factor
extend
spectrum
betalactamas
produc
escherichia
coli
patient
urinari
tract
infect
minori
matsumoto
kazushi
tanaka
yoshizumi
takechi
background
aim
studi
determin
preval
risk
factor
extend
spectrum
betalactamas
esbl
produc
escherichia
coli
e
coli
patient
urinari
tract
infect
method
one
hundr
four
esbl
produc
e
coli
isol
urin
april
march
preval
esblproduc
e
coli
patient
urinari
tract
infect
examin
univari
analys
perform
gender
age
inpati
statu
previou
hospit
recent
histori
urinari
catheter
recent
exposur
specif
antibiot
past
histori
urogenit
organ
oper
risk
factor
emerg
esblproduc
e
coli
multivari
analysi
perform
signific
variabl
result
patient
urinari
tract
infect
antimicrobi
suscept
e
coli
oral
antibiot
cefcapen
pivoxil
levofloxacin
sulfamethoxazoletrimethoprim
respect
preval
esblproduc
e
coli
conclus
overal
preval
esblproduc
e
coli
risk
appear
increas
case
previou
hospit
inpati
statu
incid
mortal
trend
infect
among
sepsi
patient
nationwid
studi
million
resid
mengts
gabriel
lee
shihhao
lee
yuehsheng
chen
wanchien
lee
shyshin
chang
szuta
chen
shyrchyr
chen
chienchang
lee
background
estim
sepsi
sourc
infect
mortal
base
nationwid
databas
linkag
death
certif
lack
aim
determin
trend
sourc
infect
outcom
sepsi
entir
million
taiwanes
popul
method
use
entir
health
insur
claim
data
nation
health
informat
project
identifi
patient
hospit
sepsi
sourc
infect
sepsi
case
identifi
use
valid
code
conform
definit
allcaus
mortal
obtain
linkag
death
certif
enzymecontain
microcapsul
mc
test
remov
three
sa
sediment
method
remain
sa
analyz
highperform
liquid
chromatographi
hplc
photodiodearray
detector
extracellular
enzym
extract
spent
mushroom
compost
smc
pleurotu
eryngii
mushroom
cultiv
farm
bacteri
commun
analyz
nextgener
sequenc
result
degrad
three
sa
enhanc
ad
mc
sediment
order
sa
degrad
smx
sdm
smz
differ
bacteri
commun
differ
sediment
exhibit
differ
sa
degrad
rate
sadegrad
bacteri
consortium
increas
adapt
four
time
readdit
sa
could
effici
degrad
sa
day
bacteri
genera
achromobact
acinetobact
alcaligen
aquamicrobium
arthrobact
brevundimona
flavobacterium
methylobacterium
microbacterium
oligotropha
paracoccu
pseudomona
rhodococcu
major
bacteri
commun
involv
sa
degrad
sediment
conclus
microbi
degrad
promis
process
sa
remov
sediment
addit
mc
sediment
enhanc
sa
degrad
mc
could
use
sa
remov
sediment
chint
lu
section
infecti
diseas
depart
intern
medicin
lohsu
medic
foundat
lotung
pohai
hospit
background
scrub
typhu
vectorborn
zoonosi
caus
orientia
tsutsugamushi
import
endem
diseas
taiwan
season
occurr
scrub
typhu
vari
accord
climat
differ
countri
diseas
occur
commonli
raini
season
forest
clear
riverbank
grassi
region
provid
optim
condit
mite
ilan
countri
northeastern
taiwan
uniqu
northeast
monsoon
climat
region
record
notifi
infecti
diseas
one
commun
hospit
ilan
year
confirm
case
case
occur
winter
case
januari
case
februari
case
decemb
find
winter
type
hospit
collect
analysi
case
data
taiwan
area
includ
ilan
countri
method
studi
monthli
data
case
number
obtain
notifi
infecti
diseas
statist
system
infecti
diseas
databas
taiwanes
center
diseas
control
scrub
typhu
th
grade
notifi
diseas
blood
sampl
patient
suspect
scrub
typhu
collect
sent
cdc
laboratori
confirm
confirm
diagnosi
scrub
typhu
base
posit
realtim
polymeras
chain
reaction
test
increas
otspecif
immunoglobulin
immunoglobulin
g
antibodi
pair
sera
use
indirect
immunofluoresc
assay
techniqu
epidemiolog
data
obtain
analysi
differ
epidemiolog
ilan
taiwan
result
year
confirm
case
total
case
taiwan
area
focu
ilan
counti
case
past
year
case
found
aborigin
area
datong
suao
township
case
plain
township
averag
number
case
per
year
recent
year
taiwan
area
data
incid
month
confirm
case
show
scrub
typhu
case
occur
throughout
entir
year
rapid
increas
number
april
may
reach
peak
juli
data
taiwan
area
except
ilan
counti
reach
peak
decemb
januari
next
year
taiwan
area
case
occur
summmer
fall
ilan
counti
case
occur
winter
peak
januari
season
variat
scrub
typhu
case
ilan
differ
report
area
taiwan
may
due
uniqu
northeast
monsoon
climat
need
studi
comparison
summer
type
area
taiwan
studi
reveal
uniqu
epidemiolog
characterist
winter
type
scrub
typhu
ilan
countri
find
may
provid
valuabl
inform
diagnosi
treatment
prevent
diseas
local
area
background
determin
whether
intestin
angiostrongylu
cantonensi
antigen
induc
protect
immun
rat
gut
antigen
prepar
femal
adult
fagp
somat
antigen
prepar
male
femal
fa
adult
worm
use
immun
rat
method
rat
immun
twice
fa
fagp
antigen
challeng
thirdstag
cantonensi
larva
differ
readout
use
monitor
protect
immun
addit
protein
profil
fa
fagp
extract
analyz
character
immunodetect
method
result
reduct
fifthstag
larva
brain
reduct
adult
worm
pulmonari
arteri
observ
rat
immun
fagp
compar
control
howev
reduct
rat
immun
fa
length
larva
adult
recov
fagpimmun
rat
shorter
recov
group
number
firststag
larva
recov
fecal
materi
fagpimmun
rat
significantli
reduc
addit
fagp
induc
highest
splenocyt
prolifer
serum
igg
titer
directli
correl
protect
immun
kda
gut
membran
protein
strongli
recogn
antifagp
antibodi
may
import
antia
cantonensi
immun
respons
conclus
demonstr
immun
respons
induc
fagp
reduc
growth
develop
reproduct
cantonensi
subsequ
infect
possibl
use
fagp
combin
fa
antigen
multifunct
vaccin
immun
protect
cantonensi
need
elucid
hope
provid
novel
strategi
parasit
vaccin
develop
check
whether
receiv
least
twice
measlescontain
vaccin
record
infect
control
offic
result
number
subject
test
peopl
lmi
fulfil
criteria
test
regard
secondari
vaccin
failur
two
vaccin
record
b
person
b
number
vaccin
subject
vaccin
record
kept
infect
control
offic
assum
examin
cost
per
person
vaccin
cost
expens
least
could
reduc
conclus
specul
measl
antibodi
decreas
markedli
year
year
order
take
measur
nosocomi
infect
hcw
need
accur
manag
vaccin
histori
twice
manag
vaccin
record
infect
control
offic
reliabl
econom
procedur
repeat
test
neuraminidas
nana
nanb
nanc
base
vaccin
prevent
pneumococc
infect
rajendraprasad
janapatla
meihua
hsu
chenghsun
chiu
background
routin
immun
pneumococc
conjug
vaccin
increas
incid
nonvaccin
serotyp
commun
clincal
isoalt
increas
need
develop
pneumococc
protein
vaccin
broader
serotyp
coverag
sinc
neuraminidas
major
virul
protein
potenti
target
vaccin
small
molecul
inhibitor
studi
explor
possibl
combin
three
neuraminidas
togeth
vaccin
antigen
devis
univers
protein
vaccin
prevent
system
pneumococc
infect
method
evalu
degre
protect
nana
nanb
nanc
protein
antigen
pneumonia
intraven
challeng
individu
combin
neuraminidas
nana
nanb
nanc
inject
subcutan
confirm
presenc
antineuraminidas
antibodi
antisera
perform
enzymelink
immunosorb
assay
elisa
pneumonia
cell
suspens
use
infect
immun
ice
tail
vein
inject
antisera
individu
neuraminidas
nana
nanb
nanc
also
test
inhibitori
effect
activ
neuraminidas
specif
antineuraminidas
serum
neutral
neuraminidas
activ
exposur
thomsenfriedenrich
antigen
ta
antigen
rbc
cell
valu
fluoresc
intens
reduc
result
observ
high
logarithm
fold
igg
class
antibodi
titr
nana
nanb
nanc
indic
three
neuraminidas
immunogen
ideal
antigen
immun
found
antisera
full
length
nana
nanalectin
effici
inhibit
neuraminidas
activ
howev
antisera
lectin
domain
nanb
nanc
suffici
neutral
enzym
activ
immun
combin
nana
nanb
nanc
caus
signific
increas
surviv
rate
rel
vaccin
group
neg
control
serotyp
surviv
respect
conclus
futur
formul
pneumococc
virul
protein
adjuv
need
develop
serotyp
independ
protect
pneumococc
infect
recommend
inclus
three
pneumococc
neuraminidas
futur
protein
vaccin
formul
prevent
ipd
ps
serotyp
still
import
caus
pediatr
invas
pneumococc
diseas
portug
decad
conjug
vaccin
catarina
silvacosta
andreia
sandra
aguiar
joana
p
lope
maria
j
brito
mario
ramirez
jose
melocristino
result
number
isol
recov
epidemiolog
year
constant
similar
except
may
due
fact
still
receiv
isol
particip
laboratori
overal
differ
capsular
type
well
nontyp
isol
detect
although
isol
express
capsular
type
includ
pcv
serotyp
includ
pcv
formul
account
signific
fraction
isol
n
among
serotyp
frequent
repres
least
isol
regard
pcv
serotyp
isol
express
serotyp
n
serotyp
n
serotyp
n
serotyp
n
n
n
frequent
found
overal
isol
penicillin
nonsuscept
resist
erythromycin
express
isol
simultan
express
erythromycin
resist
penicillin
nonsuscept
found
isol
conclus
serotyp
still
express
consider
proport
isol
respons
ipd
data
present
emphas
potenti
role
nip
diminish
pediatr
ipd
vaccin
programm
previous
describ
methodolog
aim
present
result
surveil
data
method
paediatr
case
febril
convuls
enceph
meningitisencephalopathi
kawasaki
diseas
thrombocytopenia
lymphaden
syndrom
intussuscept
admit
kkh
januarydecemb
prospect
screen
evalu
possibl
associ
vaccin
clinic
chart
review
vaccin
histori
extract
nation
immunis
registri
standardis
criteria
accord
world
health
organ
uppsala
monitor
centr
whoumc
definit
use
identifi
case
higher
probabl
associ
vaccin
criteria
includ
durat
diseas
onset
date
prior
vaccin
well
exclud
case
altern
diagnosi
base
laboratori
infect
screen
event
rate
gener
base
per
patient
admit
result
possibl
vaccinerel
monitor
event
per
admit
patient
compar
per
patient
increas
rate
mening
per
patient
per
patient
rate
febril
convuls
kawasaki
diseas
thrombocytopenia
lymphaden
lower
compar
case
gb
detect
associ
recent
vaccin
two
case
intussuscept
follow
rotaviru
vaccin
rotarix
identifi
one
case
occur
day
receipt
dose
second
day
receipt
dose
find
hkinspir
activ
childhood
vaccin
safeti
surveil
kkh
provid
reassur
safeti
childhood
vaccin
programm
singapor
signific
safeti
concern
detect
event
interest
increas
risk
intussuscept
receipt
rotaviru
vaccin
known
preliminari
analysi
mening
safeti
signal
suggest
may
attribut
wider
total
increas
asept
mening
admiss
unlik
relat
vaccin
preval
potenti
drugdrug
interact
hivinfect
adult
antiretrovir
drug
faculti
medicin
vajira
hospit
navamindhradhiraj
univers
kittisak
pholtawornkulchai
sirot
luengsupabul
background
present
multipl
tumor
rare
differenti
diagnosi
import
young
man
present
multipl
tumor
admit
tumor
biopsi
reveal
smooth
muscl
tumor
method
case
report
review
literatur
perform
result
ebv
infect
associ
mani
tumor
regard
tumor
viru
increas
number
patient
hiv
infect
incid
smooth
muscl
tumor
increas
patient
may
present
variabl
aggress
clinic
outcom
may
exhibit
favor
prognosi
compar
convent
leiomyosarcoma
conclus
medicin
advanc
presenc
multipl
smooth
muscl
tumor
hivinfect
patient
alert
vigil
familiar
distinct
tumor
present
contribut
earli
diagnosi
aminoacid
polymorph
gag
domain
alter
promot
effect
viral
replic
bud
isol
inject
drug
user
idu
taiwan
background
bell
plasi
acut
peripher
facial
nerv
affectionsever
pain
suggest
herp
simplex
zoster
infect
may
preced
vesicular
erupt
orand
progress
ramsey
hunt
syndromein
half
herp
zoster
infect
vesiculationnot
necessarili
appear
may
delay
zoster
sine
herpet
new
evid
detect
virus
pcr
within
facial
nerv
impli
bell
palsi
caus
latent
herp
virus
method
clinic
evalu
patient
year
old
withpheripher
facial
palsi
patient
clinic
assess
sever
facial
nerv
damag
score
housebrackmann
facial
nerv
grade
system
sreen
routin
blood
test
thyroid
hormon
evalu
serolog
herp
zoster
borreliaburgdoferi
mri
head
gandolinium
request
nerv
conduct
studi
result
patient
femal
male
patient
score
grade
ii
grade
iii
grade
grade
iv
hous
brackmannscal
six
patient
posit
herp
zoster
none
vesicular
erupt
eight
patient
normal
mri
two
intern
acoust
meatalseg
facial
nerv
enhanc
affect
side
conduct
studi
four
demyelin
nerv
two
sever
axon
damag
zoster
posit
antibodi
eanhanc
intern
acoust
meatal
segment
facial
nerv
affect
side
patient
yosterposit
zoster
neg
treat
corticosteroid
antivir
therapi
five
patient
facial
nerv
damag
total
recov
two
signific
improv
three
remainwith
sever
sequela
recuper
greaterat
patient
use
corticosteroid
antivir
therapi
acyclovir
valacyclovir
even
zoster
neg
antibodi
patient
sever
sequela
group
zoster
ntibodi
enhanc
mri
axon
damag
conduct
studi
conclus
new
evid
ipliestha
bell
palsi
isa
caus
latent
herp
virus
consid
zoster
even
without
erupt
start
antivir
therapi
import
sinceit
thought
caus
bell
palsi
quit
number
case
although
number
case
studi
small
signific
statist
conclus
background
sever
new
direct
antivir
agent
daa
hcv
viru
approv
market
combin
daa
soc
pegyl
interferon
ribavirin
recommend
patient
toler
interferon
therefor
sever
ifnfre
treatment
consid
includ
proteas
inhibitor
rnadepend
rna
polymeras
inhibitor
inhibitor
novel
proteas
inhibitor
acylsulfonamid
class
oral
activ
signific
plasma
liver
exposur
onceaday
dose
regimen
chc
inhibitor
superior
potenc
cellbas
assay
vitro
studi
examin
potenti
combin
reduc
hcv
replicon
coloni
method
cell
contain
genotyp
subgenom
replicon
carri
neo
gene
plate
plate
treat
either
one
two
compound
x
ec
cultur
medium
chang
twice
week
cell
split
confluenc
result
hcv
hsgneo
replicon
number
coloni
reduc
dramat
combin
number
found
nm
respect
combin
pm
pm
includ
number
coloni
reduc
level
nm
respect
anoth
replicon
hcv
pilucneoet
dramat
reduct
coloni
count
observ
combin
appli
number
found
nm
respect
pm
addit
pm
result
cell
coloni
number
nm
respect
conclus
antagonist
effect
number
resist
coloni
observ
combin
investig
signific
reduct
number
resist
coloni
observ
combin
studi
indic
combin
least
addit
synergist
antivir
effect
novel
lytic
bacteriophag
target
klebsiella
pneumonia
carbapenemaseproduc
klebsiella
pneumonia
jongsoo
jeon
yongjoon
cho
dongeun
yong
kyungwon
lee
background
klebsiella
pneumonia
carbapenemas
kpc
import
mechan
carbapenem
resist
gramneg
bacteria
late
kpcproduc
bacteria
rapidli
increas
clinic
set
high
drugresist
associ
signific
morbid
mortal
especi
kpcproduc
k
pneumonia
spread
rapidli
worldwid
becom
major
hospit
pathogen
herein
character
novel
klebsiella
phage
lyse
kpcproduc
k
pneumonia
clinic
strain
method
k
pneumonia
lytic
phage
isol
use
agar
doublelay
method
sewag
sampl
univers
hospit
south
korea
host
rang
determin
spot
test
kpck
pneumonia
clinic
strain
whole
genom
sequenc
perform
use
illumina
miseq
sequenc
isol
phage
character
transmiss
electron
microscopi
onestep
growth
curv
adsorpt
rate
thermalph
stabil
analysi
bacteri
lysi
assay
result
novel
klebsiella
bacteriophag
belong
famili
siphovirida
isometr
head
long
noncontractil
tail
show
broad
host
rang
lyse
clinic
kpck
pneumonia
strain
whole
genom
analysi
exhibit
doublestrand
dna
bp
g
c
content
put
open
read
frame
known
toxinrel
gene
identifi
silico
moreov
bioinformat
analysi
result
reveal
whole
genom
phage
novel
genom
blastn
match
klebsiella
phage
genom
ncbi
databas
onestep
growth
adsorpt
curv
show
latent
period
min
burst
size
plaqu
form
unitsinfect
cell
adsorpt
rate
within
min
strain
show
broad
ph
stabil
ph
rang
day
day
high
thermal
stabil
observ
bacteri
growth
strongli
inhibit
multipl
infect
moi
conclus
novel
klebsiella
phage
isol
character
use
clinic
kpck
pneumonia
strain
result
show
facilit
develop
altern
antibacteri
agent
treat
infecti
diseas
caus
kpck
pneumonia
vivo
safeti
efficaci
examin
studi
background
peopl
infect
human
tcell
leukemia
viru
type
remain
asymptomat
carrier
preval
taiwan
present
case
relat
adult
tcell
leukemialymphoma
atll
method
patient
retir
nurs
suffer
needlestick
injuri
year
blood
reject
donat
blood
bank
year
ago
receiv
report
blood
bank
someon
interpret
hiv
infect
hiv
infect
never
confirm
three
week
ago
intermitt
fever
night
sweat
gener
malais
develop
gener
lymphadenopathi
bilater
neck
axillari
inguin
region
three
day
prior
admiss
acut
retrovir
syndrom
suspect
hiv
eia
western
blot
neg
result
laboratori
test
reveal
mild
leukocytosi
atyp
lymphocyt
chlamydia
igm
posit
strategi
appli
follow
use
qr
code
conveni
onlin
educ
cours
regular
monitor
standard
procedur
use
red
alarm
marker
level
foley
bag
regular
audit
correct
foley
cathet
insert
inhospit
broadcast
proper
hand
wash
setup
procedur
remind
attend
doctor
nurs
oral
show
day
foley
cathet
insert
comput
use
special
trolley
foley
catheter
evalu
effect
includ
monthli
audit
correct
rate
foley
cathet
insert
daili
care
nurs
staff
test
knowledg
cauti
bundl
care
result
conduct
cauti
bundl
care
hospit
cauti
rate
personday
march
june
plan
cauti
rate
period
reduc
personday
knowledg
measur
cauti
bundl
care
increas
strategi
figur
correct
rate
foley
catheter
daili
care
chang
respect
figur
conclus
initi
period
cautibundl
care
plan
nurs
staff
thought
necessari
perform
plan
due
manpow
shortag
limit
resourc
hospit
addit
lower
cauti
rate
hospit
compar
local
one
understand
upgrad
evid
practic
guidelin
prevent
mainten
foley
cathet
later
realiz
accept
promot
plan
system
strategi
correct
execut
rate
nurs
staff
achiev
cauti
rate
reduc
studi
show
cauti
bundl
care
plan
execut
correctli
seri
promot
strategi
reduc
cauti
rate
futur
expect
cauti
bundl
care
part
regular
medic
care
comput
assist
workload
could
reduc
final
cauti
bundl
care
promot
medic
branch
health
system
promot
nurs
care
qualiti
reduc
cauti
rate
promot
ventilatorassoci
pneumonia
bundl
care
implement
rate
yule
huang
peijung
chuang
hsiaowei
wang
mingtzer
lin
chuangcheng
hsiao
respiratori
care
ward
respiratori
care
center
chief
presid
hsiao
chungcheng
hospit
new
taipei
citi
taiwan
background
ventilatorassoci
pneumonia
vap
prolong
durat
ventil
usag
length
hospit
stay
may
even
result
mortal
critic
ill
patient
prevent
vap
import
hospit
local
commun
hospit
began
take
part
vap
bundl
care
plan
sinc
nd
march
includ
total
bed
intens
care
unit
icu
bed
respiratori
care
centr
rcc
bed
gener
ward
bed
bundl
care
team
setup
crossfunct
teamwork
purpos
plan
promot
implement
rate
bundl
care
health
care
worker
would
reduc
vap
rate
protect
patient
safeti
improv
care
qualiti
lower
healthcar
cost
method
plan
initi
local
commun
hospit
sinc
march
june
accord
practic
step
poster
propaganda
educ
train
preand
posttest
abil
done
promot
percept
implement
vap
bundl
care
health
care
staff
implement
rate
evalu
weekli
field
audit
plan
began
audit
done
randomli
select
sampl
unit
patient
icu
patient
rcc
gener
ward
result
execut
vap
bundl
care
vap
rate
march
june
person
day
plan
vap
rate
person
day
period
figur
implement
rate
achiev
unit
within
seven
week
applic
plan
figur
six
week
five
week
four
week
gener
ward
rcc
icu
respect
conclus
base
psycholog
theori
habitu
behavior
would
acquir
repetit
action
experi
begin
implement
took
much
time
remind
educ
staff
form
habit
carri
bundl
care
daili
practic
yet
establish
habit
implement
rate
achiev
within
five
seven
week
differ
durat
achiev
maxim
implement
rate
could
relat
differ
bed
number
unit
less
bed
number
shorter
durat
achiev
implement
rate
vap
rate
chang
much
applic
plan
possibl
explan
vap
rate
alreadi
low
hospit
enough
time
observ
evid
chang
vap
rate
studi
show
implement
rate
achiev
within
seven
week
result
systemat
propaganda
staff
educ
train
bed
number
possibl
issu
achiev
implement
rate
futur
research
longer
durat
need
observ
chang
vap
rate
impact
bundl
care
model
ventil
associ
pneumonia
medic
intens
care
unit
shuchien
liang
yumei
ho
wenyin
huang
wenchen
yao
intens
care
unit
infect
control
background
due
progress
thorac
medicin
medic
instrument
technolog
improv
surviv
rate
patient
respiratori
failur
increas
ventilatorassoci
pneumonia
vap
vap
frequent
nosocomi
infect
intens
care
unit
icu
studi
even
found
mortal
attribut
vap
statist
icu
region
teach
hospit
averag
vap
rate
order
avoid
infect
death
patient
recommend
earli
wean
ventil
involv
reduct
vap
hospit
proper
manag
patient
safeti
method
databas
literatur
verif
team
decisionmak
januari
decemb
intervent
prevent
vap
bundl
care
intervent
project
includ
educ
train
dop
technic
learn
activ
improv
bed
equip
enhanc
combin
care
mode
includ
twice
daili
chg
oral
care
daili
discuss
earli
remov
endo
patient
continu
intraven
sedat
daili
wakeup
trial
infus
sed
discontinu
level
arous
assess
use
richmond
agit
sedat
scale
rass
head
bed
elev
degre
water
ventil
tube
empti
addit
design
bundl
care
nurs
inform
system
enhancei
learn
provid
prevent
tip
studi
result
reveal
patient
experiment
group
significantli
reduc
vap
averag
rate
vap
n
post
vap
bundl
care
averag
vap
rate
zero
toler
n
rate
staff
confid
vap
care
knowledg
complianc
ventil
care
bundl
practic
significantli
increas
preintervent
stage
postintervent
stage
accuraci
rate
rass
sedat
evalu
increas
moreov
sedat
patient
reach
rass
clinic
recommend
level
ratio
increas
reduc
iatrogen
injuri
also
enhanc
use
sed
safeti
care
continu
track
juli
vap
densiti
still
zero
toler
conclus
team
resourc
manag
establish
vap
bundl
care
design
nurs
inform
system
includ
slogan
tip
abl
provid
prompt
oper
ensur
correct
clinic
care
process
monitor
mechan
enhanc
care
accuraci
rate
achiev
goal
zero
toler
vap
enhanc
patient
safeti
vitro
analysi
activ
antimicrobi
agent
clinic
common
organ
caus
bloodstream
infect
hospitalacquir
pneumonia
intraabdomin
infect
twelv
teach
hospit
china
result
chines
antimicrobi
resist
surveil
nosocomi
infect
care
program
henan
li
chunjiang
zhao
qi
wang
ji
zeng
yan
jin
zhidong
hu
kang
liao
yanp
luo
chao
zhuo
rong
zhang
xiuli
xu
wenen
liu
yingmei
liu
yunzhuo
chu
hui
wang
depart
clinic
laboratori
